UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 20-F

 

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 20202023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File No.: 001-37600

 

NANO DIMENSION LTD.

(Exact name of registrant as specified in its charter)

 

Translation of registrant’s name into English: Not applicable

 

State of Israel

(Jurisdiction of incorporation or organization)

 

2 Ilan Ramon

Ness Ziona

7403635 Israel

(Address of principal executive offices)

 

Yoav Stern

President and Chief Executive Officer

+972-073-7509142

yoav.s@nano-di.comyoav.stern@nano-di.com

2 Ilan Ramon

Ness Ziona

7403635 Israel

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

 

Securities registered or to be registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered

American DepositoryDepositary Shares each representing one

Ordinary Shares par value NIS 5.00 per share(1)

share (1) Ordinary Shares, par value NIS 5.00 per share(2)share (2)

 NNDM Nasdaq Capital Market
Rights to Purchase American Depository Shares, each American Depositary Share representing one Ordinary Share, par value NIS 5.00 per shareNNDMNasdaq Capital Market

 

(1)Evidenced by American Depositary Receipts.

(2)Not for trading, but only in connection with the listing of the American Depositary Shares.

 

Securities registered or to be registered pursuant to Section 12(g) of the Act: None

 

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

 

 

 

 

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

 

172,063,020238,596,545 Ordinary Shares, par value NIS 5.00 per share, as of December 31, 2020.2023.

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

 

Yes No

 

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934.

 

Yes No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes No

 

Indicate by check mark whether the registrant has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.months (or for such shorter period that the registrant was required to submit such files).

 

Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “largelarge accelerated filer, “accelerated filer,” and emerging“emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer ☐Non-accelerated filer
  Emerging growth company

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards † provided pursuant to Section 13(a) of the Exchange Act.

 

The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.

 

U.S. GAAP

 

International Financial Reporting Standards as issued by the International Accounting Standards Board

 

Other

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

 

Item 17 Item 18

 

If this is an annual report, indicate by check mark whether the registrant is a shell company.

 

Yes No

 

 

 

 

 

 

TABLE OF CONTENTS

 

 INTRODUCTIONiii
 Page
INTRODUCTIONiii
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSiv
   
PART I
   
ITEM 1.IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS.1
ITEM 2.OFFER STATISTICS AND EXPECTED TIMETABLE.1
ITEM 3.KEY INFORMATION.1
A.[Removed and reserved.]Reserved]1
B.Capitalization and Indebtedness.1
C.Reasons for the Offer and Use of Proceeds.1
D.Risk Factors.1
ITEM 4.INFORMATION ON THE COMPANY.20
A.History and Development of the Company.20
B.Business Overview.2122
C.Organizational Structure.2930
D.Property, Plants and Equipment.2930
ITEM 4A.UNRESOLVED STAFF COMMENTS.2930
ITEM 5.OPERATING AND FINANCIAL REVIEW AND PROSPECTS.3031
A.Operating Results.3031
B.Liquidity and Capital Resources.3435
E.C.Off-Balance Sheet Arrangements.Research and Development, Patents and Licenses, etc.3637
F.D.Tabular Disclosure of Contractual Obligations.Trend Information.3637
ITEM 6.E.DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES.Critical Accounting Estimates.3837
A.ITEM 6.Directors, Senior Management and Employees39
A.Directors and Senior Management.3839
B.Compensation.4142
C.Board Practices.4243
D.Employees.5155
E.Share Ownership.5155
F.Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation57
ITEM 7.MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS.5358
A.Major Shareholders.5358
B.Related Party Transactions.5459
C.Interests of Experts and Counsel.5460
ITEM 8.FINANCIAL INFORMATION.5560
A.Consolidated Statements and Other Financial Information.5560
B.Significant Changes.5562
ITEM 9.THE OFFER AND LISTING.5562
A.Offer and Listing Details.5562
B.Plan of Distribution.5562
C.Markets.5562
D.Selling Shareholders.5562
E.Dilution.5562
F.Expenses of the Issue.62

i

ITEM 10.55ADDITIONAL INFORMATION.63
ITEM 10.A.ADDITIONAL INFORMATION.Share Capital.5663
A.B.Share Capital.56
B.Memorandum and Articles of Association.5663
C.Material Contracts.5663
D.Exchange Controls.5763
E.Taxation.5764
F.Dividends and Paying Agents.6472
G.Statement by Experts.6472
H.Documents on Display.6472
I.Subsidiary Information.73
J.64Annual Report to Security Holders.73

i

ITEM 11.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.6573
ITEM 12.DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.6573
A.Debt Securities.6573
B.Warrants and rights.6573
C.Other Securities.6573
D.American Depositary Shares.6674
   
PART II
 
PART II
ITEM 13.DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.6775
ITEM 14.MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.6775
ITEM 15.CONTROLS AND PROCEDURES.6775
ITEM 16.[Reserved]76
ITEM 16A.AUDIT COMMITTEE FINANCIAL EXPERT.6776
ITEM 16B.CODE OF ETHICS.6876
ITEM 16C.PRINCIPAL ACCOUNTANT FEES AND SERVICES.6876
ITEM 16D.EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES.6877
ITEM 16E.PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS.6977
ITEM 16F.CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT.6978
ITEM 16G.CORPORATE GOVERNANCE.6978
ITEM 16H.MINE SAFETY DISCLOSURE.80
ITEM 16I.70DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.80
ITEM 16J.INSIDER TRADING POLICIES80
ITEM 16K.CYBERSECURITY80
   
PART III
 
ITEM 17.PART IIIFINANCIAL STATEMENTS.83
ITEM 18.FINANCIAL STATEMENTS.83
ITEM 19.EXHIBITS.83
 
ITEM 17.SIGNATURESFINANCIAL STATEMENTS.71
ITEM 18.FINANCIAL STATEMENTS.71
ITEM 19.EXHIBITS.71
SIGNATURES7385

 

ii

 

 

 INTRODUCTION

 

INTRODUCTION

We are a leading additiveOur vision is to disrupt electronics provider. We believe our flagship proprietary DragonFly Lights-Out Digital Manufacturing (LDM) system is the first and onlymechanical manufacturing with an environmentally friendly and economically efficient electronics and precision system that produces professional multilayer circuit-boards (PCB), radio frequency (RF) antennas, sensors, conductive geometries, and molded connected devices for rapid prototyping through custom additive manufacturing. We have been actively developing our additive manufacturing Industry 4.0 solution - transforming digital designs into functioning electronic and mechanical devices - on demand, anytime, anywhere. Our technology since 2014. With our unique additivestrategy is rooted in the application of deep learning based artificial intelligence, or AI, to drive improvements in manufacturing technology for additively manufactured electronics, we are targetingcapabilities by using self-learning and self-improving systems, along with the growing market for smart electronic devices that rely on printed circuit boards, connected devices, RF components and antennas, sensors, and smart products, including Internetmanagement of Things (IoT).a distributed manufacturing network via the cloud.

 

We were incorporated under the laws of the State of Israel in December 1960. On March 7, 2016, American Depositary Shares, or ADSs, representing our Ordinary Shares, commenced trading on the Nasdaq under the symbol “NNDM.” On June 29, 2020, we effected a change in the ratio of our ADSs to Ordinary Shares fromEach one (1) ADS representing fifty (50) Ordinary Shares to a new ratio of one (1) ADS representingcurrently represents one (1) Ordinary Share. All descriptions of our ADS herein, including ADS amounts and per ADS amounts, are presented after giving effect to the ratio change.

 

Unless otherwise indicated, all references to the “Company,” “we,” “our” and “Nano Dimension” refer to Nano Dimension Ltd. and its subsidiaries, Global Inkjet Systems Ltd., or GIS, a United Kingdom corporation, Nano Dimension Technologies Ltd., or Nano Tech, an Israeli corporation, Essemtec AG, or Essemtec and Nano Dimension IP Ltd.Swiss GmbH, or Nano Swiss, Swiss corporations, Formatec Holding B.V., Israelior Formatec Holding, Admatec Europe B.V., or Admatec, and Formatec Technical Ceramics B.V., or Formatec, Dutch corporations, Nano Dimension USA Inc., or Nano USA, a Delaware corporation, Essemtec USA, LLC, a Delaware limited liability company, Nano Dimension GmbH, or Nano Germany and Essemtec Deutschland GmbH, German corporations, Nano Dimension Australia Pty Ltd., or Nano Australia, an Australian corporation, Nano Dimension (HK) Limited, a Hong Kong corporation, Essemtec France SAS, a French corporation, Nano Dimension NY Ltd., a New York corporation, and Nano Dimension Trading (Shenzhen) Ltd., a Chinese corporation.

 

References to “U.S. dollars” and “$” are to currency of the United States of America, and references to “NIS” are to New Israeli Shekels.Shekel. References to “Ordinary Shares” are to our Ordinary Shares, par value of NIS 5.00 per share. We report financial information under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, and none of the financial statements were prepared in accordance with generally accepted accounting principles in the United States.

 

iii

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Certain information included or incorporated by reference in this annual report on Form 20-F may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified.

 

These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.

 

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

 

Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things:

 

the overall global economic environment;changes in our strategy;

the impact of competition and new technologies;

general market, political andshareholder activism;

the overall global economic conditions in the countries in which we operate;environment;

projected capital expenditures and liquidity;

 
changes in our strategy;
the impact of the coronavirus, or COVID-19, pandemic, and resulting government actions on us;
litigation; and

those factors referred to in “Item 3. Key Information – D. Risk Factors,” “Item 4. Information on the Company,” and “Item 5. Operating and Financial Review and Prospects”, as well as in this annual report on Form 20-F generally.

 

Readers are urged to carefully review and consider the various disclosures made throughout this annual report on Form 20-F which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

 

You should not put undue reliance on any forward-looking statements. Any forward-looking statements in this annual report on Form 20-F are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

In addition, the section of this annual report on Form 20-F entitled “Item 4. Information on the Company” contains information obtained from independent industry sources and other sources that we have not independently verified.

 

iv

 

 

PART I

 

ITEM 1.IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

 

Not applicable.

 

ITEM 2.OFFER STATISTICS AND EXPECTED TIMETABLE

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE

 

Not applicable

ITEM 3. KEY INFORMATION

A. [Reserved]

B. CAPITALIZATION AND INDEBTEDNESS

Not applicable.

 

ITEM 3.KEY INFORMATION

C. REASONS FOR THE OFFER AND USE OF PROCEEDS

 

A.[Removed and reserved]

B.Capitalization and Indebtedness

Not applicable.

 

C.Reasons for the Offer and Use of Proceeds

D. RISK FACTORS

 

Not applicable.

D.Risk Factors

You should carefully consider the risks described below, together with all of the other information in this annual report on Form 20-F. The risks described below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business operations. If any of these risks actually occurs, our business and financial condition could suffer and the price of our ADSs could decline.

 

Summary of Risk Factors

 

Risks Related to Our Financial Condition and Capital Requirements

We are a development-stage companyinvest significant resources in research and have a limited operating history on which to assess the prospects fordevelopment of our business, have incurred losses since the date of inception of Nano Dimension Technologies Ltd.,products and anticipate that we willmay continue to incur significant losses until we are able to successfully commercialize our products;products at a greater scale;

 

We have generated limitedAlthough we generate revenues from the sale of our current products, andwe may never be profitable.profitable; and

 

Our non-financial assets may lead to impairments in the future.

Risks Related to Our Business and Industry

 

We depend entirely onhave been engaged, and will continue to engage, in mergers and acquisitions to diversify or expand our business, which may pose risks to our business and dilute the commercial successownership of our DragonFly LDM system and ink products,existing shareholders, and we may not be able to successfully scale up their commercialization;realize the anticipated benefits of these mergers or acquisitions;

 

We may not be able to introduce products acceptable to customers and we may not be able to improve the technology used in our current systems in response to changing technology and end-user needs;

 

We depend on the commercial success of selling our advanced manufacturing products and services and we may not be able to successfully scale up their commercialization; and

We may not be able to successfully manage our planned growth and expansion;expansion.

We face business disruption and related risks resulting from the recent outbreak of COVID-19, which could have a material adverse effect on our business and results of our operations.

 


Risks Related to Our Intellectual Property

 

Lack of patent protection may hinder our market competitiveness and failure to safeguard trade secrets could enable competition to use our proprietary information;

If we are unable to obtain and maintain effective patent rights for our products, we may not able to compete effectively in our markets. If we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used to compete against us;

If we are unableInability to maintain effective proprietary rights for our products, we may not be ableaffect our ability to compete effectively in our markets;effectively; and

 

We gave been subject,Third-party claims of intellectual property infringement may prevent or delay our development and may in the future be subject to further claims that our employees, consultants, or independent contractors have wrongfully or unavoidably used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.commercialization efforts.

 

Risks Related to the Ownership of the ADSs or our Ordinary Shares

 

The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, allows us to postpone the date by which we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information we provide in our reports filed with SEC which could undermine investor confidence in our company and adversely affect the market price of our ADSs or Ordinary Shares;

As a “foreign private issuer” we follow certain home country corporate governance practices instead of otherwise applicable SEC and Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.

 

Risks Related to Israeli Law and Our Operations in Israel

OurAs our headquarters and some of our operations are subject to currencylocated in Israel, we could be adversely affected by the implications of political, economic and interest rate fluctuations;military instability in Israel;

 

Provisions of Israeli law, and our amended and restated articles of association and our rights agreement may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders;

 

Our headquarters and other significant operations are located in Israel,subject to currency and therefore, our results may be adversely affected by political, economicinterest rate fluctuations; and military instability in Israel;

 

We received Israeli government grants for certain of our research and development activities. The terms of those grants may require us to pay royalties and to satisfy specified conditions in order to manufacture products and transfer technologies outside of Israel. WeIf we fail to satisfy these conditions, we may be required to pay penalties in additionand refund grants previously received.

General Risk Factors

Raising additional capital would cause dilution to repaymentholders of our securities, and may affect the grants.rights of existing shareholders;

 

Significant disruptions of our information technology systems or breaches of our data security could adversely affect our business;

We may be subject to securities litigation, which is expensive and could divert management attention; and

If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports regarding our business or our ADSs or Ordinary Shares, the price and trading volume of our ADSs or Ordinary Shares could decline.


Risks Related to Our Financial Condition and Capital Requirements

 

We are a development-stage companyinvest significant resources in research and have a limited operating history on which to assess the prospects fordevelopment of our business, have incurred significant losses since the date of inception of Nano Dimension Technologies Ltd.,products and anticipate that we willmay continue to incur significant losses until we are able to successfully commercialize our products.products at a greater scale.

 

From March 7, 2014 until August 25, 2014, we were a “shell corporation” and did not have any business activity, excluding administrative management. On August 25, 2014, we closed a merger transaction, or the Merger, with Nano Dimension Technologies Ltd., or the Subsidiary, whereby we acquired 100% of the share capital of the Subsidiary. Since the date of the Merger, we have been operating as a development-stage company and have a limited operating history on which to assess the prospects for our business, have incurred significant losses, and anticipate that we will continue to incur significant losses for the foreseeable future.

Since the date of our inception, of the Subsidiary, and as of December 31, 2020,2023, we have incurred net losses of approximately $108$591 million.

 


Since the date of the Merger,Between 2014 and 2022, we have devoted substantially alla significant amount of our financial resources to develop our products. To date,products and in our acquisitions. Since the beginning of 2023, we have generated limited revenues fromalso devoted substantial efforts in the sale and leasedevelopment of new consumables for our products. Since the Merger, wemachines, mainly inks. We have financed our current operations primarily through the issuance of equity securities. The amount of our future net losses and our ability to finance our operations will depend, in part, on completing the development of our products, the rate of our future expenditures, our ability to generate significant revenues from the sales of our products and our ability to obtain funding through the issuance of our securities, strategic collaborations or grants. We expect to continue to incur significant losses untilare working on reducing our operational and other expenses; however, we are able to generate significant revenues from the sales of our products. We anticipate that our expenses willmay increase substantially if and as we:

 

continue the development of our products;

 

establish a sales, marketing, and distribution infrastructure to successfully commercialize our products;

 

seek to identify, assess, acquire, license, and/or develop other products and subsequent generations of our current products;

 

seek to acquire other entities;

seek to maintain, protect, and expand our intellectual property portfolio;

 

seek to attract and retain skilled personnel; and

 

create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts.

 

We have generated limitedAlthough we generate revenues from the sale of our current products, andwe may never be profitable.

 

We began commercializing our products in the fourth quarter of 2017 and have generated limited revenues since the date of the Merger.2017. Our ability to generate significant revenues and achieve profitability depends on our ability to successfully complete the development of, and to commercialize, our products.products, including consumables. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to:

 

completing development of our products;products, specifically new consumables;

 

penetrating new geographies and markets;

establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products to support market demand for our products;

 

launching and commercializing products, specifically consumables, either directly or with a collaborator or distributor;

 

addressing any competing technological and market developments;


 

identifying, assessing, acquiring and/or developing new products;

 

negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;

 

maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and

 

attracting, hiring and retaining qualified personnel.

 

Our non-financial assets may lead to significant impairments in the future.

We review our cash-generating units, or CGUs, for impairment whenever events or changes in circumstances (triggering events) indicate that the carrying amount of such CGUs may not be recoverable. In those cases, an impairment to our non-financial assets, including intangible assets and property, plant and equipment might be recognized. The amount of goodwill, intangible assets and property, plant and equipment on our consolidated balance sheet may increase following acquisitions or other collaboration agreements. Changes in market conditions or other changes in the future outlook of value may lead to significant impairments in the future.

The market price of our ADSs has been, and may continue to be, highly volatile, and such volatility could cause the market price of our ADSs to decrease and could cause you to lose some or all of your investment in our ADSs.

 

During the first quarter of 2021,2023, the market price of our common stock fluctuated from a high of $17.89$3.28 per shareADS to a low of $7.88$2.21 per ADS, has fluctuated even more in past years and our share price continues to fluctuate. The market price of our ADSs may continue to fluctuate significantly in response to numerous factors, some of which are beyond our control, such as:

 

our ability to grow our revenue and customer base;

 

the announcement of new products or product enhancements by us or our competitors;

 


variations in our and our competitors’ results of operations;

 

successes or challenges in any future collaborative, licensing, or other arrangements or alternative funding sources;

 

developments in the AME / PEadditive manufacturing of electronics, additive manufacturing, surface-mount technology, industrial digital printing and printed electronics (PE) industries;

 

future issuances of ADSs or other securities;

 

the addition or departure of key personnel;

 

announcements by us or our competitors of acquisitions, investments or strategic alliances; and

 

general market conditions and other factors, including factors unrelated to our operating performance and the effects of the COVID-19 pandemic.performance;

 

the Israel-Hamas war; and

shareholder activism.


These and other market and industry factors may cause the market price and demand for our ADSs to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of our ADSs. In addition, the stock market in general, and technology-based companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a security has been volatile, holders of that security have sometimes instituted securities class action litigation against the issuer. If any of the holders of our ADSs were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our senior management would be diverted from the operation of our business. Any adverse determination in litigation could also subject us to significant liabilities.

 

We maintain our cash at financial institutions, some in balances that exceed federally insured limits.

A portion of our cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held in non-interest-bearing and interest-bearing operating accounts may exceed the Federal Deposit Insurance Corporation, or FDIC, insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. The FDIC took control of one such banking institution, Silicon Valley Bank, or SVB, on March 10, 2023 though we did not lose any assets due to this event. The FDIC also took control of Signature Bank on March 12, 2023, though we do not hold any accounts at this bank.

On March 13, 2023, the U.S. Federal Reserve announced that account holders would not bear the loss of SVB’s collapse and since that time, we have been able to make payments and move all of the funds held in SVB to other banks in the United States. Thus, we do not view the risk as material to our financial condition. However, as the FDIC continues to address the situation with SVB, Signature Bank and other similarly situated banking institutions, the risk of loss in excess of insurance limitations has generally increased. Any material loss that we may experience in the future could have an adverse effect on our ability to pay our operational expenses or make other payments and may require us to move our accounts to other banks, which could cause a temporary delay in making payments to our vendors and employees and cause other operational inconveniences.

Risks Related to Our Business and Industry

 

We depend entirely onhave been engaged, and will continue to engage, in mergers and acquisitions to diversify or expand our business, which may pose risks to our business and dilute the commercial successownership of our DragonFly LDM system and ink products,existing shareholders, and we may not be able to successfully scale up their commercialization.realize the anticipated benefits of these mergers or acquisition.

 

We have invested the majorityAs part of our effortsgrowth and product diversification strategy, we have engaged in mergers and acquisitions and will continue to evaluate opportunities to acquire or invest in other businesses or existing businesses, intellectual property or technologies and expand the breadth of markets we can address or enhance our technical capabilities. For example, we acquired all of the issued and outstanding share capital of DeepCube and NanoFabrica in April 2021, all of the issued and outstanding share capital of Essemtec in November 2021, all of the issued and outstanding share capital of GIS in January 2022, all of the issued and outstanding share capital of Formatec Holding in July 2022. In addition, we have purchased all of the intellectual property assets of The Plastic Economy, D.B.A. Additive Flow, or Additive Flow, a U.K.-based company, in August 2023. Mergers or acquisitions, such as the DeepCube, NanoFabrica, Essemtec, GIS, Formatec Holding share acquisitions, and the Additive Flow asset acquisition that we have entered into and may enter into in the future entail a number of risks that could materially and adversely affect our business, operating and financial results, including, among others:

problems integrating the acquired operations, technologies or products into our existing business and products;

diversion of management’s time and attention from our core business;

adverse effect on our existing business relationships with customers;

need for financial resources above our planned investment levels;

failures in realizing anticipated synergies;

difficulties in retaining business relationships with suppliers and customers of the acquired company;

risks associated with entering markets in which we lack experience;

risks with respect to impairment charges following acquisitions;

potential loss of key employees of the acquired company; and

potential write-offs of acquired assets.

Our failure to address these risks successfully may have a material adverse effect on our financial condition and results of operations. Any such acquisition or investment will likely require a significant amount of capital investment, which would decrease the research and developmentamount of cash available for working capital or capital expenditures. In addition, if we use our equity securities to pay for acquisitions, the value of our products. ADSs and the underlying Ordinary Shares may be diluted. If we borrow funds to finance acquisitions, such debt instruments may contain restrictive covenants that can, among other things, restrict us from distributing dividends.


Additionally, from March through May 2023, we made several non-binding offers to acquire all of the outstanding ordinary shares of Stratasys Ltd., or Stratasys. After not proceeding with these offers to acquire all ordinary shares, we made a series of special tender offers from May through July 2023 to acquire at least 51% of the outstanding shares, inclusive of the 14.1% that we already owned. The offers were dependent on a number of closing conditions being met. As these conditions were not met, we did not complete the special tender offers. In December 2023, we made an additional offer to buy all remaining shares of Stratasys, which has not yet been accepted, for $16.50 per share. The proposal was subject to the completion of a satisfactory confirmatory due diligence process and the negotiation and execution of a mutually satisfactory definitive acquisition agreement. There is no guarantee that the offer will be accepted or that an acquisition will be completed. Even if it is, the acquisition may deplete our cash and our resources. Additionally, a potential acquisition would require significant attention from our senior management and could divert their attention away from the day-to-day management of our business, which could adversely affect our business, financial condition, and operating results.

As a result,part of our strategy, acquisitions are a key pillar. Our failure to invest/acquire on favorable terms and failure to realize expected results from investments and acquisitions may adversely affect our revenue growth and profitability.

As a part of our strategy focusing on synergetic mergers and acquisitions of systems, materials, software, AI, and solutions that build up to deliver comprehensive solutions to mutual verticals market segments, we may fail to analyze the acquired business is entirely dependentand its potential long-term effect on the business. Our success depends on our ability to successfully commercialize our DragonFly LDM systemanalyze, integrate, and ink products. In the fourth quarter of 2017, we initiated commercial sales of our DragonFly LDM system. We cannot assure you that our commercialization efforts will lead to meaningful sales of our products.acquire at favorable terms.

 

We may not be able to introduce products acceptable to customers and we may not be able to improve the technology used in our current systems in response to changing technology and end-user needs.

 

The markets in which we operate are subject to rapid and substantial innovation and technological change, mainly driven by technological advances and end-user requirements and preferences, as well as the emergence of new standards and practices. Our ability to compete in the 3Dadditive manufacturing, industrial digital printing and PCBelectronics manufacturing markets will depend, in large part, on our future success in enhancing our existing products and developing new 3D printing systemsadditive manufacturing solutions and consumables that will address the increasingly sophisticated and varied needs of prospective end-users, and respond to technological advances and industry standards and practices on a cost-effective and timely basis or otherwise gain market acceptance.

 

It is likelypossible that new systems and technologies that we develop will eventuallymay supplant our existing systems or that our competitors willmay create highly competitive systems that will replace our systems.to ours. As a result, anyour existing products may be less economically beneficial.

We depend on the commercial success of selling our advanced manufacturing products and services and we may not be able to successfully scale up their commercialization.

We have invested significant efforts and financial resources in the research and development of our products. Our performance will depend highly on our ability to commercialize our products successfully and the degree of market acceptance of our products may be rendered obsolete or uneconomical byand solutions. We cannot assure you that our or others’ technological advances.commercialization efforts will lead to a meaningful, continued increase in sales of our products.

 

We may not be able to successfully manage our planned growth and expansion.

 

We expect to continue to make investments inacross our DragonFly LDM systemportfolio of products and services along with our related ink products. We expectgo-to-market platform that ourengages and delivers these to customers. Our annual operating expenses will continue tomay increase as we invest in sales and marketing, research and development, manufacturing and production infrastructure, and develop customer service and support resources for future customers. Our failure to expand operational and financial systems timely or efficiently could result in operating inefficiencies, which could increase our costs and expenses more than we had planned and prevent us from successfully executing our business plan. We may not be able to offset the costs of operation expansion by leveraging the economies of scale from our growth in negotiations with our suppliers and contract manufacturers. Additionally, if we increase our operating expenses in anticipation of the growth of our business and this growth does not meet our expectations, our financial results will be negatively impacted.

 


IfAs our business grows, we will have to manage additional product design projects, materials procurement processes, and sales efforts and marketing for an increasing number of products, as well as expand the number and scope of our relationships with suppliers, distributors and end customers. If we fail to manage these additional responsibilities and relationships successfully, we may incur significant costs, which may negatively impact our operating results. Additionally, in our efforts to be first to market with new products with innovative functionality and features, we may devote significant research and development resources to products and product features for which a market does not develop quickly, or at all. If we are not able to predict market trends accurately, we may not benefit from such research and development activities, and our results of operations may suffer.


 

As our future development and commercialization plans and strategies develop further, we expect tomay need additional managerial, operational, sales, marketing, financial and legal personnel. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, failure to deliver and timely deliver our products to customers, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional new products. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced, and we may not be able to implement our business strategy.

 

Our operating results and financial condition may fluctuate.

 

Even if we are successful in introducing our products to the market, the operating results and financial condition of our company may fluctuate from quarter to quarter and year to year and are likely to continue to vary due to a number of factors, many of which will not be within our control. If our operating results do not meet the guidanceinformation that we provide to the market placemarketplace or the expectations of securities analysts or investors, the market price of our Ordinary SharesADSs will likely decline. Fluctuations in our operating results and financial condition may be due to a number of factors, including those listed below and those identified throughout this “Risk Factors” section:

 

the degree of market acceptance of our products and services;

 

the mix of products and services that we sell during any period;

 

long sales cycles;

 

changes in the amount that that we spend to develop, acquire or license new products, consumables, technologies or businesses;

 

changes in the amounts that we spend to promote our products and services;

 

changes in the cost of satisfying our warranty obligations and servicing our installed base of systems;

 

delays between our expenditures to develop and market new or enhanced systems and consumables and the generation of sales from those products;

 

development of new competitive products and services by others;

 

difficulty in predicting sales patterns and reorder rates that may result from a multi-tier distribution strategy associated with new product categories;

 

 litigation or threats of litigation, including intellectual property claims by third parties;parties and shareholder claims;

 

changes in accounting rules and tax laws;

 

the geographic distribution of our sales;

 


our responses to price competition;

 

general economic and industry conditions that affect end-user demand and end-user levels of product design and manufacturing;

 


changes in interest rates that affect returns on our cash balances and short-term investments;

 

changes in dollar-shekelU.S. dollar-NIS exchange rates that affect the value of our net assets, future revenues and expenditures from and/or relating to our activities carried out in those currencies; and

 

 the level of research and development activities by our company.us.

 

Due to all of the foregoing factors, and the other risks discussed in this annual report on Form 20-F, you should not rely on quarter-to-quarter comparisons of our operating results as an indicator of our future performance.

 

The markets in which we participate are competitive. Our failure to compete successfully could cause any future revenues and the demand for our products not to materialize or to decline over time.

 

We aim toGiven that we have a diverse portfolio of products, we compete for customers with a wide variety of manufacturers that createfabricate specialty industrial applications as well as original equipment manufacturers. In general, these applications can be segregated into two categories. The first is high-performance electronic devices (Hi-PEDs®); mainly printed circuit boards, or PCBs, and RF antennas.electronic components. The second is advanced mechanical components; mainly high precision and sophisticated polymer, ceramic, metal, and composite applications. Our principal current competition consists of companies that produce prototype PCBs by traditional reductive manufacturing means, which include etching, pressing and drilling. Many of these companiescompetitors usually have extensive track records and relationships within thetheir respective domains. With regard to our electronics industry. While webusinesses, our competitors are not aware of any other company that currently offers an in-house 3D printer that is capable of printing multilayer PCBs,electronics design and manufacturing firms. For our mechanical components businesses, our competitors are parts manufacturers. In both domains, there are a large number of companies engaged in additive manufacturing and 3D printing solutions.incumbents operating traditional technologies, as well as new entrants bringing disruptive technologies to the market.

 

Many of our current and potential competitors have longer operating histories and more extensive name recognition than we have and may also have greater financial, marketing, manufacturing, distribution and other resources than we have. Current and future competitors may be able to respond more quickly to new or emerging technologies and changes in end-user demands and to devote greater resources to the development, promotion and sale of their products than we can. Our current and potential competitors may develop and market new technologies that render our existing or future products obsolete, unmarketable or less competitive (whether from a price perspective or otherwise). We cannot assure you that we will be able to maintain a competitive position or to compete successfully against current and future sources of competition.

 

Defects in products could give rise to product returns or product liability, warranty or other claims that could result in material expenses, diversion of management time and attention, and damage to our reputation.

 

Even if we are successful in introducing our products to the market, our products may contain undetected defects or errors that, despite testing, are not discovered until after a product has been used. This could result in delayed market acceptance of those products, claims from distributors, end-users or others, increased end-user service and support costs and warranty claims, damage to our reputation and business, or significant costs to correct the defect or error. We may from time to time become subject to warranty or product liability claims that could lead to significant expenses as we need to compensate affected end-users for costs incurred related to product quality issues.

 

This risk of product liability claims may also be greater due to the use of certain hazardous chemicals used in the manufacture of certain of our products. In addition, we may be subject to claims that our additive manufacturing systems have been, or may be, used to create parts that are not in compliance with legal requirements.

 

Any claim brought against us, regardless of its merit, could result in material expense, diversion of management time and attention, and damage to our reputation, and could cause us to fail to retain or attract customers. Currently, we maintain minimal product liability insurance. Our product liability insurance is subject to significant deductibles and there is no guarantee that such insurance will be available or adequate to protect against all such claims. Costs or payments made in connection with warranty and product liability claims and product recalls or other claims could materially affect our financial condition and results of operations.

 


If we are unable to continue to improve our AI models or if our AI models contain errors or are otherwise ineffective, our business, financial condition, and results of operations may be adversely affected.

As we have made efforts to take our in-house AI from DeepCube and commercialize it into a product available for external customers, our ability to attract new customers, retain existing customers, or increase sales of our products to existing customers will to a growing extent depend on our ability to maintain a high degree of accuracy and automation in our advanced computer vision and on our other algorithms and technologies. As with many developing technologies, AI presents risks and challenges that could affect our products’ further development, adoption, use, and therefore, our business. AI algorithms may be flawed, and data sets may be insufficient, or of poor quality, or contain biased information. Inappropriate or controversial data practices by data scientists, engineers, and end-users of our systems could impair the acceptance of AI solutions. If the analyses that AI applications assist in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability, and brand or reputational harm. For example, if our AI models fail to accurately analyze and detect upcoming machine failure, or any of the other components of our advanced computer vision fail, we may experience higher than forecasted returns, and our ability to attract new customers, retain existing customers, or increase sales of our products to existing customers and our business, financial condition, and results of operations may be adversely affected.

It is possible that our AI models may prove to be less accurate than we expect, or than they have been in the past, for a variety of reasons, including inaccurate assumptions or other errors made in building or training such models, incorrect interpretations of the results of such models, and failure to timely update model assumptions and parameters. Further, the successful performance of our AI models relies on the ability to constantly review and process large amounts of data. If we are unable to attract new customers, retain existing customers, or increase sales of our products to existing customers, the amount of data reviewed and processed by our AI models will be reduced or fail to grow at a pace that will allow us to continue to maintain or improve the accuracy and efficiency of our AI models. Additionally, such models may not be able to effectively account for matters that are inherently difficult to predict or are otherwise beyond our control, such as personal preferences that may not align with AI data. Material errors or inaccuracies in such AI models could lead our customers, both internal and external to make inaccurate or sub-optimal operational or strategic decisions, which could adversely affect our business, financial condition, and results of operations.

As the regulatory framework for AI technology evolves, our business, financial condition, and results of operations may be adversely affected.

Our business is increasing its reliance on AI products. However, in recent years, use of these methods has come under increased regulatory scrutiny, and the regulatory framework for AI technology is evolving and remains uncertain. It is possible that new laws and regulations will be adopted in the United States and in non-U.S. jurisdictions, or that existing laws and regulations may be interpreted in new ways, that would affect the operation of our Industrial AI solutions business and the way in which we can sell AI based technologies. Specifically, such laws and regulations may limit our ability to use our AI models or require us to make changes to our operations that may decrease our operational efficiency, result in an increase to operating costs, or hinder our ability to improve our services. Further, the cost of complying with such laws, rules, or regulations could be significant and would increase our operating expenses, which could adversely affect our business, financial condition, and results of operations.

Any failure or perceived failure by us to comply with AI technology-related laws, rules, and regulations could result in proceedings or actions against us by individuals, consumer rights groups, government agencies, or others. We could incur significant costs in investigating and defending such claims and, if found liable, pay significant damages or fines or be required to make changes to our business. Further, these proceedings and any subsequent adverse outcomes may subject us to significant negative publicity, and an erosion of trust. If any of these events were to occur, our business, results of operations, and financial condition could be adversely affected.

If our relationships with suppliers for our products and services, especially with single source suppliers of components of our products, were to terminate or our manufacturing arrangements were to be disrupted, our business could be interrupted.

 

We purchase component parts and raw materials that are used in our DragonFly LDM systemproducts and ink productsservices from third-party suppliers, some of whom may compete with us. While there are several potential suppliers of most of these component parts and raw materials that we use, we currently choose to use only one or a limited number of suppliers for several of these components and materials. Our reliance on a single or limited number of vendors involves a number of risks, including:

 

potential shortages of some key components;

 

product performance shortfalls, if traceable to particular product components, since the supplier of the faulty component cannot readily be replaced;

 


discontinuation of a product on which we rely;

 

potential insolvency of these vendors; and

 

reduced control over delivery schedules, manufacturing capabilities, quality and costs.

 

In addition, we require any new supplier to become “qualified” pursuant to our internal procedures. The qualification process involves evaluations of varying durations, which may cause production delays if we were required to qualify a new supplier unexpectedly. We generally assemble our systems and parts based on our internal forecasts and the availability of raw materials, assemblies, components and finished goods that are supplied to us by third parties, which are subject to various lead times. If certain suppliers were to decide to discontinue production of an assembly, component or raw material that we use, the unanticipated change in the availability of supplies, or unanticipated supply limitations, could cause delays in, or loss of, sales, increased production or related costs and consequently reduced margins, and damage to our reputation. If we were unable to find a suitable supplier for a particular component, material or compound, we could be required to modify our existing products or the end-parts that we offer to accommodate substitute components, material or compounds.

 

Discontinuation of operations at our manufacturing sites could prevent us from timely filling customer orders and could lead to unforeseen costs for us.

 

We currently assemble and test the systems that we sell, and produce consumables for our systems at a single facility.in two major facilities in Israel. Because of our reliance on all of these production facilities, a disruption at any of those facilities could materially damage our ability to supply systems or consumable materials to the marketplace in a timely manner. Depending on the cause of the disruption, we could also incur significant costs to remedy the disruption and resume product shipments. Such disruptions may be caused by, among other factors, war, earthquakes, fire, flood and other natural disasters. Accordingly, any such disruption could result in a material adverse effect on our revenue, results of operations and earnings, and could also potentially damage our reputation.

 

Our international operations expose us to additional market and operational risks, and failure to manage these risks may adversely affect our business and operating results.

 

We derive a substantial percentage of our sales from international markets. Accordingly, we face significant operational risks from doing business internationally, including:

 

fluctuations in foreign currency exchange rates;

 

potentially longer sales and payment cycles;

 

potentially greater difficulties in collecting accounts receivable;

 

potentially adverse tax consequences;

 

reduced protection of intellectual property rights in certain countries, particularly in Asia and SouthLatin America;

 

difficulties in staffing and managing foreign operations;

 

laws and business practices favoring local competition;

 


costs and difficulties of customizing products for foreign countries;

 

compliance with a wide variety of complex foreign laws, treaties and regulations;

 

an outbreak of a contagious disease, such as COVID-19, which may cause us, third party vendors and manufacturers and/or customers to temporarily suspend our or their respective operations in the affected city or country;

 

tariffs, trade barriers and other regulatory or contractual limitations on our ability to sell or develop our products in certain foreign markets; and

 

being subject to the laws, regulations and the court systems of many jurisdictions.jurisdictions; and

 

general market, political and economic conditions in the countries in which we operate including those related to recent unrest and actual or potential armed conflict in Israel and other parts of the world, such as the Russia-Ukraine war.


Our failure to manage the market and operational risks associated with our international operations effectively could limit the future growth of our business and adversely affect our operating results.

 

Under applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees.

 

We generally enter into non-competition agreements with our employees. These agreements prohibit our employees from competing directly with us or working for our competitors or clients for a limited period after they cease working for us. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict our competitors from benefiting from the expertise that our former employees or consultants developed while working for us. For example, Israeli courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer that have been recognized by the courts, such as the secrecy of a company’s confidential commercial information or the protection of its intellectual property. If we cannot demonstrate that such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees or consultants and our ability to remain competitive may be diminished.

 

We are subject to environmental laws due to the import and export of our products, which could subject us to compliance costs and/or potential liability in the event of non-compliance.

 

The export of our products internationally from our production facilities subjects us to environmental laws and regulations concerning the import and export of chemicals and hazardous substances such as the U.S. Toxic Substances Control Act and the Registration, Evaluation, Authorization and Restriction of Chemical Substances. These laws and regulations require the testing and registration of some chemicals that we ship along with, or that form a part of, our systems and other products. If we fail to comply with these or similar laws and regulations, we may be required to make significant expenditures to reformulate the chemicals that we use in our products and materials or incur costs to register such chemicals to gain and/or regain compliance. Additionally, we could be subject to significant fines or other civil and criminal penalties should we not achieve such compliance.

 

Our future success depends in part on our ability to retain our executive officers and to attract, retain and motivate other qualified personnel.

 

We are highly dependent on Yoav Stern, our President and Chief Executive Officer Amit Dror,and a member of the board of directors, Zivi Nedivi, our Customer Success Officer and Zvi Peled,President, Tomer Pinchas, our Chief RevenueOperating Officer and Chief OperationFinancial Officer, and Nick Geddes, our Chief Technology Officer. The loss of their services without a proper replacement may adversely impact the achievement of our objectives. Messrs. Stern, Dror,Nedivi, Pinchas, and PeledGeddes may leave our employment at any time subject to contractual notice periods, as applicable. Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled personnel in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition in the industry in which we operate. The inability to recruit and retain qualified personnel, or the loss of the services of our executive officers, without proper replacement, may impede the progress of our development and commercialization objectives. There is no assurance that any equity or other incentives that we grant to our employees will be adequate to attract, retain and motivate employees in the future. Moreover, certain of our competitors or other technology businesses may seek to hire our employees.

 


We face business disruption and related risks resulting from the COVID-19 pandemic, which has had a material adverse effect onmay not be able to integrate our business and results of operations.acquisitions efficiently.

 

Our operationsWe have acquired six businesses in the past three years. Further, we may engage in additional acquisitions such as of Stratasys or other businesses. The management team and businessemployees of Nano Dimension have been disrupteddedicated and adversely affected by COVID-19. The pandemic has caused stateswill continue to dedicate effort and resources to our successful commercial and technological integration of emergency to be declared in various countries, travel restrictions imposed globally, quarantines established in certain jurisdictions and various institutions and companies being closed. The COVID-19 has also adverselythe acquired companies. An ineffective integration may affect our ability to conduct our business effectively due to disruptions to our capabilities, availabilityrevenue forecasts and productivity of personnel, while we simultaneously attempt to comply with rapidly changing restrictions, such as travel restrictions, curfews and others. In particular, in January 2021, the Government of Israel announced that non-Israeli residents or citizens, except for non-nationals whose lives are based in Israel, are not allowed to enter Israel, and the number of Israeli citizens permitted to enter the country per day will be capped at 3,000. In addition, the Ministry of Health in the State of Israel issued guidelines in March 2020, which were most recently updated in March 2021, recommending people avoid gatherings in one space and providing that no gathering of more than 20 people should be held under any circumstances.profitability.

 

Employers (including us) are also required to prepare and increase as much as possible the capacity and arrangement for employees to work remotely. In addition, the U.S. government has restricted travel to the United States from foreign nationals who have recently been in China, Iran, South Africa, and certain European and Latin America countries. Although to date these restrictions have not impacted our operations other than the delay of one of our trials, the effect on our business, from the spread of COVID-19 and the actions implemented by the governments of the State of Israel, the United States and elsewhere across the globe, may worsen over time.


 

The spread of COVID-19 may also result in the inability of our suppliers to deliver supplies to us on a timely basis. In addition, we derive a certain portion of our revenue from the Asia-Pacific region. As a result of COVID-19, particularly in Asia, our sales and operations, and those of our customers and suppliers, have experienced delays or disruptions, such as difficulty obtaining components and temporary delay in sales. Although, as of the date of this annual report on Form 20-F, we do not expect any material impact on our long-term activity, the extent to which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. We are actively monitoring the pandemic and we are taking any necessary measures to respond to the situation in cooperation with the various stakeholders.

 

Risks Related to Our Intellectual Property

 

If we are unableLack of patent protection may hinder our market competitiveness and failure to obtain and maintain effective patent rights for our products, we may not be able to compete effectively in our markets. If we are unable to protect the confidentiality of oursafeguard trade secrets or know-how, suchcould enable competition to use our proprietary information may be used by others to compete against us.information.

 

Since October 2014, we have sought patent protection forto protect certain of our products, systems, designs and applications.applications with various intellectual property protection tools such as patents, trade secrets, trademarks and copyright protection. Our continued success depends in large part on our ability to obtain, maintain, monitor and enforce patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and new products.

 

We have sought to protect our proprietary position and sustain our competitive advantage by filing patent applications in the United States and in other countries, including where our major production and sales take place.place, and in those countries where our suppliers and main competitors are. Patent prosecution in the United States and the rest of the world is uncertain, expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.

 

We have a substantial and growing intellectual property portfolio, of 64 provisionalincluding over 100 patents issued worldwide and non-provisionalnearly 200 pending patent applications, with a robust pipeline. These are filed withapplications. Filed through the U.S. Patent and Trademark Office, or USPTO, the World Intellectual Property Organization, or WIPO, and variousother global patent offices, around the world, such asthese patents cover various regions including China, Japan, Taiwan, Europe, and South Korea. The patent applications, where available, were filed through the Paris Convention Treaty, or PCT,While some patents have already been issued, uncertainties remain regarding pending applications’ issuance, protection scope, and nine for which we have issued U.S., Chinese, and South Korean patents, with three more applications that were indicated as allowed but have not issued yet. We cannot offer any assurances about which, if any of the pending patent applications will issue, the scope of protection of any such patent or whether any issued patents will be found invalid and/or unenforceable or will be threatened bypotential challenges from third parties.parties, impacting commercialization prospects. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any new products that we may develop.

 


We have two patents and their continuations and foreign counterparts licensed exclusively from the Hebrew University covering someFurthermore, there is no guarantee of our underlying core technology. To the extent the licenseddiscovering all relevant prior art, which could invalidate patents. Even if patents are foundissued, challenges from third parties may lead to be invalidnarrowing, unenforceability, or unenforceable, we may be limited in ourinvalidation. Patents might not sufficiently protect intellectual property, affecting competition and business adversely. Our ability to compete and market our products. The terms of our license with Hebrew University leave full control of any and all enforcement of the licensed patents with Hebrew University. If Hebrew University elects to not enforce any or all of the licensed patents it could significantly undercut the value of any of our products, which would materially adversely affect our future revenue, financial condition and results of operations. Moreover, fluctuating currency rates may create inconsistencies in the royalty payments we have under the license.

Further, there is no assurance that all potentially relevant prior art relating to our patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our products, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patent applications and any future patents may not adequately protect our intellectual property, provide exclusivity for our new products, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impacteffectively depends on our business.

If we cannot obtain and maintainmaintaining effective patent rights for our products, we may not be ablefailure of which could result in our inability to compete effectively, andthereby potentially harming our business and results of operations would potentially be harmed.operations.

 

If we are unableInability to maintain effective proprietary rights for our products, we may not be ableaffect our ability to compete effectively in our markets.effectively.

 

In addition to the protection afforded by anyApart from patents, currently owned and that may be granted, historically, we have reliedalso rely on trade secret protectionsecrets and confidentiality agreements to protect certain non-patentable proprietary know-how, that is not patentable or that we elect not to patent, processes, and helpful devices (jigs) that are not easily known, knowable or easily ascertainable, and for which patent infringement is difficult to monitor and/or enforce and any other elements of our product development processes, that involve proprietary know-how, as well as information or technology that is not covered by patents.devices. However, trade secretssecret protection can be difficultchallenging. We employ confidentiality agreements and other security measures to protect. We seek to protectsafeguard our proprietary technology and processes, in part,data. Nevertheless, breaches or independent discoveries by entering into confidentiality agreements withcompetitors may potentially impact our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data, trade secrets and intellectual property by maintaining physical security ofrights and consequently our premisesbusiness integrity. We cannot guarantee protection against disclosure or competitors’ access to our trade secrets. Unauthorized disclosure or misappropriation could harm our competitiveness and physical and electronic security ofbusiness, while inadequate protection measures may limit recourse against third-party misappropriation, affecting our information technology systems, as well as implementing various operating procedures designed to maintain that integrity.trade secrets’ security. Agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently discovered by competitors.

 

We cannot provide any assurances that our trade secrets and other confidential proprietary information will not be disclosed in violation of our confidentiality agreements or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets andagreements. Third-party intellectual property could impairrights may hinder our competitive positionproduct commercialization, necessitating litigation or licensing, potentially costly or unattainable on reasonable terms. Likewise, identifying all relevant third-party patents or applications is challenging, compounded by U.S. confidentiality rules and publication delays worldwide. Others may have a material adverse effect onfiled patents covering our business. Additionally, if the steps takentechnology without our knowledge, while amendments to maintain our trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secret.

Intellectual property rights of third partiespublished applications could adversely affect us. Third parties may assert infringement claims, leading to costly litigation, delays, or product redesigns. Claims’ settlement may be uncertain, while failure could result in prolonged, expensive legal battles preventing commercialization of our abilityproducts.

Moreover, freedom to successfully commercializeoperate may be challenging to ensure without infringing on third-party rights, potentially affecting our competitive position. Should third-party patents cover our products, and we might be required to litigate or obtain licenses from third parties in order to develop or market our product candidates. Such litigation or licensing may be necessary for further development. Uncertainty exists regarding potential infringement claims, which could lead to significant damages, product abandonment, or costly licensing agreements. Availability of licenses could be costly or not available on commercially reasonable terms.terms is also uncertain.

 

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

It is inherently difficult to conclusively assess our freedom to operate without infringing on third party rights. Our competitive position may be adversely affected if existing patents or patents resulting from patent applications issued to third parties or other third partythird-party intellectual property rights are held to cover our products or elements thereof, or our manufacturing or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize products or our product candidates unless we successfully pursue litigation to nullify or invalidate the third partythird-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may also be pending patent applications that if they result in issued patents, could be alleged to be infringed by our new products. If such an infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our new products or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.

 


It is also possible that we have failed to identify relevant third party patents or applications. For example, U.S. patent applications filed before September 29, 2018 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our new products or platform technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our new products or the use of our new products. Third party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in pursuing the development of and/or marketing our new products. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing our new products that are held to be infringing. We might, if possible, also be forced to redesign our new products so that we no longer infringe the third party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.

 

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

 

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing new products. As our industries expand and more patents are issued, the risk increases that our products may be subject to claims of infringement of the patent rights of third parties.

Third parties may assert that we are employing their proprietary technology without authorization. There may beAny third-party patents or patent applications with claims to materials, designs or methods of manufacture related to the use or manufacture of our products. There may be currently pending patent applications that may later result in issued patents that our products may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.

If any third-party patents were held by a court of competent jurisdictioncourt to cover aspects of our formulations, processes foror designs, or methods of use, may enable the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidatecandidates unless we obtain a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case,Regardless, such a license may not be available on commercially reasonable termsat all. In addition, third parties’ claims against us may secure injunctions, halting product development. Defending these claims, regardless of merit, is costly and diverts resources. Successful infringement claims could lead to substantial damages, royalties, product redesign, or at all.challenging licensing agreements.

 

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our products. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

 

Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.

 

Changes in either the patent laws or interpretation of the patent lawstheir interpretations, in the United StatesU.S. and other countries may diminish the value of any patents that may issue from our patent applications, or narrowglobally, might affect the scope of our patents. Foreign laws may offer less protection. Scientific discoveries are often published after patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore cannot be certain thatfilings, making it uncertain if we were the first to file the invention claimedclaim these. Changes in our owned and licensed patent or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming all other requirements for patentability are met, in the United States prior to 2013, the first to make the claimed invention without undue delay in filing, was entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. Since 2013, the United States has moved to a first to file system. Changes in the way patent applications will be prosecuted could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents, all of whichprocedures could have a material adverse effect on our business and financial condition.condition and could further heighten uncertainties and costs, impacting our business and finances.

 


We may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming, and unsuccessful.

 

Competitors maymight infringe our intellectual property. If we were to initiatepursue legal proceedings against a third party to enforce a patent covering one of our new products, the defendantaction, they could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability, are commonplace. Grounds for a validity challengecommon in U.S. patent litigation. Challenges could be an alleged failure to meet any of several statutory requirements, includinginclude lack of novelty obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecutionlack of theinventive step. Post-grant proceedings add further uncertainty to patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The validity, of U.S. patents may also be challenged in post-grant proceedings before the USPTO. The outcome followingmaking legal assertions of invalidity and unenforceability isoutcomes unpredictable.

Derivation Likewise, derivation proceedings, initiated by third parties or brought by us, may be necessary to determine theresolve invention priority of inventions and/or their scope with respect to our patent or patent applications or thosescope disputes not in our favor, which may halt technology use, require costly licensing and harm business, diverting resources and funds from research and development partnerships. Furthermore, intellectual property litigation entails extensive discovery, risking disclosure of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms.confidential information. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our new products to market.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be publicPublic announcements of theproceedings’ results of hearings, motions, or other interim proceedings or developments. Ifcould negatively affect our share price if perceived unfavorably by securities analysts and/or investors, perceive these results to be negative, itand could have a material adverse effect on the price of our Ordinary Shares.

 

We are exposed to intellectual property risks from current and former employees and/or collaborators.

We have been subject, and may in the future be subject to further claims that our employees, consultants, or independent contractors have wrongfully or unavoidably used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

In theexperienced past we have been subject to litigation disputes involving theover intellectual property ownership, of our intellectual property. Inincluding a 2015 a claim was filed in the District Court in Tel-Aviv JaffaTel Aviv alleging that certain ofmisappropriation by our officers and employees misappropriated commercial secrets and technology while employed atfrom a previous employer. While this claim was settled without material effects to ourmajor business impact, we continue to employ individuals who were previously employed at ourthat came from competitors, or potential competitors. We try to ensure that our employees, consultants, and independent contractors do notnecessitating safeguards against inadvertent use theof others’ proprietary information or know-how of others in their work for us, but we may nevertheless be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employees’ former employers or other third parties.information. Litigation may result and be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defendingdefense against such claims, litigationsuccessful or not, entails substantial costs and management distractions. Additionally, we may face claims from former employees or collaborators asserting rights to compensation or ownership in our patents or intellectual property. Disputes may arise over conflicting obligations, requiring litigation; the failure to defend that could result in substantial costs and be a distraction toloss of intellectual property rights. Successful defense, while costly, could still distract management and other employees.

We may be subject to claims challenging the inventorship of our intellectual property.

We may be subject to claims that former employees, collaborators or other third parties have an interest in, or right to compensation, with respect to our current patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our products. Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

 


We may not be able to protect our intellectual property rights throughout the world.

 

Filing, prosecuting,Securing and defendingprotecting patents onglobally for our products as well as monitoring their infringement in all countries throughout the world would be prohibitively expensive, and our intellectualprocesses is financially daunting. Intellectual property rights in some countries can beare less extensivestringent than those in the United States. In addition, the laws of some foreign countries do not protectU.S., allowing competitors to exploit our technologies. Competing products developed or exported in jurisdictions with weaker enforcement may undermine our market position despite future patent efforts. Protecting intellectual property rights to the same extent as federal and state laws in the United States.

Competitors may use our technologiesabroad can be challenging, especially in jurisdictions where we have not obtained patent protection to develop their own products and may also export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products. Future patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement ofare less favorable to enforcement. This difficulty may allow competitors to market products infringing on our rights. Enforcing patents trade secrets, and other intellectual property protection, which could make it difficult for us to stop the marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantialoverseas can incur significant costs and divert our efforts and attention from other aspects of our business,resources. Moreover, such proceedings could put ourrisk invalidating or narrowing future patents, at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly,potentially inviting counterclaims. Overall, our efforts to monitor and enforce oursafeguard intellectual property rights around the worldglobally may be inadequate to obtain a significantnot yield substantial commercial advantage from the intellectual property that we develop or license.advantage.

 

Risks Related to the Ownership of Ourthe ADSs or our Ordinary Shares

 

We do not anticipate paying any dividends.dividends, except as related to the repurchase of our Ordinary Shares as provided under the Companies Law.

 

NoIn accordance with the provisions of the Israeli Companies Law 5759-1999, or the Companies Law, and the regulations promulgated thereunder, repurchase of shares is considered a dividend distribution. Except as detailed in Item 16E below, in relation to the repurchase of our Ordinary Shares, no dividends have been paid on our Ordinary Shares. We do not intend to pay cash dividends on our Ordinary Shares in the foreseeable future, and anticipate that profits, if any, received from operations will be reinvested in our business. Any decision to pay dividends will depend upon our profitability at the time, cash available and other relevant factors including, without limitation, the conditions set forth in the Israeli Companies Law of 1999, or the Companies Law.

The JOBS Act allows us to postpone the date by which we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information we provide in our reports filed with the SEC, which could undermine investor confidence in our company and adversely affect the market price of our ADSs or Ordinary Shares.

For so long as we remain an “emerging growth company” as defined in the JOBS Act, we intend to take advantage of certain exemptions from various requirements that are applicable to public companies that are not “emerging growth companies” including:

the provisions of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting; and
any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor’s report on the financial statements.

We intend to take advantage of these exemptions until we are no longer an “emerging growth company.” We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the date of our first sale of common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended, or the Securities Act, which will be December 31, 2021, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our Ordinary Shares that is held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

We cannot predict if investors will find our ADSs or Ordinary Shares less attractive because we may rely on these exemptions. If some investors find our ADSs or Ordinary Shares less attractive as a result, there may be a less active trading market for our ADSs or Ordinary Shares, and our market prices may be more volatile and may decline.

 


As a “foreign private issuer” we follow certain home country corporate governance practices instead of otherwise applicable SEC and Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.

 

Our status as a foreign private issuer also exempts us from compliance with certain SEC laws and regulations and certain regulations of the Nasdaq Stock Market, including the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent director oversight of the nomination of directors and executive compensation. In addition, we will not be required under the Securities Exchange Act of 1934, as amended, or the Exchange Act, to file current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act and we will generally be exempt from filing quarterly reports with the SEC. Also, although the Companies Law, requires us to disclose the annual compensation of our five most highly compensated senior officersoffice holders on an individual basis, this disclosure is not as extensive as that required of a U.S. domestic issuer. For example, the disclosure required under Israeli law would be limited to compensation paid in the immediately preceding year without any requirement to disclose option exercises and vested stock options, pension benefits or potential payments upon termination or a change of control. Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act.

 

These exemptions and leniencies will reduce the frequency and scope of information and protections to which you are entitled as an investor.

 

We may be a “passive foreign investment company”, or PFIC, for U.S. federal income tax purposes in the current taxable year2023 or may become one in any subsequent taxable year. There generally would be negativeadverse tax consequences for U.S. taxpayers that are holders of our ADSs or Ordinary Shares if we are or were to become a PFIC.

 

Based on the projected composition of our income and valuation of our assets, we do not expect tobelieve that we may be a PFIC for 2020, and2023, although we do not expectintend to become a PFIC in the future, although there can be noconduct an analysis to obtain assurance in this regard.of this. The determination of whether we are a PFIC is made on an annual basis and will depend on the composition of our income and assets from time to time. We will be treated as a PFIC for U.S. federal income tax purposes in any taxable year in which either (1) at least 75% of our gross income is “passive income” or (2) on average at least 50% of our assets by value produce passive income or are held for the production of passive income. Passive income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. The tests for determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets which are relevant to this determination. In addition, our PFIC status may depend in part on the market value of our ADSs or Ordinary Shares. Accordingly, because we do not intend to conduct an analysis to confirm our PFIC status, there can be no assurance that we currently are not or will not become a PFIC in the future. If we are a PFIC in any taxable year during which a U.S. taxpayer holds our ADSs or Ordinary Shares, such U.S. taxpayer would be subject to certain adverse U.S. federal income tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as a “qualified electing fund,” or QEF, or make a “mark-to-market” election, then “excess distributions” to the U.S. taxpayer, and any gain realized on the sale or other disposition of our ADSs or Ordinary Shares by the U.S. taxpayer: (1) would be allocated ratably over the U.S. taxpayer’s holding period for the ADSs or Ordinary Shares; (2) the amount allocated to the current taxable year and any period prior to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year. In addition, if the U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year with respect to which we have determined that we were not a PFIC,certain year, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election. U.S. taxpayers that have held our ADSs or Ordinary Shares during a period when we were a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto. We do not intend to notify U.S. taxpayers that hold our ADSs or Ordinary Shares if we believe we will be treated as a PFIC for any taxable year in order to enable U.S. taxpayers to consider whether to make a QEF election. In addition, we do not intend to furnish such U.S. taxpayers annually with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election for any year in which we or any of our subsidiaries are a PFIC. U.S. taxpayers that hold our ADSs or Ordinary Shares are strongly urged to consult their tax advisors about the PFIC rules, including tax return filing requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market election with respect to our ADSs or Ordinary Shares in the event that we are a PFIC. See “Item 10.E. Taxation — U.S. Federal Income Tax Considerations — Passive Foreign Investment Companies” for additional information.

 


ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable results to the plaintiff(s) in any such action.

 

The deposit agreement governing the ADSs representing our Ordinary Shares provides that holders and beneficial owners of ADSs irrevocably waive the right to a trial by jury in any legal proceeding arising out of or relating to the deposit agreement or the ADSs, including claims under federal securities laws, against us or the depositary to the fullest extent permitted by applicable law. If this jury trial waiver provision is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with a jury trial. To our knowledge, the enforceability of a jury trial waiver under the federal securities laws has not been finally adjudicated by a federal court. However, we believe that a jury trial waiver provision is generally enforceable under the laws of the State of New York, which govern the deposit agreement, by a court of the State of New York or a federal court, which have non-exclusive jurisdiction over matters arising under the deposit agreement, applying such law. In determining whether to enforce a jury trial waiver provision, New York courts and federal courts will consider whether the visibility of the jury trial waiver provision within the agreement is sufficiently prominent such that a party has knowingly waived any right to trial by jury. We believe that this is the case with respect to the deposit agreement and the ADSs. In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or counterclaim sounding in fraud or one which is based upon a creditor’s negligence in failing to liquidate collateral upon a guarantor’s demand, or in the case of an intentional tort claim (as opposed to a contract dispute), none of which we believe are applicable in the case of the deposit agreement or the ADSs. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any provision of the federal securities laws. If you or any other holder or beneficial owner of ADSs brings a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and / or the depositary. If a lawsuit is brought against us and / or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different results than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.

 

ADS holders may not have the same voting rights as the holders of our Ordinary Shares and may not receive voting materials in time to be able to exercise the right to vote.

 

Holders of the ADSs are not be able to exercise voting rights attaching to the Ordinary Shares underlying the ADSs on an individual basis. Instead, holders of the ADSs will only be able to exercise the voting rights attaching to the Ordinary Shares represented by ADSs indirectly by giving voting instructions to the depositary in accordance with and subject to the provisions of the deposit agreement. Holders of ADSs may not receive voting materials in time to instruct the depositary to vote, and it is possible that they, or persons who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote. Furthermore, the depositary will not be liable for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, you may not be able to exercise voting rights and may lack recourse if your ADSs are not voted as requested.

 

Holders of ADSs are not treated as shareholders of our Company.

Holders of ADSs are not treated as shareholders of our Company unless they withdraw the Ordinary Shares underlying the ADSs from Bank of New York Mellon, as depositary, which holds the Ordinary Shares underlying the ADSs. Holders of ADSs therefore do not have any rights as shareholders of our Company, other than the rights that they have pursuant to the deposit agreement with the depositary. For example, in your capacity as ADS holder, you will not be able to bring a derivative action, examine certain records of the Company or exercise appraisal rights.

ADS holders may be subject to limitations on transfer of their ADSs.

 

ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason in accordance with the terms of the deposit agreement.

 

ADS holders may not receive the same distributions or dividends as those we make to the holders of our Ordinary Shares, and, in some limited circumstances, they may not receive dividends or other distributions on our Ordinary Shares and they may not receive any value for them, if it is illegal or impractical to make them available to ADS holders.

 

The depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our Ordinary Shares or other deposited securities underlying the ADSs, after deducting its fees and expenses. You will receive these distributions in proportion to the number of Ordinary Shares your ADSs represent. However, the depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act of 1933, as amended, or the Securities Act, but that are not properly registered or distributed under an applicable exemption from registration. In addition, conversion into U.S. dollars from foreign currency that was part of a dividend or distribution made in respect of deposited Ordinary Shares may require the approval or license of, or a filing with, a government or an agency thereof, which may be unobtainable. In these cases, the depositary may determine not to distribute such property and hold it as “deposited securities” or may seek to effect a substitute dividend or distribution, including net cash proceeds from the sale of the dividends or distributions in accordance with the terms of the deposit agreement. We have no obligation to register under U.S. securities laws any ADSs, Ordinary Shares, rights or other securities received through such distributions. We also have no obligation to take any other action to permit the distribution of ADSs, Ordinary Shares, rights or anything else to holders of ADSs. In addition, the depositary may withhold from such dividends or distributions its fees and an amount on account of taxes or other governmental charges. This means that you may not receive the same distributions or dividends as those we make to the holders of our Ordinary Shares, and, in some limited circumstances, you may not receive any value for such distributions or dividends if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline in the value of the ADSs.

 


Risks Related to Israeli Law and Our Operations in Israel

 

As our headquarters and some of our operations are located in Israel, we may be adversely affected by the implications of political, economic and military instability in Israel.

Our executive offices are located in Israel. In addition, most of our officers and directors are residents of Israel. Accordingly, political, economic and military conditions in Israel and the surrounding region may directly affect our business. Any armed conflicts, political instability, terrorism, cyberattacks or any other hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could affect adversely our operations. Ongoing and revived hostilities in the Middle East or other Israeli political or economic factors, could harm our operations and product development and cause any future sales to decrease.

On October 7, 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks.

The intensity and duration of Israel’s current war is difficult to predict, as are such war’s implications on our business and operations. On October 7, 2023, the Company’s warehouse located in the south of Israel suffered physical damage due to a direct missile hit. While said damage did not affect our supply chains, the ongoing war may create supply and demand irregularities in Israel’s economy in general or lead to macroeconomic indications of a deterioration of Israel’s economic standing, which may have a material adverse effect on us and our ability to effectively conduct our operations.

In connection with the Israeli security cabinet’s declaration of war against Hamas and possible or currently occurring hostilities with other state or non-state actors, several hundred thousand of Israeli military reservists were drafted to perform military service. 29 of our 450 employees, none of whom are members of our management, have been called to active military duty since October 7, 2023. Some of these employees have since returned, but there can be no assurance that they will not be called to military service in the future. Five employees are still in active military duty as of March 15, 2024. In addition, we rely on service providers located in Israel and their employees may be called for service in the current or future wars or other armed conflicts with Hamas and such persons may be absent from their positions for a period of time. As of March 15, 2024, any impact as a result of the number of absences of our personnel and personnel at our service providers or counterparties located in Israel has been manageable. However, military service call ups that result in absences of personnel from our service providers or contractual counterparties in Israel may disrupt our operations and absences for an extended period of time may materially and adversely affect our business, prospects, financial condition and results of operations.

Following the attack by Hamas on Israel’s southern border, Hezbollah in Lebanon has also launched missile, rocket, and shooting attacks against Israeli military sites, troops, and Israeli towns in northern Israel. In response to these attacks, the Israeli army has carried out a number of targeted strikes on sites belonging to Hezbollah in southern Lebanon. It is possible that other terrorist organizations, including Palestinian military organizations in the West Bank or the Houthis in Yemen, as well as other hostile countries, such as Iran, will join the hostilities. Such hostilities may include terror and missile attacks. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations. Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, and although we received compensation from the Israeli government for damages our warehouse suffered due to a direct missile hit related to the current war, we cannot assure that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damage incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.

Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition or the expansion of our business. A campaign of boycotts, divestment and sanctions has been undertaken against Israel, which could also adversely impact our business.


Prior to the Hamas attack in October 2023, the Israeli government pursued extensive changes to Israel’s judicial system. In response to the foregoing developments, individuals, organizations and institutions, both within and outside of Israel, have voiced concerns that the proposed changes may negatively impact the business environment in Israel including due to reluctance of foreign investors to invest or conduct business in Israel, as well as to increased currency fluctuations, downgrades in credit rating, increased interest rates, increased volatility in securities markets, and other changes in macroeconomic conditions. The risk of such negative developments has increased, and in some cases has been realized, in light of the recent Hamas attacks and the war against Hamas declared by Israel, regardless of the proposed changes to the judicial system and the related debate. To the extent that any of these negative developments do occur, they may have an adverse effect on our business, our results of operations and our ability to raise additional funds, if deemed necessary by our management and board of directors.

Provisions of Israeli law, our amended and restated articles of association and our rights agreement may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.

Provisions of Israeli law, our amended and restated articles of association and our rights agreement could have the effect of delaying or preventing a change in control and may make it more difficult for a third party to acquire us or our shareholders to elect different individuals to our board of directors, even if doing so would be considered to be beneficial by some of our shareholders, and may limit the price that investors may be willing to pay in the future for our Ordinary Shares or ADSs. Among other things:

Israeli corporate law regulates mergers and requires that a tender offer be effected when more than a specified percentage of shares in a company are purchased;

Israeli corporate law does not provide for shareholder action by written consent, thereby requiring all shareholder actions to be taken at a general meeting of shareholders;

our amended and restated articles of association divide our directors into three classes, each of which is elected once every three years;

our amended and restated articles of association require a vote of the holders of a majority of our outstanding Ordinary Shares entitled to vote present and voting on the matter at a general meeting of shareholders (referred to as simple majority), and the amendment of a limited number of provisions, such as the provision dividing our directors into three classes, requires a vote of the holders of 70% of our outstanding Ordinary Shares entitled to vote at a general meeting; and

our amended and restated articles of association provide that director vacancies may be filled by our board of directors.

In January 2024, we entered into a rights agreement, or the Rights Plan, with the intention to protect the long-term interests of our ADS holders and enable them to realize the full potential value of their investment in the Company. The Rights Plan is designed to reduce the likelihood that any entity, person or group would gain control of, or significant influence over our Company. Pursuant to the Rights Plan, we issued one special purchase right for every one ADS outstanding at the close of business on February 5, 2024. Each right allows its holder to purchase from us one-half (0.5) of one ADS, at a purchase price of $0.01 per ADS, once the rights become exercisable. The rights would become exercisable only if an entity, person or group acquires beneficial ownership of 10% or more of our outstanding Ordinary Shares in a transaction not approved by our board of directors. The rights will expire on January 25, 2025. For more information about the Rights Plan, see exhibit 2.2 filed with this annual report on Form 20-F.

Further, Israeli tax considerations may make potential transactions undesirable to us or to some of our shareholders whose country of residence does not have a tax treaty with Israel granting tax relief to such shareholders from Israeli tax. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction during which certain sales and dispositions of shares of the participating companies are restricted. See “Item 10.E. Taxation—Israeli Tax Considerations and Government Programs” for additional information.

Our operations are subject to currency and interest rate fluctuations.

 

We incur expenses in U.S. dollars and NIS, but our functional currency is the U.S. dollar and our financial statements are denominated in U.S. dollars. The U.S. dollar is the currency that represents the principal economic environment in which we operate. As a result, we are affected by foreign currency exchange fluctuations through both translation risk and transaction risk. As a result, we are exposed to the risk that the U.S. dollar may appreciate relative to the NIS, or, if the U.S. dollar instead devalues relative to the NIS, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the NIS cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected.

 

ProvisionsWe received Israeli government grants for certain of our research and development activities. The terms of those grants may require us to pay royalties and to satisfy specified conditions in order to manufacture products and transfer technologies outside of Israel. If we fail to satisfy these conditions, we may be required to pay penalties and refund grants previously received.

Our research and development efforts have been financed in part through royalty-bearing grants in an aggregate amount of approximately $3,843,000 that we received from Israel’s Innovation Authority, or the IIA, as of March 15, 2024. As of December 31, 2023 our contingent liabilities regarding IIA grants received by us were in an aggregate amount of $1,986,000. With respect to the royalty-bearing grants we are committed to pay royalties at a rate of 3% to 3.5% on sales proceeds from our products that were developed under IIA programs up to the total amount of grants received, linked to the U.S. dollar and bear interest. Until October 25, 2023, the interest was calculated at a rate based on 12-month London Interbank Offered Rate, or LIBOR, applicable to U.S. dollar deposits. However, on October 25, 2023, the IIA published a directive concerning changes in royalties to address the expiration of the LIBOR. Under such directive, regarding IIA grants approved by the IIA prior to January 1, 2024 but which are outstanding thereafter, as of January 1, 2024 the annual interest is calculated at a rate based on 12-month Secured Overnight Financing Rate, or SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%; and, for grants approved on or following January 1, 2024 the annual interest shall be the higher of (i) the 12 months SOFR interest rate, plus 1%, or (ii) a fixed annual interest rate of 4%.


Regardless of any royalty payment, we are further required to comply with the requirements of the Israeli lawEncouragement of Industrial Research and ourDevelopment Law, 5744-1984, as amended, and restated articles of association may delay, preventrelated regulations, or otherwise impedethe Research Law, with respect to those past grants. When a merger with,company develops know-how, technology or an acquisition of, our company, which could prevent a change of control, even whenproducts using IIA grants, the terms of these grants and the Research Law restrict the transfer of such know-how, and the transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer to third parties inside or outside of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies. We may not receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits us to transfer technology or development out of Israel.

The transfer of IIA-supported technology or know-how outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred technology or know-how, our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported research project and other factors. These restrictions and requirements for payment may impair our ability to sell or otherwise transfer our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are favorablerequired to us and our shareholders.pay to the IIA.

 

ProvisionsInflation could adversely affect our business and results of Israeli lawoperations.

While inflation in the United States and global markets was relatively low before 2020, during 2021 and 2022, the economy in the United States and global markets encountered a material increase in the level of inflation. The impact of geopolitical developments such as the Russia-Ukraine and Israel-Hamas conflicts and global supply chain disruptions continue to increase uncertainty in the outlook of near-term and long-term economic activity, including whether inflation will continue and how long, and at what rate. Increases in inflation raise our amendedcosts for commodities, labor, materials and restated articles of association couldservices and other costs required to grow and operate our business, and failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, along with the uncertainties surrounding geopolitical developments and global supply chain disruptions, have caused, and may in the effect of delaying or preventing a change in controlfuture cause, global economic uncertainty and uncertainty about the interest rate environment, which may make it more difficult, costly or dilutive for a third partyus to acquire us or our shareholderssecure additional financing. A failure to elect different individualsadequately respond to our board of directors, even if doing so would be considered to be beneficial by some of our shareholders, and may limit the price that investors may be willing to pay in the future for our ordinary shares. Among other things:

Israeli corporate law regulates mergers and requires that a tender offer be effected when more than a specified percentage of shares in a company are purchased;

Israeli corporate law does not provide for shareholder action by written consent, thereby requiring all shareholder actions to be taken at a general meeting of shareholders;

our amended and restated articles of association divide our directors into three classes, each of which is elected once every three years;

our amended and restated articles of association require a vote of the holders of a majority of our outstanding ordinary shares entitled to vote present and voting on the matter at a general meeting of shareholders (referred to as simple majority), and the amendment of a limited number of provisions, such as the provision dividing our directors into three classes, requires a vote of the holders of 70% of our outstanding ordinary shares entitled to vote at a general meeting, provided the majority constitutes more than 33.33% of the total issued and outstanding share capital as of the record date of such meeting; and

our amended and restated articles of association provide that director vacancies may be filled by our board of directors.

Further, Israeli tax considerations may make potential transactions undesirable to us or to some of our shareholders whose country of residence does notthese risks could have a tax treaty with Israel granting tax relief to such shareholders from Israeli tax. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingentmaterial adverse impact on the fulfillmentour financial condition, results of numerous conditions, including a holding period of two years from the date of the transaction during which certain sales and dispositions of shares of the participating companies are restricted. See “Item 10.E. Taxation—Israeli Tax Considerations and Government Programs” for additional information.operations or cash flows.

 

It may be difficult to enforce a judgment of a United States court against us and our officers and directors in Israel or the United States, to assert United States securities laws claims in Israel or to serve process on our officers and directors and these experts.

 

We wereare incorporated inunder the laws of the State of Israel. MostService of process upon us and upon our executivedirectors and officers, and directorsa substantial majority of whom reside outside of the United States, and all of our assets and most of the assets of these persons are located outside of the United States. Service of process upon us or our non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us or our non-U.S. our directors and executive officers may be difficult to obtain within the United States. We have been informed byFurthermore, because the majority of our legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original actions instituted in Israel,assets and a substantial number of our directors and officers are located outside of the United States, a judgment obtained against us, or obtainany of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws.laws, may not be collectible in the United States and may not be enforced by an Israeli court. It also may be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally, it may be difficult for an investor, or any other person or entity, to initiate an action with respect to U.S. securities laws in Israel. Israeli courts may refuse to hear a claim based on aan alleged violation of U.S. securities laws against us or our non-U.S. officers and directors because Israel mayreasoning that Israeli court is not be the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be provedproven as a fact by expert witnesses, which can be a time-consuming, and costly process. Certain matters of the procedure will also be governed by Israeli law. There is little binding case law in Israel addressingthat addresses the matters described above. Additionally, Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against us or our non-U.S. officers and directors.


Moreover, an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of the State of Israel, if it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that was given in the same matter between the same parties, or if a suit in the same matter between the same parties was pending before a court or tribunal in Israel at the time the foreign action was brought.

Our headquarters and other significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel.

Our executive offices are located in Israel. In addition, most of our officers and directors are residents of Israel. Accordingly, political, economic and military conditions in Israel may directly affect our business. Any armed conflicts, political instability, terrorism, cyberattacks or any other hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could affect adversely our operations. Ongoing and revived hostilities in the Middle East or other Israeli political or economic factors, could harm our operations and solution development and cause any future sales to decrease.

In addition, instability in the region may lead to deterioration in the political and trade relationships that exist between the State of Israel and certain other countries. Any armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions, could harm our results of operations and could make it more difficult for us to raise capital. Parties with whom we do business may sometimes decline to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary in order to meet our business partners face to face. Several countries, principally in the Middle East, still restrict doing business with Israel and Israeli companies, and additional countries may impose restrictions on doing business with Israel and Israeli companies if hostilities in Israel or political instability in the region continues or increases. Similarly, Israeli companies are limited in conducting business with entities from several countries. For instance, in 2008, the Israeli legislature passed a law forbidding any investments in entities that transact business with Iran. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements.

Our commercial insurance does not cover losses that may occur as As a result of eventsthe difficulty associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assureenforcing a judgment against us in Israel, you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.

Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial conditions or the expansion of our business. A campaign of boycotts, divestment and sanctions has been undertaken against Israel, which could also adversely impact our business.

In addition, Israel is experiencing a level of unprecedented political instability. The Israeli government has been in a transitionary phase since December 2018, when the Israeli Parliament, or the Knesset, first resolved to dissolve itself and call for new general elections. Since then, Israel held general elections three times – in April and September of 2019 and in March of 2020. A fourth election is due to take place on March 23, 2021. The Knesset has not passed a budget for the year 2021, and certain government ministries, which may be critical to the operation of our business, are without necessary resources and may not receive sufficient funding moving forward. In the event that the current political stalemate is not resolved during 2021, our abilitybe able to conduct our business effectively may be adversely affected.

Finally, many Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they reach the age of 40 (or older, for reservists who are military officerscollect any damages awarded by either a U.S. or who have certain occupations) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such call-ups, which may include the call-up of members of our management. Such disruption could materially adversely affect our business, prospects, financial condition and results of operations.foreign court.

 


Your rights and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies.

 

We are incorporated under Israeli law. The rights and responsibilities of holders of our Ordinary Shares are governed by our amended and restated articles of association and the Companies Law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders in typical U.S. corporations. In particular, pursuant to the Companies Law, each shareholder of an Israeli company has to act in good faith and in a customary manner in exercising his or her rights and fulfilling his or her obligations toward the Company and other shareholders and to refrain from abusing his or her power in the Company, including, among other things, in voting at the general meeting of shareholders, on amendments to a company’s articles of association, increases in a company’s authorized share capital, mergers and certain transactions requiring shareholders’ approval under the Companies Law. In addition, a controlling shareholder of an Israeli company or a shareholder who knows that it possesses the power to determine the outcome of a shareholder vote or who has the power to appoint or prevent the appointment of a director or officer in the Company, or has other powers toward the Company has a duty of fairness toward the Company. However, Israeli law does not define the substance of this duty of fairness. There is little case law available to assist in understanding the implications of these provisions that govern shareholder behavior.

We received Israeli government grants for certain of our research and development activities. The terms of those grants may require us to pay royalties and to satisfy specified conditions in order to manufacture products and transfer technologies outside of Israel. We may be required to pay penalties in addition to repayment of the grants.

Our research and development efforts have been financed in part through royalty-bearing grants in an aggregate amount of approximately $1,865,000 that we received from Israel’s Innovation Authority, or the IIA, as of March 8, 2021. As of December 31, 2020, our contingent liabilities regarding IIA grants received by us were in an aggregate amount of $1,076,000. With respect to the royalty-bearing grants we are committed to pay royalties at a rate of 3% to 5% on sales proceeds from our products that were developed under IIA programs up to the total amount of grants received, linked to the U.S. dollar and bearing interest at an annual rate of London Interbank Offered Rate, or LIBOR, applicable to U.S. dollar deposits. The United Kingdom’s Financial Conduct Authority, which regulates the LIBOR, announced in July 2017 that it will no longer persuade or require banks to submit rates for LIBOR after 2021. Accordingly, there is considerable uncertainty regarding the publication of LIBOR beyond 2021. While it is not currently possible to determine precisely whether, or to what extent, the withdrawal and replacement of LIBOR would affect us, the implementation of alternative benchmark rates to LIBOR may increase our financial liabilities to the IIA. Management continues to monitor the status and discussions regarding LIBOR. We are not yet able to reasonably estimate the expected impact.

Regardless of any royalty payment, we are further required to comply with the requirements of the Israeli Encouragement of Industrial Research and Development Law, 5744-1984, as amended, and related regulations, or the Research Law, with respect to those past grants. When a company develops know-how, technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer of such know-how, and the transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer to third parties inside or outside of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies. We may not receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits us to transfer technology or development out of Israel.

 


The transfer of IIA-supported technology or know-how outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred technology or know-how, our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported research project and other factors. These restrictions and requirements for payment may impair our ability to sell or otherwise transfer our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are required to pay to the IIA.

 

General Risk Factors

 

Raising additional capital would cause dilution to holders of our existing shareholders,securities, and may affect the rights of existing shareholders.shareholders and ADS holders.

 

We may seek additional capital through a combination of private and public equity offerings, debt financingsfinancing and collaborations and strategic and licensing arrangements. To the extent that we raise additional capital through the issuance of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a holder of our ADSs.

 

Significant disruptions of our information technology systems or breaches of our data security could adversely affect our business.

 

A significant invasion, interruption, destruction or breakdown of our information technology systems and/or infrastructure by persons with authorized or unauthorized access could negatively impact our business and operations. We could also experience business interruption, information theft and/or reputational damage from cyber-attacks, which may compromise our systems and lead to data leakage either internally or at our third partythird-party providers. Our systems have been, and are expected to continue to be, the target of malware and other cyber-attacks. Although we have invested in measures to reduce these risks, we cannot assure you that these measures will be successful in preventing compromise and/or disruption of our information technology systems and related data.

 

We may be subject to securities litigation, which is expensive and could divert management attention.

 

In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management’s attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us to significant liabilities.

 

Additionally, we have invested substantial resources, both financial and management attention, in litigating claims filed by our activist shareholder, Murchinson Ltd. For more information on the lawsuits, please see “Item 8.A – Legal Proceedings.” Our management devotes attention and resources to these claims, and any adverse determination in litigation could also subject us to significant liabilities.

If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports regarding our business or our ADSs or Ordinary Shares, and the price and trading volume of our ADSs or Ordinary Shares could decline.decline.

 

The trading market for our ADSs or Ordinary Shares will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our ADSs or Ordinary Shares, or provide more favorable relative recommendations about our competitors, the price of our ADSs or Ordinary Shares would likely decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the price or trading volume of our ADSs or Ordinary Shares to decline.

 


ITEM 4.INFORMATION ON THE COMPANY

ITEM 4. INFORMATION ON THE COMPANY

 

A.History and Development of the Company

A. History and Development of the Company

 

Our legal and commercial name is Nano Dimension Ltd. We were incorporated in the State of Israel in December 1960, and are subject to the Companies Law. From March 7,In August 2014, until August 25, 2014, we were a “shell corporation” and did not have any business activity, excluding administrative management. On August 25, 2014, we closed the Merger with the Subsidiary, whereby we acquired 100% of the share capital of the Subsidiary. The SubsidiaryNano Tech. Nano Tech was incorporated in the State of Israel in July 2012. The Merger

From 2012 until 2021, we operated solely as a 3D printing company focused on designing and manufacturing systems used in the fabrication of electronics. During this time, we leveraged our expertise in printing two materials in the same system to product PCBs and electronic devices.

Starting in April 2021, we commenced a mergers and acquisitions program, which continues to this day, that has resulted in a changenumber of control wherebytransformative transactions that have changed the managementCompany considerably. On April 23, 2021, we acquired all of the Companyissued and outstanding share capital of DeepCube. DeepCube technology applies numerous patented breakthrough algorithms to improve data analysis and deployments of advanced Deep Learning-based artificial intelligence systems. The machine learning application includes faster and more accurate training of deep learning models, and drastically improves inference performance and real-time metrics. Its proprietary framework can be deployed on top of any hardware, especially fitting edge devices and real-time applications. DeepCube’s artificial intelligence / machine learning / deep learning solutions demonstrate 10 times speed improvements and memory reduction, allowing efficient deployment of deep leaning models on edge devices and for real-time applications. In September 2022, DeepCube was replacedmerged with Nano Tech.

On April 26, 2021, we acquired all of the issued and outstanding share capital of NanoFabrica. NanoFabrica is a prominent player in the field of precision digital manufacturing. Its industrial additive manufacturing systems have an unprecedented micron-resolution with ultra-fine features, details, accuracy, and precision – enabled by the managementinnovative micro adaptive projection technology. NanoFabrica brings the power of additive manufacturing to applications that require high precision, overlapping our typical target markets of Nano Dimension, such as aerospace, aviation, high-end electronics and automotive, medical, optics, research, education and more. NanoFabrica’s technology and machines are designed to enable digital mass manufacturing of precise and complex parts. In September 2022, NanoFabrica was merged with Nano Tech.

On November 2, 2021, we acquired all of the Subsidiary.issued and outstanding share capital of Essemtec. Essemtec is a leader in adaptive highly flexible surface mount technology, or SMT, pick-and-place equipment, sophisticated dispenser suitable for both high-speed and micro-dispensing, and intelligent production material storage and logistic system. Its products are equipped with a sophisticated software package which makes extensive and efficient material management possible.

On January 4, 2022, we acquired all of the issued and outstanding share capital of GIS. GIS is a leading developer and supplier of high-performance control electronics, software, and ink delivery systems. GIS is known for inventing and delivering state-of-the-art 2D and 3D printing inkjet hardware and unique operating software. GIS has more than 130 customers around the world with a focus on high-value, precision-oriented applications such as specialized direct-to-container packaging, printed electronics functional fluids, and 3D printing, which can all be controlled by the proprietary software system.

On July 7, 2022, we acquired all of the issued and outstanding share capital of Formatec Holding. Formatec Holding has two subsidiaries - Admatec and Formatec, based in the Netherlands, are comprised of two complementary businesses operating together. They are a leading developer and manufacturer of additive manufacturing and 3D printing systems for ceramic and metal end-user parts. Their industry-grade systems - powered by digital light processing technology - use materials with superior mechanical, electrical, thermal, biological, and chemical properties to produce an array of parts for medical, jewelry, industrial, and investment casting uses. Admatec and Formatec’s industrial production service division is a design-to-production partner for industrial-scale customers via its service bureau platform that combines the advantages of injection molding and additive manufacturing. Both means of production have served as a strategic advantage in working with customers, from early-stage ideas into serial production of end-use parts.


On August 11, 2023, we acquired all of the intellectual property assets of Additive Flow. Additive Flow develops high-performance and high-quality simulation software for mechanical, thermal, thermo-mechanical properties, along with frequency and fatigue across a range of materials and processes. Its product addresses design, production, and quality decisions, while optimizing for cost, weight, manufacturing productivity, and manufacturing yield – all simultaneously.

Additionally, from March through May 2023, we made several non-binding offers to acquire all of the outstanding ordinary shares of Stratasys. After not proceeding with these offers to acquire all ordinary shares, we made a series of special tender offers from May through July 2023 to acquire at least 51% of the outstanding shares, inclusive of the 14.1% that we already owned. The offers were dependent on a number of closing conditions being met. As these conditions were not met, we did not complete the special tender offers. In December 2023, we made an additional offer to buy all remaining shares of Stratasys, which has not yet been accepted, for $16.50 per share. The proposal was subject to the completion of a satisfactory confirmatory due diligence process and the negotiation and execution of a mutually satisfactory definitive acquisition agreement. There is no guarantee that the offer will be accepted or that an acquisition will be completed.

 

ADSs representing our Ordinary Shares currently trade in the United States on the Nasdaq Capital Market under the symbol “NNDM.”

 

Our registered office and principal place of business is located at 2 Ilan Ramon St., Ness Ziona 7403635, Israel. Our telephone number in Israel is +972 -73-7509142.+972-73-7509142.

 

Our website address is www.nano-di.com. The information contained on our website or available through our website is not incorporated by reference into and should not be considered a part of this annual report on Form 20-F, and the reference to our website in this annual report on Form 20-F is an inactive textual reference only. The SEC also maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our filings with the SEC will also be available to the public through the SEC’s website at www.sec.gov. Nano USA is our agent in the United States, and its address is 13798 NW 4th Street,300 5th Ave., Suite 315, Sunrise, FL 33325.1010, Waltham, MA 02451.

 

We are an emerging growth company, as defined in Section 2(a) of the Securities Act, as implemented under the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies including but not limited to not being required to comply with the auditor attestation requirements of the SEC rules under Section 404 of the Sarbanes-Oxley Act. We could remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the date of our first sale of common equity securities pursuant to an effective registration statement under the Securities Act, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our Ordinary Shares that is held by non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

We are a foreign private issuer as defined by the rules under the Securities Act and the Exchange Act. Our status as a foreign private issuer also exempts us from compliance with certain laws and regulations of the SEC and certain regulations of the Nasdaq Stock Market, including the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent director oversight of the nomination of directors and executive compensation. In addition, we will not be required to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies registered under the Exchange Act.

 

Our cash used in investing activities for 2018, 20192021, 2022 and 20202023 amounted to $1,232,000, $641,000$496,680,000, $67,673,000 and $87,011,000,$166,600,000, respectively. The cash was used primarily for investment in bank deposits and purchases of fixed assets. Our purchases of fixed assets primarily include leasehold improvements, computers, and equipment used for the development of our products, and we financed these expenditures primarily from cash on hand.

 


B.Business Overview

 

We are a leading additive

B. Business Overview

Our vision is to disrupt electronics provider. We believe our flagship proprietary DragonFly LDM system is the first and onlymechanical manufacturing with an environmentally friendly and economically efficient electronics and precision system that produces professional multilayer PCBs, RF antennas, sensors, conductive geometries, and molded connected devices for rapid prototyping through custom additive manufacturing. We have been actively developing our additive manufacturing technology since 2014. With our uniqueIndustry 4.0 solution - transforming digital designs into functioning electronic and mechanical devices - on demand, anytime, anywhere.

At Nano Dimension, we believe that additive manufacturing technology for(AM), which is known to some as 3D printing, of electronics and precision applications are key to future growth in the manufacturing industry. According to an Emergen Research report titled “3D Printing Market”, published in March 2022, a 3D HUBS trend report titled “3D Printing Trend Report 2022”, published in May 2022, and an IDTechEx report titled “3D Electronics/Additive Electronics 2022-2032” from April 2022, the additive manufacturing and additively manufactured electronics, or AME, market, which consists of the sales of parts and the systems that make them, is expected to grow from $16 billion to more than $100 billion by 2030 at a compound annual growth rate, or CAGR, of above 20%.

Our technology strategy is rooted in the application of deep learning-based AI to drive improvements in manufacturing capabilities by using self-learning and self-improving systems, along with the management of a distributed manufacturing network via the cloud.

Our deep learning-based AI led manufacturing systems are used to 3D print and assemble high-performance electrical and mechanical applications. Our series of 3D printing, robotics, and control systems enable key enhancements such as weight reduction, miniaturization, agile innovation, and rapid fabrication of critical components that have met the needs of thousands of customers in the most technologically advanced, competitive, and innovative industries such as aerospace/defense, automotive, electronics and PCB, industrial, medical, and research and development/academia.

Our deep learning-based AI platform “Deepcube” is novel compared to other AI solutions based on its ability to improve hardware performance; thus, enabling its application on a distributed network of manufacturing solutions. This is based on DeepCube’s pioneering software inference accelerator, which drastically improves yield, quality, and throughput on additive manufacturing hardware. DeepCube’s propriety algorithms increase the speeds of data analysis tenfold, making it a unique hardware performance accelerator. In July 2023, we announced that we have made notable progress in accelerating our plans to commercialize the industrial AI services of DeepCube by making its propriety technology available for use by external customers. We signed an agreement with a large multinational electronics company to leverage DeepCube’s deep learning-based AI technology. We also entered a memorandum of understanding with another international industrial company and are targetingin the growing marketlatter stages of discussions with several more leading industrial and advanced manufacturing companies for smartthe commercial use of its DeepCube technology.

Our portfolio of 3D printers include: (i) AME inkjet printers known as DragonFly IV that produce PCBs and electronic devices that rely on printed circuit boards, connected devices, RF components and antennas, sensors, and smart products, including IoT.

Additive manufacturing industry analysts predict that 3D printed electronics is likely to be the next high-growth application for product innovation, with its market size forecasted to reach $2.4 billion by 2025 based on a market study.

Traditionally, electronic circuitry is developed through a back-and-forth process that involves design, trial and error and third-party manufacturer outsourcing. We believe that the traditional process for developing complex and advanced electronics is outdated. Until now, additive manufacturing technology has been unable to offer a solution for the electronics market, mainly because of the difficulty of printing multiple layers of electricallysimultaneously depositing proprietary conductive and dielectric substances while integrating in situ capacitors, antennas, coils, transformers, and electromechanical components, (ii) Micro Additive Manufacturing (Micro-AM) Digital Light Processing, or DLP, printers known as Fabrica 2.0 that achieve production-grade micron-level resolution polymer and composite parts, and (iii) Industrial AM DLP printers known as Admaflex utilizing a patented DLP foil system that fabricates strong and complex ceramic and metal parts. Our 3D printing portfolio is complemented by a range of consumables, also known as materials, at a high resolution that is suitable for professional electronics.including: inks, resins, and slurries. We arealso offer software to provide engineers with the firsttools to develop an integrated solution for additive manufacturing of electronics. We are disrupting, leading,bring precision and defining how electronics are made.electrical parts from design-to-manufacturing.

 

Our DragonFly LDM precision systemsuite of Additive Electronics robotics includes: (i) SMT suite of production equipment for additive manufacturingHi-PEDs® and PCB assembly via Essemtec, and (ii) Ink Delivery Systems, or IDS, technology covering hardware and software solutions via GIS.

We have a suite of printed electronics uses our proprietary liquid nano-conductivesoftware products and dielectric inksservices that are designed specificallysupport the aforementioned offerings. While there is an extensive list of these products, one to print multilayer circuitrynote is Additive Flow. It is a key enabling software for design and simulation, which is one of the key steps in 3D electronics. We believe that our DragonFly LDM precision system will obviate the reliance on third-party manufacturers during the development, short run manufacturing and prototyping of smart connected products, such as sensors, conductive geometries, antennas and RF components, professional multilayer PCBs and molded connected devices for rapid prototyping and custom additive manufacturing.printing.

 

In 2020, 20192021, 2022 and 2018,2023, we increased our sales and commercialization efforts and sold 61 systems worldwide during those years.to broaden the synergies of our different groups. As a part of scaling our operations, we have three Customer Experience Centers, or CECs,offices spanning across the United States, Hong KongGermany, UK, Switzerland, Australia, the Netherlands and Israel. The CECs are designedThese offices serve to accelerate the adoption of additive manufacturing for electronics developmentbroaden our customer engagement across regions and serve as customerfocal points for advancing our strategic objectives to lead in Western markets.


Industry Overview

Limitation of traditional manufacturing and training facilitiesthe potential of additive manufacturing.

The global manufacturing industry for electronics (PCB and sales support centers.high-performance electronics) and mechanical manufacturing (injection molding, CNC (Computer Numerical Control) machining, sheet metal, and casting) is comprised primarily of subtractive technologies with numerous difficulties and limitations. Designers and engineers have been limited to the constraints of existing processes that have impacted their end products, thus affecting the firm’s bottom line and the value provided to their customers. Existing means of manufacturing also place a high reliance on leveraging suppliers and partners in the Far East, which adds time and risk of IP theft.

 

Industry Overview

Additive manufacturing of 3D Printed electronics as part of Industry 4.0

Additive manufacturing or 3D printing in general is athe process of making a three-dimensional solid object from a digital model. 3D printing is achieved usingUsing an additive process, where successive layers of material are laid down in different shapes. 3D printingAdditive manufacturing is also considered distinct from traditional machining techniques, which mostly rely on the removal of material by methods such as cutting or drilling (subtractive processes).

 

Additive manufacturing provides numerous advantages compared to traditional electronics and mechanical manufacturing. Additive manufacturing provides:

Design flexibility: Traditional manufacturing methods, such as electronics and mechanical manufacturing, have limited design flexibility. This is because they rely on subtractive manufacturing techniques, where material is removed from a solid block or sheet of material to create the desired shape. On the other hand, additive manufacturing allows for the creation of complex geometries and shapes that would be difficult or impossible to produce using traditional methods.

Low setup costs: Traditional manufacturing methods often require expensive tooling and setup costs. This makes them less suitable for small production runs or custom projects. On the other hand, additive manufacturing does not require tooling and setup costs and is, therefore more cost-effective for quick turnaround prototyping and small production runs.

Accelerated time-to-market: Traditional manufacturing methods can have long lead times due to the time required for tooling and setup. On the other hand, additive manufacturing eliminates the need for extensive tooling and setup, thus enabling shorter lead times.

Assembly consolidation: Traditional manufacturing methods often require multiple components to be manufactured separately and then assembled together, which can add additional costs and time to the manufacturing process. On the other hand, additive manufacturing can consolidate multiple components into a single, complex part, reducing the need for assembly and further streamlining the manufacturing process.

Material savings: Traditional manufacturing methods often produce significant material wastage, especially in subtractive manufacturing techniques where excess material is removed. On the other hand, additive manufacturing can produce parts with little to no wastage, which is more environmentally friendly and cost-effective.

Additive manufacturing as a pillar of Industry 4.0

Industry 4.0, also known as the Fourth Industrial Revolution, refers to the current trend of integrating advanced technologies such as AI, the Internet of Things, or IoT, robotics, and automation into manufacturing and other industries. The goal of Industry 4.0 is to create more intelligent, efficient, flexible, and productive manufacturing solutions.


We perceive that additive manufacturing is at a defining inflection point, by worldwidegiven an ever-growing commitment to industry 4.0 transformation by companies large and small.small companies. To underscore the potential of additive manufacturing, during the past 24 months several Fortune 500 and other tier onetier-one companies operating across a number of distinct industries have made substantial investments to decisively enter the additive manufacturing market. Examples include leading companies in aerospace and defense, dental/cosmetics, and apparel and footwear. With the production world increasingly depending on additive manufacturing, we see exciting advancements internally and externally focused on new printing technologies, in metalmaterials, and in liquid-polymers.the integration of additional industry 4.0 solutions such as robotics and AI.

 

The industry 4.0 manufacturing revolution includes the electrificationelectrical and mechanical precision manufacturing of mission-critical products across multiple industries, and refers to the connectivity, the sensors and electronic circuitry which are crucial in every product, from satellites to sneakers, smart carsmedical devices and IoT devices. This electrification is the horizon of Nano Dimensiondevices that require precision and that is where we elevate industry 4.0 – by making additive manufacturing complete with the 3D printing of smart products made digitally.electronic components. We believe that fully 3D printedadditively manufactured smart connected products are the next phase of industry 4.0.

 


Traditional Printed Circuit Boards (PCB)Additive manufacturing has the potential to be key in the re-shoring trend.

 

A conventional PCB isRecent geopolitical, economic, and supply chain events have caused many advanced Western firms to consider re-shoring manufacturing and/or their manufacturing suppliers. According to a board containingsurvey conducted by Thomas titled “83% of North American Manufacturers Are Likely to Reshore Their Supply Chains in 2021” published in July 2021, a patternleading online sourcing platform, 83% of conducting material, such as copper, which becomes an electrical circuit when electrical componentsNorth American manufacturers are attached to it. It is the basic platform used to interconnect electronic componentsconsidering re-shoring production. Re-shoring provides supply chain resilience, cost savings, customization, in-house/local IP, and can be found in most electronic products, including computers and computer peripherals, communications equipment, cellular phones, high-end consumer electronics, automotive and aeronautical components and medical and industrial equipment. Conventional PCBs are more product-specific than other electronic components because generally they are unique for a specific electronic device or appliance. Conventional PCBs can be classified as single-sided, double-sided and multilayer boards.

A multilayer electronic circuit contains two or more different conductive layers, while an older single-layer circuit contains only one layer of conductors. In the past, in inexpensive circuits, there were single or dual layer circuits. Advanced circuits, which are required for modern products (such as mobile phones, computer cards and more), contain advanced multilayer circuits with a much larger number of layers. Modern electronics have become more complex and often contain thousands of connections between various components of the same electronic circuit. In order to enable this complexity in a limited area and to prevent electronic short circuits, the connections are divided into a number of layers that are connected within the same multilayer electronic circuit. Our DragonFly LDM system is designed to efficiently print prototype PCBs, circuits and antennas that conform to the requirements of modern complex electronics.

One of the main issuesindustry 4.0 solutions offer tools with the potential capabilities to leverage this opportunity.

Additive manufacturing has historically been used for prototyping and proof of concept manufacturing.

Additive manufacturing has mainly been used for prototyping and proof of concept because it offers a high degree of design freedom and flexibility in creating complex geometries that may be difficult or impossible to produce using traditional processmanufacturing methods. Additionally, additive manufacturing allows for rapid iteration and testing of PCB prototype development is the outsourced manufacturing delay. Modern and advanced PCBs are complex and are often comprised of more than ten layers. As a general rule,multiple design concepts, reducing the time forand cost associated with product development. However, advancements in additive manufacturing depends on the complexity and number of layers that a PCB contains. Consequently the timetechnology have made it takes to receive an advanced PCB prototype from a third party manufacturer may reach several weeks. While the life cycle of modern products is shortening, the need for rapid prototyping increases. Our DragonFly LDM system offers a solution to the pain of a slow time-to-market turnaround of advanced PCB prototypes, and enables developers of PCBs the freedom to innovate and painlessly employ an efficient trial-and-error process on a day to day basis.

Another issue with the traditional process of PCB prototyping is confidentiality. The usage of outsource services in orderpossible to produce a PCB prototype forces the developer to share the PCB design files of ahigh-quality parts at larger scales, enabling its use in production applications, thus playing an increasingly important role in future product months before the product is expected to reach the market. Our DragonFly LDM system is intended to be an in-house solution to this issue.manufacturing processes.

 

Market Opportunity

 

We are positioned to continue to take advantage of manufacturing industry trends. The future of the 3D printed electronics marketmanufacturing looks promising with opportunities in IoT connected products, communication, computer/peripheral, and promising; businesses across industries such as aerospace/defense, automotive, industrieselectronics and in aerospace.PCB, industrial, medical, and research and development/academia have started researching and acquiring advanced additive manufacturing systems and solutions. We estimate market potential by looking at several market referencesreferences. According to an Emergen Research report titled “3D Printing Market”, published in March 2022, a 3D HUBS trend report titled “3D Printing Trend Report 2022”, published in May 2022, and an IDTechEx report titled “3D Electronics/Additive Electronics 2022-2032” from April 2022, the additive manufacturing and AME, market are together expected to grow from $16 billion to more than $100 billion by 2030 at a CAGR of above 20%.

The current industry practices present challenges to electronics and manufacturing, including the 3D printed electronics market, the total PCBpoor energy efficiency, slow production time and high costs, long time to get to market, and PCB software design market.

Technavio’s market research analysts predictpotential risks for IP theft. We provide systems and solutions for additive precision and electronics manufacturing, a unique offering that enables a compelling proposition to the total PCB market will grow at a compound annual growth rate, or CAGR,most innovative and advanced manufacturers seeking rapid fabrication of more than 6% by 2021. Other analysts estimate that the PCB market will reach an estimated $72.6 billion by 2022.high-performance components.

 


Within the total PCB market is the more specific market of PCB design software. We believe that many users of design software would benefit from the use of an in-house additive manufacturing system. Future Market Insights forecasts the global PCB design software market to increase at 12.9% CAGR during 2016-2026, and reach $4.75 billion in revenues by the end of 2026.

 

Additive manufacturing industry analysts predict that 3D printed electronics is likely to be the next high-growth application for product innovation, with its market size forecasted to reach approximately $2.4 billion by 2025. Many industry leaders expect the 3D printed electronics industry to expand quickly as manufacturing companies and consumer industries discover new methods and applications for 3D printed electronic technology. The chart below gives an indication of the size of the 3D printed electronics market, and illustrates that it is both large and growing.

 

Strategy

 

Source: DataM Intelligence, 2018

Strategy

By creating our own installed-base of printers that require our own dedicated inks – we are establishing a “Razor and Blades” business model in which our customers buy the printer first and then continue to purchase the dedicated inks and maintenance over time.

We market and sell our products and services worldwide, primarily to companies that develop products with electronic components, including companies in the defense industry, including the U.S. Armed Forces, the automotive sector, consumer electronics, semiconductor, aerospace, and medical industries and to research institutes. Our primary market is the U.S., though we have also experienced growth in Asia Pacific and Europe and expect that trend to continue.

Our goal is to expedite our growth and to further advance our breakthrough technologies and commercialization efforts. To achieve these objectives, we plan to:are focused on three main pillars:

 

 Increase sales. Research & development (R&D): We are committed to the development of systems, materials, software, AI, and solutions that will advance our capabilities and core technology surrounding additive manufacturing of electronic and precision applications. Since our founding, we have invested significant resources into the development of our existing portfolio. In connection of our acquisitions in 2021 and 2022, we have acquired significant R&D resources and talent that expand our R&D base. R&D is a core pillar, approximately 40% of our employees are focused on R&D or application development (who are significantly involved in supporting development and feedback for our R&D), and approximately 30 employees are data scientists and algorithm engineers dedicated to AI development.

Go-To-Market (GTM): We are advancing our commercialization efforts and infrastructure to connect, development relationships, and allocating more resources to activities executedmake sales. Our GTM efforts are led by our U.S.management with prior successes in building and growing technology-focused sales and marketing organizations. Our organization is global, with offices in the United States, Netherlands, the United Kingdom, Switzerland, Germany, Israel, Hong Kong headquarters, including increasing sales manpower.and Australia, providing significant reach and local market expertise. We have invested in creating the critical talent, technology, and physical infrastructure for the Go-To-Market of advanced manufacturing for our existing portfolio and the base for any new releases or acquisitions.

Increase amount of applications and advanced electronics applicable use cases. In collaboration with our customers, create applications that can expedite the usage of our products for production grade products and consequently increase our sales. Our main focus is in collaboration with customers in the fields of automotive, aerospace, medical devices and defense.

 


 Form alliances with industry leaders. We plan to collaborate with companies in the fields of design and manufacturing in order to expedite the adoption of our technology by the market.

Capitalize on our nano-conductive and dielectric inks, and software technology products. We plan to exploit our inks as supplemental products to our DragonFly LDM system. We also plan to increase the software options and enable levels of licensing that we could monetize.

Our strategic growth plan includes the following:

Current state: Monetize commercially available products and services for additive electronics design.

Horizon 1: Deliver higher speed production-grade additive electronics systems and more materials and services.

Horizon 2: Deliver hybridized capabilities that combine mechanical functionality within electrified geometries.

M&A:

Mergers & acquisitions (M&A): We are focusing on two kindssynergetic M&A of acquisition targets: One would expand our go-to-market channelssystems, materials, software, AI, and givesolutions that build up to deliver comprehensive solutions to mutual vertical market segments. We have a team of M&A professionals and partners who have and continue to help us exposureidentify and evaluate a range of opportunities, most of which are in North America and Europe, that will help us deliver on the above strategy, while also providing a return-on-investment for shareholders. In December 2023, we submitted a preliminary all cash proposal to vertical markets, whilepurchase all the other targets include a setoutstanding shares of companiesStratasys that we believedid not already own for $16.50 per share in cash. We currently own approximately 14.02% of Stratasys’ outstanding shares and have transformative technologiesbeen its largest shareholder since July 2022. Our offer has not yet been accepted. The proposal was subject to the completion of a satisfactory confirmatory due diligence process and productsthe negotiation and execution of a mutually satisfactory definitive acquisition agreement. There is no guarantee that the offer will be accepted or that an acquisition will be completed.

Products

3D printers

AME systems, which are complementary to our product roadmap. Our search has evolved as we have expanded our geographical footprint.inkjet printers (DragonFly series) that produce Hi-PEDs® by simultaneously depositing proprietary conductive and dielectric substances while integrating in situ capacitors, antennas, coils, transformers, and electromechanical components.

Products

Our products currently consist of three main product lines – our DragonFly LDM precision system, proprietary ink products and software.

DragonFly LDM Precision System for additive manufacturing of printed electronics

Our DragonFly LDM can print sensors, conductive geometries, RF devices, antennas, professional multilayer PCBs, and molded connected devices for rapid prototyping and custom additive manufacturing.

 

Micro additive manufacturing systems, which are DLP printers (Fabrica series) that achieve production-grade polymer and composite parts with ultra-high features, details, accuracy, and precision.

Industrial additive manufacturing systems, which are DLP printers (Admaflex series) utilizing a patented foil system that fabricates strong and complex ceramic and metal parts.

Additive Electronics Robotics and control systems

SMT, for electronics assembly equipment for electronic components on Hi-PEDs® and PCBs, catering to various manufacturing and volume requirements.

IDS, which are control electronics, software, and ink delivery systems for digital printing.


Our DragonFly LDM precision system is the first

Consumables and only system that we are awaretechnology

We offer a range of that is customized specifically to print multilayer PCBscomplementary consumables and technology for advanced electronics. The Dragonfly LDM is designed to allow users the ability to print ready-to-use electronics and connected devices in-house, within hours. Possible applicationsuse with each of our products include aerospace, smart cars, IoT-connected products, RF components3D printers, robotics, and encapsulated sensors for military and civil applications.systems:

 

Our DragonFly LDM system is designed to print electronic conductors and dielectric (non-conductive) layers based on a user’s specific design plan. Our DragonFly LDM system uses at least two types of ink (i.e. conductive and dielectric) in order to lay down successive layers that literally build ready-to-use electronics. The printer receives digital files as input and converts them into print jobs in order to build the multilayer PCB, sensors, antenna or circuit. No cutting or drilling is required in the process of additive manufacturing of a multilayer PCB with our DragonFly LDM precision system.

Materials: We sell a range of materials that are developed in-house for each of our 3D printers, which include: nanoparticle conductive and dielectric inks, polymer and composite resins, and ceramic and metal slurries. The sale of these materials provides a recurring revenue stream from customers of our 3D printers.

 

Our DragonFly LDM system includes our dedicated and proprietary print-job editing software named ‘Switch’ and a printing control software named DragonFly, which enable smooth and seamless usage for our customers. Our software is not intended to be a replacement for PCB or computer aided design (CAD) design software, but rather conveniently allow our customers to continue to design their smart parts with their preferred PCB/CAD design software. After the user has concluded the design, the files are simply sent to the DragonFly LDM in Gerber (.gbr) or stereolithographic (.stl) format with a user-friendly interface, similar to the usage of commonplace inkjet and laser printers. Our proprietary software employs traditional methods of 3D printing by virtually converting end products to be printed (such as PCBs) into a large number of thin slices, which are then printed one on top of the other.

Additionally, and depending on the sales channel employed, we will offer different levels of product warranty and after-sales services. We anticipate that channel partners, such as established distributors will typically be key to providing support and warranty services to the wider market. In instances where deeper and more strategic relationships are at stake, we intend to provide dedicated account management, both in terms of support and servicing, which may be fee or subscription-based. We plan to support and train a select number of experienced channel partners with the capabilities to ensure that end customers are satisfied with our products and any after-sales services and support that we may offer in the future.

Our DragonFly LDM system has multiple advantages, including:

In-house prototypesSoftware: We offer software for each of our solutions. For industrial AI, our DeepCube offering is at the core of our in-house and low volume production. Our DragonFly LDMcustomer oriented work in improving the efficiency of industrial systems through visual inspection and maintenance. For our 3D printers, the software enables design and manufacturing and includes (i) our “FLIGHT” software for our AME system, offers its users an efficient, quick, available, accessible(ii) AM printer software for Fabrica and immediate solutionAdmaflex systems providing in-process monitoring, traceability, and print preparation, and (iii) simulation software for prototype productionmechanical, thermal, thermo-mechanical properties, along with frequency and fatigue across a range of smart products such as encapsulated sensors, antennas, multilayer PCBsmaterials and free-form geometry 3D circuits. Currently, electronics companies and others engaged inprocesses by Additive Flow. For our SMT solutions, our SMART software suite provides all the development of products based on PCBs are forcedrequirements for a modern electronic manufacturing environment. For our IDS solutions, our Atlas software provides a unique, modular software suite to rely on service suppliers that manufacture PCBs through a complex and inefficient process.manage the entire data path from image to print for the inkjet industry.

Turn-around of multilayer advanced smart parts can often take weeks and involves significant costs. Also, for electronics in development, several cycles of prototyping are often necessary until the specs of the final electronic part are created. This means that a developer of a new electronic product may have to repeat the process of going through a service supplier several times during lab testing – which may increase cost and slow the momentum of product development.

Our DragonFly LDM system obviates the reliance on external service suppliers and provides electronics companies and others the luxury of an office-friendly system in their in-house research laboratory with the ability to print prototypes of PCBs as required for electronic device development – all during a relatively short period of time.

Information security and professional secrecy. Contracting with external service suppliers (outsourcing) in order to create prototypes of PCBs during early stages of the development process of novel electronic devices may unnecessarily compromise the security of sensitive and confidential information. Currently, however, there is hardly a practical solution. By allowing companies to bring prototype development in-house, our DragonFly LDM system offers a practical solution to this issue.
Industry first. We believe that we are a pioneer and a leader in our industry. We are not aware of any other company in the global electronics market that currently offers a 3D printer that prints professional grade smart parts.

 


Supplementary ProductsIntellectual Property

Conductive Ink

We have developed a uniquely formulated nano-conductive ink for use in our systems. Using advanced nano-technology, we have developed a liquid ink that contains nano-particles of conductive materials such as silver and copper. Nano-particles are particles between 1 and 100 nanometers in size. By employing this technology, we are able to create a liquid ink that maintains its transport properties and electric conductivity. The liquid properties of our nano-conductive ink allow us to take advantage of inkjet printing technology for fast and efficient 3D printing of PCBs.

Our wet-chemistry approach to making silver nano-particles starts with a raw material compound containing silver which may be acquired from a number of chemical suppliers. The patented process, licensed from the Hebrew University, is highly efficient and very clean. We can reliably extract 10 to 100 nanometer sized particles of pure silver. We are able to control the size, shape and dispersion of the silver nano-particles in accordance with specific printing requirements. We can also formulate inks for a variety of substrates and printing profiles.

In addition, in July 2016, we filed a patent application with the USPTO for the development of a new nano metric conductive ink, which is based on a unique synthesis. The new nano-particle synthesis further minimizes the size of the silver nano-particles in our ink products. The new process achieves silver nano-particles as small as 4 nano-meters. We believe that accurate control of nano-particles’ size and surface properties will allow for improved performance of our DragonFly LDM system. The innovative ink enables lower melting temperatures and more complete sintering (fusing of particles into solid conductive trace), leading to an even higher level of conductivity. The innovative ink has the potential to accelerate printing speeds and save ink for the 3D printing of electronics.

Dielectric Ink

Our proprietary dielectric ink is a unique ink that contains dielectric and dielectric materials that are not electrically conductive. The use of non-conductive ink is crucial in the production of multilayer circuit boards, as the conducting layers that are placed on top of each other must be separated by dielectric layers. Our internally developed, proprietary dielectric ink is a unique one-part-epoxy material. The dielectric ink can withstand high temperature (e.g., five hundred degrees Fahrenheit and more) without distorting its shape, which is a necessary requirement for professional PCBs and electronics components.

Both our nano-conductive and dielectric ink products have completed development stages and we have begun to manufacture these products in-house. We plan to commercialize these ink products as a supplementary product to our systems. Based on our proprietary technology, our ink products may be adjusted specifically for additional uses.

Software

Our proprietary software, the ‘DragonFly’ and ‘Switch’ are used to manage the design file and printing process. The Switch software enables seamless transition into an additive manufacturing workflow.

In July 2016, we completed the development of the initial version of our software package and we have been adding features and improvements to it from time to time. The Switch is included in our DragonFly LDM system. The Switch software enables preparation of production files of printed electronic circuits using the DragonFly LDM system. The software supports customary formats in the electronics industry such as Gerber files, as well as vertical interconnect access (VIA) and DRILL files. The Switch software presents a unique interface that displays Gerber files and an accurate and detailed description of the PCB’s structure, which facilitates a highly precise conversion to a 3D file format.

Multilayer 3D files can be prepared from standard file formats, with the software allowing for adjustments in numerous parameters such as layer order and thickness.

When the print-job is ready the user simply loads the design file from Switch straight into the Dragonfly LDM printer and uses the DragonFly software to manage and control the print.

 


Intellectual Property

We seek patent protection as well as other effective intellectual property rights for our products, services and technologies in the United States and internationally. Our policy is to pursue, maintain and defend intellectual property rights developed internally and to protect the technology, inventions and improvements that are commercially important to the development of our business.

 

We have a growingan ever-growing portfolio of sevenover 100 issued U.S. and foreign patents and 64approximately 200 provisional and non-provisional patent applications with the USPTO, WIPO filed through the PCT,Patent Cooperation Treaty, and with the respective patent offices of China, Europe, South Korea, Japan and Taiwan. A provisional patent application is a preliminary application that can be filed less formally than a non-provisional application, and establishes a priority date for the patenting process for the invention disclosed therein.

 

Our growing patent portfolio can be divided into fourfive main areas:

 

1. Mechanical:Mechanical: covering printervarious printers’ components and peripherals, with threefor example- granted U.S. patents (9,227,444, 9,259,933, 9,878,549 and 9,878,549),11,141,909) for ink jet 3D printers, indirect stereo lithography and DLP, as well as several patent applications, directed to components and systems varying from print heads regeneration systems, print heads cleaning and ink recycling systems.

 

2. Chemical:Chemical: covering ink compositions and related nanoparticles, both dielectric and conducting. Of these, two applicationsFor example, several were granted in the U.S. (10,385,175, 10,626,233)10,626,233, 11,155,004), Chinese (201580058899.5)(112955326) and South Korean (10-2017-7013551) Patentpatent offices. Other chemical applications are directed to ceramic inks, flexible ink (indicated as allowable)(10,893,612), oxidation-resistant conductive inks,Ceramic Ink Compositions (US 11,155,004), and support inks.inks (11,629,261).

 

3. Applications:Applications: covering 3D printing applications and computer applications. The 3D printing applications are directed to various methods of printing additive manufacturing electronics, flexible printed circuits (FPCs) and high-density interconnects (HDIs) circuits with embedded components. Additional filings were directed inter-alia to composite printing, shielded traces (10,905,017) cooling pads and infrastructures,, fabricating SMT mounting sockets (11,395,412), bridging members between integrated circuits, or ICs, vertically embedded integrated circuit (IC) wells and their interconnectivity, as well as coreless transformers.transformers (US 11,694,837). Additional applications are directed to the method of controlling a deposition system comprising a print head array (11,633,961, 11,780,239).

 


4. Industrial Design/Design:Design: covering the ornamental aspects of the printer and various printer components,components. While currently there are no design patents granted, or pending, we intend to file design patents when appropriate, for example for Ink containers and ink cartridges’ adapters.

5. Artificial Intelligence/ Deep Learning: Covering an efficient technique of machine learning that is provided for training a plurality of convolutional neural networks with one granted U.S. patent (D543,612)increased speed and accuracy using a genetic evolutionary model (US 10,339,450); storing sparse neural network (US 10,366,322); approximating multi-synaptic/filters neural network that can be partially-activated by iteratively executing partial pathways to generate partial outputs (US 10,515,306, 10,878,321); mimicking pre-trained target model without access to the pre-trained target model or its original training dataset (US 10,699,194); training or prediction of a neural network (US 11,055,617); training or prediction of neural networks using a cluster-connected neural networks (US 11,164,084); system and method for mimicking a neural network without access to the original training dataset or the target model (US 11,907,854); and system and method for efficient evolution of deep convolutional neural networks using filter-wise recombination and propagated mutations (US 11,710,044).

 

In addition to patent applications, in September 2014, we entered into an exclusive license agreement with the Research and Development Company of the Hebrew University of Jerusalem, Ltd., or Yissum, for two patents that cover the unique method of manufacturing our consumable nano-conductive ink for the 3D printing of electronic circuits. The agreement was amended and restated in April 2015. Pursuant to the license agreement, we will be required to pay Yissum low to mid-single digit percentage royalties on sales of our conductive ink. The exclusive license agreement is in effect for the longer of remaining usable life of the patents and patent applications, or 15 years from the first commercial sale of a product relating to the licensed technology in the country in which the first commercial sale occurred. Currently, the status of the license is under review and it is possible that

In addition, we may terminate the license to one of the patents.

Competition

Many companies providing 3D printing services concentrate their efforts on printing prototypes in resin polymers or other plastics. We differentiate ourselves from these companies by focusing on the niche market of in-house PCB printing using ahave identified several trade secrets associated with chemical formulations, combination of nano-conductivejigs (manufacturing aids), and dielectric inks,preferred suppliers and have taken the necessary steps to that extent we consider ourselves a pioneermaintain these trade secrets.

In addition to the patent portfolio describe above, in our industry. However, it may be possible for more developed 3D printing companies to adapt their products to print PCBs. Accordingly,Admatec division, our competitors may include other companies providing 3D printing services with substantial customer bases and working history. Older, well-established companies providing 3D printing and rapid prototyping services with records of success currently attract customers. Therepatent portfolio can be no assurance that wedivided to three main areas:

1.Mechanical: covering foils (e.g., UK 3094478), conditioning units (e.g., US 11,141,909), laserflex (e.g., NL 2015381), and abrasive;
2.Applications: control of glass temperature (e.g., NL 2021611); and
3.Materials: metals and precursors (e.g., 2018890)

In addition to the patent portfolio describe above, our Essemtec division filed a provisional application (63/542,334) directed to assemblies and methods for heating PCBs, ICs, advanced packaging, or APs, wafers and the like, in material dispensing processes, using an assembly operable to create a customizable hot-air bath accounting for surface topology, for soaking the PCBs, ICs, APs, wafers and the like.

In addition to the patent portfolio describe above, in our GIS division, our patent portfolio can maintain a competitive position against current or future competitors, particularly those with greater financial, marketing, service, technical and other resources. Our failure to maintain a competitive position within the market could have a material adverse effect on our business, financial condition and results of operations.be divided into two main areas:

 

1.Direct to shape: methods for printing onto 3-dimensional surface (e.g., US 11,463,603); and
2.Drive electronics: electronics for improved performance when driving piezo inkjet print heads (e.g., US 9,079,396 and US 8,860,388).

Competition

We also compete with companies that usesuppliers of additive manufacturing solutions, printers, materials, and software, as well as suppliers for traditional prototype developmentmanufacturing of PCBselectronics and customized manufacturing technologies, and expect future competition to arise from theprecision mechanical parts. The development of new technologies or techniques.techniques not encompassed by the patents that we own may result in additional future competition.

 


To the best of our knowledge, ourMany companies provide solutions for additive manufacturing systemover a range of product segments that can often be split by type of applications depending on materials, size, and accuracy. The additive manufacturing industry is rapidly growing, and the first and only one ofmarket is still in its kind, and as of the date of this annual report on Form 20-F, there are no three-dimensional ink injection printers that print multilayer electronic circuits for the purposes of in-house PCB prototype development. However, there are many companies worldwide that manufacture PCBs.

In the United States and globally, we face many competitors that specialize in contract electronic manufacturing, and specifically the manufacturing of prototype PCBs.infancy. We estimate that there are approximately 1,800differentiate ourselves from other companies in the United Statesindustry by (i) focusing on key applications areas that manufacture are not the focus of other players in the market, such as AME, precision-AM, and high-performance ceramics and metal AM, (ii) patented and/or differentiated features developed from continued R&D for our portfolio, and (iii) combining our printer and solutions multidisciplinary vertically integrated portfolio for precision manufacturing and electronics with our leading AI (Deep Learning) platform DeepCube that together provide PCBs on a per-order basis.industry-leading performance and compounding future performance enhancements.

 


Research and Development

 

From time to time, we explore the application of our technology to additional areas within 3D printing and other industries.

 

In January 2017,2023, we successfully 3D printedannounced the delivery of the Admaflex130 Evolution, which is the first of its next generation high precision ceramics and metal fabrication system, to the Karlsruhe Institute of Technology.

In February 2023, we announced a purchase order from a supplier to the U.S. government defense industry, for our DragonFly IV. In March 2023, we received another purchase order from a leading Western intelligence agency for our DragonFly IV. In June 2023, we announced the sale of our DragonFly IV system to the University of Stuttgart, Germany, Institute of Smart Sensors and 3rd Institute of Physics.

In July 2023, we announced that we had closed a series of multilayer rigid PCBs, connected through printed flexible conductive connections. Thislandmark sales of additive manufacturing printers and additive electronics robotics systems in the second quarter of 2023, which sales are material given their size and customer profiles, which are leading, large-scale businesses and organizations. While the names of the customers cannot be shared as they are defense related and/or focus on IP sensitive work, a partial list of the organizations includes: a space exploration company, a satellite equipment innovator, a national defense agency, a nuclear research group, and a computer manufacturer.

In August 2023, we announced that we received our largest single purchase order in our history, both in terms of the dollar value and number of systems, for digital manufacturing additive robotics solutions from a leading western highly advanced industrial leader. The sale includes multiple robotics systems designed and made by integrated technologies from Nano Dimension’ divisions. The advanced Additive Robotics manufacturing equipment are critical in modern digital-industrial production.

In September 2023, we announced the filing of a new patent titled “Large Language Models for the Log File Analysis of Industrial Machines,” or the LLM Log Patent, which is critical for real-time data analysis and scalable deployment across our own systems as well as industrial solutions provided to outside customers. The focus of the LLM Log Patent is “log data alpha-numeric streams”, which relate to the operation and parameters of a given industrial process providesand can generate hundreds of parallel subsystems. Currently, real-time analysis of these logs is not possible given the quantity of data; thus, queries and investigations are usually reserved for failure cases long after the occurrence and are limited in scale.

In November 2023, we announced a solutionbreakthrough in the development of a material that is a critical enabler for the advancement of AME. Materials, which are commonly known as consumables, are an important factor in the success of additive manufacturing at industrial scale. The functionality of the materials and their acceptance according to traditional production limitations inindustry standards are both critical. Our launch of INSU200, a dielectric ink boasting industry-leading thermo-mechanical properties, addresses both with increased functionality and greater alignment with industry standards, even going so far as to set new standards. In terms of functionality, the new material can withstand the rigorous demands of Restriction of Hazardous Substances, or ROHS, compliant reflow soldering processes. With regards to industry standards, the new material aligns with a number of reliability standards set by IPC (Association Connecting Electronics Industries), the leading global association for the electronics industry, such as continuous transfer of conductors between circuits, loose contacts, size of connections betweenand the circuits as well as fabrication of multilayer flexible material.FED (Fachverband Elektronik-Design e.V.) in Europe.

 


In January 2017,2024, we successfully 3D printed electrical circuits,announced the filing of a new patent application titled “Large Language Models for Efficient Anomaly Detection in Log Files of Industrial Machines,” or the Log Analysis Patent, which we embedded electrical components, through placement, as an integral partis targeted for real-time data analysis and scalable deployment across our own systems and industrial solutions provided to outside customers. The Log Analysis Patent addresses one of the printing process. We filedcore challenges for automated anomaly detection. While machine logs are usually a patent applicationvaluable source of information for industrial systems, they are increasingly difficult and expensive to analyze as the underlying systems have grown in complexity and the volume of log data they contain has multiplied. Furthermore, logs are typically analyzed after events have happened and not in real-time, thereby missing the opportunity to apply corrective actions. To overcome these problems, we have extended our existing AI patents with a Large Language Model that can operate independently of engineering labels. With this, the USPTO for this unique development.technology exploits the existing sentiment that is expressed in the machine logs. This enables a fully automated process of AI-powered prediction of manufacturing anomalies before they occur, based either solely on logs or in combination with other machine data and being efficient enough to process billions of log lines.

 

In February 2017, we received a budget from MEIMAD committee of the IIA which will be used to finance a project to develop 3D printing of advanced ceramic materials in inkjet technology. The total approved budget for this project is approximately $372,000, of which the IIA will finance 50%. The terms of the grant provide that we will be required to pay royalties on future sales of any funded technology up to the full grant amount.

For the years ended December 31, 2018, 20192021, 2022 and 2020,2023, we incurred $8,623,000, $8,082,000$41,686,000, $75,763,000 and $9,878,000,$62,004,000, respectively, of research and development expenses.

 

Grants from Israel’s Innovation Authority

 

Our research and development efforts are financed in part through royalty-bearing grants from the IIA. As of December 31, 2020,2023, we have received the aggregate amount of $1,865,000$3,843,000 from the IIA for the development of our additive manufacturing system and nano-inks. With respect to such grants, we are committed to pay royalties of 3% to 5%3.5% on sales proceeds from our products that were developed under IIA programs up to the total grant amount plus annualof grants received, linked to the U.S. dollar and bearing interest. Until October 25, 2023, the interest was calculated at a rate based on 12-month LIBOR applicable to U.S. Dollar deposits. However, on October 25, 2023, the IIA published a directive concerning changes in royalties to address the expiration of the LIBOR. Under such directive, regarding IIA grants approved by the IIA prior to January 1, 2024 but which are outstanding thereafter, as of January 1, 2024 the annual interest is calculated at a rate based on 12-month SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%; and, for grants approved on or following January 1, 2024 the annual interest shall be the higher of (i) the 12 months SOFR interest rate, plus 1%, or (ii) a fixed annual interest rate of 4%. Regardless of any royalty payment, we are further required to comply with the requirements of the Research Law, with respect to those past grants. When a company develops know-how, technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer of such know-how, change of control transactions and the transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval of the IIA. In addition, any change of control and any change of ownership of our Ordinary Shares that would make a non-Israel citizen or resident an “interested party,” as defined in the Research Law, requires prior written notice from the IIA. We do not believe that these requirements will materially restrict us in any way.

 

Production and Manufacturing

 

We purchase the raw materials required for the production of our products, including components of additive manufacturing systems and materials to produce our nano-inks products. To date, allthe majority of our printers, including our DragonFly LDM,manufacturing equipment are manufacturedassembled in-house.

 

With respect to our ink products, we intend to keep full control of the value chain, from research and development through self-manufacturing and global sales. We have a production facility to support the commercialization and production of our proprietary nano-conductive ink and dielectric ink for our DragonFly additive manufacturing system. We believe that the size and capacity of this facility, located in the same building as our offices, will be sufficient to support our future commercialization activities. We have achieved certificationare certified by the SII (Standard Institute of Israel) for twothree international standards- the OHSAS 18001:2007ISO 45001:2018 for occupational health and safety within the workplace, and the ISO 14001:2015 Standard – EMS (Environmental Management System). and the ISO 9001:2015 for quality throughout in our production processes.

 


Sales and Marketing

 

We began commercializing our first professional grade 3D Printer, the DragonFly Pro 3D printer, during the fourth quarter of 2017. In July 2019, we introduced our new DragonFly LDM printing technology. We are now focused on accelerating our direct reach to end-customers through direct sales.

Potential Material Impact of COVID-19

The COVID-19 pandemic has negatively impacted the global economy, disrupted consumer spending and global supply chains and created significant volatility and disruption of financial markets. Although to date the COVID-19 pandemic has mainly affected our current revenues and has not had a material adverse effect on us, and we do not expect any material impact on our long-term activity, the COVID-19 pandemic may have a material adverse effect onglobal sales and marketing organization. In some instances we have sales and marketing leaders selling several products from our business and financial performanceportfolio, in other instances we have dedicated people selling certain products. The focus of our efforts are in Western markets, along with some sales in the future. The extentAsia-Pacific Region. We work through a combination of the impact of the COVID-19 pandemic, including our ability to execute our business strategies as planned, will depend on future developments, including the durationdirect sales and severity of the pandemic, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. See “Item 3.D. Risk Factors – We face business disruption and related risks resulting from the COVID-19 pandemic, which has had a material adverse effect on our business and results of operations.”through channel partners.

 

C.Organizational Structure

C. Organizational Structure

 

We currently have fourthe following wholly owned subsidiaries: Nano Dimension Technologies Ltd.,GIS, which wasis incorporated in 2012the United Kingdom, Essemtec, which is incorporated in Switzerland and has three subsidiaries, Nano Tech, which is incorporated in the State of Israel, Nano Dimension IP Ltd., which was incorporated in 2018 in the State of Israel, Nano Dimension USA Inc., which wasis incorporated in 2017Delaware, Nano Dimension GmbH, which is incorporated in Delaware, andGermany, Nano Dimension (HK) Limited, which wasis incorporated in 2018Hong Kong, Nano Dimension Australia PTY Ltd, which is incorporated in Hong Kong.Australia, Formatec Holding, Admatec and Formatec, which are incorporated in the Netherlands, and other insignificant subsidiaries.

 

D.Property, Plant and Equipment

D. Property, Plant and Equipment

 

Our offices, research and development facility, manufacturing facility and in-house laboratory are located at our headquarters at 2 Ilan Ramon, and Ilan Ramon 6, Ness Ziona 74036,7403635, Israel, where we currently occupy altogether approximately 34,00090,000 square feet. We lease our headquarters under threenine separate leases. The first lease,Three of the leases, which accountsaccount for about 37%33% of our office space, ends onwill end in August 31, 2024, three of the second lease,leases, which accountsaccount for about 37%33% of our office space, ends on December 31, 2023, andend in 2026, three of the third lease,leases, which accountsaccount for about 26%33% of our office space, ends on August 31, 2021.end in 2027. We have an option to extend two of theour lease agreements for an additional two to five years with aan approximately 5% to 10% increase of the monthly rental fee. We expect to extend the lease agreement ended in August 2021 for an additional five years. The total monthly rent payment for the facilities in Israel is currently approximately $62,000. From March 2018 through February 2020, we had offices$170,000. We also have a facility in Santa Clara, California,Azrieli Center, Tel-Aviv, Israel, where we occupiedcurrently lease and occupy approximately 1,9156,700 square feet. The total monthly rent payment for the facilities in Santa Clara wasTel-Aviv is currently approximately $3,400. Effective from February 1, 2020, we entered into an administrative services agreement between Nano Dimension USA Inc. and Breezer Holdings LLC, whereby the Company will lease space and will use logistic services for of our office in Boca Raton, Florida, for consideration of $6,000 per month. This agreement was terminated in September 2020, when we moved our$25,000. Our U.S. office to Sunrise, Florida,is in Waltham, Massachusetts, where we currently lease and occupy approximately 5,30025,400 square feet. The total monthly rent payment for the facilities in FloridaWaltham is currently approximately $10,000. Since March 2019,$65,000. In addition, in December 2022, we also have officesopened an additional office in Hong Kong Science Park, where weMunich, Germany to house expanded sales operations and customer support. We currently lease and occupy approximately 1,50013,500 square feet. The totalfeet in our Munich, Germany office, and our monthly rent payment for the facilities is approximately $35,000. We also have smaller offices in Hong Kong is currently approximately $7,000.Australia. Essemtec has offices in Aesch, Switzerland, which are owned by us. GIS has offices in Cambridge, United Kingdom, Admatec has offices in Alkmaar, the Netherlands, and Formatec has offices in Goirle, the Netherlands.

 

We consider that our current office space is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the conduct of our business.

 

ITEM 4A.UNRESOLVED STAFF COMMENTS

ITEM 4A. UNRESOLVED STAFF COMMENTS

None.

 

None.


ITEM 5.OPERATING AND FINANCIAL REVIEW AND PROSPECTS

ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS

 

Management’s Discussion and Analysis of
Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this annual report on Form 20-F. This discussion and other parts of this annual report on Form 20-F contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under “Item 3.D. Risk Factors” and elsewhere in this annual report in Form 20-F. We report financial information under IFRS as issued by the IASB and none of the financial statements were prepared in accordance with generally accepted accounting principles in the United States. Our discussion and analysis for the year ended December 31, 20192022 can be found in our annual report on Form 20-F for the fiscal year ended December 31, 2019,2022, filed with the SEC on March 10, 2020.31, 2023.

 

Overview

 

To date, we have generated limited revenues from the sale and lease of our products. In the fourth quarter of 2017 we begunbegan commercializing our products and our ability to generate significant revenues and achieve profitability depends on our ability to successfully complete the development of, and to continue to commercialize, our products.products, including consumables. As of December 31, 2020,2023, we had an accumulated deficit of $108,457,000.$591,207,000. Our financing activities are described below under “Liquidity and Capital Resources.” We currently estimate that we have the necessary capital in order to establish our commercial infrastructure.

 

5.AOperating Results

5. A Operating Results

 

Operating Expenses

 

Our current operating expenses consist of three components – research and development expenses, sales and marketing expenses, and general and administrative expenses.

 

Research and Development Expenses net

 

Our research and development expenses consist primarily of salaries and related personnel expenses, subcontractorshare-based payments expenses, subcontractors expenses, materials ,depreciation, rental fees, patent registration fees, rental fees, materials, and other related research and development expenses.

 

The following table discloses the breakdown of research and development expenses:

  Year ended
December 31,
 
(in thousands of U.S dollars) 2019  2020 
Payroll  4,834   6,531 
Subcontractors  82   258 
Patent registration  144   160 
Materials  1,001   940 
Rental fees and maintenance  197   173 
Depreciation  1,534   1,588 
Other expenses  339   249 
Grants  (49)  (21)
Total  8,082   9,878 

 


  Year ended December 31, 
(in thousands of U.S dollars) 2022 2023 
Payroll  35,638  33,462 
Share-based payment expenses  17,424  7,722 
Subcontractors  10,344  6,717 
Patent registration  506  689 
Materials  6,881  6,584 
Rental fees and maintenance  642  1,081 
Depreciation  3,038  3,859 
Other expenses  1,290  1,890 
Total  75,763  62,004 

Subcontractor

Subcontractors expenses include expenses for development consultants and service providers, whichwho are not employees. The services provided by these consultants and service providers include, but are not limited to, chemistry consulting, software and electronics subcontractors and consulting and chip processing consulting.

 

Our development expenses are presented net of government grants.

Sales and Marketing Expenses

 

Sales and marketing expenses consist primarily of salaries and related expenses, marketing commissions and advertising services, travel expenses, share-based payments expenses, depreciation, rental fees and travel.other related sales and marketing expenses.

 


The following table discloses the breakdown of sales and marketing expenses:

 

  Year ended
December 31,
 
(in thousands of U.S dollars) 2019  2020 
Payroll  2,873   5,326 
Marketing, commissions and advertising  1,808   577 
Depreciation  212   223 
Travel abroad  317   235 
Rental fees and maintenance  114   201 
Other expenses  145   35 
Total  5,469   6,597 
  Year ended December 31, 
(in thousands of U.S dollars) 2022  2023 
Payroll  20,057   19,075 
Share-based payment expenses  8,616   2,490 
Marketing and advertising  5,057   4,685 
Depreciation  1,502   1,369 
Travel abroad  2,567   2,555 
Rental fees and maintenance  392   319 
Other expenses  642   1,214 
Total  38,833   31,707 

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of professional services, salaries professional service fees, director fees,and related expenses, share-based payments expenses, office expenses, depreciation, taxes andtravel expenses, fees and other general and administrative expenses.

 

The following table discloses the breakdown of general and administrative expenses:

  Year ended
December 31,
 
(in thousands of U.S dollars) 2019  2020 
Payroll  872   1,377 
Share-based payments  155   16,837 
Professional services  1,358   1,064 
Directors pay  187   - 
Office expenses  359   386 
Depreciation  78   76 
Fees  22   22 
Travel abroad  37   44 
Rental fees and maintenance  43   46 
Other expenses  159   435 
Total  3,270   20,287 

 

  Year ended December 31, 
(in thousands of U.S dollars) 2022  2023 
Payroll  9,321   14,032 
Share-based payments  4,940   8,448 
Professional services  9,701   29,122 
Office expenses  2,704   1,613 
Depreciation  563   926 
Travel abroad  743   674 
Rental fees and maintenance  286   515 
Other expenses  2,199   2,924 
Total  30,457   58,254 


Comparison of the year ended December 31, 20202023 to the year ended December 31, 20192022

 

Results of Operations

  Year ended December 31, 
(in thousands of U.S dollars) 2022  2023 
Consolidated Statements of Operations Data      
Revenues  43,633   56,314 
Cost of revenues  24,943   30,759 
Cost of revenues - write-down of inventories and amortization of assets recognized in business combination and technology  4,639   97 
Gross profit  14,051   25,458 
Research and development expenses, net  75,763   62,004 
Sales and marketing expenses  38,833   31,707 
General and administrative expenses  30,457   58,254 
Other income, net     1,627 
Impairment losses on intangible assets  40,523    
Operating loss  (171,525)  (124,880)
Finance expense (income), net  56,506   (69,282)
Loss before taxes  (228,031)  (55,598)
Taxes benefit  (264)  (62)
Loss for the year  (228,295)  (55,660)
Loss attributable to non-controlling interests  (872)  (1,110)
Loss attributable to owners  (227,423)  (54,550)

 

  Year ended
December 31,
 
U.S. dollars in thousands 2019  2020 
Consolidated Statements of Operations Data      
Revenues  7,070   3,399 
Cost of revenues  4,312   1,563 
Cost of revenues- amortization of intangible  772   771 
Gross profit  1,986   1,065 
Research and development expenses, net  8,082   9,878 
Sales and marketing expenses  5,469   6,597 
General and administrative expenses  3,270   20,287 
Operating loss  14,835   35,697 
Finance expense (income), net  (6,482)  12,797 
Total comprehensive loss  8,353   48,494 
Loss attributable to holders of Ordinary Shares  8,353   48,494 

Revenues

 

Our revenues for the year ended December 31, 20202023 amounted to $3,399,000,$56,314,000, representing a decreasean increase of $3,671,000$12,681,000 or 52%29%, compared to $7,070,000$43,633,000 for the year ended December 31, 2019.2022. The decreaseincrease is attributed mostly to fewerincreased and more effective sales of DragonFlyefforts across our product lines, including our 3D printers and robotics systems, especially in 2020, whichWestern Europe and the Company primarily attributes to the impact of COVID-19, which caused many entities to hold-off on capital expenditures. Our revenues are derived mainly from sales of our systems, consumables and support services to our customers. In 2020, we sold 4 systems, and in 2019, we sold 27 systems.United States.

 

Cost of Revenues

 

Our cost of revenues excluding write-down of inventories and amortization of assets recognized in business combination and technology for the year ended December 31, 20202023 amounted to $2,334,000,$30,759,000, representing a decreasean increase of $2,750,000$5,816,000 or 54%23%, compared to $5,084,000,$24,943,000, for the year ended December 31, 2019.2022. Cost of revenues consists mainly of $764,000raw materials, materials and consumables in respectthe amount of $18,696,000, payroll and related expenses in the costamount of printers and DragonFly LDM system upgrades sold, $629,000 in respect of service cost, $168,000 for ink$9,586,000 and other consumables,related costs (depreciation and an additional $771,000rental maintenance expenses) in respectthe amount of amortization of intangible assets.$2,477,000. The decreaseincrease resulted primarily from the above-mentioned decreaseincrease in revenues.

 

Gross Profit

 

Our gross profit for the year ended December 31, 2020,2023, amounted to $1,065,000,$25,458,000, compared to a gross profit of $1,986,000$14,051,000 for the year ended December 31, 2019.2022. The increase resulted from an increase in our revenues, improved operational efficiencies and a decrease in write-down of inventories and amortization of assets recognized in business combination and technology.

 


Research and Development Expenses, net

 

Our research and development expenses for the year ended December 31, 20202023 amounted to $9,878,000,$62,004,000, representing an increasea decrease of $1,796,000$13,759,000, or 22%18%, compared to $8,082,000$75,763,000 for the year ended December 31, 2019.2022. The increase resulted primarily from an increasedecrease is attributed to a decrease of $9,702,000 in share-based payments expenses, as well as decrease of $3,627,000 in subcontractors’ expenses and a decrease of $2,176,000 in payroll and related expenses due to more research and development resources, as well as an increase in share-based payments expenses.

 

Sales and marketing Expenses

Our researchsales and developmentmarketing expenses amounted to $31,707,000 for the year ended December 31, 2020 are presented net2023, a decrease of government grants in the amount of $21,000. Our research and development expenses$7,126,000 or 18%, compared to $38,833,000 for the year ended December 31, 2019 are presented net2022. The decrease resulted primarily from a decrease of government grants$6,126,000 in the amountshare-based payments expenses and a decrease of $49,000.$982,000 in payroll and related expenses.

 

SalesGeneral and marketingAdministrative Expenses

 

Our salesgeneral and marketingadministrative expenses totaled $6,597,000$58,254,000 for the year ended December 31, 2020,2023, an increase of $1,128,000$27,797,000 or 21%91%, compared to $5,469,000$30,457,000 for the year ended December 31, 2019.2022. The increase resulted primarily from an increase of $2,453,000$19,421,000 in professional services, mainly from proxy contest related expenses, including the matters relating to activist shareholders and ADS holders, such as proxy advisory, voting, and litigation, as well as an increase of $3,508,000 in share-based payments expenses and an increase of $4,711,000 in payroll and related expenses, less a decrease of $1,231,000 in marketing, commissionsexpenses. See “Item 8.A Consolidated Statements and advertising expenses. During 2020, we decided to invest increased resources in sales and marketing activities, thus we increased the number of our sales and marketing personnel.Other Financial Instruments - Legal Proceedings” for more information.

 


General and Administrative ExpensesOther Income, Net

Our general and administrative expenses totaled $20,287,000other income, net for the year ended December 31, 2020, an increase of $17,017,000 or 520%,2023 was $1,627,000 compared to $3,270,000$0 for the year ended December 31, 2019.2022. The increase resulted primarilywas attributed to additional compensation from an increasegovernment authorities for damaged inventory, less reorganization costs which we incurred during 2023.

Impairment Losses

During 2022, there was a decline in our share price, such that as of $16,939,000 in payroll and related share-based payment expenses, mainly as a resultDecember 31. 2022, our fair value, which is based on the share price, was lower than our book value of equity. Hence, we evaluated our CGUs to which goodwill is allocated. Given the recoverable amount of the issuancesaid CGUs, determined on the basis of warrantsthe value in use of the units, the goodwill, intangibles and property, plant and equipment relating to our President and Chief Executive Officer.the groups of the said CGUs was reduced by approximately $40,523,000. In 2023, no impairment losses were recognized.

 

Operating Loss

 

As a result of the foregoing, our operating loss for the year ended December 31, 20202023 was $35,697,000,$124,880,000, as compared to an operating loss of $14,835,000$171,525,000 for the year ended December 31, 2019, an increase2022, a decrease of $20,862,000$46,645,000 or 141%27%.

 

Finance Expense and Income

 

Finance expense and income mainly consist of bank interest, revaluation of financial assets and liabilities and lease liabilities, fundraising expenses, revaluation of liability in respect of government grants, bank fees, and exchange rate differences.

 

We recognized net financial expensesincome of $12,797,000$69,282,000 for the year ended December 31, 2020,2023, compared to net financial incomeexpenses of $6,482,000$56,506,000 for the year ended December 31, 2019.2022. The increase in expenseschange is primarily due to an increase of $86,253,000 from revaluation of our investment in Stratasys, which is measured at fair value, as well as an increase of $27,455,000 in bank interest income, and an increase of $17,703,000 due to exchange rate differences. These were partially offset by a decrease of $4,977,000 in financial income due to revaluation of financial liabilities with respect to warrants issued in the offerings we did in 2019, measured at fair value mainly due to the increase in our ADS price.through profit or loss.

 


Total Comprehensive Loss

 

As a result of the foregoing, our total loss for the year ended December 31, 20202023 was $48,494,000,$55,660,000, as compared to $8,353,000$228,295,000 for the year ended December 31, 2019,2022, a decrease of $172,635,000, or 76%.

5.B Liquidity and Capital Resources

Overview

Since our inception through December 31, 2023, we have funded our operations principally with $1,550,642,000 from the issuance of Ordinary Shares, warrants and convertible notes. As of December 31, 2023, and following (i) the execution of a $96 million Repurchase Plan during 2023; and (ii) the acquisition of the Stratasys shares, we had $309,571,000 in cash and cash equivalents and an increaseadditional $541,967,000 in short-term unrestricted bank deposits.

The table below presents our cash flows:

  December 31, 
(in thousands of U.S. dollars) 2022  2023 
Operating activities  (92,054)  (105,069)
         
Investing activities  (67,673)  (166,600)
         
Financing activities  (5,273)  (105,414)
         
Net decrease in cash  (168,264)  (375,791)

Operating Activities

Net cash used in operating activities of $40,141,000$105,069,000 during the year ended December 31, 2023 was primarily used for payment of salaries and related personnel expenses, payments for materials and inventory, rent, travel, professional services and other miscellaneous expenses.

Net cash used in operating activities of $92,054,000 during the year ended December 31, 2022 was primarily used for payment of salaries and related personnel expenses, payments for materials and inventory, rent, travel, professional services and other miscellaneous expenses.

Investing Activities

Net cash used in investing activities of $166,600,000 during the year ended December 31, 2023 was primarily used for investments of our cash in bank deposits and fixed assets.

Net cash used in investing activities of $67,673,000 during the year ended December 31, 2022 was used for investment in securities and fixed assets, as well as acquisition of subsidiaries, less cash invested in bank deposits.


In August 2023, we announced that we acquired the technology and intellectual property of the U.K.-based company Additive Flow, which supplies solutions for 3D design simulation and optimization, for GBP 1.76 million. Additive Flow has developed high-performance and high-quality simulation software for mechanical, thermal, thermo-mechanical properties, along with frequency and fatigue across a range of materials and processes. Their product addresses design, production, and quality decisions, while optimizing for cost, weight, manufacturing productivity, and manufacturing yield.

Financing Activities

Net cash used in financing activities of $105,414,000 in the year ended December 31, 2023 was mainly due to repurchase of our ADSs and lease payments.

Net cash provided by financing activities of $5,273,000 in the year ended December 31, 2022 was mainly due to lease payments.

In February 2023, we announced that we would put into action our previously announced share repurchase plan, or 481%.the $100 million Repurchase Plan, allowing us to invest up to $100 million to repurchase our ADSs from time to time, in open market transactions, and/or in privately negotiated transactions or in other legally permissible ways, depending on market conditions, share price, trading volume and other factors. The $100 million Repurchase Plan was approved by the Israeli court in in August 2022 for a period of up to 12 months and was later extended by an additional two months. The $100 million Repurchase Plan expired on October 12, 2023, with $4,160,138 remaining, and thereafter no longer eligible for repurchases under such plan. All repurchases made in 2023 were made pursuant to the $100 million Repurchase Plan.

 

In August 2023, our board of directors authorized a repurchase plan, or the $200 million Repurchase Plan, allowing us to invest up to $200 million to repurchase ADSs from time to time, in open market transactions, and/or in privately negotiated transactions or in any other legally permissible ways, depending on market conditions, share price, trading volume and other factors. The Israeli court approved the $200 million Repurchase Plan on October 17, 2023 for a twelve-month period. As of March 15, 2024, 17,110,217 shares have been repurchased under the Repurchase Plan.

Under the aforementioned repurchase plans, we may repurchase all or a portion of the authorized repurchase amount. The plans do not obligate us to repurchase any specific number of the Ordinary Shares represented by ADS, and may be suspended or terminated at any time at management’s discretion. See “Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers” for additional information.

Current Outlook

To date, we have not achieved profitability and have sustained net losses in every fiscal year since our inception, and we have financed our operations primarily through proceeds from issuance of our Ordinary Shares, warrants and convertible notes. Our primary requirements for liquidity and capital resources are to finance working capital, capital expenditures, general corporate purposes and to advance our M&A strategy. We believe that our current resources will be sufficient to meet our business needs for at least the next 12 months.

In addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including:

the progress and costs of our research and development activities;

the progress of commercial sales of our products;

the costs of manufacturing our products;

the costs of filing, prosecuting, enforcing and defending patent claims, intellectual property rights and other legal claims;


the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and

the magnitude of our general and administrative expenses.

5.C Research and development, patents and licenses, etc.

For a description of our research and development programs and the amounts that we have incurred over the last two years pursuant to those programs, please see “Item 5. Operating and Financial Review and Prospects— A. Operating Results— Operating Expenses— Research and Development Expenses” and “Item 5. Operating and Financial Review and Prospects— A. Operating Results— Comparison of the year ended December 31, 2023 to the year ended December 31, 2022— Research and Development Expenses”

5.D Trend Information

The trends impacting us are described elsewhere in this annual report on Form 20-F, including in Items 4.B. and 5.B. As noted therein, among other trends, we have been engaged, and plan to continue to engage, in mergers and acquisitions to diversify or expand our business, which may pose risks to our business, and we may not realize the anticipated benefits of these mergers or acquisitions.

5.E Critical Accounting Policies and EstimateEstimates

 

We describe our significant accounting policiesmaterial Accounting Policies more fully in Note 23 to our financial statements for the year ended December 31, 2020,2023, included elsewhere in this annual report on Form 20-F. We believe that the accounting policies belowdescribed in Note 3 to our financial statements are critical in order to fully understand and evaluate our financial condition and results of operations.

 

We prepare our financial statements in accordance with IFRS as issued by the IASB. At the time of the preparation of the financial statements, our management is required to use estimates, evaluations, and assumptions which affect the application of the accounting policy and the amounts reported for assets, obligations, income, and expenses. Any estimates and assumptions are continually reviewed. The changes to the accounting estimates are credited during the period in which the change to the estimate is made.

Revenue Recognition

The Company recognizes revenue pursuant to IFRS 15 when the customer obtains control over the promised goods or services. The revenue is measured according to the amount of the consideration to which the Company expects to be entitled in exchange for the goods or services promised to the customer, other than amounts collected for third parties. On the contract’s inception date the Company assesses the goods or services promised in the contract with the customer and identifies as a performance obligation any promise to transfer to the customer goods or services (or a bundle of goods or services) that are distinct. The Company identifies goods or services promised to the customer as being distinct when the customer can benefit from the goods or services on their own or in conjunction with other readily available resources and the Company’s promise to transfer the goods or services to the customer is separately identifiable from other promises in the contract. The Company’s identified performance obligations include printer, ink, maintenance, which is generally provided for a period of up to one year, training and installation. Revenue is allocated among performance obligations in a manner that reflects the consideration that the Company expects to be entitled to for the promised goods based on the standalone selling prices of the goods or services of each performance obligation. The Company allocates the transaction price to the identified performance obligations based on the residual approach, while allocating the estimated standalone selling prices for performance obligations relating to maintenance, training and installation services, and the residual is allocated to the printer. Revenues allocated to the printers, installation and training, and ink and other consumables are recognized when the control is passed at a point in time. Maintenance revenue is recognized ratably, on a straight-line basis, over the period of the services. Revenue from training and installation is recognized during the time of performance.

 


Fair value measurement of financial instruments

We account for financial liabilities relating to warrants and financial derivatives at fair value through profit or loss. The fair value of these instruments are determined by using the Monte Carlo simulation method and the Black-Scholes model and assumptions regarding unobservable inputs used in the valuation model including the probability of meeting revenue targets, and weighted average cost of capital, all of which can lead to profit or loss from a change in the fair value of these instruments.

5.BLiquidity and Capital Resources

Overview

Since our inception through December 31, 2020, we have funded our operations principally with $745,145,000 from the issuance of Ordinary Shares, warrants and convertible notes. As of December 31 2020, we had $585,338,000 in cash and additional $85,596,000 in bank deposits.

The table below presents our cash flows:

  December 31, 
  2019  2020 
  (in thousands of U.S. dollars) 
Operating activities  (12,684)  (9,646)
         
Investing activities  (641)  (86,763)
         
Financing activities  13,441   677,726 
         
Net increase in cash  116   581,317 

Operating Activities

Net cash used in operating activities of $9,646,000 during the year ended December 31, 2020 was primarily used for payment of salaries and related personnel expenses, payments for materials, rent, travel, professional services and other miscellaneous expenses.

Net cash used in operating activities of $12,684,000 during the year ended December 31, 2019 was primarily used for payment of salaries and related personnel expenses, payments for materials, rent, travel, professional services and other miscellaneous expenses.

Investing Activities

Net cash used in investing activities of $86,763,000 during 2020 was primarily used for investments of our cash in bank deposits and fixed assets.

Net cash used in investing activities of $641,000 during 2019 was primarily used for investments of our cash in fixed assets.

Financing Activities

Net cash provided by financing activities of $677,726,000 in the year ended December 31, 2020 was mainly from the issuance of Ordinary Shares.

Net cash provided by financing activities of $13,441,000 in the year ended December 31, 2019 was mainly from the issuance of Ordinary Shares, warrants and convertible notes.


On February 5, 2019, pursuant to an underwriting agreement with A.G.P./Alliance Global Partners, as the underwriter for a public offering of our ADSs, rights to purchase and warrants that were offered pursuant to a registration statement on Form F-1 (Registration No. 333-228521), we issued 1,600,000 units, each consisting of one ADS, one warrant to purchase one ADS, and one right to purchase 0.75 of an ADS, at a price of $7.50 per Unit. The net proceeds to us from the sale of the units was approximately $10,600,000.

On September 4, 2019, pursuant to a securities purchase agreement, we issued to certain accredited investors convertible promissory notes with an aggregate original principal amount of $4,276,000 and an additional approximately $2,700,000 to be received in two subsequent closings. In February 2020, we and the holders of approximately 86% of the convertible promissory notes agreed to terminate substantially all remaining obligations arising under the private placement, including the two subsequent closings.

On February 7, 2020, pursuant to an underwriting agreement with ThinkEquity, a Division of Fordham Financial Management, Inc., or ThinkEquity, as the underwriter for a public offering of our ADSs that were offered pursuant to a shelf takedown under a registration statement on Form F-3 (Registration No. 333-228521), we issued 2,588,318 ADS, at a price per ADS of $1.50. The gross proceeds to us from the sale of the ADSs were approximately $3,882,477.

On April 28, 2020, pursuant to an underwriting agreement with ThinkEquity, as the underwriter for a public offering of our ADSs that were offered pursuant to a registration statement on Form F-1 (Registration No. 333-237222), we issued 17,858,000 ADS or pre-funded ADS purchase warrants, or the Pre-Funded Warrants, each to purchase one ADS in lieu thereof. Additionally, 1,204,114 ADSs were sold pursuant to a partial exercise of the underwriter’s over-allotment option. Each ADS was sold to the public at a price per ADS of $0.70. Each Pre-Funded Warrant was sold to the public at a price per Pre-Funded Warrant of $0.6999, exercisable at any time after the date of issuance upon payment of the exercise price of $0.0001 per ADS. All of the Pre-Funded Warrants were exercised in May 2020. The gross proceeds to us from the sale of the ADSs were approximately $13,343,000.

Between May 2020 and February 2021, we entered into several securities purchase agreements, or the Purchase Agreements, with certain investors for the purchase and sale of an aggregate of 216,422,015 ADS, in several registered direct offerings, or the RD Offerings, offered pursuant to several shelf takedowns under certain registration statements on Form F-3 (Registration Nos. 333-237668, 333-249184, 333-249559, 333-251004 and 333-251155). The aggregate gross proceeds to us from the sale of the ADSs in the RD Offerings were approximately $1,525,766,803. With each RD Offering we also entered into an agreement, or the Placement Agency Agreement, with ThinkEquity, as sole placement agent, or the Placement Agent, pursuant to which the Placement Agent agreed to serve as the placement agent for us in connection with that RD Offering. We agreed to pay the Placement Agent a cash placement fee that ranged between 3.00% to 7.00% of the gross proceeds received for the ADSs in that specific RD Offering. In addition, pursuant to the Placement Agency Agreement in certain of the RD Offerings, we agreed to issue to the Placement Agent or its designees warrants to purchase designated percentages of the ADSs sold such RD Offerings.

Current Outlook

To date, we have not achieved profitability and have sustained net losses in every fiscal year since our inception, and we have financed our operations primarily through proceeds from issuance of our Ordinary Shares. Our primary requirements for liquidity and capital resources are to finance working capital, capital expenditures, general corporate purposes and to advance our M&A strategy. We believe that our current resources will be sufficient to meet our business needs for at least the next 12 months.

In addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including:

the progress and costs of our research and development activities;
the progress in the launch of the commercial DragonFly LDM system;
the costs of manufacturing our DragonFly LDM system and ink products;
the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and
the magnitude of our general and administrative expenses.


5.CResearch and development, patents and licenses, etc.

For a description of our research and development programs and the amounts that we have incurred over the last two years pursuant to those programs, please see “Item 5. Operating and Financial Review and Prospects— A. Operating Results— Operating Expenses— Research and Development Expenses, net” and “Item 5. Operating and Financial Review and Prospects— A. Operating Results— Comparison of the year ended December 31, 2020 to the year ended December 31, 2019— Research and Development Expenses, net.”

5.DTrend Information

The COVID-19 pandemic has impacted companies in Israel and around the world, and as its trajectory remains highly uncertain, we cannot predict the duration and severity of the outbreak and its containment measures. Further, we cannot predict impacts, trends and uncertainties involving the pandemic’s effects on economic activity, the size of our labor force, our third-party partners, our investments in marketable securities, and the extent to which our revenue, income, profitability, liquidity, or capital resources may be materially and adversely affected. See also “Item 3.D. – Risk Factors– We face business disruption and related risks resulting from the COVID-19 pandemic, which has had a material adverse effect on our business and results of operations.”

5.EOff-Balance Sheet Arrangements

We currently do not have any off-balance sheet arrangements.

5.FTabular Disclosure of Contractual Obligations

The following table summarizes our significant contractual obligations at December 31, 2020:

  Total  Less than 1 year  1-3 years  3-5 years  More than 5 years 
  (in thousands of U.S. dollars) 
Lease Liability $3,766   1,148   1,046   1,572     
Liability in respect of warrants (*)  11,986   11,986             
Liability in respect of government grants (**)  1,076   226   850         

(*)The term of the liability in respect of warrants is not determined, thus there is no certainty that the liability will be settled in less than 1 year as stated above.
(**)The contractual obligation in respect of government grants presented above is based on our estimation regarding expected revenues, thus there is no certainty that the liability will be settled in 1-3 years as stated above.

Other financial and operating data:

 

Year Ended
December 31,
(inIn thousands of U.S. dollars) 2020

Year Ended

December 31,

2023

 
EBITDA (loss)  (46,08494,958)
Adjusted EBITDA (loss)  (12,56699,942)

 


EBITDA is a non-IFRS measure and is defined as earnings before interest expense (income),income, income tax, depreciation and amortization. We believe that EBITDA, as described above, should be considered in evaluating the company’s operations. EBITDA facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by variations in capital structures (affecting interest expenses (income), net), and the age and depreciation charges and amortization of fixed and intangible assets, respectively (affecting relative depreciation and amortization expense, respectively) and EBITDA is useful to an investor in evaluating our operating performance because it is widely used by investors, securities analysts and other interested parties to measure a company’s operating performance without regard to the items mentioned above.

 


Adjusted EBITDA is a non-IFRS measure and is defined as earnings before other financial expense (income),income, income tax, depreciation and amortization, share-based payments and share-based payments.other extraordinary income, net, which consists of additional compensation for damaged inventory, less reorganization costs (see Notes 6 and 18(C) to our financial statements). Other financial expense (income), net includes exchange rate differences as well as finance income for revaluation of liability in respect of government grants, finance expense for revaluation of liability in respect of warrants, as well as changes in lease liability.assets and liabilities. We believe that Adjusted EBITDA, as described above, should also be considered in evaluating the company’s operations. Like EBITDA, Adjusted EBITDA facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by variations in capital structures (affecting other financial expenses (income), net), and the age and depreciation charges and amortization of fixed and intangible assets, respectively (affecting relative depreciation and amortization expense, respectively), as well as from share-based payment expenses, and Adjusted EBITDA is useful to an investor in evaluating our operating performance because it is widely used by investors, securities analysts and other interested parties to measure a company’s operating performance without regard to non-cash items, such as expenses related to share-based payments.

 

The following is a reconciliation of net loss to EBITDA and Adjusted EBITDA:

 

Year Ended
December 31,
(inIn thousands of U.S. dollars) 2020

For the
Year Ended
December 31,

2023

 
Net loss  (48,49455,660)
Tax expenses62
Depreciation6,544
Interest income  (24845,904)
Depreciation and amortization2,658
EBITDA (loss)  (46,08494,958)
Finance income from revaluation of assets and liabilities(21,887)
Exchange rate differences  (1231,571)
FinanceShare-based compensation expenses20,101
Other extraordinary income, for revaluation of liability in respect of government grantsnet  (751,627)
Finance expense for revaluation of liability in respect of warrants12,825
Finance expense for revaluation of changes in lease liability390
Share-based payments20,501
Adjusted EBITDA (loss)  (12,56699,942)

 


ITEM 6.DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

A.Directors and Senior Management

A. Directors and Senior Management

The following table sets forth information regarding our executive officers, key employees and directors as of March 10, 2021:15, 2024:

NameAgePosition
Yoav Stern6770President and Chief Executive Officer, Director
Yael SandlerTomer Pinchas3450Chief Financial Officer & Chief Operating Officer
Amit DrorNick Geddes4548Customer Success Officer, Director
Dr. Jaim Nulman65Chief Technology Officer and Executive Vice President, Products
Zvi PeledZivi Nedivi7265Chief Operating Officer and Chief Revenue OfficerPresident
Simon Anthony-FriedYoav Nissan-Cohen (1)4774DirectorChairman of the Board of Directors
Eli David Simon Anthony-Fried (1)3950Director
Yaron EitanMichael X. Garrett (1)62Director
Oded Gera (1) (2) (3)6571Director
Roni Kleinfeld (1) (2) (3)6467Director
J. Christopher Moran (1) (2) (3)6164Director
Nira Poran (1) (2) (3)64Director

(1)Indicates independent director under Nasdaq Stock Market rules.
(2)Member of our Audit Committee and Financial Statements Examination Committee.
(3)Member of our Compensation Committee.


In September 2023, Col. (Ret.) Channa Caspi announced that she will be stepping down from our board of directors due to personal medical circumstances.

In October 2023, as part of setting our board of directors to be efficient and effective, we followed Institutional Shareholder Services guidelines, thereby announcing that Mr. Igal Rotem and Mr. Amit Dror will be stepping down from our board of directors effective immediately as part of a planned transition. At the same time, Mr. Amit Dror also resigned from his position as our Customer Success Officer.

In December 2023, we terminated our employment agreement with Mr. Hanan Gino, who served as our Chief Product Officer and Head of Technology M&A since April 2021.

In March 2024, we terminated our employment agreement with Mrs. Yael Sandler, who served as our Chief Financial Officer since June 2015 until January 2024.

Yoav Stern, President and Chief Executive Officer and Director

Mr. Yoav Stern has served as our President and Chief Executive Officer since January 2020. Mr. Stern has served as our Chairman of the board of directors from May 2021 until September 2023, and has continued to serve on the board of directors since then. Mr. Stern has been an investor, chief executive officer and/or chairman of hi-tech companies. Mr. Stern has led companies in the fields of software and IT, video surveillance, audio and voice over IP, semiconductors equipment, fiber optics, defense-technologies, communication solutions, aerospace, and homeland security. Mr. Stern spent most of his business career in the United States, running both public and private companies with global operations including in United Kingdom, Germany, Australia, India and Singapore. Since 1997, Mr. Stern has also served as the Co-Chairman of Bogen Communication International and Bogen Corporation, and prior to joining Nano Dimension, from 2011 to 2016, Mr. Stern was the president and chief executive officer of DVTEL Inc., headquartered in New Jersey, USA. Mr. Stern has a B.Sc. in Mathematics and Computer Science, a Diploma in Automation and Mechanical Engineering and an M.A. in International Relations from New York University. Mr. Stern is a graduate of the Israeli Air Force Academy and served as an F-15 Pilot and D. Squadron Commander, as well as the Commander of the Combat Operational Training Unit of the Israeli Air Force.

 

Yael Sandler,


Tomer Pinchas, Chief Financial Officer and Chief Operating Officer

Ms. Yael SandlerMr. Tomer Pinchas has served as our Chief Operating Officer since October 2022. Mr. Pinchas also served as interim Chief Financial Officer since June 2015. From 2014from August 2023 until 2015, Ms. Sandler served ashe assumed the Group Controllerrole permanently in January 2024. Mr. Pinchas brings 18 years of RealMatch Ltd. From 2011 through December 2014, Ms. Sandler held various positions at Somekh-Chaikin (KPMG Israel), where she gained valuableglobal experience working with public companiesin finance, M&A and companies pursuing initial public offerings. Ms. Sandler completed the professional course of the Israeli Navy in 2005 andoperations management. He recently served as a submarine simulator instructorChief Financial Officer at Kryon Systems Ltd. from March 2018 to August 2022, a global company that offers intelligence robotic process automation for enterprises digital transformation solution, responsible for all financial management, legal and commander until 2007. Ms. Sandlerrevenue operations functions. Prior to joining Kryon Systems Ltd., Mr. Pinchas served as a Chief Financial Officer at myThings Inc. from July 2016 to March 2018, a personalized retargeting company providing advertisers with display advertisements in real time. Previously, Mr. Pinchas served as a Chief Financial Officer at DVTel, Inc. from 2007 to 2016, a developer of IP video surveillance solutions, where he led the due diligence, negotiation and acquisition of DVTel, Inc. by FLIR Systems Inc. Mr. Pinchas’ experience also includes working at top public accounting firms, including PwC in New York City from 2005 to 2006. Mr. Pinchas is a Certified Public Accountant in Israel. Ms. Sandler earnedgraduate of the General Management Program at Harvard Business School and holds a B.A. with honorsB.A in Accounting and Economics from the Hebrew University of Jerusalem and a M.B.T. with honorsFinance from the College of Management in Rishon LeZion.Management.

Amit Dror, Customer Success Officer, Director

Mr. Amit Dror has served as our Chief Customer Satisfaction Officer since January 2020. Prior to that, Mr. Dror served as our Chief Executive Officer from August 2014 until January 2020. Mr. Dror has also served on our board of directors since August 2014. Mr. Dror co-founded Eternegy Ltd. in 2010 and served as its chief executive officer and a director from 2010 to 2013. Mr. Dror also co-founded the Milk & Honey Distillery Ltd. in 2012. He developed vast experience in project, account and sales management across a range of roles at ECI Telecom Ltd., Comverse Technology, Inc., Eternegy Ltd. and Milk & Honey Distillery Ltd. Mr. Dror has a background that covers technology management, software, business development, fundraising and complex project execution. Mr. Dror is a Merage Institute Graduate.

Dr. Jaim Nulman,Nick Geddes, Chief Technology Officer and Executive Vice President, Products

Dr. Jaim NulmanMr. Nick Geddes has served as our Chief Technology Officer and Executive Vice President Products since May 2018. Dr. Nulman was a vice president with Applied Materials, Inc.July 2022. Mr. Geddes co-founded GIS in Santa Clara, California, where he served for 15 years in a variety of positions at both the product divisions2006 and corporate levels developing and driving commercialization of semiconductor manufacturing technology, applications, and equipment. While at Applied Materials he drove the development of ionized metal physical vapor deposition for enhance step coverage. Dr. Nulman pioneered rapid thermal processing technologies for ultra-thin gate dielectrics in semiconductors. Dr. Nulman is also co-founder and chairman of Yali Pharmaceuticals Group, LLC., a company developing medicines for treatment of pathogen induced inflammation of the body. Dr. Nulman also founded eTe Solutions, LLC, a company engaged in consulting services for commercialization of high tech technology. He holds several patents in the area of semiconductor processing and equipment. Dr. Nulman is a Senior member of the Institute for Electrical and Electronic Engineers (IEEE). He holds a B.Sc. degree in Electrical Engineering from the Technion – Israel Institute of Technology, M.Sc. and Ph.D. in Electrical Engineering with focus on semiconductor devices and technology from Cornell University, and an Executive M.B.A. from Stanford University. Dr. Nulman also served as instructor for NATO’s Advanced Technology summer programs and the University of Berkeley Extension in the area of Rapid Thermal Processing.

Zvi Peled,GIS’s Chief Operating Officer and Chief RevenueTechnology Officer from 2006 through 2021. Mr. Geddes has remained deeply involved in both the technical and commercial areas of GIS, driving innovative solutions from conception through to product. Prior to GIS, Nick worked as inkjet consultant, and for six years at USB Investment Bank as a Director in Debt Capital Markets. Nick has a master’s degree from Cambridge University in Computer Science.

Zivi Nedivi, President

Mr. Zvi PeledZivi Nedivi has served as our Chief Operating Officer and Chief Revenue OfficerPresident since May 2020. From 2015 to 2020,April 2021. Mr. Peled wasNedivi has been the VP Sales-Americas,chief executive officer of the Security Business Unit in FLIR Systemsseveral technology companies, including Cyalume Technologies Inc., a public company focused on intelligent sensingworld leader in chemical-lighting solutions for defense, industrial,that manufactures chemiluminescent ammunition and commercial applications. Previously, Mr. Peledinfra-red devices used by U.S. and NATO military forces as well as law enforcement agencies. He was also the chief operating officer andof Lumenis Ltd., a developer of innovative energy-based technologies. From 1990 to 2005, he was the chief revenuesexecutive officer of DVTELKellstrom Industries, Inc., an advanced data management company. A graduate of the Israel Air Force Academy, he was a video surveillanceF-15 fighter pilot for seven years and artificial intelligence softwareheld the rank of major.

Yoav Nissan-Cohen, Chairman of the Board of Directors

Mr. Yoav Nissan-Cohen has served on our board of directors since December 2022 and hardware high-techhas been Chairman of the board of directors since September 2023. Mr. Nissan-Cohen’s career covers almost 40 years of scientific research, technology development, and executive management. He worked as a research scientist in General Electric’s Research and Development Center in New York from 1988 to 1991. In 1991, he joined National Semiconductor, and in 1993 he was one of the founders of Tower Semiconductor Ltd. (TLV: TSEM), where he served as chief executive officer, took the company whichpublic on the Nasdaq Capital Market, and built a $1.5 billion advanced semiconductor facility. Mr. Nissan-Cohen was acquired by FLIR Systems Inc.a venture partner in 2015. Previously, Mr. Peled wasa large VC fund, and later served as the Presidentchairman and chief executive officer of Apollo Network ServicesAmimon, Inc., a semiconductor company, from 2005 to 2013, providing the only solution for a zero-latency wireless camera link for various medical and other video applications. Mr. Nissan-Cohen has been an executive board member in Weebit Nano (ASX: WBT) since January 2018, a semiconductor company developing a new class of semiconductor memory chips, and the chairman of VisionLab Ltd., a private company that manages large projectsspecializing in the field of defense, energyadvanced vision-based solutions for industrial and transportation for Finmeccanica. He was also the chief executive officer of Flash Networksmilitary applications, as well as TeraCyte Analytics Ltd., a technological leader offering mobile data access gateway. Earlierbiotechnology company which developed a platform for high throughput temporal analysis of live single-cells, with breakthrough applications for research, discovery, and development of new drugs and therapies. Mr. Nissan-Cohen holds a Ph.D. in his career, Mr. Peled spent 20 years with Elbit Systems Ltd., an international defense company engagedphysics from the Hebrew University in a wide range of electronics related programs worldwide.Jerusalem.

 


Simon Anthony-Fried, Director

Mr. Simon Friedhas served on our board of directors since August 2014. Mr. Anthony-Fried is one of our co-founders and served as our Chief Business Officer from August 2014 until December 2017. In January 2018, Mr. Anthony-Fried relocated to California, and was appointed as the President of our wholly-owned subsidiary, Nano Dimension USA Inc.USA. In June 2019, Mr. Anthony-Fried returned to Israel and served as our Chief Business Officer until December 2019. Mr. Anthony-Fried was a co-founder of Diesse Solutions Ltd., a project management, risk and marketing consultancy, and served as its chief executive officer from 2004 to 2014. He has worked as a risk management and corporate governance consultant to the Financial Services Authority in the United Kingdom and as a senior strategy consultant at Monitor Company, a Boston based boutique strategy consulting firm from 2000 to 2002. Mr. Anthony-Fried has a background that covers marketing and sales strategy, management, business development, financial services regulation, fundraising and c-suite consulting. Mr. Anthony-Fried has worked extensively on global projects in both the B2B and B2C markets driving significant strategic change to global marketing organizations. He also currently serves as a director of the Milk & Honey Distillery Ltd. Mr. Anthony-Fried holds a B.Sc. in Experimental Psychology from University College London, an M.Sc. in Judgment and Risk from Oxford University and an M.B.A. from SDA Bocconi in Milan.

Eli David,Michael X. Garrett, Director

Mr. Garrett has served on our board of directors since October 2023. General Garrett is a retired United States Army four-star general with nearly 40 years of service, most recently serving as Commanding General, United States Army Forces Command, the largest command in the U.S. Army, from March 2019 until his retirement in July 2022. General Garrett’s 38-year active military career culminated in three years commanding U.S. Army Forces Command and its 750,000 combat and support personnel across the United States, from 2019 to 2022. His earlier command tours include U.S. Army Central and its Army Soldiers serving throughout the Middle East; U.S. Army Alaska; and the U.S. Army’s first Alaska-based airborne brigade, which Garrett established and deployed into Iraq in the mid-2000s. General Garrett served nearly 40 years on active duty as an Infantryman, Paratrooper, and Ranger who ultimately rose to the rank of four-star general as Commander of U.S. Army Forces Command from 2019 to 2022. General Garrett’s military decorations include the Distinguished Service and Defense Superior Service medals; he is also a Distinguished Member of the 75th Ranger Regiment. General Garrett is a member of the board of directors of Textron Inc., First Command Financial Planning, Inc., and Semper Fi & America’s Fund. He is Chairman of the Board of Commissioners for the American Battle Monuments Commission and serves as an Executive in Residence for Fayetteville State University.

Dr. Eli David

Oded Gera, Director

Mr. Oded Gera has served on our board of directors since JanuaryApril 2021. Dr. DavidMr. Gera has served as Senior Global Advisor in Rothschild & Co. Global Advisory from 2018. He is a leading AI expert specializingthe former Chairman and Founder of Rothschild & Co. in deep learning and evolutionary computation. HeIsrael. Mr. Gera has published over fifty papersserved as Lord Jacob Rothschild’s Entrepreneur in leading artificial intelligence journals and conferences, primarily focusing on applications of deep learning and genetic algorithms in various real-world domains. Since 2005, he has been teaching courses on deep learning and evolutionary computation at Bar-Ilan University and supervising the research of graduate students in these fields. Dr. David has co-founded several successful deep learning-based companies, and also servesResidence from 2004 to 2007, as well as an AI consultantadvisor to several Fortune 500 companies, and major venture capital and private equity firms. Mr. David holds a B.Sc., M.Sc. and Ph.D in Computer Science from Bar-Ilan University.

Yaron Eitan, Director

Mr. Yaron Eitan has served on ourthe board of directors since February 2020.of Robeco Sustainable Private Equity Fund from 1998 to 2006. Prior to his service at Rothchild & Co., Mr. Eitan isGera was the Chief Executive Officer of The Israel Diamond Exchange, which was subsequently bought by a technology entrepreneur,public company in 1996. Previously, he was the founder and investor with over 30 years of experience building and running privately held and publicly traded companies in the United States and Israel. Since January 2018, Mr. Eitan has served as the chief executive officer and co-founder of DeepCube Ltd., a deep learning software accelerator for inference. Mr. Eitan is also the co-founder and since December 2018 has served as the Chairman of both Emporus Technologies Ltd., which deploys deep learning in capital markets, and Marpai Health Inc., a company utilizing advanced analytics in healthcare. Mr. Eitan is also a co-founder and since April 2014 has served as the co-Chairman of 340Basics Technologies, Inc., a healthcare IT company. Previously, Mr. Eitan founded and from 1998 until today was the chief executive officer of Selway Capital, a venture capital incubator for high tech start-up companies. Mr. Eitan founded and from 2002 until 2015 acted as a Chairman and/or chief executive officer for DVTEL, Inc., Magnolia Broadband, Inc., and Geotek Communications Inc., a publicly traded company in wireless communications. From 2013 until April 2018, Mr. Eitan was also a partner at CNTP, a $300 million technology venture fund. Mr. Eitan has a B.A. in Economics from Haifa University and an M.B.A. from the Wharton School of Businessowner of the University of Pennsylvania.Oded Gera fashion house, which became a household name in Israel.

Roni Kleinfeld, Director

Mr. Roni Kleinfeldhas served on our board of directors since November 2012. He has over 25 yearyears of experience as a chief executive officer in public and private companies. He was the chief executive officer of Maariv Holdings Ltd. from 1993 to 2002, the chief executive officer of Hed Artzi Records Ltd. from 2002 to 2007, the chief executive officer of Maariv- Modiin Publishing House Ltd. from 2007 to 2010, and the chief executive officer of OMI Ltd. from 2010 to 2011. Mr. Kleinfeld has also served as director of many companies over the past ten years, including: Excite Ltd. from 2007 to 2011, Makpel Ltd. from 2007 to 2010, Elbit Imaging Ltd. (Nasdaq: EMITF) since 2010, Elran Ltd. from 2010 to 2016, Dancher Ltd. from 2012 to 2014, Mendelson Ltd. from 2012 to 2016, White Smoke Ltd. since 2012, Edri – El Ltd. since 2015, Cofix Group Ltd. since 2015, and Luzon Group since 2017. Mr. Kleinfeld has a B.A. in economics from the Hebrew University in Jerusalem.

 


J.Christopher Moran, Director

 

J. Christopher Moran, Director

Mr. J. Christopher Moran has served on our board of directors since February 2020. Mr. Moran is a Vice-President of Lockheed Martin Corporation and the Executive Director and General Manager of Lockheed Martin Ventures, the venture capital investment arm of Lockheed Martin Corporation. Mr. Moran is responsible for leading the corporation’s investments in small technology companies, which support Lockheed Martin’s strategic business objectives. Prior to joining Lockheed Martin in 2016, and from 1984 to 2016, Mr. Moran served in a variety of increasingly responsible positions at Applied Materials, Inc. Most recently, Mr. Moran was the head of the Business Systems and Analytics group in the Applied Global Services Organization. Mr. Moran was with Applied for over 32 years, including as the head of Corporate Strategy and the General Manager of Applied Ventures LLC, the strategic investing arm of Applied Materials. Mr. Moran is a graduate of the Massachusetts Institute of Technology where he obtained both his Bachelor and Mastermaster’s degrees in Mechanical Engineering.

Nira Poran, Director

Ms. Nira Poran has served on our board of directors since February 2020. Ms. Poran has extensive experience in managing content-technology-companies, international business initiatives and corporate and communal business development efforts. From 1992 to 1994, Ms. Poran served as an Adviser of Public Affairs for the Prime Minister of Israel where she supervised the Status of Women portfolio. In this role, she was involved in various committees and activities, including different parliament committees. She also represented the State of Israel in UN conferences in Vienna and New York. Ms. Poran is the Executive Director of the Association of Corporate Counselors, Israel Chapter. From 2012 to 2014, she was a legal adviser in the firm ZAG/JUN ZEJUN, a cooperation between an Israeli and Chinese law firm. Prior to that, from 2005 to 2013, Ms. Poran was the co-founder and chief executive officer and later the Chairperson of the Board of Mars Interactive Games Ltd. Ms. Poran earned a MA with honors in Gender Studies and an LLM, International and Public Law, from Tel Aviv University and Northwestern University in Chicago, IL.

Family Relationships

There are no family relationships between any members of our executive management and our directors.

Arrangements for Election of Directors and Members of Management

There are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management or our directors were selected.

B.Compensation

B. Compensation

Compensation

The following table presents in the aggregate all compensation we paid to all of our directors and senior management as a group for the year ended December 31, 2020.2023. The table does not include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during this period.

All amounts reported in the tables below reflect the cost to the Company, in thousands of U.S. dollars, for the year ended December 31, 2020.2023. Amounts paid in NIS are translated into U.S. dollars at the rate of NIS 3.2153.627 = U.S.$ dollar 1.00, and amounts paid in GBP are translated into U.S. dollars at the rate of GBP 0.785 = U.S. dollar 1.00 based on the average representative rate of exchange between the NIS and the U.S. dollar as reported by the Bank of Israel in the year endedon December 31, 2020.29, 2023.

 

  Salary and Related Benefits, including Pension, Retirement and Other Similar Benefits  Share-Based Compensation 
All directors and senior management as a group, consisting of 16 persons $5,126  $7,100 

  Salary and
Related Benefits,
including Pension,
Retirement and Other
Similar Benefits
  Share-Based
Compensation
 
All directors and senior management as a group, consisting of 12 persons (1) $1,587,000  $18,870,000 

(1)(1)Includes Ofir Baharav.Mrs. Yael Sandler, who was terminated from her position as our Chief Financial Officer in March 2024, Mr. BaharavAmit Dror, who resigned from his position as Chief Customer Success Officer in October 2023, and Mr. Hanan Gino, who was terminated from his position as our boardChief Product Officer and Head of directors on March 10, 2021.M&A in December 2023.

 


In accordance with the Companies Law, the table below reflects the compensation granted to our five most highly compensated officers and directors during or with respect to the year ended December 31, 2020.

2023.


Annual Compensation- in thousands of U.S. dollars - Convenience Translation (*)

Executive Officer and Directors 

Salary and
Related Benefits,
including Pension,
Retirement and Other
Similar Benefits

  Share-Based
Compensation
  Total 
Yoav Stern $588  $14,032  $14,590 
             
Amit Dror $255  $1,129  $1,384 
             
Zvi Peled $226  $772  $998 
             
Yael Sandler $257  $493  $750 
             
Dr. Jaim Nulman $291  $240  $531 
Executive Officers and Directors Salary and Related Benefits, including Pension, Retirement and Other Similar Benefits  Share-Based Compensation(1)  Total 
Yoav Stern $1,125  $  $1,125 
             
Zivi Nedivi $545  $2,665  $3,210 
             
Nick Geddes $1,064  $1,172  $2,236 
             
Hanan Gino $390  $1,588  $1,978 
             
Tomer Pinchas $414  $1,004  $1,418 

(*)Using the exchange rate as of December 29, 2023, which was 3.627 (NIS/USD) and 0.785 (GBP/USD)

(1)Computed based on Black-Scholes-Merton formula, binomial pricing model or Monte Carlo simulations.

Employment and Services Agreements with Executive Officers

We have entered into written employment or services agreements with each of our executive officers. All of these agreements contain customary provisions regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent that these liabilities are not covered by directorsdirectors’ and officersofficers’ insurance. MembersSome members of our senior management are eligible for bonuses each year. The bonuses are payable upon meeting objectives and targets that are set by our chief executive officer, and approved annually by our board of directors that also set the bonus targets for our chief executive officer.officer, and approved annually according to the Companies Law requirements.

For a description of the terms of our options and option plans,plan, see “Item 6.E. Share OwnershipOwnership” below.

��

Directors’ Service Contracts

Other than with respect to our directors that are also executive officers, weWe currently do not have written agreements with any director providing for benefits upon the termination of his employment with our company.

C.Board Practices

C. Board Practices

Introduction

Our board of directors presently consists of eightseven members. We believe that Ms. Poran and Messrs. Baharav, David, Eitan,Nissan-Cohen, Fried, Garrett, Gera, Kleinfeld, and Moran, are “independent” for purposes of Nasdaq Stock Market rules. Our amended and restated articles of association provides that the number of board of directors’ members shall be set by the general meeting of the shareholders provided that it will consist of not less than three and not more than twelve members. Pursuant to the Companies Law, the supervision of the management of our business is vested in our board of directors. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors. OurPursuant to the Companies Law, our Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors.


Mr. Yoav Stern has been our Chief Executive Officer since January 20, 2020, and has been compensated in accordance with the terms of an agreement, or the Amended and Restated Management Services Agreement, approved by our shareholders on July 7, 2020, by and between the Company and Mr. Yoav Stern, through his fully owned entity, DoubleShore Inc. The term of Mr. Stern’s agreement was for a period of three years and was set to expire on December 31, 2022. On December 19 and 20, 2022, our compensation committee and board of directors, subjectrespectively, approved the renewal of Mr. Stern’s agreement as of January 1, 2023 and until the next general meeting of shareholders. The renewed agreement was approved in accordance the Companies Law exemptions regarding interested party transactions (regulation 1B4), according to which, the compensation committee and the board of directors may decide to renew the engagement with its Chief Executive Officer or Director in terms which are not materially different from his/her previous terms or in terms which are not favorable compared to the employmentprevious engagement, provided in any case that they adhere with our compensation policy. On September 7, 2023, a general meeting of shareholders was held and Mr. Stern’s agreement that weexpired and all payments due to Mr. Stern in connection therewith were made. Since September 7, 2023, Mr. Stern has received no compensation for his ongoing services and there is no certainty when Mr. Stern shall have entered intoan approved compensatory arrangement with him. the Company for his services, if at all. Per the approval of our compensation committee and board of directors, the Company pays for expenses incurred in connection with Mr. Stern’s role as our Chief Executive Officer.

All other executive officers are appointed by our Chief Executive Officer. TheirIf the executive officers are also officer holders as defined under the Companies Law, their terms of employment are subject to the approval of the board of directors’ compensation committee and of the board of directors, and if such terms of employment are not consistent with our compensation policy, then such terms require the approval of our shareholders, and are subject to the terms of any applicable employment agreements that we may enter into with them.

shareholders.


Our directors (other than the external directors, when applicable) are divided into three classes that are each elected at the third annual general meeting of our shareholders, in a staggered fashion (such that one class is elected each annual general meeting), and serve on our board of directors unless they are removed by a vote of 70% of the total voting power of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events, in accordance with the Companies Law and our amended and restated articles of association.

In addition, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on our board of directors or in addition to the acting directors (subject to the limitation on the number of directors), untilfor the next annual general meetingremaining period of time during which the director whose service has ended was filled would have held office, or special general meeting in whichcase of a vacancy due to the number of directors may be appointed or terminated.serving being less than the maximum number pursuant to Article 38 to our amended and restated articles of association.

Under the Companies Law, nominations for directors may be made by any shareholder holding at least one percent of our outstanding voting power. However, any such shareholder may make such a nomination only if a written notice of such shareholder’s intent to make such nomination has been given to our board of directors. Any such notice must include certain information, the consent of the proposed director nominee(s) to serve as our director(s) if elected and a declaration signed by the nominee(s) declaring that there is no limitation under the Companies Law preventing their election and that all of the information that is required to be provided to us in connection with such election under the Companies Law and our amended and restated articles of association has been provided.

 

However, under new exemptions applicable as of March 12, 2024, generally referred to as the New Exemptions, one or more shareholders of an Israeli company whose shares are listed outside of Israel (e.g. Nasdaq), may request its company’s board of directors to include an appointment of a candidate for a position on the board of directors or the termination of a board member as an item on the agenda of a future general meeting, provided that the shareholder hold at least five percent of the voting rights of the company, instead of the one percent required in the past. The decision whether to include the suggested item on the agenda is subject to the Company’s discretion, under the provisions of the Companies Law.


Under the Companies Law, our board of directors must determine the minimum number of directors who are required to have accounting and financial expertise. In determining the number of directors required to have such expertise, our board of directors must consider, among other things, the type and size of the company and the scope and complexity of its operations. Our board of directors has determined that the minimum number of directors of our company who are required to have accounting and financial expertise is two.

The board of directors may elect one director to serve as the chairman of the board of directors to preside at the meetings of the board of directors, and may also remove that director as chairman. Pursuant to the Companies Law, neither the chief executive officer nor any of his or her relatives is permitted to serve as the chairman of the board of directors, and a company may not vest the chairman or any of his or her relatives with the chief executive officer’s authorities. In addition, a person who reports, directly or indirectly, to the chief executive officer may not serve as the chairman of the board of directors; the chairman may not be vested with authorities of a person who reports, directly or indirectly, to the chief executive officer; and the chairman may not serve in any other position in the company or a controlled company, but he or she may serve as a director or chairman of a controlled company. However, the Companies Law permits a company’s shareholders to determine, for a period not exceeding three years from each such determination, that the chairman or his or her relative may serve as chief executive officer or be vested with the chief executive officer’s authorities, and that the chief executive officer or his or her relative may serve as chairman or be vested with the chairman’s authorities. Such determination of a company’s shareholders requires either: (1) the approval of at least two-thirds of the shares of those shareholders present and voting on the matter (other than controlling shareholders and those having a personal interest in the determination); or (2) that the total number of shares opposing such determination does not exceed 2% of the total voting power in the company. Currently, we havecompany (“special majority”). On May 25, 2021, our shareholders approved in a separatespecial majority that Mr. Stern will serve as the chairman and the chief executive officer.officer for a period of three years. On September 15, 2023, we announced that Mr. Yoav Nissan-Cohen was appointed to serve as the chairman of our board of directors, while Mr. Stern continues to serve as our chief executive officer and director.

The board of directors may, subject to the provisions of the Companies Law, delegate any or all of its powers to committees of the board, and it may, from time to time, revoke such delegation or alter the composition of any such committees, subject to certain limitations. Unless otherwise expressly provided by the board of directors, the committees shall not be empowered to further delegate such powers. The composition and duties of our audit committee, financial statement examination committee and compensation committee are described below.

The board of directors oversees how management monitors compliance with our risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by us. The board of directors is assisted in its oversight role by an internal auditor. The internal auditor undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to our audit committee.


External Directors

Under the Companies Law, except as provided below, companies incorporated under the laws of the State of Israel that are publicly traded, including Israeli companies with shares listed on the Nasdaq, are required to appoint at least two external directors who meet the qualification requirements set forth in the Companies Law. The definitions of an external director under the Companies Law and independent director under Nasdaq Stock Market rules are similar such that it would generally be expected that our twothe external directors will also comply with the independence requirement under Nasdaq Stock Market rules.

Pursuant to regulations under the Companies Law, the board of directors of a company such as us is not required to have external directors if: (i) the company does not have a controlling shareholder (as such term is defined in the Companies Law); (ii) a majority of the directors serving on the board of directors are “independent,” as defined under Nasdaq Rule 5605(a)(2); and (iii) the company follows Nasdaq Rule 5605(e)(1), which requires that the nomination of directors be made, or recommended to the board of directors, by a Nominating Committee of the board of directors consisting solely of independent directors, or by a majority of independent directors. The Company meets all these requirements. On November 20, 2017, our board of directors resolved to adopt the corporate governance exemption set forth above, and accordingly we no longer have external directors as members of our board of directors.

 


Fiduciary Duties of Office Holders

The Companies Law imposes a duty of care and a duty of loyalty on all office holders of a company.

The term “office holder” is defined in the Companies Law as a general manager, chief business manager, deputy general manager, vice general manager, any other person assuming the responsibilities of any of these positions regardless of that person’s title, a director and any other manager directly subordinate to the general manager.

The duty of care requires an office holder to act with the level of skill with which a reasonable office holder in the same position would have acted under the same circumstances. The duty of care of an office holder includes a duty to use reasonable means to obtain:

information on the advisability of a given action brought for his or her approval or performed by him or her by virtue of his or her position; and

all other important information pertaining to these actions.

The duty of loyalty of an office holder requires an office holder to act in good faith and for the benefit of the company, and includes a duty to:

refrain from any conflict of interest between the performance of his or her duties in the company and his performance of his other duties or personal affairs;

refrain from any action that constitutes competition with the company’s business;

refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and

disclose to the company any information or documents relating to the company’s affairs which the office holder has received due to his or her position as an office holder.

Approval of Related Party TransactionsTransaction under Israeli Law

General

Under the Companies Law, we may approve an action by an office holder from which the office holder would otherwise have to refrain, as described above, if:

the office holder acts in good faith and the act or its approval does not cause harm to the company; and

the office holder disclosed the nature of his or her interest in the transaction (including any significant fact or document) to the company at a reasonable time before the company’s approval of such matter.

 


Disclosure of Personal Interests of an Office Holder

The Companies Law requires that an office holder disclose to the company, promptly, and, in any event, not later than the board meeting at which the transaction is first discussed, any direct or indirect personal interest that he or she may have and all related material information known to him or her relating to any existing or proposed transaction by the company. If the transaction is an extraordinary transaction, the office holder must also disclose any personal interest held by:

the office holder’s relatives; or

any corporation in which the office holder or his or her relatives holds 5% or more of the shares or voting rights, serves as a director or general manager or has the right to appoint at least one director or the general manager.

An office holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction. Under the Companies Law, an extraordinary transaction is a transaction:

not in the ordinary course of business;

not on market terms; or

that is likely to have a material effect on the company’s profitability, assets or liabilities.

The Companies Law does not specify to whom within us nor the manner in which required disclosures are to be made. We require our office holders to make such disclosures to our board of directors.

Under the Companies Law, once an office holder complies with the above disclosure requirement, the board of directors may approve a transaction between the company and an office holder, or a third party in which an office holder has a personal interest, unless the articles of association provide otherwise and provided that the transaction is not detrimental to the company’s interest. If the transaction is an extraordinary transaction, first the audit committee and then the board of directors, in that order, must approve the transaction. Under specific circumstances, shareholder approval may also be required. A director who has a personal interest in an extraordinary transaction, which is considered at a meeting of the board of directors or the audit committee, may not be present at this meeting or vote on this matter, unless a majority of the board of directors or the audit committee, as the case may be, has a personal interest. If a majority of the board of directors has a personal interest, then shareholder approval is generally also required.

Under the Companies Law, all arrangements as to compensation of office holders require approval of the compensation committee and board of directors, and compensation of office holders who are the Chief Executive Officer or directors must also be also approved, subject to certain exceptions, by the shareholders, by a special majority, in that order.

Disclosure of Personal Interests of a Controlling Shareholder

Under the Companies Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company. Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder has a personal interest, as well as transactions for the provision of services whether directly or indirectly by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions concerning the terms of engagement of a controlling shareholder or a controlling shareholder’s relative, whether as an office holder or an employee, require the approval of the audit committee or the compensation committee, as the case may be, the board of directors and a majority of the shares voted by the shareholders of the company participating and voting on the matter in a shareholders’ meeting. In addition, the shareholder approval must fulfill one of the following requirements:

at least a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or

the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights in the company.

 


In addition, any extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three years requires the abovementionedabove mentioned approval every three years; however, such transactions not involving the receipt of services or compensation can be approved for a longer term, provided that the audit committee determines that such longer term is reasonable under the circumstances. Under the Companies Law regulations, subject to certain terms, such transactions can be extended or approved after three years only by the audit committee and the Board.

The Companies Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction with a controlling shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the vote in question. Failure to so indicate will result in the invalidation of that shareholder’s vote.

The term “controlling shareholder” is defined in the Companies Law as a shareholder with the ability to direct the activities of the company, other than by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder holds 50% or more of the voting rights in a company or has the right to appoint the majority of the directors of the company or its general manager. In certain related party transactions, a shareholder who holds 25% or more of the voting rights at the general meeting of the company will be referred to as the “controlling shareholder”, if no other shareholder holds more than 50% of the voting rights in the company.

Duties of Shareholders

Under the Companies Law, a shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in exercising its rights and performing its obligations to the company and other shareholders, including, among other things, voting at general meetings of shareholders on the following matters:

amendment of the articles of association;

increase in the company’s authorized share capital;

merger; and

the approval of related party transactions and acts of office holders that require shareholder approval.

A shareholder also has a general duty to refrain from oppressing other shareholders.

The remedies generally available upon a breach of contract will also apply to a breach of the above mentionedabove-mentioned duties, and in the event of oppression of other shareholders, additional remedies are available to the injured shareholder.

In addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under a company’s articles of association, has the power to appoint or prevent the appointment of an office holder, or has another power with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not describe the substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness, taking the shareholder’s position in the company into account.

 


Committees of the Board of Directors

Our board of directors has established threeseven standing committees, the audit committee (which also acts as the Financial Statements committee), the compensation committee, the independent committee, the strategy committee, the M&A and operation committee, the litigation – proxy fight committee and the financial statement examinationESG committee.

Audit Committee

Under the Companies Law, we are required to appoint an audit committee. Our audit committee, acting pursuant to a written charter, is comprised of Ms. PoranMessrs. Gera, Moran and Messrs. Baharav, Eitan and Moran.Kleinfeld.

Our audit committee acts as a committee for review of our financial statements as required under the Companies Law, and in such capacity oversees and monitors our accounting; financial reporting processes and controls; audits of the financial statements; compliance with legal and regulatory requirements as they relate to financial statements or accounting matters; the independent registered public accounting firm’s qualifications, independence and performance; and provides the board of directors with reports on the foregoing.


Under the Companies Law, our audit committee is responsible for:

(i)i.determining whether there are deficiencies in the business management practices of our company, and making recommendations to the board of directors to improve such practices;

ii.
(ii)determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under Companies Law) (see “Item 7.B. Approval of Related Party Transactions under Israeli Law”);

iii.
(iii)examining our internal controls and internal auditor’s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities;

iv.
(iv)examining the scope of our auditor’s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment of our auditor; and

v.
(v)establishing procedures for the handling of employees’ complaints as to the management of our business and the protection to be provided to such employees.

Our audit committee may not conduct any discussions or approve any actions requiring its approval (see “Item 7.B. Approval of Related Party Transactions under Israeli Law”), unless at the time of the approval a majority of the committee’s members are present.

Nasdaq Stock Market Requirements for Audit Committee

Under the Nasdaq Stock Market rules, we are required to maintain an audit committee consisting of at least three members, all of whom are independent and are financially literate and one of whom has accounting or related financial management expertise.

As noted above, the members of our audit committee include Mr. Yaron Eitan,Kleinfeld, Mr. Christopher Moran and Ms. Nira Poran,Mr. Gera, each of whom is “independent,” as such term is defined in under Nasdaq Stock Market rules. Mr. KleinfeldGera serves as the chairman of our audit committee. All members of our audit committee meet the requirements for financial literacy under the Nasdaq Stock Market rules. Our board of directors has determined that each member of our audit committee is an audit committee financial expert as defined by the SEC rules and has the requisite financial experience as defined by the Nasdaq Stock Market rules.

 


Financial Statement Examination Committee

Under the Companies Law, the board of directors of a public company in Israel must appoint a financial statement examination committee, which consists of members with accounting and financial expertise or the ability to read and understand financial statements. According to a resolution of our board of directors, the audit committee has been assigned the responsibilities and duties of a financial statement examination committee, as permitted under relevant regulations promulgated under the Companies Law. From time to time as necessary and required to approve our financial statements, the audit committee holds separate meetings, prior to the scheduled meetings of the entire board of directors regarding financial statement approval. The function of a financial statement examination committee is to discuss and provide recommendations to its board of directors (including the report of any deficiency found) with respect to the following issues: (1) estimations and assessments made in connection with the preparation of financial statements; (2) internal controls related to the financial statements; (3) completeness and propriety of the disclosure in the financial statements; (4) the accounting policies adopted and the accounting treatments implemented in material matters of the company; and (5) value evaluations, including the assumptions and assessments on which evaluations are based and the supporting data in the financial statements. Our independent registered public accounting firm and our internal auditor are invited to attend all meetings of the audit committee when it is acting in the role of the financial statement examination committee.

Compensation Committee

Under the Companies Law, the board of directors of any public company must establish a compensation committee. Under the Nasdaq rules, we are required to maintain a Compensation Committeecompensation committee consisting entirely of independent directors (or the determination of such compensation solely by the independent members of our board of directors).


Our compensation committee is acting pursuant to a written charter, and consists of Mr. Yaron Eitan, Mr. RoniMessrs. Gera, Moran and Kleinfeld, and Ms. Nira Poran, each of whom is “independent,” as such term is defined under Nasdaq rules. Our compensation committee complies with the provisions of the Companies Law, the regulations promulgated thereunder, and our amended and restated articles of association. Our compensation committee also complies with committee membership and charter requirements prescribed under the Nasdaq Stock Market rules.

Our compensation committee reviews and recommends to our board of directors: (1) the annual base compensation of our executive officersoffice holders and directors; (2) annual incentive bonus plans, including the specific goals and amount; (3) equity compensation; (4) employment agreements, severance arrangements, and change in control agreements/provisions; (5) retirement grants and/or retirement bonuses; and (6) any other benefits, compensation, compensation policies or arrangements.

The duties of the compensation committee include the recommendation to the company’s board of directors of a policy regarding the terms of engagement of office holders, to which we refer as a compensation policy. That policy must be adopted by the company’s board of directors, after considering the recommendations of the compensation committee. The compensation policy is then brought for approval by our shareholders. On December 26, 2018, our shareholders approved our compensation policy, which was further approved on July 7, 2020, for three more years. In June 2022, our shareholders approved our amended compensation policy. The amended compensation policy provided, among other things, for annual restricted share units grants for our non-executive board members and one-time grants for new non-executive directors appointed by our board of directors or elected by annual general meeting of our shareholders.

The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of executive officersoffice holders and directors, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain factors, including advancement of the company’s objectives, the company’s business and its long-term strategy, and creation of appropriate incentives for executives. It must also consider, among other things, the company’s risk management, size and the nature of its operations. The compensation policy must furthermore consider the following additional factors:

the knowledge, skills, expertise and accomplishments of the relevant director or executive;

the director’s or executive’s roles and responsibilities and prior compensation agreements with him or her;


the relationship between the terms offered and the average and median compensation of the other employees of the company;

the impact of disparities in salary upon work relationships in the company;

the possibility of reducing variable compensation at the discretion of the board of directors; and the possibility of setting a limit on the exercise value of non-cash variable compensation; and

as to severance compensation, the period of service of the director or executive, the terms of his or her compensation during such service period, the company’s performance during that period of service, the person’s contribution towards the company’s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company.

The compensation policy must also include the following principles:

the link between variable compensation and long-term performance and measurable criteria;

the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation;

the conditions under which a director or executive would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company’s financial statements;

the minimum holding or vesting period for variable, equity-based compensation; and

maximum limits for severance compensation.

The compensation policy must also consider appropriate incentives from a long-term perspective and maximum limits for severance compensation.


The compensation committee is responsible for (1) recommending the compensation policy to a company’s board of directors for its approval (and subsequent approval by our shareholders); (2) administration of the Company’s clawback policy; and (2)(3) duties related to the compensation policy and to the compensation of a company’s office holders as well as functions previously fulfilled by a company’s audit committee with respect to matters related to approval of the terms of engagement of office holders, including:

recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years);

recommending to the board of directors periodic updates to the compensation policy;

assessing implementation of the compensation policy; and

determining whether the compensation terms of the chief executive officer of the company need not be brought to approval of the shareholders.

 


Nasdaq Stock Market Requirements for Compensation Committee

Under Nasdaq rules, we are required to maintain a compensation committee consisting of at least two members, all of whom are independent. In addition, in affirmatively determining the independence of any director who will serve on the compensation committee of a board of directors, the board of directors must consider all factors specifically relevant to determining whether a director has a relationship to the company which is material to that director’s ability to be independent from management in connection with the duties of a compensation committee member.

As noted above, the members of our compensation committee include Messrs. Baharav, EitanMoran, Gera and Kleinfeld, each of whom is “independent,” as such term is defined under Nasdaq rules. Mr. Roni KleinfeldOded Gera serves as the chairman of our compensation committee.

Internal Auditor

Under the Companies Law, the board of directors must also appoint an internal auditor nominated by the audit committee. Our internal auditor is Daniel Spira.Yisrael Gewirtz from Fahn Kanne Control Management Ltd. Grant Thornton Israel. The role of the internal auditor is to examine whether a company’s actions comply with the law and proper business procedure. The internal auditor may not be an interested party or office holder, or a relative of any interested party or office holder, and may not be a member of the company’s independent accounting firm or its representative. The Companies Law defines an interested party as a holder of 5% or more of the shares or voting rights of a company, any person or entity that has the right to nominate or appoint at least one director or the general manager of the company or any person who serves as a director or as the general manager of a company. Our internal auditor is not our employee, but the managing partner of a firm which specializes in internal auditing.

Remuneration of Directors

Under the Companies Law, remuneration of directors is subject to the approval of the compensation committee, thereafter by the board of directors and thereafter by the general meeting of the shareholders. If the remuneration of the directors is in accordance with the regulations applicable to remuneration of the external directors, if any, then such remuneration shall be exempt from the approval of the general meeting of the shareholders.

Insurance

Under the Companies Law, a company may, if specified in its articles of association, obtain insurance for any of its office holders for:

a breach of his or her duty of care to the company or to anotherany other person;

a breach of his or her duty of loyalty to the company, provided that the office holder acted in good faith and had reasonable causegrounds to assume that his or herthe act that resulted in such breach would not prejudice the company’s interests;interests of the company; and

a financial liability imposed upon him or her in favor of another person concerning an act performed byon such office holder in his or her capacity as an officer holder.favor of any other person.

Our amended and restated articles of association also allow us to obtain insurance for any of our officer holders for any other event, occurrence, matter or circumstance under any law with respect to which the Company may, or will be able to, insure an office holder, and to the extent such law requires the inclusion of a provision permitting such insurance in our amended and restated articles of association, then such provision shall be deemed to be included in our amended and restated articles of association (including, without limitation, in accordance with Section 56h(b)(1) of the Israeli Securities Law, if and to the extent applicable, and Section 50P of the Israeli Economic Competition Law).

We currently have directors’ and officers’ liability insurance, providing total coverage of $12$30 million for the benefit of all of our directors and officers, in respect of which we paid a twelve-month premium of approximately $700,000,$733,340, which expires on OctoberNovember 4, 2021.2024.


 


Indemnification

TheSubject to the provisions of the Companies Law, provides that a companythe Company may retroactively indemnify an office holder against:of the Company, if specified in its articles of association, with respect to the following liabilities and expenses, provided that such liabilities or expenses were imposed on such office holder or incurred by such office holder due to an act performed by or an omission of the office holder in such office holder’s capacity as an office holder of the Company:

i.a financial liability imposed on him or heran office holder in favor of another person by any court judgment, concerningincluding a judgment given as a result of a settlement or an arbitrator’s award which has been confirmed by a court in respect of an act performed in his or her capacity as anby the office holder;

ii.reasonable litigation expenses, including attorneys’ fees, expended by the office holder as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, or in connection with a financial sanction, provided that (1) no indictment (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no financial liability asin lieu of a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding or if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and

iii.reasonable litigation expenses,costs, including attorneys’attorney’s fees, expended by an office holder or which were imposed on an office holder by a court in proceedings filed against the office holder by the Company or charged to himin its name or her by a court relating to an act performedany other person or in his or her capacity as an office holder, in connection with: (1) proceedings that the company institutes, or that another person institutes on the company’s behalf, against him or her; (2) a criminal charge in respect of which hethe office holder was acquitted or she was acquitted; or (3)in a criminal charge forin respect of which he or shethe office holder was convicted for a criminalan offense that doeswhich did not require proof of criminal thought.intent.

iv.any other event, occurrence, matter or circumstance under any law with respect to which the Company may, or will be able to, insure an office holder, and to the extent such law requires the inclusion of a provision permitting such insurance in our amended and restated articles of association, then such provision shall be deemed to be included and incorporated in our amended and restated articles of association (including, without limitation, in accordance with Section 56h(b)(1) of the Israeli Securities Law, if and to the extent applicable, and Section 50P of the Israeli Economic Competition Law).

Our amended and restated articles of association allow us to indemnify our office holders up to a certain amount. The Companies Law also permits a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability imposed on him or her, as described above, then the undertaking should be limited:limited to sub-sections i to iii described above, and to sub-section iv described above, provided that:

the undertaking to categories ofindemnify is limited to such events that thewhich our board of directors determines areshall deem to be likely to occur in light of the operations of the companyCompany at the time that the undertaking to indemnify is made;made and
in amount for such amounts or criterion determined by the board ofwhich our directors may, at the time of the giving of such undertaking to indemnify, deem to be reasonable under the circumstances; and

the undertaking to indemnify shall set forth such events which our directors shall deem to be likely to occur in light of the operations of the Company at the time that the undertaking to indemnify is made, and the amounts and/or criterion which our directors may, at the time of the giving of such undertaking to indemnify, deem to be reasonable under the circumstances.


 

We have entered into indemnification agreements with certainall of our directors and with certain members of our senior management. Each such indemnification agreement provides the office holder with indemnification permitted under applicable law and up to a certain amount, and to the extent that these liabilities are not covered by directorsdirectors’ and officersofficers’ insurance.

ExculpationExemption

UnderSubject to the provisions of the Companies Law an Israeli companyand the Securities Law, the Company may not exculpate anexempt and release, in advance, if specified in its articles of association, any office holder from any liability to the Company for damages arising out of a breach of his or herthe office holder’s duty of loyalty, butcare towards the Company.

Notwithstanding the foregoing, the Company may exculpatenot exempt its directors in advance from his liability for damages with respect to violation of his duty of care to the Company with respect to distributions. In addition, the Company may not exempt an office holder from his or her liability to the company,Company with regard to a resolution and/or a transaction in whole which the controlling shareholder and/or in part, for a breach of his or her duty of care (other than in relation to distributions). Our amended and restated articles of association provide that we may exculpate any office holder from liability to us to the fullest extent permitted by law. Under the indemnification agreements, we exculpate and release our office holders from any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by law.has a personal interest.

Limitations

The Companies Law provides that we may not exculpate or indemnify an office holder nor enter into an insurance contract that would provide coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the case of indemnity or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally or recklessly (as opposed to merely negligently); (3) any action taken with the intent to derive an illegal personal benefit; or (4) any fine levied against the office holder.

The foregoing descriptions summarize the material aspects and practices of our board of directors. For additional details, we also refer you to the full text of the Companies Law, as well as of our amended and restated articles of association, which are exhibits to this annual report on Form 20-F and are incorporated herein by reference.

There are no service contracts between us or our subsidiaries, on the one hand, and our directors in their capacity as directors, on the other hand, providing for benefits upon termination of service.

Special General Meeting of Shareholders by Murchinson

In January 2023, Murchinson Ltd., or Murchinson (which is an advisor or sub-advisor of one of our major ADS holders), submitted a request to our board of directors for us to convene a special general shareholders meeting which would include certain amendments to our amended and restated articles of association as well as removal of four currently serving directors – Mr. Stern, Mr. Gera, Mr. Rotem and Mr. Nissan-Cohen- and appointment of two new director nominees, proposed by Murchinson. After careful consideration, our board of directors rejected Murchinson’s request because it failed to comply with requirements under laws and regulations in Israel and the United States, as well as with our amended and restated articles of association.

In March 2023, despite our rejection, Murchinson conducted an illegal shareholders meeting. Due to the illegality of the shareholders meeting, our board of directors does not recognize the results of this shareholders meeting.

On September 7, 2023, we convened an Annual General Meeting of Shareholders, or the AGM. At the AGM, our shareholders approved the re-election of a slate of nominees, comprised of the following individuals, together constituting the Nano Slate, as Class III directors until the third annual general meeting of shareholders following such re-election and until he or she ceases to serve in office in accordance with the provisions of the Company’s articles of association or any law, whichever is the earlier: Yoav Nissan Cohen, Oded Gera and Col. (Res.) Channa (Hanny) Caspi; The shareholders further approved an amendment to article 42 of our amended and restated articles of association and rejected a proposal to amend same put forth by Murchinson. The shareholders further rejected proposals put forth by Murchinson to remove Mr. Stern, Mr. Dror, Mr. Anthony-Fried, Mr. Moran, and Mr. Kleinfeld from the board of directors.

 


D.Employees.

Under the New Exemptions, one or more shareholders of an Israeli company whose shares are listed outside of Israel may request its company’s board of directors to include an appointment of a candidate for a position on the board of directors or the termination of a board member as an item on the agenda of a future general meeting, provided that the shareholder hold at least five percent of the voting rights of the company, instead of the one percent required in the past. The decision whether to include the suggested item on the agenda is subject to the Company’s discretion, under the provisions of the Companies Law.

 

Moreover, under the New Exemptions, the board of directors of an Israeli company whose shares are listed outside of Israel shall convene a special meeting at the request of one or more shareholders holding at least 10 percent of the issued and outstanding share capital, instead of five percent as required in the past, or the Non Exempted Holding, and at least one percent of the voting rights in the company, or one or more shareholders holding at least 10 percent of the voting rights in the company, provided that if the applicable law as applicable to companies incorporated in the country which the Company is listed for trade, establishes a right to demand convening of such a meeting for those holding a percentage of holdings lower than 10 percent , then the Non Exempted Holding shall apply.


D. Employees.

As of December 31, 2018,2021, we had fourseven senior management, full-time employees, two of whom also serveserved as directors in our Company. In addition, we had 91 full-time338 employees. Ten employees and eight part-time employees. Four employees arewere located in Hong Kong, 11and China, 95 employees were located in Europe, 31 employees were located in the United States and the rest were located in Israel.

 

As of December 31, 2019,2022, we had three11 senior management, full-time employees, one of whom also servesserved as a director in our Company. In addition, we had 65 full-time553 employees. SixEleven employees arewere located in Hong Kong, FourAsia Pacific, 228 employees were located in Europe, 40 employees were located in the United States and the rest were located in Israel

As of December 31, 2023, we had 10 senior management, full-time employees, one of whom also served as a director in our Company. In addition, we had 509 employees. Three employees were located in Asia Pacific, 243 employees were located in Europe, 24 employees were located in the United States and the rest were located in Israel.

As

In October 2023 our board of December 31, 2020, we had five senior management, full-timedirectors approved, as part of a reorganization plan in several departments of the Company, the termination of certain Company employees one of whom also serves as a director in our Company. In addition, we had 87 full-time employees. Four employees are located in Hong Kong, three employees were located in Europe, nine employees were located in the United States and the rest were located in Israel.worldwide, with preferable terms.

None of our employees are represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relations with all of our employees. However, in Israel, we are subject to certain Israeli labor laws, regulations and national labor court precedent rulings, as well as certain provisions of collective bargaining agreements applicable to us by virtue of extension orders issued in accordance with relevant labor laws by the Israeli Ministry of Economy and which apply such agreement provisions to our employees even though they are not part of a union that has signed a collective bargaining agreement.

E.Share Ownership.

E. Share Ownership.

The following table lists as of March 8, 2021,15, 2024, the number of our shares beneficially owned by each of our directors, our executive officers and our directors and executive officers as a group:

 

  

Number of

Ordinary Shares

Beneficially

Owned (1)

  Percent of
Class (2)
 
Executive Officers and Directors        
Ofir Baharav (former Chairman of the Board of Directors)  3,180(3)   * 
Amit Dror  30,282(4)   * 
Eli David  -     
Yaron Eitan  250,050(5)   * 
Simon Anthony-Fried  69,436(6)   * 
Roni Kleinfeld  3,180(7)   * 
Christopher Moran  -(8)     
Dr. Jaim Nulman  18,412(9)   * 
Zvi Peled  -(10)     
Nira Poran  -(11)     
Yael Sandler  17,142(12)   * 
Yoav Stern  2,642,775(13)   1.1%
         
All directors and executive officers as a group (12 persons)  3,034,457   1.2%

  

Number of

Ordinary Shares

Beneficially

Owned (1)

  Percent of Class (2) 
Executive Officers and Directors      
Yoav Stern  32,355,893(3)  12.9%
Tomer Pinchas  166,667(4)  * 
Nick Geddes  350,000(5)  * 
Zivi Nedivi  485,715(6)  * 
Yoav Nissan-Cohen  13,333(7)  * 
Simon Anthony-Fried  45,710(8)  * 
Michael X. Garrett  (9)   
Oded Gera  15,916(10)  * 
Roni Kleinfeld  8,378(11)  * 
J. Christopher Moran  51,249(12)  * 
All directors and executive officers as a group (10 persons)  33,492,861   13.5%

*Less than 1%.


(1)Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Ordinary Shares relating to options currently exercisable or exercisable or RSUs vesting within 60 days of the date of this table are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person. Except as indicated by footnote, and subject to community property laws where applicable, the persons named in the table above have sole voting and investment power with respect to all shares shown as beneficially owned by them.


(2)The percentages shown are based on 248,833,035221,368,434 Ordinary Shares issued and outstanding as of March 8, 202115, 2024, (which excludes shares purchased under our repurchase plan), plus Ordinary Shares relating to options currently exercisable or exercisable within 60 days of the date of this table, which are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person.

(3)Consists of optionsMr. Stern holds 27,742,103 Series B warrants to purchase 3,180 Ordinary Shares at an exercise price of NIS 27.55$6.16 per share exercisable within 60 days. Stern YOI Ltd. Partnership is a Nevada limited partnership. Mr. Stern is a managing member of Stern YOI Ltd. Partnership. In addition, Mr. Stern holds 4,613,790 Ordinary Shares.

(4)Mr. Pinchas holds 783,333 RSUs that are exercisabledo not vest within 60 days. In addition, Mr. BaharavPinchas holds options to purchase 3,180166,667 Ordinary Shares at an exercise price of NIS 27.55 andShares.

(5)Mr. Geddes holds exercisable options to purchase 200,000 Ordinary Shares at an exercise price of $0.70$3.79 per share. In addition, Mr. Geddes holds options to purchase 200,000 Ordinary Shares at an exercise price of $3.79 per share that are not exercisable within 60 days. Mr. Baharav’s options have expiration dates ranging from July 2025 to July 2027.
(4)Includes options to purchase 5,500 Ordinary Shares at an exercise price of NIS 275 per share,days, and options to purchase 11,460 Ordinary Shares at an exercise price of NIS 27.55 per share850,000 RSUs that are exercisabledo not vest within 60 days. In addition, Mr. DrorGeddes holds options150,000 Ordinary Shares.

(6)Mr. Nedivi holds 1,314,285 unvested RSUs and an unvested option to purchase 11,4601,000,000 Ordinary Shares at anvaried exercise price of NIS 27.55 per shareprices that are not exercisable within 60 days. In addition, Mr. DrorNedivi holds 485,715 Ordinary Shares.

(7)Mr. Nissan-Cohen holds 92,667 RSUs that do not vest within 60 days. In addition, Mr. Nissan-Cohen holds 13,333 Ordinary Shares.

(8)Mr. Anthony-Fried holds options to purchase 500,0001,666 Ordinary Shares at an exercise price of $0.70 per share that are not exercisable within 60 days. Mr. Dror’s options have expiration dates ranging from July 2024 to July 2027.
(5)Consists of warrants to purchase 250,050 Ordinary Shares at an exercise price of $2.25 per share that are exercisable within 60 days. In addition, Mr. Eitan holds warrants to purchase 1,249,950 Ordinary Shares at an exercise price of $2.25 per share that are not exercisable within 60 days. Mr. Eitan’s warrants have expiration date of September 2027. In addition, Mr. Eitan holds options to purchase 100,000 Ordinary Shares at an exercise price of $0.70 per share that are not exercisable within 60 days. Mr. Eitan’s options have expiration dates ranging from July 2025 to July 2027.
(6)Includes options to purchase 5,000 Ordinary Shares at an exercise price of NIS 275.00 per share, options to purchase 3,180 Ordinary Shares at an exercise price of NIS 27.55 per share and options to purchase 17,500 Ordinary Shares at an exercise price of $0.70 per share that are exercisable within 60 days. In addition, Mr. Anthony-Fried holds options to purchase 3,180 Ordinary Shares at an exercise price of NIS 27.55 that are not exercisable within 60 days. In addition, Mr. Anthony-Fried holds options to purchase 17,500 Ordinary Shares at an exercise price of $0.70 per share that are not exercisable within 60 days. Mr. Anthony-Fried’s options have expiration dates ranging from July 2024 to July 2027.
(7)Consists of options to purchase 3,180 Ordinary Shares at an exercise price of NIS 27.55 per share that are exercisable within 60 days. In addition, Mr. Kleinfeld holds options to purchase 3,180 Ordinary Shares at an exercise price of NIS 27.55$80.11 per share, and options to purchase 35,000 Ordinary Shares at an exercise price of $0.70 per share that are not exercisable within 60 days, and 9,044 Ordinary Shares. In addition, Mr. Anthony-Fried holds 51,136 RSUs that do not vest within 60 days.

(9)Mr. Garrett holds 30,000 RSUs that do not vest within 60 days.

(10)Mr. Gera holds 62,084 RSUs that do not vest within 60 days. In addition, Mr. Kleinfeld’s options have expiration dates ranging from July 2024 to July 2027.Gera holds 15,916 Ordinary Shares.

(8)(11)Mr. Kleinfeld holds 49,802 RSUs that do not vest within 60 days. In addition, Mr. Kleinfeld holds 8,378 Ordinary Shares.

(12)Mr. Moran holds options to purchase 35,000 Ordinary Shares at an exercise price of $0.70 per share, that are not exercisable within 60 days. Mr. Moran’s options have expiration dates ranging from July 2025 to July 2027.
(9)Includesand options to purchase 5,04211,916 Ordinary Shares at an exercise price of NIS 50.70 per share and options to purchase 13,370 Ordinary Shares at an exercise price of NIS 25.80$9.33 per share that are exercisable within 60 days. In addition, Mr. NulmanMoran holds options to purchase 4581,084 Ordinary Shares at an exercise price of NIS 50.70 per share, options to purchase 9,550 Ordinary Shares at an exercise price of NIS 25.80$9.33 per share and options to purchase 900,000 Ordinary Shares at an exercise price of $0.70 per share37,667 RSUs that aredo not exercisable within 60 days. Mr. Nulman’s options have expiration dates ranging from May 2023 to May 2027.
(10)Mr. Peled holds options to purchase 900,000 Ordinary Shares at an exercise price of $0.70 per share and options to purchase 50,000 Ordinary Shares at an exercise price of $7.50 per share that are not exercisable within 60 days. Mr. Peled’s options have expiration dates ranging from May 2025 to January 2028.
(11)Ms. Poran holds options to purchase 35,000 Ordinary Shares at an exercise price of $0.70 per share that are not exercisable within 60 days. Ms. Poran’s options have expiration dates ranging from July 2025 to July 2027.
(12)Includes options to purchase 1,000 Ordinary Shares at an exercise price of NIS 83.07 per share, options to purchase 5,000 Ordinary Shares at an exercise price of NIS 275 per share, and options to purchase 11,142 Ordinary Shares at an exercise price of NIS 27.55 per share that are exercisable within 60 days. In addition, Ms. Sandler holds options to purchase 7,958 Ordinary Shares at an exercise price of NIS 27.55, options to purchase 500,000 Ordinary Shares at an exercise price of $0.70 per share, options to purchase 100,000 Ordinary Shares at an exercise price of $1.58 per share and options to purchase 50,000 Ordinary Shares at an exercise price of $7.50 per share that are not exercisable within 60 days. Ms. Sandler’s options have expiration dates ranging from May 2021 to January 2028.
(13)Includes warrants to purchase 688,040 Ordinary Shares at an exercise price of $0.75 per share that are exercisablevest within 60 days. In addition, Mr. SternMoran holds warrants to purchase 4,128,2424,333 Ordinary Shares at an exercise price of $0.75 per share that are not exercisable within 60 days. Mr. Stern’s warrants have an expiration date in August 2027. This amount does not include Series B warrants that may be purchased by Mr. Stern. Mr. Stern may invest an additional amount up to $50,000 to buy Series B Warrants, in an amount equal to 10% of the Company’s fully diluted capital. The exercise price per ADS under the Series B Warrants will be the average of the daily volume weighted average price of the ADSs for the 10 consecutive trading days ending on the trading day that is immediately prior to the date of the applicable notice to purchase the Series B Warrants.Shares.


2015 Stock Option Plan

We maintain one equity incentive plan – our Employee Stock Option Plan (2015), or the 2015 Plan. As of March 8, 2021,15, 2024, the number of Ordinary Shares reserved for the exercise of options granted under the plan was 12,000,000.64,000,000. In addition, RSUs and options to purchase 6,724,87316,647,551 Ordinary Shares were issued and outstanding as of such date.


 

Our 2015 Plan was adopted by our board of directors in February 2015, and expires onin February 2025. Our employees, directors, officer, consultants, advisors, suppliers and any other person or entity whose services are considered valuable to us are eligible to participate in this plan. We are authorized to issue equity-based compensation to our executive officers and/or directors and/or employees and/or subsidiaries in the amount that shall not exceed 20% of our issued and outstanding share capital on a fully diluted basis, as will be at the time of the issuance. The foregoing limitation does not preclude from our board of directors’ authority to change and/or determine the amount of equity-based compensation to be issued in accordance with the 2015 Plan.

Our 2015 Plan is administered by our board of directors, regarding the granting of options and the terms of option grants, including exercise price, method of payment, vesting schedule, acceleration of vesting and the other matters necessary in the administration of these plan. Eligible Israeli employees, officers and directors, would qualify for provisions of Section 102(b)(2) of the Israeli Income Tax Ordinance, or the Tax Ordinance. Pursuant to such Section 102(b)(2), qualifying options and shares issued upon exercise of such options are held in trust and registered in the name of a trustee selected by the board of directors. TheIn order to be eligible under Section 102, the trustee may not release these options or shares to the holders thereof for two years from the date of the registration of the options in the name of the trustee. Under Section 102, any tax payable by an employee from the grant or exercise of the options is deferred until the transfer of the options or ordinary shares by the trustee to the employee or upon the sale of the options or ordinary shares, and gains may qualify to be taxed as capital gains at a rate equal to 25%, subject to compliance with specified conditions. Our Israeli non-employee service providers and controlling shareholders may only be granted options under Section 3(9) of the Tax Ordinance, which does not provide for similar tax benefits. The 2015 Plan also permits the grant to Israeli grantees of options that do not qualify under Section 102(b)(2).

Upon termination of employment for any other reason, other than in the event of death, disability, all unvested options will expire and all vested options will generally be exercisable for 3 months following termination, or such other period as determined by the plan administrator, subject to the terms of the 2015 Plan and the governing option agreement.

Upon termination of employment due to death or disability, all the vested options at the time of termination will be exercisable for 12 months, or such other period as determined by the plan administrator, subject to the terms of the 2015 Plan and the governing option agreement.

On March 13, 2019, our board of directors adopted an appendix to the 2015 Plan for U.S. residents. Under this appendix, the 2015 Plan provides for the granting of options to U.S. residents in compliance with the U.S. Internal Revenue Code of 1986, as amended. On July 3, 2019, our shareholders approved the adoption of the 2015 Plan together with the appendix for U.S. residents.

In September 2022, we re-priced the share options granted to a small group of certain directors and senior management, after receiving approval to do so from the Israeli tax authorities. In accordance with the repricing, every two old share options will be converted into one RSU, without an exercise price. The vesting period of the new RSUs will be 4 years. Additionally, in January, February, March, October, November and December, 2023, our board of directors approved an acceleration of vesting of unvested options and RSUs in case of change of control, as well as in other special circumstances, to several employees and executives.

F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation

Not applicable.


 

ITEM 7.MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

A.Major Shareholders

We are not awareA. Major Shareholders

As of March 15, 2024, we had several major shareholders and ADS holders. Nomis Bay Ltd., BPY Limited, EOM Management Ltd., Murchinson, James Keyes, Jason Jagessar, Chaja Carlebach, and Marc J. Bistricer entered into a joint filing agreement in which they agreed to joint filing on behalf of each of their statements on Schedule 13D with respect to our Ordinary Shares. These parties reported that they jointly own 15,550,000 Ordinary Shares and ADSs, which is 6.6% of our Ordinary Shares.

Additionally, Anson Funds Management LP, Anson Management GP LLC, Mr. Bruce R. Winson, Anson Advisors Inc., Mr. Amin Nathoo and Mr. Moez Kassam entered into a joint filing agreement in which they agreed to joint filing on behalf of each of their statements on Schedule 13D with respect to our ADSs. These parties reported that they jointly own 20,391,213 ADSs, or 8.7%, of our Ordinary Shares. Anson Funds Management LP is a Texas limited partnership, Anson Management GP LLC, is the general partner of Anson Funds Management LP and a Texas limited liability company, Mr. Bruce R. Winson, is the principal of Anson Funds Management LP and the managing member of Anson Management GP LLC. Anson Advisors Inc. is an Ontario, Canada corporation, Mr. Amin Nathoo is a director and the Secretary and Chief Compliance Officer of Anson Advisors Inc., and Mr. Moez Kassam is also a director of Anson Advisors Inc. and is the CEO and President of Anson Advisors Inc.

Finally, Mr. Stern is also a major shareholder (see “Item 6.E. Share Ownership”).

In January 2024, we entered into the Rights Plan, which replaced our prior rights agreement that expired by its terms, with the intention to protect the long-term interests our ADS holders and enable them to realize the full potential value of their investment in the Company. The Rights Plan is designed to reduce the likelihood that any entity, person or group would gain control of, or significant influence over our Company. Pursuant to the Rights Plan, we issued one special purchase right for every one ADS outstanding at the close of business on February 5, 2024. Each right allows its holder to purchase from us one-half (0.5) of one ADS, at a purchase price of $0.01 per ADS, once the rights become exercisable. The Rights would become exercisable (and such Person will be deemed to be an Acquiring Person) if at any time after such announcement, (i) the Person increases its ownership percentage to an amount equal to or greater than the greater of (1) 10% and (2) the sum of (I) the lowest number of Ordinary Shares beneficially owned by such Person as a percentage of the outstanding Ordinary Shares as of any beneficial ownertime from and after the time of 5%the public announcement of the declaration of the Rights and (II) 0.001% or (ii) would have been an “Acquiring Person” under that certain Rights Agreement by and between the Company and the Rights Agent dated as of January 27, 2023 prior to the expiration of the rights issued under such agreement. The rights will expire on January 25, 2025. For more of our outstanding Ordinary Shares.information about the Rights Plan, see exhibit 2.2 filed with this annual report on Form 20-F.

Changes in Percentage Ownership by Major Shareholders

Over the course of 2020,2023, there werewas an increase in: (i) joint beneficial ownership of Nomis Bay Ltd., BPY Limited, EOM Management Ltd., Murchinson, James Keyes, Jason Jagessar, Chaja Carlebach, and Marc J. Bistricer from 5.2% to 6.6%, and (ii) Anson Funds Management LP, Anson Management GP LLC, Mr. Bruce R. Winson, Anson Advisors Inc., Mr. Amin Nathoo and Mr. Moez Kassam from 5.1% to 8.7%. In addition, over the course of 2023, there was a decrease in Mr. Stern’s beneficial ownership from 12.7% to 12.3%.

Over the course of 2022, there was an increase in: (i) joint beneficial ownership of Nomis Bay Ltd., BPY Limited, EOM Management Ltd., Murchinson, James Keyes, Jason Jagessar, Chaja Carlebach, and Marc J. Bistricer from 0% to 5.2%, and (ii) Anson Funds Management LP, Anson Management GP LLC, Mr. Bruce R. Winson, Anson Advisors Inc., Mr. Amin Nathoo and Mr. Moez Kassam (from 0% to 5.1%).

Over the course of 2021, Mr. Stern’s beneficial ownership increased from 12.1% to 12.7%.

We are not aware of any increases or decreases in the percentage ownership of some of our formerother significant shareholders: (i) Laurence W. Lytton (from 9.3% to 0%) and (ii) AIGH Capital Management, LLC, AIGH Investment Partners, L.L.C. and Mr. Orin Hirschman, or AIGH (from 6.9% to 2.5%).shareholders.


 

Over the course of 2019, there were decreases in the percentage ownership of some of our former significant shareholders: entities affiliated with AIGH (from 9.6% to 6.9%); (ii) Iroquois Capital Management L.L.C., Richard Abbe and Kimberly Page (from 13.2% to 0.1%) and (iii) Itshak Sharon (Tshuva), Delek Group Ltd. and Phoenix Holdings Ltd., or Hapheonix Group (from 10.1% to 4.5%).

Over the course of 2018, there were increases in the percentage ownership of entities affiliated with Hapheonix Group (from 5.6% to 10.1%), while there were decreases in the percentage ownership of our former significant shareholders and executive officers: (i) Amit Dror (from 5.1% to 1.6%); (ii) Sharon Fima (from 5.1% to 2.7%); (iii) Dagi Shahar Ben-Noon (from 5.1% to 2.7%); (iv) Simon Anthony-Fried (from 5.1% to 2.7%); and (v) Michael Ilan Management and Investments Ltd. (from 6.9% to 0.7%).


Record Holders

Based upon a review of the information provided to us by The Bank of New York Mellon, the depositorydepositary of the ADSs, as of March 1, 2021,15, 2024, there were 45120 holders of record of the ADSs on record with the Depository Trust Company.

These numbers are not representative of the number of beneficial holders of our shares nor is it representative of where such beneficial holders reside, since many of these shares were held of record by brokers or other nominees.

The Company is not controlled by another corporation, by any foreign government or by any natural or legal persons except as set forth herein, and there are no arrangements known to the Company which would result in a change in control of the Company at a subsequent date.

B.Related Party Transactions

B. Related Party Transactions

Employment or Services Agreements

We have entered into written employment or services agreements with each of our executive officers. All of these agreements contain customary provisions regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law. In addition, we have entered into agreements with eachcertain executive officerofficers and directorall of our directors pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent that these liabilities are not covered by directors’ and officers’ insurance.

Mr. Yoav Stern has been our Chief Executive Officer since January 20, 2020, and has been compensated in accordance with the terms of an agreement, or the Amended and Restated Management Services Agreement, approved by our shareholders on July 7, 2020, by and between the Company and Mr. Yoav Stern, through his fully owned entity, DoubleShore Inc. The term of Mr. Stern’s agreement was for a period of three years and was set to expire on December 31, 2022. On December 19 and 20, 2022, our compensation committee and board of directors, respectively, approved the renewal of Mr. Stern’s agreement as of January 1, 2023 and until the next general meeting of shareholders. The renewed agreement was approved in accordance the Companies Law exemptions regarding interested party transactions (regulation 1B4), according to which, the compensation committee and the board of directors may decide to renew the engagement with its Chief Executive Officer or Director in terms which are not materially different from his/her previous terms or in terms which are not favorable compared to the previous engagement, provided in any case that they adhere with our compensation policy. On September 7, 2023, a general meeting of shareholders was held and Mr. Stern’s agreement expired and all payments due to Mr. Stern in connection therewith were made. Since September 7, 2023, Mr. Stern has received no compensation for his ongoing services and there is no certainty when Mr. Stern shall have an approved compensatory arrangement with the Company for his services, if at all. Per the approval of our compensation committee and board of directors, the Company pays for expenses incurred in connection with Mr. Stern’s role as our Chief Executive Officer.

Options

Since our inception we have granted options to purchase our Ordinary Shares to our officers and certain of our directors. Such option agreements may contain (and employment agreements of certain executive officers contain) acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our option plans under “Share Ownership—2015 Stock Option Plan.” If the relationship between us and an executive officer or a director is terminated, except for cause (as defined in the various option plan agreements), options that are vested will generally remain exercisable for 90 days after such termination.


 

Warrants

In August 2020, following the approvalC. Interests of our shareholders, in consideration for his services as our PresidentExperts and Chief Executive Officer, and as appropriate incentive, we entered into a private placement of warrants, or the Stern Transaction, with our President and Chief Executive Officer, Mr. Yoav Stern. In consideration of $150,000, we issued to Mr. Stern warrants to purchase 6,880,402 ADSs of the Company. The warrants have an exercise price of $0.75 per ADS, will vest over a period of two and a half years and will expire after 7 years. Simultaneously with the issuance of the warrants, Mr. Stern forfeited options to purchase 581,000 ADSs, previously granted to him. In addition, as long as Mr. Stern is employed by the Company or is a member of the Company’s board of directors, Mr. Stern may invest an additional amount up to $50,000 to buy Series B Warrants, in an amount equal to 10% of the Company’s fully diluted capital. The exercise price per ADS under the Series B Warrants will be the average of the daily volume weighted average price of the ADSs for the 10 consecutive trading days ending on the trading day that is immediately prior to the date of the applicable notice to purchase the Series B Warrants. In the same general meeting of shareholders that approved the Stern Transaction, the Company’s shareholders approved the amended terms of compensation of the Company’s President and Chief Executive Officer.Counsel

In September 2020, the Company issued 1,500,000 warrants to purchase 1,500,000 ADSs to the Company’s director, Mr. Yaron Eitan, in consideration of $150,000. The warrants have an exercise price of $2.25 per ADS, will vest over a period of three years and will expire after 7 years.

C.Interests of Experts and Counsel

Not applicable.


ITEM 8.FINANCIAL INFORMATION.

ITEM 8. FINANCIAL INFORMATION.

A.Consolidated Statements and Other Financial Information.

A. Consolidated Statements and Other Financial Information.

See “Item 18. Financial Statements.”

Legal Proceedings

From time to time, we may become a party to various litigation matters incidental to the conduct of our business. Except as disclosed below, we are involved in various routinenot presently party to any legal proceedings incidentalthe resolution of which we believe would have a material adverse effect on our business, prospects, financial condition, liquidity, results of operation, cash flows or capital levels.

DeepCube Litigation

On December 7, 2022, we were served with a motion requesting the discovery of documents in the Tel Aviv District Court (Economic Department) by an ADS holder, Mr. Kfir Sapir asserting, among other things, that the purchase price in our acquisition of DeepCube did not accurately reflect the acquired company’s value, that there were flaws in the approval process for the acquisition during the meeting of our board of directors, which allegedly resulted in a breach of the directors’ fiduciary duties, and that we had undervalued DeepCube in our financial reports for 2021, suggesting that the acquired company had no worth. Following our response, on October 19, 2023, upon a request from the Plaintiff, the court dismissed the matter without prejudice because the Plaintiff intended to file a derivative action. On September 5, 2023, Mr. Sapir filed a motion to certify a derivative action according to section 198 to the Companies Law against the Company and its directors with the Tel Aviv District Court, arguing the decision to acquire DeepCube for approximately $40 million in cash and $30 million ADSs, was unreasonable, based on his notion that DeepCube is only a “startup company” with allegedly no revenues and no products. A court hearing is scheduled for July 3, 2024.

Murchinson Litigations in Israeli Courts

On February 12, 2023, Murchinson Ltd., BPY Limited, Nomis Bay Ltd., Boothbay Absolute Return Strategies, LP. and Boothbay Diversified Alpha Master Fund, LP., collectively Murchinson or Murchinson and Affiliates submitted a statement of claim to the Lod District Court (Economic Department), or the Court, in which they asserted that our shares registered under Form S-8, filed with the SEC on January 27, 2023, were allocated unlawfully and in bad faith, resulting in the deprivation of shareholders’ rights. Murchinson also requested that the Court cancel the registration of the newly registered shares on the Company’s Form S-8. Furthermore, Murchinson demanded that the Court order us to refrain from any allocation of shares from the newly registered shares, or, in the alternative, to make any allocation subject to shareholder meeting approval or condition any future allocations from the newly registered shares on specific criteria related to employee and official compensation. Pre-trial hearings were held on June 18, 2023 and on February 21, 2024.

Separately, on February 27, 2023, we filed a claim against Murchinson in the Court, challenging Murchinson’s right to convene a shareholders’ meeting, contending that they are not shareholders (but rather ADS holders). Following a hearing on June 18, 2023, the matter was stayed until a verdict is reached in the Second Murchinson Claim, as described below.

On March 26, 2023, Murchinson filed for temporary relief in Court, or the Second Murchinson Claim, in which it claimed that it had the right to convene a special general meeting of shareholders on March 20, 2023, and that the decisions in that special general meeting would be valid and legally binding. Specifically, the meeting Murchinson wanted to convene would amend the article of association and appoint two directors, or the Alleged Directors, and remove from office Yoav Stern, Oded Gera, Igal Rotem and Dr. Yoav Nissan-Cohen. Following a hearing and submission of motions, on April 16, 2023, the Court rejected Murchinson’s request for temporary relief and request that we refrain from doing any business outside the ordinary course of business. The Court, however, granted the alternative relief of appointing the Alleged Directors as board observers. We filed, with the Supreme Court of Israel, a request for interlocutory appeal, but was denied. The Second Murchinson Claim is currently pending before the Court.


On August 31, 2023, Murchinson filed a complaint against the Company and Mr. Yoav Stern, arguing that we wrongfully counted proxy cards at our business.September 7, 2023, annual general meeting, or the AGM, and that the required majority for the dismissal of directors at the AGM are a simple majority rather than a special majority of 70%. In connection with this complaint, Murchinson requested temporary relief requesting that the Court instruct the Company (1) to refrain from implementing the decisions reached at the AGM; or (2) to refrain from convening board of directors and committee meetings with members comprising Ms. Hanna Caspi, Mr. Oded Gera and Dr. Yoav Cohen-Nissan; or (3) to refrain from doing any business outside the ordinary course of business, including changes in our capital. A hearing took place on September 5, 2023, during which the Court denied the request for temporary relief. The Company filed a counterstatement of claims to Murchinson’s complaint on January 18, 2024, and its statement of defense on January 21, 2024. A hearing was held on February 21, 2024, in which the court scheduled further proceedings starting in September 2024.

On March 18, 2024, we filed a motion for temporary injunction in the Court against Murchinson, and Affiliates and Mr. Moshe Sarfati, a senior analyst at Murchinson, or the Respondents, in which we claim that the Respondents had contacted officers at certain third-party companies with whom we have had business discussions, and committed tortious interference. We asked the Court to issue an injunction against the Respondents:

I.To refrain from contacting third parties – including companies in the field of 3D printing and/or companies engaged in negotiations with the Company – regarding the Company’s affairs, and to present them with misleading presentations casting doubt over the legality of the current board of directors of the Company and implying that the current board of directors and management are not authorized to make decisions regarding the Company’s transactions, or to threaten them that Respondents will act to thwart any negotiation, collaboration, or transaction with the Company under the guidance of the Company’s current board of directors.

II.To avoid interfering with or undermining the Company’s business activities, including any attempts to thwart transactions advancing the Company’s interests with third parties, including merger, acquisition, or stock exchange transactions. We also asked the Court to order the Respondents to provide a written affidavit to be submitted by each of the Respondents, detailing all communications made to third parties engaged in business relations with the Company, with the aim of interfering in the Company’s business affairs.

On March 21, 2024, we filed a complaint with the Court requesting a declaration that Respondents had breached their duties and requesting the remedies specified above. A hearing is scheduled for March 26, 2024.

Murchinson Litigation in U.S. Courts

On March 27, 2023, we filed a complaint in the United States District Court for the Southern District of New York alleging claims against Murchinson and Affiliates as well as Anson Funds, or Anson. The complaint alleges that defendants improperly engaged in coordinated efforts to acquire a large stake in the Company and interfered with its business operations, in violation of U.S. securities laws, New York law, and pertinent contracts governing our ADSs. The Complaint also alleges that defendants’ conduct was in violation of Section 13(d) of the Exchange Act and constituted breach of contract, tortious interference with prospective business relationships, and unjust enrichment. After we filed the complaint, on May 2, 2023 and June 23, 2023, Murchinson and Anson filed amended disclosures with the SEC. On July 10, 2023, the United States District Court dismissed our federal securities claims against Murchinson and Anson and declined to exercise supplemental jurisdiction concerning our state law claims, dismissing them without prejudice. On August 9, 2023, we appealed the District Court’s decision dismissing our claims arising under Section 13(d) of the Exchange That appeal remains pending.

On July 14, 2023, we filed a complaint against Murchinson and Affiliates and Anson in the Supreme Court of the State of New York. The complaint in this action alleges that Murchinson and Affiliates breached multiple provisions of the contract that governs there holdings of our ADSs and were unjustly enriched through their improper trading of our ADSs. On August 3, 2023, the Supreme Court of the State of New York issued a decision temporarily staying the Company’s claims pending a post-trial ruling in the Second Murchinson Claim. We do not believeanticipate that any further action will take place in this matter until the stay is lifted.

On May 1, 2023, Murchinson filed a complaint in the Southern District of New York alleging that the outcomes of these legal proceedings have hadCompany and its directors violated New York Civil Rights Law §§ 70-a and 76-a when they initiated the above-referenced litigation in the recent past,Southern District of New York. On August 9, 2023, we filed a motion to dismiss the complaint in its entirety, arguing, inter alia, that the Southern District of New York lacks jurisdiction to hear the claims and that Murchinson’s complaint fails on the merits. The Company’s motion to dismiss remains pending.

Stratasys Litigation

On April 25, 2023, we filed a motion for the issuance of temporary relief against Stratasys and its board of directors, requesting that the Tel Aviv District Court prevent Stratasys from sabotaging a special tender offer that we announced we intended to publish according to the mechanism prescribed in the Companies Law for implementing an unlawful “poison pill.” On May 7, 2023, we filed a statement of claim, or will have (with respectthe Poison Pill Claim, against Stratasys and its board of directors. Following a hearing held in connection with the Poison Pill Claim, on July 18, 2023, the Tel Aviv District Court suggested, without making a conclusive decision, that he believes that there is no per se prohibition against such a plan as long as it does not discriminate between shareholders. On August 8, 2023, the court stayed the proceedings in the Poison Pill Claim. On November 16, 2023, we asked the Tel Aviv District Court to anyresume the proceedings and to set dates for final briefing. The matter is currently pending proceedings), significant effects onbefore the Tel Aviv District Court.


Dividends

Except as detailed in Item 16E in relation to the repurchase of our financial position or profitability.

Dividends

WeOrdinary Shares, which is considered a dividend under the Companies Law, we have never declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.

Under the Companies Law, we may declare and pay dividends only if, upon the determination of our board of directors, there is no reasonable concern that the distribution will prevent us from being able to meet the terms of our existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according to our then last reviewed or audited financial statements, provided that the end of the period to which the financial statements relate is not more than six months prior to the date of distribution, generally referred to as the Earnings Criteria. In the event that we do not meet such earnings criteria, we may seek the approval of the court in order to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due, generally referred to as the Solvency Criteria.

However, under the New Exemptions, an Israeli company whose shares are listed outside of Israel, is permitted to perform distribution in a way of repurchasing its own shares, even if the Earnings Criteria is not met, without the need for court’s approval. The exemption is subject to certain conditions, including, among others: (i) The distribution meets the Solvency Criteria; and (ii) no rejection was filed by any of the company’s creditors to the court. If any creditor objects to the distribution, the company will be required to obtain the court’s approval for the distribution. 

Payment of dividends may be subject to Israeli withholding taxes. See “Item 10.E. Taxation”, for additional information.

B.Significant Changes

B. Significant Changes

No significant change, other than as otherwise described in this annual report on Form 20-F, has occurred in our operations since the date of our consolidated financial statements included in this annual report on Form 20-F.

ITEM 9.THE OFFER AND LISTING

ITEM 9. THE OFFER AND LISTING

A.Offer and Listing Details

On March 7, 2016, ourA. Offer and Listing Details

Our ADSs, which represent our Ordinary Shares, commenced tradingare traded on the Nasdaq Capital Market under the symbol “NNDM.” Each ADS currently represents one Ordinary Share. Our ADSs are subject to the Rights Plan.

B.Plan of Distribution

B. Plan of Distribution

Not applicable.

C.Markets

C. Markets

Our ADSs are listed on the Nasdaq Capital Market.

D. Selling Shareholders

Not applicable.

E. Dilution

Not applicable.

F. Expenses of the Issue

Not applicable.


 

D.Selling Shareholders

Not applicable.

E.Dilution

Not applicable.

F.Expenses of the Issue

Not applicable.


ITEM 10.ADDITIONAL INFORMATION

ITEM 10. ADDITIONAL INFORMATION

A.Share Capital

A. Share Capital

Not applicable.

B.Memorandum and Articles of Association

B. Memorandum and Articles of Association

A copy of our amended and restated articles of association is attached as Exhibit 1.1 to this annual report on Form 20-F. The information called for by this Item is set forth in Exhibit 2(d)2.2 to this annual report on Form 20-F and is incorporated by reference into this annual report on Form 20-F.

C.Material Contracts

C. Material Contracts

The following is a summary of each material contract, other than material contracts entered into in the ordinary course of business, to which we are or have been a party, for the two years immediately preceding the date of this annual report on Form 20-F:

Amended and Restated LicenseShare Purchase Agreement, dated April 2, 2015,January 4, 2022, by and among Nano Dimension Ltd. and the Selling Shareholders (related to the acquisition of Essemtec), filed as Exhibit 10.1 to Report on Form 6-K (File No. 001-37600), filed on January 5, 2022. See Item 5.B “Liquidity and Capital Resources - Financing Activities” for more information about this agreement.

Share Purchase Agreement, dated January 4, 2022, by and among Nano Dimension Ltd. and the Selling Shareholders (related to the acquisition of GIS), filed as Exhibit 10.1 to Report on Form 6-K (File No. 001-37600), filed on January 5, 2022. See Item 5.B “Liquidity and Capital Resources - Financing Activities” for more information about this agreement.

Equity Purchase Agreement, dated July 7, 2022, by and between Nano Dimension Ltd. and Lapmaster Wolters Limited, and, solely for purposes of Sections 7.6 and 9.15, Lapmaster Group Holdings LLC., filed as Exhibit 10.1 to Report on Form 6-K (File No. 001-37600), filed on July 8, 2022. See Item 5.B “Liquidity and Capital Resources - Financing Activities” for more information about this agreement.

Deed of Variation of Share Purchase Agreement, dated July 11, 2022, by and among Nano Dimension Ltd., the CompanySelling Shareholders Representative (on behalf of the Selling Shareholders) and Yissum Research Development CompanyNicholas Campbell Geddes, filed as Exhibit 10.1 to Report on Form 6-K (File No. 001-37600), filed on July 14, 2022. See Item 5.B “Liquidity and Capital Resources - Financing Activities” for more information about this agreement.

Rights Agreement, dated January 27, 2023, by and between Nano Dimension Ltd. and the Bank of The Hebrew University of Jerusalem, Ltd.,New York Mellon, filed as Exhibit 4.1 to Report on Form 20-F/A6-K (File No. 001-37600), filed on FebruaryJanuary 27, 2023 (expired on January 29, 2016.2024).

Rights Agreement, dated January 25, 2024, by and between Nano Dimension Ltd. and the Bank of New York Mellon, filed as Exhibit 4.1 to Report on Form 6-K (File No. 001-37600), filed on January 25, 2024. See Item 4.A “Business Overview—Intellectual Propertyexhibit 2.2 filed with this annual report on Form 20-F for more information about this document.agreement.

Nano Dimension Ltd. Employee Stock Option Plan (2015), filed as Exhibit 99.1 to Form 6-K filed on June 10, 2019. See Item 6 “Directors, Senior Management and Employees” for more information about this document.

Nano Dimension Ltd. Amended and Restated Executive Officers Compensation Policy, filed as Exhibit A to Exhibit 99.1 to Form 6-K filed on June 2, 2020. See Item 6 “Directors, Senior Management and Employees” for more information about this document.

Form of Warrant to purchase Ordinary Shares Represented by American Depositary Shares, dated January 30, 2019, filed as Exhibit 4.2 to Form F-1 (File No. 001-228521) filed on January 30, 2019.

Form of Securities Purchase Agreement, dated August 30, 2019, filed as Exhibit 99.2 to Form 6-K, filed on September 3, 2019.

Form of Convertible Promissory Note, dated September 4, 2019, filed as Exhibit 99.3 to Form 6-K, filed on September 3, 2019.

Form of Warrant to purchase Ordinary Shares Represented by American Depositary Shares, dated September 4, 2019, filed as Exhibit 99.4 to Form 6-K.

Form of Registration Rights Agreement, dated August 30, 2019, filed as Exhibit 99.5 to Form 6-K, filed on September 3, 2019.

Securities Purchase Agreement, dated August 5, 2020, between Nano Dimension Ltd. and Stern YOI Ltd. Partnership, filed as Exhibit 4.4 to Form F-3 (File No. 333-252848), filed on February 8, 2021.

Form of Series A Warrant to purchase Ordinary Shares Represented by American Depositary Shares, dated August 5, 2020, between Nano Dimension Ltd. and Stern YOI Ltd. Partnership, filed as Exhibit 4.5 to Form F-3 (File No. 333-252848), filed on February 8, 2021.

Securities Purchase Agreement, dated September 6, 2020, between Nano Dimension Ltd. and YEDNE LLC, filed as Exhibit 4.6 to Form F-3 (File No. 333-252848), filed on February 8, 2021.

Form of Warrant to purchase Ordinary Shares Represented by American Depositary Shares, dated September 6, 2020, between Nano Dimension Ltd. and YEDNE LLC, filed as Exhibit 4.7 to Form F-3 (File No. 333-252848), filed on February 8, 2021.


D.Exchange Controls

D. Exchange Controls

There are currently no Israeli currency control restrictions on payments of dividends or other distributions with respect to our Ordinary Shares or the proceeds from the sale of the shares, except for the obligation of Israeli residents to file reports with the Bank of Israel regarding certain transactions. However, legislation remains in effect pursuant to which currency controls can be imposed by administrative action at any time.

The ownership or voting of our Ordinary Shares by non-residents of Israel, except with respect to citizens of countries that are in a state of war with Israel, is not restricted in any way by our memorandum of association or amended and restated articles of association or by the laws of the State of Israel.


 

E. Taxation.

E.

Taxation.

Israeli Tax Considerations and Government Programs

The following is a description of the material Israeli income tax consequences of the ownership of our Ordinary Shares. The following also contains a description of material relevant provisions of the current Israeli income tax structure applicable to companies in Israel, with reference to its effect on us. To the extent that the discussion is based on new tax legislation which has not been subject to judicial or administrative interpretation, there can be no assurance that the tax authorities will accept the views expressed in the discussion in question. The discussion is not intended, and should not be taken, as legal or professional tax advice and is not exhaustive of all possible tax considerations.

The following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our Ordinary Shares and ADSs. Shareholders should consult their own tax advisors concerning the tax consequences of their particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.

General Corporate Tax Structure in Israel

Israeli companies are generally subject to corporate tax. As of January 2016, the corporate tax rate was 25%. As of January 1, 2017, the corporate tax rate was reduced to 24% and as of January 1, 2018, the corporate tax rate was further reduced to 23%. However, the effective tax rate payable by a company that derives income from a Preferred Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli company are generally subject to the prevailing corporate tax rate.

Law for the Encouragement of Industry (Taxes), 5729-1969

The Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax benefits for “Industrial Companies.”

The Industry Encouragement Law defines an “Industrial Company” as an Israeli resident-company, of which 90% or more of its income in any tax year, other than income from defense loans, is derived from an “Industrial Enterprise” owned by it. An “Industrial Enterprise” is defined as an enterprise whose principal activity in a given tax year is industrial production.

The following corporate tax benefits, among others, are available to Industrial Companies:

amortization of the cost of purchased a patent, rights to use a patent, and know-how, which are used for the development or advancement of the company, over an eight-year period, commencing on the year in which such rights were first exercised;

under limited conditions, an election to file consolidated tax returns with related Israeli companies; and

expenses related to a public offering are deductible in equal amounts over three years.

Eligibility for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.


Tax Benefits and Grants for Research and Development

Under the Research Law, programs which meet specified criteria and are approved by the IIA are eligible for grants of up to 50%85% of the project’s expenditure, as determined by the research committee, in exchange for the payment of royalties from the revenues generated from the sale of products and related services developed, in whole or in part pursuant to, or as a result of, a research and development program funded by the IIA. The royalties are generally at a range of 3.0% to 5.0%3.5% of revenues until the entire IIA grant is repaid, together with an annual interest. Until October 25, 2023, the interest generally equal to the 12 monthwas calculated at a rate based on 12-month London Interbank Offered Rate, or LIBOR, applicable to U.S. dollar deposits thatdeposits. However, on October 25, 2023, the IIA published a directive concerning changes in royalties to address the expiration of the LIBOR. Under such directive, regarding IIA grants approved by the IIA prior to January 1, 2024 but which are outstanding thereafter, as of January 1, 2024 the annual interest is calculated at a rate based on 12-month Secured Overnight Financing Rate, or SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%; and, for grants approved on or following January 1, 2024 the first business dayannual interest shall be the higher of each calendar year.(i) the 12 months SOFR interest rate, plus 1%, or (ii) a fixed annual interest rate of 4%.


 

The terms of the Research Law also require that the manufacture of products developed with government grants be performed in Israel. The transfer of manufacturing activity outside Israel may be subject to the prior approval of the IIA. Under the regulations of the Research Law, assuming we receive approval from the IIA to manufacture our IIA funded products outside Israel, we may be required to pay increased royalties. The increase in royalties depends upon the manufacturing volume that is performed outside of Israel as follows:

Manufacturing Volume Outside of Israel Royalties
to the IIA as
a Percentage
of Grant
 
Up to 50%  120%
between 50% and 90%  150%
90% and more  300%

 

If the manufacturing is performed outside of Israel by us, the rate of royalties payable by us on revenues from the sale of products manufactured outside of Israel will increase by 1% over the regular rates. If the manufacturing is performed outside of Israel by a third party, the rate of royalties payable by us on those revenues will be equal to the ratio obtained by dividing the amount of the grants received from the IIA and our total investment in the project that was funded by these grants. The transfer of no more than 10% of the manufacturing capacity in the aggregate outside of Israel is exempt under the Research Law from obtaining the prior approval of the IIA. A company requesting funds from the IIA also has the option of declaring in its IIA grant application an intention to perform part of its manufacturing outside Israel, thus avoiding the need to obtain additional approval. On January 6, 2011, the Research Law was amended to clarify that the potential increased royalties specified in the table above will apply even in those cases where the IIA approval for transfer of manufacturing outside of Israel is not required, namely when the volume of the transferred manufacturing capacity is less than 10% of total capacity or when the company received an advance approval to manufacture abroad in the framework of its IIA grant application. For applications to manufacture abroad, submitted to the IIA after October 25, 2023, the maximum increased liability is up to 150% of the IIA grants, plus interest accrued thereon, instead of 300%.

The know-how developed within the framework of the IIA plan may not be transferred to third parties outside Israel without the prior approval of a governmental committee charted under the Research Law. The approval, however, is not required for the export of any products developed using grants received from the IIA. The IIA approval to transfer know-how created, in whole or in part, in connection with an IIA-funded project to third party outside Israel where the transferring company remains an operating Israeli entity is subject to payment of a redemption fee to the IIA calculated according to a formula provided under the Research Law that is based, in general, on the ratio between the aggregate IIA grants to the company’s aggregate investments in the project that was funded by these IIA grants, multiplied by the transaction consideration. The transfer of such know-how to a party outside Israel where the transferring company ceases to exist as an Israeli entity is subject to a redemption fee formula that is based, in general, on the ratio between the aggregate IIA grants to the total financial investments in the company, multiplied by the transaction consideration. According to the January 2011 amendment, the redemption fee in case of transfer of know-how to a party outside Israel will be based on the ratio between the aggregate IIA grants received by the company and the company’s aggregate R&D expenses, multiplied by the transaction consideration. According to regulations promulgated following the 2011 amendment, the maximum amount payable to the IIA in case of transfer of know how outside Israel shall not exceed 6 times the value of the grants received plus interest, and in the event that the receiver of the grants ceases to be an Israeli corporation such payment shall not exceed 6 times the value of the grants received plus interest, with a possibility to reduce such payment to up to 3 times the value of the grants received plus interest if the R&D activity remains in Israel for a period of three years after payment to the IIA.

IIA and maintain at least 75% of the research and development employees the Company had for the six months before the know-how was transferred, subject to additional conditions specified in the regulations.


Transfer of know-how within Israel is subject to an undertaking of the recipient Israeli entity to comply with the provisions of the Research Law and related regulations, including the restrictions on the transfer of know-how and the obligation to pay royalties, as further described in the Research Law and related regulations.

These restrictions may impair our ability to outsource manufacturing, engage in change of control transactions or otherwise transfer our know-how outside Israel and may require us to obtain the approval or the IIA for certain actions and transactions and pay additional royalties to the IIA. In particular, any change of control and any change of ownership of our Ordinary Shares that would make a non-Israeli citizen or resident an “interested party,” as defined in the Research Law, requires a prior written notice to the IIA in addition to any payment that may be required of us for transfer of manufacturing or know-how outside Israel. If we fail to comply with the Research Law, we may be subject to criminal charges.charges or to mandatory repayment of grants received by us (together with interest and penalties).


 

Tax Benefits for Research and Development

Israeli tax law allows, under certain conditions, a tax deduction for expenditures, including capital expenditures, for the year in which they are incurred. Expenditures are deemed related to scientific research and development projects, if:

The expenditures are approved by the relevant Israeli government ministry, determined by the field of research;

The research and development must be for the promotion of the company; and

The research and development is carried out by or on behalf of the company seeking such tax deduction.

The amount of such deductible expenses is reduced by the sum of any funds received through government grants for the finance of such scientific research and development projects. No deduction under these research and development deduction rules is allowed if such deduction is related to an expense invested in an asset depreciable under the general depreciation rules of the income Tax Ordinance, 1961. Expenditures not so approved are deductible in equal amounts over three years.

From time to time, we may apply the Office of the IIA for approval to allow a tax deduction for all research and development expenses during the year incurred. There can be no assurance that such application will be accepted.

Law for the Encouragement of Capital Investments, 5719-1959

The Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in production facilities (or other eligible assets).

Tax Benefits

The Investment Law grants tax benefits for income generated by a “Preferred Company” through its “Preferred Enterprise” (as such terms are defined in the Investment Law) The definition of a Preferred Company includes a company incorporated in Israel that is not fully owned by a governmental entity, and that has, among other things, Preferred Enterprise status and is controlled and managed from Israel. A Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to its income derived by its Preferred Enterprise, unless the Preferred Enterprise is located in a specified development zone, in which case the rate will be 7.5% as of January 1, 2017.

Dividends paid out of income attributed to a Preferred Enterprise are generally subject to withholding tax at source at the rate of 20% or such lower rate as may be provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, no tax is required to be withheld.

Taxation of our Shareholders

Capital Gains Taxes Applicable to Non-Israeli Resident Shareholders. A non-Israeli resident who derives capital gains from the sale of shares in an Israeli resident company should be exempt from Israeli tax so long as the shares were not held through a permanent establishment that the non-resident maintains in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemption if Israeli residents: (i) have a controlling interest of 25% or more in such non-Israeli corporation or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.


 


Additionally, a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example, under Convention Between the Government of the United States of America and the Government of the State of Israel with respect to Taxes on Income, as amended, or the United States-Israel Tax Treaty, the sale, exchange or other disposition of shares by a shareholder who is a United States resident (for purposes of the treaty) holding the shares as a capital asset and is entitled to claim the benefits afforded to such a resident by the U.S.-Israel Tax Treaty, or Treaty U.S. Resident, is generally exempt from Israeli capital gains tax unless: (i) the capital gain arising from such sale, exchange or disposition is attributed to real estate located in Israel; (ii) the capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii) the capital gain arising from the such sale, exchange or disposition is attributed to a permanent establishment in Israel, under certain terms; (iv) such Treaty U.S. Resident holds, directly or indirectly, shares representing 10% or more of the voting capital during any part of the 12-month period preceding the disposition, subject to certain conditions; or (v) such Treaty U.S. Resident is an individual and was present in Israel for 183 days or more during the relevant taxable year.

In some instances where our shareholders may be liable for Israeli tax on the sale of their ordinary shares,Ordinary Shares, the payment of the consideration may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale.

Taxation of Non-Israeli Shareholders on Receipt of Dividends. Non-Israeli residents are generally subject to Israeli income tax on the receipt of dividends paid on our Ordinary Shares at the rate of 25%, which tax will be withheld at source, unless relief is provided in a treaty between Israel and the shareholder’s country of residence. With respect to a person who is a “substantial shareholder” at the time of receiving the dividend or on any time during the preceding twelve months, the applicable tax rate is 30%. A “substantial shareholder” is generally a person who alone or together with such person’s relative or another person who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the “means of control” of the corporation. “Means of control” generally include the right to vote, receive profits, nominate a director or an executive officer, receive assets upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source of such right. However, a distribution of dividends to non-Israeli residents is subject to withholding tax at source at a rate of 20% if the dividend is distributed from income attributed to a Preferred Enterprise, unless a reduced tax rate is provided under an applicable tax treaty. For example, under the United States-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our Ordinary Shares who is a Treaty U.S. Resident is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated by a Preferred Enterprise, that are paid to a United States corporation holding 10% or more of the outstanding voting capital throughout the tax year in which the dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more than 25% of the gross income for such preceding year consists of certain types of dividends and interest. Notwithstanding the foregoing, dividends distributed from income attributed to an Preferred Enterprise are not entitled to such reduction under the tax treaty but are subject to a withholding tax rate of 15% for a shareholder that is a U.S. corporation, provided that the condition related to our gross income for the previous year (as set forth in the previous sentence) is met. If the dividend is attributable partly to income derived from a Preferred Enterprise, and partly to other sources of income, the withholding rate will be a blended rate reflecting the relative portions of the two types of income. We cannot assure you that we will designate the profits that we may distribute in a way that will reduce shareholders’ tax liability.

U.S. Tax Considerations

U.S. Federal Income Tax Considerations

THE FOLLOWING SUMMARY IS INCLUDED HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE OF ORDINARY SHARES AND AMERICAN DEPOSITORYDEPOSITARY SHARES, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE CHANGES IN THE TAX LAWS.


 

Subject to the limitations described in the next paragraph, the following discussion summarizes the material U.S. federal income tax consequences to a “U.S. Holder” arising from the purchase, ownership and sale of the Ordinary Shares and ADSs. For this purpose, a “U.S. Holder” is a holder of Ordinary Shares or ADSs that is: (1) an individual citizen or resident of the United States, including an alien individual who is a lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal income tax laws; (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other than a partnership that is not treated as a U.S. person under any applicable U.S. Treasury regulations) created or organized under the laws of the United States or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which is includable in gross income for U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons (within the meaning of Section 7701(a)(30) of the Internal Revenue Code of 1986, as amended, or the Code) have authority to control all substantial decisions of the trust; or (5) a trust that has a valid election in effect to be treated as a U.S. person to(within the extent provided inmeaning of Section 7701(a)(30) of the Code) for U.S. Treasury regulations.federal income tax purposes.

 


If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our ADSs or Ordinary Shares, the tax treatment of an owner of such entity will depend on the status of the owners, the activities of the entity or arrangement and certain determinations made at the owner level. Accordingly, entities or arrangements treated as partnerships for U.S. federal income tax purposes and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences applicable for them.

This summary is for general information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations that may be relevant to a decision to purchase our Ordinary Shares or ADSs. This summary generally considers only U.S. Holders that will own our Ordinary Shares or ADSs as capital assets.assets within the meaning of Section 1221 of the Code. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences to a person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer’s status as a U.S. Holder. This summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary and proposed U.S. Treasury regulations promulgated thereunder, administrative and judicial interpretations thereof, (including with respect to the Tax Cuts and Jobs Act, or the TCJA, as defined below), and the U.S./Israel Income Tax Treaty, all as in effect as of the date hereof and all of which are subject to change, possibly on a retroactive basis, and all of which are open to differing interpretations. We will not seek a ruling from the IRS with regard to the U.S. federal income tax treatment of an investment in our Ordinary Shares or ADSs by U.S. Holders and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below.

 

This discussion does not address all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based on such holder’s particular circumstances and in particular does not discuss any estate, gift, generation-skipping, transfer, state, local, excise or foreign tax considerations. In addition, this discussion does not address the U.S. federal income tax treatment of a U.S. Holder who is: (1) a bank, life insurance company, regulated investment company, or other financial institution or “financial services entity:” (2) a broker or dealer in securities or foreign currency; (3) a person who acquired our Ordinary Shares or ADSs in connection with employment or other performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds our Ordinary Shares or ADSs as a hedge or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for U.S. federal income tax purposes; (6) a tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a U.S. Holder that expatriates out of the United States or a former long-term resident of the United States; or (9) a person having a functional currency other than the U.S. dollar.dollars; or (10) S corporations, partnerships or other entities or arrangements treated as partnerships or other flow-through entities for U.S. federal income tax purposes (and investors therein). This discussion does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly or constructively, at any time, Ordinary Shares or ADSs representing 10% or more of our voting power. Additionally, the U.S. federal income tax treatment of partnerships (or other pass-through entities) or persons who hold Ordinary Shares or ADSs through a partnership or other pass-through entity are not addressed.

 


In general, for U.S. federal income tax purposes, U.S. Holders of our ADSs will be treated as owning the underlying Ordinary Shares represented by those ADSs. Accordingly, exchanges of Ordinary Shares for ADSs, and ADSs for Ordinary Shares will not be subject to U.S. federal income tax.

 

Each prospective investor is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing, holding or disposing of our Ordinary Shares or ADSs, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws.

 

Taxation of Dividends Paid on Ordinary Sharesor ADSs

 

We do not intend to pay dividends in the foreseeable future. In the event that we do pay dividends, and subject to the discussion under the heading “Passive Foreign Investment Companies” below and the discussion of “qualified dividend income” below, a U.S. Holder will be required to include in gross income as ordinary income the amount of any distribution paid on Ordinary Shares or ADSs (including the amount of any Israeli tax withheld on the date of the distribution), to the extent that such distribution does not exceed our current and accumulated earnings and profits, as determined for U.S. federal income tax purposes. The amount of a distribution which exceeds our earnings and profits will be treated first as a non-taxable return of capital, reducing the U.S. Holder’s tax basis for the Ordinary Shares to the extent thereof, and then capital gain. We do not expect to maintain calculations of our earnings and profits under U.S. federal income tax principles and, therefore, U.S. Holders should expect that the entire amount of any distribution generally will be reported as dividend income.

 

In general, preferential tax rates for “qualified dividend income” and long-term capital gains are applicable for U.S. Holders that are individuals, estates or trusts. For this purpose, “qualified dividend income” means, inter alia, dividends received from a “qualified foreign corporation.” A “qualified foreign corporation” is a corporation that is entitled to the benefits of a comprehensive tax treaty with the United States which includes an exchange of information program. The IRS has stated that the Israel/U.S. Tax Treaty satisfies this requirement and we believe we are eligible for the benefits of that treaty.

 


In addition, our dividends will be qualified dividend income if our Ordinary Shares or ADSs are readily tradable on the Nasdaq Capital Market or another established securities market in the United States. Dividends will not qualify for the preferential rate if we are treated, in the year the dividend is paid or in the prior year, as a PFIC, as described below under “Passive Foreign Investment Companies.” A U.S. Holder will not be entitled to the preferential rate: (1) if the U.S. Holder has not held our Ordinary Shares or ADSs for at least 61 days of the 121 day period beginning on the date which is 60 days before the ex-dividend date, or (2) to the extent the U.S. Holder is under an obligation to make related payments on substantially similar property. Any days during which the U.S. Holder has diminished its risk of loss on our Ordinary Shares or ADSs are not counted towards meeting the 61-day holding period. Finally, U.S. Holders who elect to treat the dividend income as “investment income” pursuant to Code section 163(d)(4) will not be eligible for the preferential rate of taxation.

 

The amount of a distribution with respect to our Ordinary Shares or ADSs will be measured by the amount of the fair market value of any property distributed, and for U.S. federal income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by us in NIS will be included in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includible in the income of the U.S. Holder, andregardless of whether the payment is in fact converted into U.S. Holders will havedollars at that time. Any foreign currency gain or loss a tax basis in such NIS for U.S. federal income tax purposes equal to such U.S. dollar value. If the U.S. Holder subsequently convertsrealizes on a subsequent conversion of the NIS into U.S. dollars or otherwise disposes of it, any subsequent gain or loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss.

 


Taxation of the Disposition of Ordinary Shares or ADSs

 

Except as provided under the PFIC rules described below under “Passive Foreign Investment Companies,” upon the sale, exchange or other disposition of our Ordinary Shares or ADSs, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder’s tax basis for the Ordinary Shares or ADSs in U.S. dollars and the amount realized on the disposition in U.S. dollar (or its U.S. dollar equivalent determined by reference to the spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency). A U.S. Holder’s initial tax basis in shares generally will equal the cost of such shares. If any foreign tax is imposed on the sale, exchange or other disposition of our ADSs or Ordinary Shares, a U.S. Holder’s amount realized will include the gross amount of the proceeds of the deposits before deduction of the tax. The gain or loss realized on the sale, exchange or other disposition of Ordinary Shares or ADSs will be long-term capital gain or loss if the U.S. Holder has a holding period of more than one year at the time of the disposition. Individuals who recognize long-term capital gains may be taxed on such gains at reduced rates of tax. The deduction of capital losses is subject to various limitations.

 

Gain realized by a U.S. Holder on a sale, exchange or other disposition of Ordinary Shares or ADSs will generally be treated as U.S. source income for U.S. foreign tax credit purposes. A loss realized by a U.S. Holder on the sale, exchange or other disposition of Ordinary Shares or ADSs is generally allocated to U.S. source income. The deductibility of a loss realized onBecause gain for the sale exchange or other taxable disposition of our ADSs or Ordinary Shares will be treated as U.S. source income, and you may use foreign tax credits against only the portion of United States federal income tax liability that is attributed to foreign source income in the same category, your ability to utilize a foreign tax credit with respect to any foreign tax imposed on any such sale or ADSs is subject to limitations.other taxable disposition, if any, may be significantly limited. An additional 3.8% net investment income tax (described below) may apply to gains recognized upon the sale, exchange or other taxable disposition of our Ordinary Shares or ADS by certain U.S. Holders who meet certain income thresholds.

 

Passive Foreign Investment Companies

 

Special U.S. federal income tax laws apply to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC for U.S. federal income tax purposes for any taxable year that either:

 

75% or more of our gross income (including our pro rata share of gross income for any company, in which we are considered to own 25% or more of the shares by value), in a taxable year is passive; or

 

At least 50% of our assets, averaged over the year and generally determined based upon fair market value (including our pro rata share of the assets of any company in which we are considered to own 25% or more of the shares by value) are held for the production of, or produce, passive income.

 

For this purpose, passive income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities transactions and from notional principal contracts. Cash is treated as generating passive income.

We do not expect that we will begenerally treated as a PFIC for the current taxable year. passive asset, subject to certain exceptions that qualify as working capital.

The tests for determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets which are relevant to this determination. In addition, our PFIC status may depend in part on the market value of our Ordinary Shares or ADSs. Accordingly, there can be no assurance that we currently are not or will not become a PFIC. Due to our substantial cash position, we believe that we may be treated as a PFIC for 2023, although we do not intend to conduct an analysis to obtain assurance of this.

 


If we currently are or become a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon receipt of certain distributions by us and upon disposition of our Ordinary Shares or ADSs at a gain: (1) have such distribution or gain allocated ratably over the U.S. Holder’s holding period for the Ordinary Shares or ADSs, as the case may be; (2) the amount allocated to the current taxable year and any period prior to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year,year; and (4) an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year. In addition, when shares of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder, the tax basis of such shares would not receive a step-up to fair market value as of the date of the decedent’s death, but instead would be equal to the decedent’s basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC may also be subject to these special U.S. federal income tax rules.

 


The PFIC rules described above would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held the Ordinary Shares or ADSs while we are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such a QEF election is required for each taxable year that we are a PFIC to include in income such U.S. Holder’s pro rata share of our ordinary earnings as ordinary income and such U.S. Holder’s pro rata share of our net capital gains as long-term capital gain, regardless of whether we make any distributions of such earnings or gain. In general, a QEF election is effective only if we make available certain required information. The QEF election is made on a shareholder-by-shareholder basis and generally may be revoked only with the consent of the IRS. We do not intend to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election for any year in which we or any of our subsidiaries are a PFIC. Therefore, the QEF election will not be available with respect to our Ordinary Shares or ADSs.

 

In addition, the PFIC rules described above would not apply if we were a PFIC and a U.S. Holder made a mark-to-market election. A U.S. Holder of our Ordinary Shares or ADSs which are regularly traded on a qualifying exchange, including the Nasdaq Capital Market, can elect to mark the Ordinary Shares or ADSs to market annually, recognizing as ordinary income or loss each year an amount equal to the difference as of the close of the taxable year between the fair market value of the Ordinary Shares or ADSs and the U.S. Holder’s adjusted tax basis in the Ordinary Shares or ADSs. Losses are allowed only to the extent of net mark-to-market gain previously included income by the U.S. Holder under the election for prior taxable years.

 

U.S. Holders who hold our Ordinary Shares or ADSs during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC. U.S. Holders are strongly urged to consult their tax advisors about the PFIC rules.

 

Tax on Net Investment Income

 

Subject to certain adjustments under the PFIC rules, U.S. Holders who are individuals, estates or trusts will generally be required to pay a 3.8% Medicare tax on their net investment income (including dividends on and gains from the sale or other disposition of our Ordinary Shares or ADSs), or in the case of estates and trusts on their net investment income that is not distributed. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder’s total adjusted income exceeds applicable thresholds.

 

Tax Consequences for Non-U.S. Holders of Ordinary Shares or ADSs

 

Except as provided below, an individual, corporation, estate or trust that is not a U.S. Holder referred to below as a non-U.S. Holder, generally will not be subject to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of, our Ordinary Shares or ADSs.

 

A non-U.S. Holder may be subject to U.S. federal income tax on a dividend paid on our Ordinary Shares or ADSs or gain from the disposition of our Ordinary Shares or ADSs if: (1) such item is effectively connected with the conduct by the non-U.S. Holder of a trade or business in the United States and, if required by an applicable income tax treaty is attributable to a permanent establishment or fixed place of business in the United States; or (2) in the case of a disposition of our Ordinary Shares or ADSs, the individual non-U.S. Holder is present in the United States for 183 days or more in the taxable year of the disposition and other specified conditions are met. Any dividend income or gain described in clause (1) above will be subject to U.S. federal income tax on a net income tax basis in the same manner as a U.S. Holder and, with respect to corporate holders, a branch profits tax imposed at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) may also apply to its effectively connected earnings and profits (subject to adjustments). Any dividend income or gain described in clause (2) above that is not effectively connected with the conduct by a Non-U.S. Holder of a trade or business within the U.S. generally will be subject to 30% withholding tax (or such lower rate as may be specified by an applicable income tax treaty) net of certain U.S. source capital losses.

 


In general, non-U.S. Holders will not be subject to backup withholding with respect to the payment of dividends on our Ordinary Shares or ADSs if payment is made through a paying agent, or office of a foreign broker outside the United States. However, if payment is made in the United States or by a U.S. related person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder provides an applicable IRS Form W-8 (or a substantially similar form) certifying its foreign status, or otherwise establishes an exemption.

 

The amount of any backup withholding from a payment to a non-U.S. Holder will be allowed as a credit against such holder’s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.

 

Information Reporting and Withholding

 

A U.S. Holder may be subject to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of Ordinary Shares or ADSs. In general, backup withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will not apply with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations. Backup withholding is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided that the required information is timely furnished to the IRS.

 

F.Dividends and Paying Agents

F. Dividends and Paying Agents

 

Not applicable.

 

G.Statement by Experts

G. Statement by Experts

 

Not applicable.

 

H.Documents on Display

H. Documents on Display

 

We are subject to certain information reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements will file reports with the SEC. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC willare also available to the public through the SEC’s website at www.sec.gov.

 

As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act. However, we will file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and may submit to the SEC, on a Form 6-K, unaudited quarterly financial information.

 

We maintain a corporate website http://www.nano-di.com. Information contained on, or that can be accessed through, our website and the other websites referenced above do not constitute a part of this annual report on Form 20-F. We have included these website addresses in this annual report on Form 20-F solely as inactive textual references.

 

I.Subsidiary Information.


 

I. Subsidiary Information.

Not applicable.

 


J. Annual Report to Security Holders.

Not Applicable.

ITEM 11.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

In the ordinary course of our operations, we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.

 

Quantitative and Qualitative Disclosure About Market Risk

 

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our current investment policy is to invest available cash in bank deposits, mainly with banks that have a credit rating of at least A-minus.A-minus, money market accounts and money market funds. Accordingly, a substantial majority of our cash and cash equivalents is held in deposits that bear interest. Given the current low rates of interest we receive, we will not be adversely affected if such rates are reduced. Our market risk exposure is primarily a result of NIS/U.S. dollar exchange rates, which is discussed in the following paragraph.

 

Foreign Currency Exchange Risk

 

Our results of operations and cash flow are subject to fluctuations due to changes in NIS/U.S. dollar currency exchange rates. The vast majority of our liquid assets is held in U.S. dollars, and a certain portion of our expenses is denominated in NIS. Changes of 5% and 10% in the U.S. Dollar/NIS exchange rate would increase/decrease ournot have had a material effect in relation to the Company’s loss for 2020 by 0.7% and 1.3%, respectively. However, these historical figures may not be indicative of future exposure, as we expect that the percentage of our NIS denominated expenses will materially decrease in the near future, therefore reducing our exposure to exchange rate fluctuations. Our functional and presentation currency is the U.S. dollar.2023.

 

We hedge our foreign currency exchange risk to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.

ITEM 12.DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

 

A.Debt Securities.

A. Debt Securities.

 

Not applicable.

 

B.Warrants and rights.

B. Warrants and rights.

 

Not applicable.

 

C.Other Securities.

C. Other Securities.

 

Not applicable.

 


D.American Depositary Shares

 

D. American Depositary Shares

Fees and Expenses

 

Persons depositing or withdrawing shares or ADS holders must pay: For:
$5.00 (or less) per 100 ADSs (or portion of 100 ADSs). Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property. Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates.
   
$.05 (or less) per ADS. Any cash distribution to ADS holders.
   
A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs. Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders.
   
$.05 (or less) per ADS per calendar year. Depositary services.
   
Registration or transfer fees. Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares.
   
Expenses of the depositary. Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement). Converting foreign currency to U.S. dollars.
   
Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes. As necessary.
   
Any charges incurred by the depositary or its agents for servicing the deposited securities. As necessary.

 

The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

 

From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.

 

As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Israeli law governs shareholder rights. The depositary is the registered holder of the shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A Deposit Agreement among us, the depositary, ADS holders, and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.


PART II

 

ITEM 13.DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

 

None.

 

ITEM 14.MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

 

None.

 

ITEM 15.CONTROLS AND PROCEDURES

ITEM 15. CONTROLS AND PROCEDURES

 

(a) Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2020,2023, or the Evaluation Date. Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under the Exchange Act and that such information is accumulated and communicated to management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure.were effective.

 

(b) Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based principally on the framework and criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission as of the end of the period covered by this report. Based

Previously Identified Material Weaknesses in Internal Control Over Financial Reporting

We previously identified and disclosed in our Annual Report on Form 20-F for the year ended December 31, 2022, a material weakness in our internal control over financial reporting relating to the design and maintenance of effective change management controls over certain information technology systems that evaluation, oursupport the financial reporting processes of a subsidiary (Essemtec).

Remediation Efforts of Previously Disclosed Material Weaknesses:

During the year ended December 31, 2023, management has done the following to remediate the material weakness:

formalized change management policies, processes, and procedures to ensure that all changes made to systems are tested and approved prior to migration to production;

removed permanent access for a third-party vendor responsible for maintaining the system and only granting temporary access as needed for change activities; and

increased resource allocation to the subsidiary IT team to allow for more attention on SOX control documentation.

implemented a monitoring tool to capture changes made to the ERP system.


As a result of these remediation activities and based on testing of the new and modified controls for operating effectiveness, management concluded that the previously reported material weakness was remediated and that our internal control over financial reporting was effective as of December 31, 2020 at providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.2023.

 

(c) Attestation Report of the Registered Public Accounting Firm

 

ThisSee report of Somekh Chaikin, a member firm of KPMG International, which is included on page F-3 of the consolidated financial statements included in this annual report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting due to an exemption for emerging growth companies provided in the JOBS Act.on Form 20-F.

 

(d) Changes in Internal Control over Financial Reporting

 

DuringOther than steps taken in connection with the year ended December 31, 2020,completion of the remediation process described above, there were no changes in our internal control over financial reporting that occurred during the year ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 16. [Reserved]

ITEM 16A.AUDIT COMMITTEE FINANCIAL EXPERT

ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT

 

Our board of directors has determined that each member of our audit committee is an audit committee financial expert, as defined under the rules under the Exchange Act, and is independent in accordance with applicable Exchange Act rules and Nasdaq Stock Market rules.

 


ITEM 16B.CODE OF ETHICS

ITEM 16B. CODE OF ETHICS

 

We have adopted a written code of ethics that applies to our officers and employees, including our principal executive officer, principal financial officer, principal controller and persons performing similar functions as well as our directors. Our Code of Business Conduct and Ethics is posted on our website at www.nano-di.com. Information contained on, or that can be accessed through, our website does not constitute a part of this annual report on Form 20-F and is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the code, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC including the instructions to Item 16B of Form 20-F. We have not granted any waivers under our Code of Business Conduct and Ethics.

 

ITEM 16C.PRINCIPAL ACCOUNTANT FEES AND SERVICES

ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

Somekh Chaikin, a member firm of KPMG International, located in Tel Aviv, Israel, PCAOB ID 1057, has served as our principal independent registered public accounting firm for each of the two years ended December 31, 20192022 and 2020.2023.

 


The following table provides information regarding fees paid by us to Somekh Chaikin and/or other member firms of KPMG International for all services, including audit services, for the years ended December 31, 20192022 and 2020:2023:

 

  Year Ended
December 31,
 
  2019  2020 
Audit fees (1) $190,000  $250,000 
Audit-related fees  -   - 
Tax fees (2)  44,000   15,000 
All other fees  -   - 
         
Total $234,000  $265,000 
  Year Ended December 31, 
(in U.S dollars) 2022  2023 
Audit fees (1)  997,889   875,909 
Audit-related fees (2)  210,229   68,722 
Tax fees (3)  147,025   116,859 
All other fees      
Total  1,355,143   1,061,490 

 

(1)Includes professional services rendered in connection with the audit of our annual financial statements, review of our interim financial statements, and
(2)Includes fees relating to fundraising.for other services, such as due diligence services in connection with acquisitions.
(2)(3)Tax fees are the aggregate fees billed (in the year) for professional services rendered for tax compliance and tax advice other than in connection with the audit.

 

Pre-Approval of Auditors’ Compensation

 

Our audit committee has a pre-approval policy for the engagement of our independent registered public accounting firm to perform certain audit and non-audit services. Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee pre-approves annually a catalog of specific audit and non-audit services in the categories of audit services, audit-related services and tax services that may be performed by our independent registered public accounting firm. If a type of service, that is to be provided by our auditors, has not received such general pre-approval, it will require specific pre-approval by our audit committee. The policy prohibits retention of the independent registered public accounting firm to perform the prohibited non-audit functions defined in applicable SEC rules. All the fees set forth above were pre-approved by the Audit Committee.

 

ITEM 16D.EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

 

Not applicable.

 


ITEM 16E.PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

 

As of March 15, 2024, the following equity securities were purchased as part of our $100 million Repurchase Plan, described below, and by affiliated purchasers:

Period 

Total
Number

of Shares

Purchased

  

Average
Price

Paid per Share

  Total
Number of
Shares
Purchased as Part of Publicly Announced Plans or Programs
  

Maximum Number of Shares (or Approximate Dollar Value) that May Yet be Purchased Under the Plans or Programs

 
Repurchase Program            
February 1-28, 2023  3,795,690  $2.88   3,795,690  $89,049,685 
March 1-31, 2023  2,453,187  $2.97   2,453,187  $81,768,245 
June 1-30,2023  1,807,311  $2.68   1,807,311  $76,928,895 
July 1-31,2023  13,942,389  $3.19   13,942,389  $32,425,758 
August 1-31,2023  3,127,742  $3.08   3,127,742  $22,782,297 
September 1-30,2023  3,787,648  $2.68   3,787,648  $12,634,517 
October 1-31,2023  3,102,387  $2.73   3,102,387  $4,160,138 
Total  32,016,354  $2.89   32,016,354  $4,160,138 


In February 2023, we announced that we would put into action our previously announced $100 million Repurchase Plan allowing us to invest up to $100 million to repurchase our ADSs from time to time. in open market transactions, and/or in privately negotiated transactions or in any other legally permissible ways, depending on market conditions, share price, trading volume and other factors. The $100 million Repurchase Plan was approved by the Israeli court in August 2022 for a period of up to 12 months and was later extended for a period of two months. The $100 million Repurchase Plan expired on October 12, 2023, with $4,160,138 remaining, and thereafter no longer eligible for repurchases under such plan. All repurchases made in 2023 were made pursuant to the $100 million Repurchase Plan.

In August 2023, our board of directors authorized the $200 million Repurchase Plan, allowing us to invest up to $200 million to repurchase ADSs from time to time, in open market transactions, and/or in privately negotiated transactions or in any other legally permissible ways, depending on market conditions, share price, trading volume and other factors. The Israeli court approved the $200 million Repurchase Plan in August 2023 and extended it for a twelve-month period in October 2023. The $200 million Repurchase Plan went into effect on October 17, 2023. As of March 15, 2024, 17,110,217 shares have been repurchased under the $200 million Repurchase Plan.

ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT

Not applicable.

 

ITEM 16F.CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT

ITEM 16G. CORPORATE GOVERNANCE

 

Not applicable.

ITEM 16G.CORPORATE GOVERNANCE

Under Nasdaq rules, we may elect to follow certain corporate governance practices permitted under the Companies Law in lieu of compliance with corresponding corporate governance requirements otherwise imposed by the Nasdaq Stock Market rules for U.S. domestic issuers.

 

In accordance with Israeli law and practice and subject to the exemption set forth in Rule 5615 of the Nasdaq Stock Market rules, we have elected to follow the provisions of the Companies Law, rather than the Nasdaq Stock Market rules, with respect to the following requirements:

 

Distribution of periodic reports to shareholders; proxy solicitation. As opposed to the Nasdaq Stock Market rules, which require listed issuers to make such reports available to shareholders in one of a number of specific manners, Israeli law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. In addition to making such reports available on a public website, weshareholders. We currently make our audited financial statements available to our shareholders at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt from the SEC’s proxy solicitation rules.

 

Quorum.Quorum. While the Nasdaq Stock Market rules require that the quorum for purposes of any meeting of the holders of a listed company’s common voting stock, as specified in the company’s bylaws, be no less than 33 1/3% of the company’s outstanding common voting stock, under Israeli law, a company is entitled to determine in its articles of association the number of shareholders and percentage of holdings required for a quorum at a shareholders meeting. Our amended and restated articles of association provide that a quorum of two or more shareholders holding at least 25% of the voting rights in person or by proxy is required for commencement of business at a general meeting. However, the quorum set forth in our amended and restated articles of association with respect to an adjourned meeting consists of any number of shareholders present in person or by proxy.

 

Compensation of officers. Israeli law and our amended and restated articles of association do not require that the independent members of our board of directors (or a compensation committee composed solely of independent members of our board of directors) determine an executive officer’s compensation, as is generally required under the Nasdaq Stock Market rules with respect to the chief executive officer and all other executive officers. Instead, compensation of executive officers, who are office holders as defined under the Companies Law, is determined and approved by our compensation committee and our board of directors, and in certain circumstances by our shareholders, either in consistency with our office holderholders compensation policy or, in special circumstances in deviation therefrom, taking into account certain considerations stated in the Companies Law.

 


Shareholder approval is generally required for officerexecutive officers compensation in the event (i) approval by our board of directors and our compensation committee is not consistent with our office holderexecutive officers compensation policy, or (ii) compensation required to be approved is that of our chief executive officer who is not a director or an executive officer who is also the controlling shareholder of our company (including an affiliate thereof). Such shareholder approval shall require a special majority vote of the shares present and voting at a shareholders meeting, provided either (i) such majority includes a majority of the shares held by non-controlling shareholders who do not otherwise have a personal interest in the compensation arrangement that are voted at the meeting, excluding for such purpose any abstentions disinterested majority, or (ii) the total shares held by non-controlling and disinterested shareholders voted against the arrangement does not exceed 2% of the voting rights in our company.

 


Additionally, approval of the compensation of an executive officer who is also a director requires a simple majority vote of the shares present and voting at a shareholders meeting, if consistent with our office holderexecutive officers’ compensation policy. Our compensation committee and board of directors may, in special circumstances, approve the compensation of an executive officeroffice holder (other than a director, a chief executive officer or a controlling shareholder) or approve the compensation policy despite shareholders’ objection, based on specified arguments and taking shareholders’ objection into account. Our compensation committee may further exempt an engagement with a nominee for the position of chief executive officer, who meets the non-affiliation requirements set forth for an external director, from requiring shareholder approval, if such engagement is consistent with our office holder compensation policy and our compensation committee determines based on specified arguments that presentation of such engagement to shareholder approval is likely to prevent such engagement. To the extent that any such transaction with a controlling shareholder is for a period exceeding three years, approval is required once every three years.

 

A director or executive officeroffice holder may not be present when the board of directors of a company discusses or votes upon a transaction in which he or she has a personal interest, except in case of ordinary transactions, unless the chairman of the board of directors determines that he or she should be present to present the transaction that is subject to approval.

 

Shareholder approval. We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather than seeking approval for corporation actions in accordance with Nasdaq Listing Rule 5635. In particular, under this Nasdaq Stock Market rule, shareholder approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer’s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment of equity compensation arrangements (although under the provisions of the Companies Law there is no requirement for shareholder approval for the adoption/amendment of the equity compensation plan); and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity is issued (or sold) below a specified minimum price. By contrast, under the Companies Law, shareholder approval is required for, among other things: (i) transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders are all required, (ii) extraordinary transactions with controlling shareholders of publicly held companies, including private offerings to controlling shareholders, which require the special majority, and (iii) terms of employment or other engagement of the controlling shareholder of us or such controlling shareholder’s relative, which require the special majority. In addition, under the Companies Law, a merger requires approval of the shareholders of each of the merging companies.

 


Approval of Related Party Transactions.Transactions. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transaction as set forth in the Companies Law, which requires the approval of the audit committee, or the compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Nasdaq Stock Market rules.

 

Annual Shareholders Meeting. As opposed to the Nasdaq Stock Market Rule 5620(a), which mandates that a listed company hold its annual shareholders meeting within one year of the company’s fiscal year-end, we are required, under the Companies Law, to hold an annual shareholders meeting each calendar year and within 15 months of the last annual shareholders meeting,. and in any case once every calendar year.

 

ITEM 16H.MINE SAFETY DISCLOSURE

ITEM 16H. MINE SAFETY DISCLOSURE

 

Not applicable.

 

ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

ITEM 16J. INSIDER TRADING POLICIES

Not applicable.

ITEM 16K. CYBERSECURITY

We recognize the critical importance of maintaining the trust and confidence of our customers, clients, business partners and employees. The board of directors is actively involved in oversight of our crisis management plan, or the Crisis Management Plan, and cybersecurity represents an important component of our overall approach to risk management. Our cybersecurity policies, standards, processes and practices are fully integrated into our Crisis Management Plan and are based on recognized frameworks established by the National Institute of Standards and Technology, the International Organization for Standardization and other applicable industry standards. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.


Risk Management and Strategy

As part of the critical elements of our overall risk management approach, our cybersecurity program is focused on the following key areas:

Governance: As discussed in more detail under the heading “Governance,” the board of directors’ oversight of cybersecurity risk management is supported by the Crisis Management Team, or CMT, which regularly interacts with it and with Mr. Yaniv Luzon, our Chief Information Security Officer, or CISO, other members of management and relevant management committees.

Collaborative Approach: We implemented a comprehensive, cross-functional approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.

Technical Safeguards: We deploy technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence.

Incident Response and Recovery Planning: We have established and maintain a comprehensive Crisis Management Plan that fully addresses our response to a cybersecurity incident, and such plan is tested and evaluated on a regular basis.

Third-Party Risk Management: We maintain a comprehensive, risk-based approach to identifying and overseeing cybersecurity risks presented by third parties, including vendors, service providers and other external users of our systems, as well as the systems of third parties that could adversely impact our business in the event of a cybersecurity incident affecting those third-party systems.

Education and Awareness: We provide regular, mandatory training for personnel regarding cybersecurity threats as a means to equip our personnel with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices.

We engage in the periodic assessment and testing of our policies, standards, processes and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including audits, assessments, tabletop exercises, threat modeling, vulnerability testing, and other exercises focused on evaluating the effectiveness of our cybersecurity measures and planning. We may engage third parties to perform assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported to the CMT and to Company’s management, and we adjust our cybersecurity policies, standards, processes and practices as necessary based on the information provided by these assessments, audits and reviews. For further information, see “Item 3.D. Risk Factors—General Risk Factors--Significant disruptions of our information technology systems or breaches of our data security could adversely affect our business.


Governance

The board of directors, in coordination with the CMT, oversees our risk management process, including the management of risks arising from cybersecurity threats. Company’s management and the CMT each receive regular presentations and reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends and information security considerations arising with respect to our peers and third parties. The board of directors and CMT also receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed. On an annual basis, Company’s management and the CMT discuss our approach to cybersecurity risk management with the members of the Cybersecurity Council, which includes the Company’s CISO.

The CISO, in coordination with the CMT, which includes our CEO, CFO, COO, President, Human Resources, General Counsel, and Global IT Director, works collaboratively across the Company to implement a program designed to protect our information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company’s incident response and recovery plans. To facilitate the success of our cybersecurity Crisis Management Plan, multidisciplinary teams throughout the Company are deployed to address cybersecurity threats and to respond to cybersecurity incidents. Through ongoing communications with these teams, the CISO and the CMT monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to the board of directors when appropriate.

Mr. Luzon has been our CISO since November 2021. He has several years of experience in security management. Prior to joining our Company, from 2016 through 2021, he served as Information Security Manager for the Israeli Ministry of Religious Services. Mr. Luzon has an M.B.A. from the College of Management and Academic Studies. He is a Technion Certified CISO, Information Security, of Technion – Israel Institute of Technology.

Cybersecurity threats, including as a result of any previous cybersecurity incidents, have not materially affected or are reasonably likely to affect our Company, including our business strategy, results of operations or financial condition.


PART III

 

ITEM 17.FINANCIAL STATEMENTS

ITEM 17. FINANCIAL STATEMENTS

 

We have elected to provide financial statements and related information pursuant to Item 18.

ITEM 18.FINANCIAL STATEMENTS

ITEM 18. FINANCIAL STATEMENTS

 

The consolidated financial statements and the related notes required by this Item are included in this annual report on Form 20-F beginning on page F-1.

 

ITEM 19. EXHIBITS

The exhibits filed with or incorporated into this Annual Report are listed below.

ITEM 19.ExhibitEXHIBITS.

Exhibit Description
1.1 Amended and Restated Articles of Association of Nano Dimension Ltd., filed as exhibit 99.1 to Form 6-K filed on February 16, 2021,December 11, 2023, and incorporated herein by reference.
   
2.1 Amended and Restated Form of Depositary Agreement, dated as of April 15, 2019, among Nano Dimension Ltd., The Bank of New York Mellon as Depositary, and owners and holders from time to time of ADSs issued thereunder, including the Form of American Depositary Shares, filed as Exhibit 1 to the Form F-6 (File No. 333-252477) filed on January 27, 2021, and incorporated herein by reference.
2(d)Description of Securities, filed herewith.
   
4.1^2.2 Description of Securities, filed herewith.
4.1^Amended and Restated License Agreement, dated April 2, 2015, by and between the Company and Yissum Research Development Company of The Hebrew University of Jerusalem, Ltd., filed as Exhibit 4.1 to Form 20-F/A filed on February 29, 2016, and incorporated herein by reference.
   
4.2 Nano Dimension Ltd. Employee Stock Option Plan (2015), filed as Exhibit 99.1 to Form 6-KS-8 (File No. 333-269436) filed on June 10, 2019,January 27, 2023, and incorporated herein by reference.
   
4.3 Nano Dimension Ltd. Amended and Restated Executive Officers Compensation Policy, filed as Exhibit A to Exhibit 99.1 to Form 6-K filed on June 2, 2020,7, 2022, and incorporated herein by reference.
   
4.4 Form of Warrant to purchase Ordinary Shares Represented by American Depositary Shares, dated January 30, 2019, filed as Exhibit 4.2 to Form F-1 (File No. 001-228521) filed on January 30, 2019, and incorporated herein by reference.
   
4.5 Form of Warrant to purchase Ordinary Shares Represented by American Depositary Shares, dated September 4, 2019, filed as Exhibit 99.4 to Report on Form 6-K (File No. 001-37600), filed on September 3, 2019, and incorporated herein by reference.


4.6 
4.6Securities Purchase Agreement, dated August 5, 2020, between Nano Dimension Ltd. and Stern YOI Ltd. Partnership, filed as Exhibit 4.4 to Form F-3 (File No. 333-252848), filed on February 8, 2021, and incorporated herein by reference.
4.7Form of Series A Warrant to purchase Ordinary Shares Represented by American Depositary Shares, dated August 5, 2020, between Nano Dimension Ltd. and Stern YOI Ltd. Partnership, filed as Exhibit 4.5 to Form F-3 (File No. 333-252848), filed on February 8, 2021, and incorporated herein by reference.
   
4.84.7 Securities Purchase Agreement, dated September 6, 2020, between Nano Dimension Ltd. and YEDNE LLC, filed as Exhibit 4.6 to Form F-3 (File No. 333-252848), filed on February 8, 2021, and incorporated herein by reference.
4.9Form of Warrant to purchase Ordinary Shares Represented by American Depositary Shares, dated September 6, 2020, between Nano Dimension Ltd. and YEDNE LLC, filed as Exhibit 4.7 to Form F-3 (File No. 333-252848), filed on February 8, 2021, and incorporated herein by reference.


4.10Form of Indemnification Agreement, filed as Exhibit 10.10 to Form F-1 (File No. 333- 213372) filed on August 30, 2016, and incorporated herein by reference.
   
8.14.8 ListForm of Subsidiaries,Indemnification Agreement, filed as Exhibit 8.1 to Form 20-F, filed on March 15, 2018, and incorporated herein by reference.herewith.
   
12.14.9 

Rights Agreement, dated January 25, 2024, by and between Nano Dimension Ltd. and the Bank of New York Mellon, filed as Exhibit 4.1 to Report on Form 6-K (File No. 001-37600), filed on January 25, 2024, and incorporated herein by reference.

8.1List of Subsidiaries, filed herewith.
12.1Certification of the Chief Executive Officer pursuant to ruleRule 13a-14(a) of the Securities Exchange Act of 1934, filed herewith.
   
12.2 Certification of the Chief Financial Officer pursuant to ruleRule 13a-14(a) of the Securities Exchange Act of 1934, filed herewith.
   
13.1 Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, furnished herewith.
   
13.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, furnished herewith.
   
15.1 Consent of Somekh Chaikin (Member firm of KPMG International), filed herewith.
   
10197.1 Nano Dimension Ltd. Clawback Policy, dated November 27, 2023, filed herewith.
101The following financial information from the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2020,2023, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Financial Position; (ii) Consolidated Statements of Profit or Loss; (iii) Consolidated Statements of Changes in Equity; (iv) Consolidated Statements of Cash Flows; and (v) Notes to Consolidated Financial Statements, tagged as blocks of text and in detail.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

^Confidential treatment was granted with respect to certain portions of this exhibit pursuant to 17.C.F.R. §240.24b-2. Omitted portions were filed separately with the SEC.SEC.

 


SIGNATURES

 

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on Form 20-F filed on its behalf.

 

 NANO DIMENSION LTD.
   
Date: March 11, 202121, 2024By:/s/ Yoav Stern
  Yoav Stern
  President and Chief Executive Officer

 


 

Nano Dimension Ltd.

Consolidated Financial Statements as of December 31, 2020

 


Table of Contents

 

  Page
   
Report of Independent Registered Public Accounting Firm (Somekh Chaikin, Tel Aviv, Israel, Auditor Firm ID: 1057) F-3F-2
   
Consolidated Financial Statements as of December 31, 20202023  
   
Consolidated Statements of Financial Position F-4
   
Consolidated Statements of Profit or Loss and Other Comprehensive Income F-5
   
Consolidated Statements of Changes in Equity F-6
   
Consolidated Statements of Cash Flows F-7F-9
   
Notes to the Consolidated Financial Statements F-8F-10 - F-36F-53

 


F-1

Report of Independent Registered Public Accounting Firm

 

To the ShareholdersStockholders and Board of Directors

Nano Dimension Ltd.:

 

OpinionOpinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting

We have audited the accompanying consolidated statements of financial position of Nano Dimension Ltd. and its subsidiaries (the “Company”)Company) as of December 31, 20192022 and 2020,2023, the related consolidated statements of profit or loss and other comprehensive income, changes in equity, and cash flows for each of the years in the three-year period ended December 31, 2020,2023, and the related notes (collectively, the “consolidatedconsolidated financial statements”)statements). We also have audited the Company’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 20192022 and 2020,2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2020,2023, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023 based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

Change in Accounting PrincipleBasis for Opinions

As discussed in Note 2O to theThe Company’s management is responsible for these consolidated financial statements, the Company has changedfor maintaining effective internal control over financial reporting, and for its method of accounting for leases as of January 1, 2019, due to the adoption of International Financial Reporting Standard 16, Leases.

Basis for Opinion

These consolidated financial statements are the responsibilityassessment of the Company’s management.effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on thesethe Company’s consolidated financial statements and an opinion on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding offraud, and whether effective internal control over financial reporting but not for the purpose of expressing an opinion on the effectivenesswas maintained in all material respects.

Our audits of the Company’s internal control overconsolidated financial reporting. Accordingly, we express no such opinion.

Our auditsstatements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinion.opinions.

 

F-2

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

/s/ Somekh Chaikin 

Member Firm of KPMG International

We have served as the Company’s auditor since 2015.

Tel-Aviv, Israel

March 21, 2024

F-3

Somekh ChaikinNano Dimension Ltd
Member FirmConsolidated Statements of KPMG InternationalFinancial Position as at
U.S. dollars in thousands (except share and per share data)

    December 31, 
  Note 2022  2023 
Assets          
Cash and cash equivalents 4.A  685,362   309,571 
Bank deposits 4.C  346,663   541,967 
Restricted deposits 4.B  60   60 
Trade receivables 5.A  6,342   12,710 
Other receivables 5.B  6,491   11,290 
Inventory 6  19,400   18,390 
Total current assets    1,064,318   893,988 
           
Restricted deposits 4.B  850   881 
Investment in securities 20.C  114,984   138,446 
Deferred tax 16.E  115    
Other receivables 5.B  809    
Property plant and equipment, net 7  5,843   16,716 
Right-of-use assets 21  16,539   12,072 
Intangible assets 8     2,235 
Total non-current assets    139,140   170,350 
Total assets    1,203,458   1,064,338 
           
Liabilities          
Trade payables    3,722   4,696 
Financial derivatives and deferred consideration 20.D  8,798    
Other payables 10  24,150   29,738 
Current portion of other long-term liability    363   38 
Total current liabilities    37,033   34,472 
           
Liability in respect of government grants 11  1,492   1,895 
Employee benefits 18  1,462   2,773 
Liability in respect of warrants 20.D  69    
Lease liability 21  12,374   8,742 
Deferred tax liabilities 16.E     75 
Loan from banks    736   595 
Total non-current liabilities    16,133   14,080 
Total liabilities    53,166   48,552 

Equity

    December 31, 
  Note 2022  2023 
Non-controlling interests    767   1,011 
           
Share capital 12  388,406   400,700 
Share premium and capital reserves    1,296,194   1,299,542 
Treasury shares    (1,509)  (97,896)
Foreign currency translation reserve    583   2,929 
Remeasurement of net defined benefit liability (IAS 19)    2,508   707 
Accumulated loss    (536,657)  (591,207)
Equity attributable to owners of the Company    1,149,525   1,014,775 
           
Total equity    1,150,292   1,015,786 
           
Total liabilities and equity    1,203,458   1,064,338 

F-4

Nano Dimension Ltd
We have served as the Company’s auditor since 2015.Consolidated Statements of Profit or Loss and Other Comprehensive Income
Tel-Aviv, IsraelU.S. dollars in thousands (except share and per share data)

    For the Year Ended 
    December 31, 
  Note 2021  2022  2023 
Revenues 13  10,493   43,633   56,314 
Cost of revenues 14  5,730   24,943   30,759 
Cost of revenues - write-down of inventories and amortization of assets recognized in business combination and technology 8  3,641   4,639   97 
Total cost of revenues    9,371   29,582   30,856 
Gross profit    1,122   14,051   25,458 
Research and development expenses, net 15.A  41,686   75,763   62,004 
Sales and marketing expenses 15.B  22,713   38,833   31,707 
General and administrative expenses 15.C  19,644   30,457   58,254 
Other income, net 15.D        1,627 
Impairment losses on intangible assets 8  140,290   40,523    
Operating loss    (223,211)  (171,525)  (124,880)
Finance income 15.E  17,909   22,965   70,934 
Finance expenses 15.E  428   79,471   1,652 
Loss before taxes on income    (205,730)  (228,031)  (55,598)
Taxes benefit (expenses) 16  4,906   (264)  (62)
Loss for the year    (200,824)  (228,295)  (55,660)
Loss attributable to non-controlling interests    (47)  (872)  (1,110)
Loss attributable to owners    (200,777)  (227,423)  (54,550)
               
Loss per share              
Basic loss per share 17.A  (0.81)  (0.88)  (0.22)
Diluted loss per share 17.B  (0.83)  (0.88)  (0.22)
               
Other comprehensive income items that after initial recognition in comprehensive income were or will be transferred to profit or loss              
Foreign currency translation differences for foreign operations    (46)  (844)  2,368 
Other comprehensive income items that will not be transferred to profit or loss              
Remeasurement of net defined benefit liability (IAS 19), net of tax 18     2,508   (1,801)
Total other comprehensive income (loss) for the year    (46)  1,664   567 
Total comprehensive loss for the year    (200,870)  (226,631)  (55,093)
Comprehensive loss attributable to non-controlling interests    (69)  (892)  (1,088)
Comprehensive loss attributable to owners of the Company    (200,801)  (225,739)  (54,005)

F-5

Nano Dimension Ltd
March 10, 2021Consolidated Statements of Changes in Equity
U.S. dollars in thousands (except share and per share data)

 


Nano Dimension Ltd.

Consolidated Statements of Financial Position as at

     December 31, 
  Note  2019  2020 
     Thousands
USD
  Thousands
USD
 
Assets         
Cash 3.A   3,894   585,338 
Bank deposits     -   85,596 
Restricted deposits 3.B   31   62 
Trade receivables 4.A   1,816   713 
Other receivables 4.B   570   1,126 
Inventory 5   3,543   3,314 
Total current assets     9,854   676,149 
            
Restricted deposits 3.B   377   406 
Property plant and equipment, net 6   4,743   5,092 
Right of use assets 19   2,673   3,169 
Intangible assets 7   5,211   4,440 
Total non-current assets     13,004   13,107 
Total assets     22,858   689,256 
            
Liabilities           
Trade payables     850   776 
Other payables 9   3,575   5,910 
Total current liabilities     4,425   6,686 
            
Liability in respect of government grants 10   1,044   850 
Lease liability 19   2,089   2,618 
Liability in respect of warrants 18   3,698   11,986 
Total non-current liabilities     6,831   15,454 
Total liabilities     11,256   22,140 
            
Equity           
Share capital 11   6,441   257,225 
Share premium and capital reserves     65,202   518,426 
Treasury shares     (1,509)  (1,509)
Presentation currency translation reserve     1,431   1,431 
Accumulated loss     (59,963)  (108,457)
Total equity     11,602   667,116 
Total liabilities and equity     22,858   689,256 

The accompanying notes are an integral part of these consolidated financial statements.

  Share capital  Share premium and capital reserves  Remeasurement of IAS 19  Treasury shares  Foreign currency translation reserve  Accumulated loss  Total  Non-controlling interests  Total equity 
For the year ended December 31, 2023:                           
Balance as of January 1, 2023  388,406   1,296,194   2,508   (1,509)  583   (536,657)  1,149,525   767   1,150,292 
Investment of non-controlling party in subsidiary                       1,332   1,332 
Loss for the year                 (54,550)  (54,550)  (1,110)  (55,660)
Other comprehensive income (loss) for the year        (1,801)     2,346      545   22   567 
Exercise of warrants, options and vesting of RSUs  12,294   (12,294)                     
Repurchase of treasury shares           (96,387)        (96,387)     (96,387)
Share-based payment acquired     (4,459)              (4,459)     (4,459)
Share-based payments     20,101               20,101      20,101 
Balance as of December 31, 2023  400,700   1,299,542   707   (97,896)  2,929   (591,207)  1,014,775   1,011   1,015,786 

 


Nano Dimension Ltd.

Consolidated Statements of Profit or Loss and Other Comprehensive IncomeF-6

 

    For the Year Ended
December 31,
 
  Note 2018  2019  2020 
    Thousands
USD
  Thousands
USD
  Thousands
USD
 
Revenues 12  5,100   7,070   3,399 
               
Cost of revenues 13  3,594   4,312   1,563 
               
Cost of revenues - amortization of intangible 7  772   772   771 
               
Total cost of revenues    4,366   5,084   2,334 
               
Gross profit    734   1,986   1,065 
               
Research and development expenses, net 14.A  8,623   8,082   9,878 
               
Sales and marketing expenses 14.B  4,259   5,469   6,597 
               
General and administrative expenses 14.C  3,002   3,270   20,287 
               
Operating loss    (15,150)  (14,835)  (35,697)
               
Finance income 14.D  54   8,765   446 
               
Finance expense 14.D  392   2,283   13,243 
               
Total comprehensive loss    (15,488)  (8,353)  (48,494)
               
Basic and diluted loss per share (USD) (after 1:50 reverse split effective June 29, 2020, see also note 11A) 16  (8.40)  (2.38)  (1.13)

The accompanying notes are an integral part of these consolidated financial statements.

 


Nano Dimension Ltd.

Consolidated Statements of Changes in Equity

  Share
capital
  Share
premium and
capital
reserves
  Treasury
shares
  Presentation
currency
translation
reserve
  Accumulated loss  Total
equity
 
For the year ended December 31, 2020: Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
Balance as of January 1, 2020  6,441   65,202   (1,509)  1,431   (59,963)  11,602 
Loss for the year          -   -   (48,494)  (48,494)
Issuance of Ordinary Shares, net  244,511   405,604   -   -   -   650,115 
Exercise of warrants, options and conversion of convertible notes  6,273   1,450   -   -   -   7,723 
Share-based payments  -   46,170   -   -   -   46,170 
                         
Balance as of December 31, 2020  257,225   518,426   (1,509)  1,431   (108,457)  667,116 

  Share
capital
  Share
premium and
capital
reserves
  Treasury
shares
  Presentation
currency
translation
reserve
  Accumulated loss  Total
equity
 
For the year ended December 31, 2019: Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
Balance as of January 1, 2019  3,291   63,969   (1,509)  1,431   (51,610)  15,572 
Loss for the year  -   -   -   -   (8,353)  (8,353)
Issuance of Ordinary Shares, net  2,216   (633)  -   -   -   1,583 
Exercise of warrants, options and conversion of convertible notes  934   1,421   -   -   -   2,355 
Share-based payments  -   445   -   -   -   445 
                         
Balance as of December 31, 2019  6,441   65,202   (1,509)  1,431   (59,963)  11,602 

  Share
capital
  Share
premium and
capital
reserves
  Treasury
shares
  Presentation
currency
translation
reserve
  Accumulated loss  Total
equity
 
For the year ended December 31, 2018: Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
Balance as of January 1, 2018  2,307   52,059   (1,509)  1,431   (36,122)  18,166 
Loss for the year  -   -   -   -   (15,488)  (15,488)
Issuance of Ordinary Shares, net  981   11,490   -   -   -   12,471 
Exercise of warrants and options  3   (3)  -   -   -   - 
Share-based payments  -   423   -   -   -   423 
                         
Balance as of December 31, 2018  3,291   63,969   (1,509)  1,431   (51,610)  15,572 

The accompanying notes are an integral part of these consolidated financial statements.

Nano Dimension Ltd
Consolidated Statements of Changes in Equity
U.S. dollars in thousands (except share and per share data)

 


Nano Dimension Ltd.

Consolidated Statements of Cash Flows

  For the Year Ended
December 31,
 
  2018  2019  2020 
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
Cash flow from operating activities:         
Net loss  (15,488)  (8,353)  (48,494)
Adjustments:            
Depreciation  1,943   2,666   2,658 
Financing expenses (income), net  412   2,035   (60)
Revaluation of financial liabilities accounted at fair value  -   (8,707)  12,825 
Loss from disposal of property plant and equipment  537   18   - 
Share-based payments  402   439   20,501 
   3,294   (3,549)  35,924 
Changes in assets and liabilities:            
Decrease (increase) in inventory  (1,410)  (442)  229 
Decrease (increase) in other receivables  13   -   (556)
Decrease (increase) in trade receivables  (1,219)  (503)  1,103 
Increase in other payables  287   718   2,247 
Increase (decrease) in trade payables  1,134  (555)  (99)
Decrease in other long-term liabilities  (58)  -   - 
   (1,253)  (782)  2,924 
Net cash used in operating activities  (13,447)  (12,684)  (9,646)
             
Cash flow from investing activities:            
Investment in bank deposits  -   -   (85,500)
Interest received  -   -   152 
Change in restricted bank deposits  86   (40)  (60)
Acquisition of property plant and equipment  (1,319)  (601)  (1,359)
Proceeds from sale of property plant and equipment  1   -   4 
Net cash used in investing activities  (1,232)  (641)  (86,763)
             
Cash flow from financing activities:            
Proceeds from issuance of Ordinary Shares, warrants and convertible notes, net  12,471   14,367   676,133 
Exercise of warrants and options  -   282   2,837 
Lease payments  -   (1,095)  (1,118)
Amounts recognized in respect of government grants liability, net  9   (113)  (126)
Net cash provided by financing activities  12,480   13,441   677,726 
Increase (decrease) in cash  (2,199)  116   581,317 
Cash at beginning of the year  6,103   3,753   3,894 
Effect of exchange rate fluctuations on cash  (151)  25   127 
Cash at end of year  3,753   3,894   585,338 
             
Non-cash transactions:            
Property plant and equipment acquired on credit  9   -   25 
Conversion of convertible notes and warrants to equity  -   2,073   4,886 

The accompanying notes are an integral part of these consolidated financial statements.

  Share
capital
  Share premium
and capital
reserves
  Remeasurement of IAS 19  Treasury shares  Presentation / Foreign currency translation reserve  Accumulated loss  Total  Non-controlling interests  Total equity 
For the year ended December 31, 2022:                           
Balance as of January 1, 2022  386,665   1,266,027      (1,509)  1,407   (309,234)  1,343,356   875   1,344,231 
Investment of non-controlling party in subsidiary                       784   784 
Loss for the year                 (227,423)  (227,423)  (872)  (228,295)
Other comprehensive loss for the year        2,508      (824)     1,684   (20)  1,664 
Exercise of warrants, options and vesting of RSUs  1,741   (1,741)                     
Share-based payment acquired     (1,005)              (1,005)     (1,005)
Share-based payments     32,913               32,913      32,913 
Balance as of December 31, 2022  388,406   1,296,194   2,508   (1,509)  583   (536,657)  1,149,525   767   1,150,292 

 


Nano Dimension Ltd.

Notes to the Consolidated Financial StatementsF-7

 

Nano Dimension Ltd
Consolidated Statements of Changes in Equity
U.S. dollars in thousands (except share and per share data)

  Share capital  Share premium and capital reserves  Treasury shares  Presentation / Foreign currency translation reserve  Accumulated loss  Total  Non-controlling interests  Total equity 
For the year ended December 31, 2021:                        
Balance as of January 1, 2021  257,225   518,426   (1,509)  1,431   (108,457)  667,116      667,116 
Investment of non-controlling party in subsidiary                    944   944 
Loss for the year              (200,777)  (200,777)  (47)  (200,824)
Other comprehensive loss for the year           (24)     (24)  (22)  (46)
Issuance of ordinary shares, net (*)  114,024   682,322            796,346      796,346 
Exercise of warrants, options and vesting of RSUs  6,219   (3,176)           3,043      3,043 
Share issuance as part of business combination  9,197   29,522            38,719      38,719 
Share-based payments     38,933            38,933      38,933 
Balance as of December 31, 2021  386,665   1,266,027   (1,509)  1,407   (309,234)  1,343,356   875   1,344,231 

(*)See Note 12 for more information regarding issuance of ordinary shares.

F-8

Nano Dimension Ltd
Consolidated Statements of Cash Flows
U.S. dollars in thousands (except share and per share data)

  For the Year Ended December 31, 
Statements of Cash Flows 2021  2022  2023 
Cash flow from operating activities:         
Net loss  (200,824)  (228,295)  (55,660)
Adjustments:            
Depreciation and amortization  7,383   7,283   6,544 
Impairment losses  140,290   40,523    
Financing income net  (6,873)  (1,769)  (46,281)
Revaluation of financial liabilities accounted at fair value  (10,608)  (4,516)  461 
Revaluation of financial assets accounted at fair value     62,791   (23,462)
Loss from disposal of property plant and equipment and right-of-use assets  567   948   326 
Increase in deferred tax  (5,013)  (581)  (11)
Share-based payments  29,782   32,563   20,101 
Other  (70)  166   164 
   155,458   137,408   (42,158)
Changes in assets and liabilities:            
(Increase) decrease in inventory  2,382   (4,603)  (340)
Increase in other receivables  (429)  (1,978)  (5,775)
Increase in trade receivables  (449)  (1,992)  (5,603)
Increase in other payables  1,139   5,281   4,856 
Increase (decrease) in employee benefits     1,497   (1,478)
Increase in trade payables  74   628   1,089 
   2,717   (1,167)  (7,251)
Net cash used in operating activities  (42,649)  (92,054)  (105,069)
             
Cash flow from investing activities:            
Change in bank deposits  (416,019)  141,555   (189,060)
Interest received  3,706   17,465   41,529 
Change in restricted bank deposits  (32)  (327)  (27)
Acquisition of property plant and equipment  (9,761)  (9,388)  (9,098)
Acquisition of intangible asset  

      (1,524)
Acquisition of subsidiaries, net of cash acquired  (74,574)  (31,057)   
Payment of a liability for contingent consideration in a business combination     (10,708)  (9,255)
Acquisition of financial assets in fair value through profit and loss     (177,775)   
Decrease in deposit in escrow     3,362    
Other     (800)  835 
Net cash used in investing activities  (496,680)  (67,673)  (166,600)
             
Cash flow from financing activities:            
Proceeds from issuance of ordinary shares, warrants and convertible notes, net  805,497       
Exercise of warrants and options  212       
Lease payments  (1,494)  (4,151)  (4,823)
Repayment long-term bank debt  (814)  (406)  (536)
Proceeds from non-controlling interests  944   510   1,089 
Amounts recognized in respect of government grants liability  (96)  (221)  (298)
Payments of share price protection recognized in business combination     (1,005)  (4,459)
Repurchase of treasury shares        (96,387)
Net cash from (used in) financing activities  804,249   (5,273)  (105,414)
Increase (decrease) in cash and cash equivalents  264,920   (165,000)  (377,083)
Cash and cash equivalents at beginning of the year  585,338   853,626   685,362 
Effect of exchange rate fluctuations on cash  3,368   (3,264)  1,292 
Cash and cash equivalents at end of the year  853,626   685,362   309,571 
             
Non-cash transactions:            
Intangible asset acquired on credit        711 
Property plant and equipment acquired on credit  249   52   214 
Recognition of a right-of-use asset  1,919   15,196   929 
Conversion of convertible notes and warrants to equity  2,830       

F-9

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Note 1General

 

A.Reporting Entity

 

Nano Dimension Ltd. (the “Company”) is an Israeli resident company incorporated in Israel. The address of the Company’s registered office is 2 Ilan Ramon St., Ness Ziona, Israel. Unless otherwise indicated, all references to the “Company,” refer to Nano Dimension Ltd. and its subsidiaries, Global Inkjet Systems Ltd. (“GIS”), a United Kingdom corporation, Nano Dimension Technologies Ltd. (“Nano Tech”), an Israeli corporation, Essemtec AG (“Essemtec”) and Nano Dimension Swiss GmbH (“Nano Swiss”), Swiss corporations, Formatec Holding B.V. (“Formatec Holding”), Admatec Europe B.V. (“Admatec”), and Formatec Technical Ceramics B.V. (“Formatec”), Dutch corporations, Nano Dimension USA Inc. (“Nano USA”), a Delaware corporation, Essemtec USA, LLC, a Delaware limited liability company, Nano Dimension GmbH (“Nano Germany”) and Essemtec Deutschland GmbH, German corporations, Nano Dimension Australia Pty Ltd. (“Nano Australia”), an Australian corporation, Nano Dimension (HK) Limited, a Hong Kong corporation, Essemtec France SAS, a French corporation, Nano Dimension NY Ltd., a New York corporation, and Nano Dimension Trading (Shenzhen) Ltd., a Chinese corporation. The consolidated financial statements of the Company as of December 31, 2020,2023, comprise the Company and its subsidiaries in Israel, in the United States, in Switzerland, in Germany, in the United Kingdom, in the Netherlands, Australia and in Hong Kong (together referred to as the “Group”). The Company engages by means of the subsidiary Nano Dimension Technologies Ltd. (“Nano-Technologies”), in the development of a three-dimensional (“3D”)advance additive manufacturing system and nanotechnology based conductive and dielectric inks, which are supplementary products to the additive manufacturing system.(also known as “3D”) solutions. Since March 2016, the Company’s American Depositary Shares (“ADSs”) have been trading on the Nasdaq Capital Market.

The Ordinary Shares of the Company were registered for trade on the Tel Aviv Stock Exchange (TASE)Market (“Nasdaq”).

 

On May 20, 2020,Since August 25, 2014, the Company voluntary delistedhas devoted substantially all of its Ordinary Sharesfinancial resources to develop its products and has financed its operations primarily through the issuance of equity securities. The amount of the Company’s future net profits or losses will depend, in part, on the rate of its future expenditures, its ability to generate significant revenues from the TASE.sale of its products, and its ability to obtain funding through the issuance of securities, strategic collaborations or grants. In the fourth quarter of 2017 the Group began commercializing its products and its ability to generate significant revenues and achieve profitability depends on its ability to successfully complete the development of, and to continue to commercialize, its products, including consumables.

 

B.Since August 25, 2014, the Company has devoted substantially all of its financial resources to develop its products and has financed its operations primarily through the issuance of equity securities. The amount of the Company’s future net profits or losses will depend, in part, on the rate of its future expenditures, its ability to generate significant revenues from the sale of its products, and its ability to obtain funding through the issuance of securities, strategic collaborations or grants. StartingMaterial events in the fourth quarter of 2017, the Group began to commercialize its products and has generated revenues, mainly from sales of its 3D printers. The Group’s ability to generate revenue and achieve profitability depends on its ability to successfully commercialize its products.reporting period

 

C.(1)Equity OfferingsChange in interest curves and inflation expectations

 

During 2020,Since 2021, inflation rates in Israel and the Company conducted several public offeringsworld have been rising – in 2021 and 2022, the Consumer Price Index in Israel increased, an increase that continued also in 2023. Along with the worldwide rise in prices, central banks around the world decided to raise interest rates with the aim of curbing rising prices. The changes in interest rates and the rise in inflation rates had a significant effect on items in the United States, with aggregate gross proceeds of approximately $710,000,000, before deducting underwriting discounts and commissions and other offering-related expenses. After the reporting period, the Company conducted additional public offeringsfinancial statements as described in the United States, with aggregate gross proceeds of $833,000,000, before deducting underwriting discounts and commissions and other offering-related expenses.following notes:

 

D.EffectNote 18 on employee benefits, with respect to remeasurement of the coronavirus pandemic on the Group's businessactuarial liabilities.

 

Note 20 on financial risks, with respect to linkage and currency risk.

(2)Iron Swords War in Israel

On October 7, 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the outbreak of the coronavirus (COVID-19)attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in China in December 2019,parallel to their continued rocket and it reaching many other countries as well at the beginning of 2020,terror attacks (the “Iron Swords War”). Following this, there was a decrease in Israel’s economic activity in many areas around the world, including Israel, the U.S., Europe and Asia-Pacific.business activity. The spread of the virussecurity situation has led, inter alia, to a decreasedisruption in global transportation, restrictions on travelthe chain of supply and work that were announced by the State of Israel and other countries around the world. Asproduction, a result of the COVID-19 pandemic’s global effects, many entities held off on capital expenses; thus, the Company witnessed a significant decrease in the Group's revenues during 2020.

Since this event is not undervolume of national transportation, a shortage in manpower as well as a decrease in the controlvalue of financial assets and a rise in the Group,exchange rate of foreign currencies in relation to the Group is continuing to regularly follow the changesNIS. There was no material impact on the markets in IsraelCompany’s operations and the world and is examining the mid- and long-term effects on the business resultsrevenues.

F-10

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Note 2 – Basis of the Group.Preparation

 

E.The Operating Cycle

The operating cycle period of the Group is 12 months.


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 2Summary of Significant Accounting Policies

The accounting policies of the Group set out below have been applied consistently for all periods presented in these consolidated financial statements, and have been applied consistently by Group entities, except for the change in accounting policy from January 1, 2019 as described in note 2.O below.

A.Basis for presentationStatement of the financial statementscompliance

 

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS)(“IFRS”) as issued by the International Accounting Standards Board.

The consolidated financial statements have been prepared on the historical cost basis, except when otherwise indicated.

 

The consolidated financial statements were authorized for issuance by the Company’s board of directors on March 10, 2021.20, 2024.

 

B.Functional and presentation currency

These consolidated financial statements are presented in U.S. dollars (“USD”), which is the Company’s functional currency, and have been rounded to the nearest thousand, except when otherwise indicated. The USD is the currency that represents the principal economic environment in which the Company operates.

C.Basis of measurement

The consolidated financial statements have been prepared on the historical cost basis, except for the following assets and liabilities:

Financial instruments, derivatives and other assets and liabilities measured at fair value through profit or loss;

Deferred tax assets and liabilities; and

Assets and liabilities for employee benefits.

For further information regarding the measurement of these assets and liabilities see Note 3 regarding material accounting policies.

D.Operating Cycle

The operating cycle period of the Group is 12 months.

E.Use of estimates and judgments

 

The preparation of financial statements in conformity with IFRS as issued by the International Accounting Standards Board requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

 

The preparation of accounting estimates used in the preparation of the Group’s financial statements requires management of the Company to make assumptions regarding circumstances and events that involve considerable uncertainty. Management of the CompanyThe Company’s management prepares the estimates on the basis of past experiences, various facts, external circumstances, and reasonable assumptions according to the pertinent circumstances of each estimate. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

 

Below is information

F-11

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Information about significant assumptions made by the Group with respect to the future and other reasons for uncertainty with respect to estimates that have a significant risk of resulting in a material adjustment to carrying amounts of assets and judgments:liabilities in the next financial year are included in the following notes:

 

-Acquisitions of subsidiary

The Group measures the fair value of the consideration transferred (including contingent consideration) and fair value of the assets acquired and liabilities assumed, in business combination transactions. For information on details on fair value measurement in acquisition of subsidiaries, see Note 9 regarding business combinations.

Estimated impairment of non-financial assets

In 2021 and 2022, the Group examined whether there was an impairment of goodwill, intangibles and property, plant and equipment that were allocated to cash generating units, in accordance with the accounting policy presented in Note 3 below. Recoverable amounts of cash-generating units were determined on the basis of value-in-use calculations. These calculations require the use of estimates.

During those years, 2021 and 2022, there was a decline in the value of the Group’s cash-generating units to which goodwill is allocated. Given the recoverable amount of the said cash-generating units, determined on the basis of the value in use of the units, the goodwill, intangibles and property, plant and equipment relating to the Group of the said cash-generating units was reduced by approximately $40,523 and $140,290 in the years 2022 and 2021, respectively.

For information on key assumptions used in calculation of the recoverable amount, see Note 8.D regarding intangible assets and Note 7 regarding property, plant and equipment.

Fair value measurement of financial instruments

 

The Company accounts for financial liabilities relating to convertible notes,contingent liabilities arising from a business combination, warrants and related derivatives at fair value through profit or loss. The fair values of these instruments are determined by using the Monte Carlo simulation method and the Black-Scholes model and assumptions regarding unobservable inputs used in the valuation model including the probability of meeting revenue targets, and weighted average cost of capital, all of which can lead to profit or loss from a change in the fair value of these instruments.

 

When determining the fair value of an asset or liability, the Group uses observable market data as much as possible. There are three levels of fair value measurements in the fair value hierarchy that are based on the data used in the measurement, as follows:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly.

Level 3: inputs that are not based on observable market data (unobservable inputs).

For information on details regarding fair value measurement at Level 2 and sensitivity analysis see Note 18.D20.D regarding financial instruments.

 

F-12

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

F.-Share-based payment transactionsInitial application of new standards, amendments to standards and interpretations

 

Estimating fair value for share-based payment transactions requires determinationAmendment to IAS 1, Presentation of Financial Statements: “Disclosure of Accounting Policies” (“the Amendment”)

According to the Amendment, companies must provide disclosure of their material accounting policies rather than their material Accounting Policies. Pursuant to the Amendment, accounting policy information is material if, when considered with other information disclosed in the financial statements, it can be reasonably be expected to influence decisions that the users of the most appropriate valuation model, which dependsfinancial statements make on the terms and conditionsbasis of those financial statements.

The Amendment also clarifies that accounting policy information is expected to be material if, without it, the users of the grant. This estimatefinancial statements would be unable to understand other material information in the financial statements. The Amendment also requires determinationclarifies that immaterial accounting policy information need not be disclosed.

The Amendment is initially applied in the annual financial statements for 2023. As a result of applying the Amendment, the extent of the most appropriate inputsaccounting policy disclosure provided in the financial statements for 2023 was reduced and adjusted according to the valuation model, including the expected lifeCompany’s specific circumstances.

Note 3 – Material Accounting Policies

The accounting policies of the share optionGroup set out below have been applied consistently for all periods presented in these consolidated financial statements, and volatilityhave been applied consistently by Group entities.

A.Basis of consolidation

(1)Business combination

The Group accounts for business combinations using the acquisition method when the acquired set of activities and making assumptions about them. Forassets meets the measurementdefinition of a business and control is transferred to the Group. In determining whether a particular set of activities and assets is a business, the Group assesses whether the set of assets and activities acquired includes, at a minimum, an input and substantive process and whether the acquired set has the ability to produce outputs. If substantially all of the fair value of equity-settled transactions at the grant date,gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, then the Company usesGroup may implement the Black-Scholes formula orconcentration test, according to which the Binomial pricing model.


Nano Dimension Ltd.

Notes toset of assets and activities acquired do not constitute a business. Control exists when the Consolidated Financial Statements

Note 2Summary of Significant Accounting Policies (Continued)

C.Basis of consolidation Subsidiaries

A subsidiary is an entity controlled by the Company. The Company controls an entity when itGroup is exposed, to, or has rights, to variable returns from its involvement with the entityacquiree and it has the ability to affect those returns through its power over the entity.acquiree. Substantive rights held by the Group and others are taken into account when assessing control.

The Group recognizes goodwill on an acquisition according to the fair value of the consideration transferred, less the net amount of the identifiable assets acquired and the liabilities assumed. Any goodwill that arises is tested annually for impairment.

Any contingent consideration is measured at fair value at the date of acquisition. If an obligation to pay contingent consideration that meets the definition of a financial instrument is classified as equity, then it is not remeasured and settlement is accounted for within equity. Otherwise, other contingent consideration is classified as a financial liability and remeasured at fair value at each reporting date, and subsequent changes in the fair value of the contingent consideration are recognized in profit or loss.

If share-based payment awards (“replacement awards”) are required to be exchanged for awards held by the acquiree’s employees (“acquiree’s awards”), then all or a portion of the amount of the acquirer’s replacement awards is included in measuring the consideration transferred in the business combination. This determination is based on the market-based measure of the replacement awards compared with the market-based measure of the acquiree’s awards and the extent to which the replacement awards relate to pre-combination service.

F-13

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

(2)Subsidiaries

Subsidiaries are entities controlled by the Group. The financial statements of the subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control is lost. The accounting policies of the subsidiaries are aligned with the policies adopted by the Group.

 

D.(3)FunctionalNon-controlling interest

Non-controlling interests comprise the equity of a subsidiary that cannot be attributed, directly or indirectly, to the parent company.

Profit or loss and any part of other comprehensive income are allocated to the owners of the Company and the non-controlling interests. Total profit or loss and other comprehensive income is allocated to the owners of the Company and the non-controlling interests even if the result is a negative balance of non-controlling interests.

B.Foreign currency and presentation currency

 

(1)(1)Functional and presentation currency

These consolidated financial statements are presented in U.S. dollars (“USD”), which is the Company’s functional currency, and have been rounded to the nearest thousands, except when otherwise indicated. The USD is the currency that represents the principal economic environment in which the Company operates.

(2)Foreign currency transactions

 

Transactions in currencies other than the U.S. dollarUSD are translated tointo the functional currency of the Group at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortized cost in foreign currency translated at the exchange rate at the end of the year.

 

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.

 

Foreign currency differences arising onfrom translation are recognized in profit or loss.

 

(2)(3)Index linked financial items

 

Financial assets and liabilities which according to their terms are linked to changes in the Israeli Consumer Price Index (the “Index”) are adjusted according to the relevant Index on every reporting date in accordance with the terms of the agreement. Linkage differences deriving from said adjustment are recorded to profit and loss.

 

(3)(4)Below are details regarding the exchange rate of the New Israeli Shekel (“NIS”) and the Euro and the Index of the NIS:

  Consumer Price Index  Euro  NIS 
December 31, 2020  101.1   1.22   0.31 
December 31, 2019  101.8   1.12   0.29 
December 31, 2018  101.2   1.14   0.27 
Change in percentages:            
Year ended December 31, 2020  (0.69)  (9.32)  (2)
Year ended December 31, 2019  0.6   (2)  8.45)
Year ended December 31, 2018  0.8   (4.4)  (7.5 


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 2Summary of Significant Accounting Policies (Continued)

E.Financial instruments

(1)Non-derivative financial assetsForeign operations

 

Initial recognitionThe assets and measurementliabilities of financial assetsforeign operations, including goodwill and fair value adjustments arising upon acquisition, are translated to USD at exchange rates at the reporting date. The income and expenses of foreign operations are translated to USD at exchange rates at the dates of the transactions, mainly the average exchange rates during the period.

 

The Group initially recognizes trade receivables on the date that they are created. All other financial assetsForeign currency differences are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables.

Derecognition of financial assets

Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset were transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset.

Classification of financial assets into categories and the accounting treatment of each category

Financial assets are classified at initial recognition to one of the following measurement categories: amortized cost; fair value through other comprehensive income – investments in debt instruments; fair value through other comprehensive income – investmentsand are presented in equity instruments; or fair value through profit or loss.in the foreign currency translation reserve (hereinafter – “translation reserve”).

 

The Group does not expectWhen a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to incur any credit loss, thus the financial statements do not include provision for expected credit loss.

All financial assets not classified as measured at amortized cost or fair value through other comprehensive income as described above, as well as financial assets designated at fair value throughthat foreign operation is reclassified to profit or loss are measured at fair value through profit or loss. On initial recognition,as a part of the Group designates financial assets at fair value through profitgain or loss if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

The Group has balances of cash, trade and other receivables and deposits that are held within a business model whose objective is collecting contractual cash flows. The contractual cash flows of these financial assets represent solely payments of principal and interest that reflect consideration for the time value of money and the credit risk. Accordingly, these financial assets are measured at amortized cost.

Cash includes cash balances available for immediate use. Deposits include short-term deposits with banking corporations (with original maturities of three months or more) that are readily convertible into known amounts of cash and are exposed to insignificant risks of change in value.on disposal.

 


Nano Dimension Ltd.

Notes to the Consolidated Financial StatementsF-14

Note 2Summary of Significant Accounting Policies (Continued)

E.Nano Dimension Ltd
Notes to Consolidated Financial instruments (Continued)Statements
U.S. dollars in thousands (except share and per share data)

(2)Non-derivative financial liabilities

 

Non-derivative financial liabilities include trade and other payables.

Initial recognition of financial liabilities

The Group initially recognizes financial liabilities on the trade date at which the Group becomesGenerally, foreign currency differences from a partymonetary item receivable from or payable to the contractual provisions of the instrument.

Subsequent measurement of financial liabilities

Financial liabilitiesa foreign operation, including foreign operations that are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Transaction costs directly attributable to an expected issuance of an instrument that will be classified as a financial liability are recognized as an asset in the framework of deferred expenses in the statement of financial position. These transaction costs are deducted from the financial liability upon its initial recognition, or are amortized as financing expenses in the statement of profit or loss and other comprehensive income when the issuance is no longer expected to occur.

Derecognition of financial liabilities

Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged or cancelled.

Offset of financial instruments

Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company currently has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.

(3)Derivative financial liabilities

Measurement of derivative financial instruments

Derivatives are recognized initially at fair value attributable transaction costssubsidiaries, are recognized in profit or loss as incurred. Subsequent to initial recognition, derivativesin the consolidated financial statements.

(4) Below are measured at fair value,details regarding the Consumer Price Index of the New Israeli Shekel (“NIS”) and changes therein are recognized in profit or loss, as financing income or expense.the exchange rate of Euro, Swiss Franc (“CHF”) and British Pound (“GBP”):

  Consumer Price Index  Euro  CHF  NIS  GBP 
December 31, 2023  111.20   1.11   1.19   0.28   1.27 
December 31, 2022  108.00   1.07   1.08   0.28   1.20 
December 31, 2021  102.60   1.13   1.09   0.32   1.35 
Change in percentages:                    
Year ended December 31, 2023  2.96   3.71   9.70   (2.98)  5.80 
Year ended December 31, 2022  5.26   (5.62)  (0.54)  (11.62)  (10.80)
Year ended December 31, 2021  1.48   (7.38)  (3.54)  3.23   (0.74)

 

F.C.Property plant and equipment

Property plant and equipment are presented according to cost, including directly attributed acquisition costs, minus accumulated depreciation and losses from accrued decrease in value. Improvements and upgrades are included in the assets’ costs whereas maintenance and repair costs are recognized in profit and loss as accrued.

Gains and losses on disposal of a fixed asset item are determined by comparing the net proceeds from disposal with the carrying amount of the asset, and are recognized in their corresponding section, in profit or loss.

The cost of printers used for internal purposes, which are classified as property, plant and equipment, includes the cost of materials and direct labor, and any other costs directly attributable to bringing the assets to a working condition for their intended use.


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 2Summary of Significant Accounting Policies (Continued)

F.Property plant and equipment (Continued) Revenue recognition

 

The depreciation is calculated in equal yearly rates during the period of the useful life span of the assets, as follows:

%
Machinery and equipment (mainly 7%)7 – 25
Computers20 – 33
Office furniture and equipment7 – 15
Leasehold Improvements7 – 10
Printers leased to customers25

Depreciation methods, useful lives and residual values are reviewed at the end of each reporting year and adjusted if appropriate.

G.Inventory

Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on the weighted averages method, and includes expenditure incurred in acquiring the inventories and the costs incurred in bringing them to their existing location and condition. In the case of manufactured inventories and work in progress, cost includes an appropriate share of production overheads based on normal operating capacity. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

H.Impairment of non-financial assets

The carrying amounts of the Group’s non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated.

The recoverable amount of an asset is the greater of its value in use and its fair value, minus the costs of disposal. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects the assessments of market participants regarding the time value of money and the risks specific to the asset, for which the estimated future cash flows from the asset were not adjusted.

An impairment loss is recognized if the carrying amount of an asset exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss.

I.Provisions

A provision for claims is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably and it is probable that an outflow of economic benefits will be required to settle the obligation. When the value of time is material, the provision is measured at its present value.


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 2Summary of Significant Accounting Policies (Continued)

J.Treasury shares and Ordinary Shares

When share capital recognized as equity is repurchased by the Group, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity, and the resulting surplus on the transaction is carried to share premium, whereas a deficit on the transaction is deducted from retained earnings.

Ordinary Shares are classified as equity. Incremental costs directly attributable to the issuance of Ordinary Shares and share options are recognized as a deduction from equity, net of any tax effects.

K.Revenue recognition

The Company recognizes revenue when the customer obtains control over the promised goods or services. The revenue is measured according to the amount of the consideration to which the Company expects to be entitled in exchange for the goods or services promised to the customer, other than amounts collected for third parties.

The Company accounts for a contract with a customer only when the following conditions are met:

(a)The parties to the contract have approved the contract (in writing, orally or according to other customary business practices) and they are committed to satisfying the obligations attributable to them;
(b)The Company can identify the rights of each party in relation to the goods or services that will be transferred;

(c)The Company can identify the payment terms for the goods or services that will be transferred;
(d)The contract has a commercial substance (i.e. the risk, timing and amount of the entity’s future cash flows are expected to change as a result of the contract); and
(e)It is probable that the consideration, to which the Company is entitled to in exchange for the goods or services transferred to the customer, will be collected.

If a contract with a customer does not meet all of the above criteria, consideration received from the customer is recognized as a liability until the criteria are met or when one of the following events occurs: the Company has no remaining obligations to transfer goods or services to the customer and any consideration promised by the customer has been received and cannot be returned; or the contract has been terminated and the consideration received from the customer cannot be refunded. 

On the contract’s inception date, the CompanyGroup assesses the goods or services promised in the contract with the customer and identifies as a performance obligation any promise to transfer to the customer goods or services (or a bundle of goods or services) that are distinct.

 

The CompanyGroup identifies goods or services promised to the customer as being distinct when the customer can benefit from the goods or services on their own or in conjunction with other readily available resources and the Company’sGroup’s promise to transfer the goods or services to the customer is separately identifiable from other promises in the contract. The Company’sGroup’s identified performance obligations include: printer, ink, maintenance (which is generally provided for a period of up to one year), training and installation.

 


Nano Dimension Ltd.

NotesIn some cases, the Group recognizes a warranty as a distinct service to the Consolidated Financial Statementscustomer and is, therefore, a distinct performance obligation.

Note 2Summary of Significant Accounting Policies (Continued) 

K.Revenue recognition (Continued) 

 

Revenue is allocated among performance obligations in a manner that reflects the consideration that the CompanyGroup expects to be entitled to for the promised goods based on the standalone selling prices (“SSP”) of the goods or services of each performance obligation. SSP are estimated for each distinct performance obligation and judgment may be required in their determination. The best evidence of SSP is the estimated price of a product or service if the Company would sell them separately in similar circumstances and to similar customers.

 

The CompanyGroup allocates the transaction price to the identified performance obligations based on the residual approach, while allocating the estimated standalone selling prices for performance obligations relating to maintenance, training and installation services, and the residual is allocated to the printer.

 

Revenues allocated to the printers, installation and training, and ink and other consumables are recognized when the control is passed in accordance with the contract terms at a point in time.

 

Maintenance revenue is recognized ratably, on a straight-line basis, over the period of the services. Revenue from training and installation is recognized duringat the time of performance.

 

Revenues from the provision of development services, which are contingent on the existence of milestones, are recognized solely on the existence of the relevant milestone.

When the consideration for the contract is in a form other than cash, the Group measures the non-cash consideration at fair value. In trade-up contracts, the Group delivers new printer and receives previous model printer and cash. The Group needs to evaluate the fair value of the printer received. In doing so, the Group measures the difference between the SSP of the new printer and the cash received.

F-15

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

D.Financial instruments

(1)

Trade receivables

The Group initially recognizes trade receivables on the date that they are created. A trade receivables without a significant financing component is initially measured at the transaction price and subsequently measured at amortized cost. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables.

On each reporting date, the Group assesses whether the trade receivables carried at amortized cost are credit-impaired. The Group’s policy for estimating the credit losses on trade receivables includes analysis of such items as aging, credit worthiness, payment history, and historical bad debt experience.

Provisions for expected credit losses of financial assets measured at amortized cost are deducted from the gross carrying amount of the financial assets.

(2)Investment in securities

The Group measures investment in equity instruments in fair value through profit and loss.

(3)Derivative financial liabilities

Measurement of derivative financial instruments

Derivatives are recognized initially at fair value. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are recognized in profit or loss, as financing income or expense. Inter alia, the Group implements the said accounting treatment to changes in the fair value of warrants that contain a cashless exercise mechanism. For further information, see Note 20.

(4)Repurchase of share capital

When share capital recognized as equity is repurchased by the Group, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized when the Group hasas a right to consideration for goods or services it transferred to the customer that is conditional on other than the passing of time, such as future performance of the Group. Contract assetsdeduction from equity. Repurchased shares are classified as receivables whentreasury shares. When treasury shares are sold or reissued subsequently, the rights in their respect become unconditional.

A contract liabilityamount received is recognized whenas an increase in equity, and the Group has an obligationresulting surplus on the transaction is carried to transfer goods or services toshare premium, whereas a deficit on the customer for which it received consideration (or the considerationtransaction is payable)deducted from the customer.retained earnings.

 

L.E.ResearchProperty plant and development and intangible assetsequipment

 

Expenditure on research activities, undertaken withProperty, plant and equipment are presented according to cost, including directly attributed acquisition costs, minus accumulated depreciation and losses from accrued decrease in value.

The cost of printers used for internal purposes, which are classified as property, plant and equipment, includes the prospectcost of gaining new scientific or technical knowledgematerials and understanding,direct labor, and any other costs directly attributable to bringing the assets to a working condition for their intended use.

Depreciation is recognized in profit or loss when incurred.on a straight-line basis over the estimated useful lives of each part of the fixed asset item, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset.

 

Development activities involve a plan or design

F-16

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

The estimated useful lives for the production of new or substantially improved productscurrent and processes. comparative periods are as follows:

%
Machinery, equipment and vehicles7 – 25
Computers (mainly 33%)10 – 33
Office furniture and equipment7 – 20
Leasehold Improvements (mainly 25%)10 – 33
Buildings3.5

F.Intangible assets

(1)Research and development

Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset.

 

The expenditure capitalized in respect of development activities includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use.

In the fourth quarter of 2016, the Group ceased todid not capitalize development expenses and began to amortizebecause the Group estimated that not all aforementioned conditions were met.

(2)Other intangible assets

Other intangible asset arising from capitalization of development expenses, uponassets that are acquired by the initiation of its beta program. In subsequent periods, capitalized development expenditure isGroup are measured at cost minusless accumulated amortization and accumulated impairment losses.

 


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 2Summary of Significant Accounting Policies (Continued)

M.(3)Amortization of intangible assets

 

Amortization is a systematic allocation of the amortizable amount of an intangible asset over its useful life. The amortizable amount is the cost of the asset, minus its residual value. Amortization is recognized in profit or loss on a straight-line basis, over the estimated useful lives of the intangible assets from the date they are available for use, since these methods most closely reflect the expected pattern of consumption of the future economic benefits embodied in each asset.

 

G.Impairment of non-financial assets

The estimated useful lives

Determining cash-generating units

For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the capitalized development costs havecash inflows of other assets or groups of assets (the “cash-generating unit”). The Group recognized six cash generating units.

Allocation of goodwill to cash-generating units or a group of cash-generating units

For the purposes of goodwill impairment testing, cash-generating units to which goodwill has been determined byallocated are aggregated so that the Company’s management as 10 years. Amortization methods, useful lives and residual valueslevel at which impairment testing is performed reflects the lowest level at which goodwill is monitored for internal reporting purposes.

Goodwill acquired in a business combination is allocated to a group of cash-generating units, including those existing in the Group before the business combination, that are reviewedexpected to benefit from the synergies of the combination. Therefore, the Group tests the goodwill acquired from the acquisitions of its subsidiaries, at the endGroup’s level, since the goodwill cannot be allocated to individual cash-generating units.

F-17

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

The Group’s corporate assets

The Group recognizes technology assets, including technology assets recognized in business combinations, as corporate assets that do not generate separate cash inflows and are utilized by more than one cash-generating unit. Those technology assets cannot be allocated reasonably and consistently to cash-generating units and therefore are allocated to the Group level.

Recognition of each reporting yearimpairment loss

An impairment loss is recognized if the carrying amount of an asset or a cash-generating unit exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. Impairment losses recognized in respect of a group of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and adjusted if appropriate.then to reduce the carrying amounts of the other assets in the cash-generating units on a pro rata basis.

 

N.H.Government grantsProvisions

 

Government grants areA provision for claims is recognized initially at fair value when thereif, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably and it is reasonable assuranceprobable that theyan outflow of economic benefits will be received andrequired to settle the Group will comply withobligation. When the conditions associated withvalue of time is material, the grant.provision is measured at its present value.

 

A provision for warranties is recognized when the underlying products or services are sold. The provision is based on historical warranty data and a weighting of all possible outcomes against their associated probabilities.

I.Government grants

Grants received from the Israeli Innovation Authority (the “Innovation Authority”(“IIA”), with respect to research and development projects, are accounted for as forgivable loans according to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance. Grants received from the Innovation Authority are recognized as a liability according to their fair value on the date of their receipt, unless it is reasonably certain, on that date, that the amount received will not be refunded.receipt. The amount of the liability is reexamined each period, and any changes in the present value of the cash flows discounted at the original interest rate of the grant are recognized in profit or loss. The difference between the amount received and the fair value on the date of receiving the grant is recognized as a deduction of research and development expenses. Expenses related to revaluation of the liability in respect of government grants were recognized in the statements of profit or loss and other comprehensive income as finance expenses.

 

O.J.Leases

Policy applicable before January 1, 2019

Determining whether an arrangement contains a lease

At inception or upon reassessment of an arrangement, the Group determines whether such an arrangement is or contains a lease. An arrangement is a lease or contains a lease if the following two criteria are met:

The fulfilment of the arrangement is dependent on the use of a specific asset or assets; and

The arrangement contains rights to use the asset.

Leases that do not transfer substantially all the risks and rewards incidental to ownership of an underlying asset were classified as operating leases.

The Group recognized operating lease payments as expenses on a straight-line basis over the lease term.


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 2Summary of Significant Accounting Policies (Continued)

O.Leases (Continued)

Policy applicable from January 1, 2019

Determining whether an arrangement contains a lease

On the inception date of the lease, the Group determines whether the arrangement is a lease or contains a lease, while examining if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. In its assessment of whether an arrangement conveys the right to control the use of an identified asset, the Group assesses whether it has the following two rights throughout the lease term:

(a)The right to obtain substantially all the economic benefits from use of the identified asset; and

(b)The right to direct the identified asset’s use.

For lease contracts that contain non-lease components, such as services or maintenance, that are related to a lease component, the Group elected to account for the contract as a single lease component without separating the components.

 

Leased assets and lease liabilities

Contracts that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments, (these payments do not include certain variable lease payments), and concurrently recognizes a right-of-use asset at the same amount of the lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease.liability.

 

Since the interest rate implicit in the Group’s leases is not readily determinable, the incremental borrowing rate of the lessee is used. Subsequent to initial recognition, the right-of-use asset is accounted for using the cost model, and depreciated on a straight-line basis over the shorter of the lease term or useful life of the asset.asset, as follows:

Buildings1-5 years
Vehicles3 years

The lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably certain that the lessee will or will not exercise the option, respectively.

 

The Group has elected to apply the practical expedient by which short-term leases of up to one year and/or leases in which the underlying asset has a low value, are accounted for such that lease payments are recognized in profit or loss on a straight-line basis, over the lease term, without recognizing an asset and/or liability in the statement of financial position.

 

The lease term

F-18

The lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably certain that the lessee will or will not exercise the option, respectively.

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Variable lease payments

Variable lease payments that depend on an index or a rate, are initially measured using the index or rate existing at the commencement of the lease and are included in the measurement of the lease liability. When the cash flows of future lease payments change as the result of a change in an index or a rate, the balance of the liability is adjusted against the right-of-use asset.

Other variable lease payments that are not included in the measurement of the lease liability are recognized in profit or loss in the period in which the event or condition that triggers payment occurs.

 


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 2Summary of Significant Accounting Policies (Continued)

O.Leases (Continued)

Depreciation of right-of-use asset

After lease commencement, a right-of-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over the useful life or contractual lease period, whichever is earlier, as follows:

Buildings1-5 years
Motor vehicles3 years

Reassessment of lease liability

Upon the occurrence of a significant event or a significant change in circumstances that is under the control of the Group and had an effect on the decision whether it is reasonably certain that the Group will exercise an option, which was not included before in the lease term, or will not exercise an option, which was previously included in the lease term, the Group re-measures the lease liability according to the revised leased payments using a new discount rate. The change in the carrying amount of the liability is recognized against the right-of-use asset, or recognized in profit or loss if the carrying amount of the right-of-use asset was reduced to zero.

Lease modifications

When a lease modification increases the scope of the lease by adding a right to use one or more underlying assets, and the consideration for the lease increased by an amount commensurate with the stand-alone price for the increase in scope and any appropriate adjustments to that stand-alone price to reflect the contract’s circumstances, the Group accounts for the modification as a separate lease.

In all other cases, on the initial date of the lease modification, the Group allocates the consideration in the modified contract to the contract components, determines the revised lease term and measures the lease liability by discounting the revised lease payments using a revised discount rate.

For lease modificationscontracts that decrease the scope of thecontain non-lease components, such as services or maintenance, which are related to a lease component, the Group recognizeselected to account for the contract as a decrease insingle lease component without separating the carrying amount of the right-of-use asset in order to reflect the partial or full cancellation of the lease, and recognizes in profit or loss a profit (or loss) that equals the difference between the decrease in the right-of-use asset and re-measurement of the lease liability.components.

For other lease modifications, the Group re-measures the lease liability against the right-of-use asset.

P.K.Financing income and expenses

 

Financing income is comprised of interest income on deposits, revaluation of liability in respect of government grants, foreign currency gains and fair value changes of financial liabilities and assets through profit and loss.

 

Financing expenses are comprised of bank fees, exchange rate differences, revaluation of liability in respect of government grants and fair value changes of financial liabilities through profit and loss.

In the statements of cash flows, interest paid is presented as part of cash flows from financing activities and interest received is presented as part of cash flows from investing activities.

 

Foreign currency gains and losses on financial assets and financial liabilities are reported on a net basis as either financing income or financing expenses depending on whether foreign currency movements are in a net gain or net loss position.

 


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 2Summary of Significant Accounting Policies (Continued)

Q.L.Employee benefitsIncome tax expense

 

Severance payIncome tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they relate to a business combination or recognized directly in equity or in other comprehensive income to the extent they relate to items recognized directly in equity or in other comprehensive income.

Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

A deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Deferred tax assets that were not recognized are reevaluated at each reporting date and recognized if it has become probable that future taxable profits will be available against which they can be utilized.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their current tax assets and liabilities will be realized simultaneously.

For more information regarding the deferred tax assets and liabilities, see note 16.

M.Employee benefits

Post-employment benefits

 

The Group’s liability for severance pay for its employees is mainly calculated pursuant to Israeli Severance Pay Law (1963) (the “Severance Pay Law”). The Group’s liability is covered by monthly deposits with severance pay funds and insurance policies. For allmost of the Group’s employees, the payments to pension funds and to insurance companies exempt the Group from any obligation towards its employees, in accordance with Section 14 of the Severance Pay Law, which is accounted for as a defined contribution plan (as defined below).plan. Accumulated amounts in pension funds and in insurance companies are not under the Group’s control or management and, accordingly, neither those amounts nor the corresponding accrual for severance pay are presented in the consolidated statements of financial position.

 

APost-employment benefits for Essemtec employees are treated as defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees.plans.

 

Share-based payment transactions

F-19

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

 

N.Share-based payment transactions

The Group mainly uses grants of restricted share units (“RSUs”) in order to incentivize the performance of officers and other key employees, and to members of the board of directors and observers who are not employees. The grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. Share-based payment arrangements in which the subsidiary grants rights to parent company equity instruments to its employees are accounted for by the Group as equity-settled share-based payment transactions.

The amount recognized as an expense in respect of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect the number of awards that are expected to vest.

Note 4.A – Cash and cash equivalents

  December 31, 
  2022  2023 
Denominated in NIS  37,812   24,537 
Denominated in USD  639,318   278,993 
Denominated in GBP  2,643   663 
Denominated in EURO  4,176   3,913 
Denominated in CHF  1,380   1,437 
Other  33   28 
   685,362   309,571 

Note 4.B – Restricted deposits

The Group has restricted deposits of $881 for the lease of its offices and labs and $60 for credit cards. The deposits are not linked and bear an annual interest rate of 0.01%-5.1%. The Group expects to lease its offices and labs for a period of more than a year, thus the restricted deposit was classified as a non-current asset. The restricted deposit for the credit cards was classified as a current asset.

Note 4.C – Bank deposits

The Group has unrestricted bank deposits of $541,967 (2022: $346,663), which are presented under current assets. The deposits bear an annual and fixed interest rate of between 4.6%-7.17%.

The deposits period is between three months to one year.

F-20

R.Nano Dimension Ltd
LossNotes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Note 5.A – Trade receivables

  December 31, 
  2022  2023 
Trade receivables  6,770   13,370 
Provision for impairment (*)  (428)  (660)
   6,342   12,710 

(*) All impairment losses derive from contracts with customers.

Note 5.B – Other receivables

  December 31, 
  2022  2023 
Government authorities  2,495   1,956 
Prepaid expenses  1,895   1,777 
Others (*)  2,910   7,557 
   7,300   11,290 
         
Presented under current assets  6,491   11,290 
Presented under non-current assets  809    

(*) Including $6,353 in receivables for reimbursement of damaged inventory (see note 6).

Note 6 – Inventory

  December 31, 
  2022  2023 
Raw materials and work in progress  14,924   12,134 
Finished goods  4,476   6,256 
   19,400   18,390 

During the reporting period, the Group’s warehouse located in the south of Israel suffered physical damage due to a direct missile hit related to the Iron Swords War, as described in Note 1(B)(2). As a result, damaged inventory in the amount of $4,959 was written off. The damage was covered by government authorities, part of which was received in November 2023, and the remainder in February 2024. The Group presents basic and diluted loss per share foris in the process of claiming additional compensation from its Ordinary Shares. Basic loss per share is calculated by dividinginsurance policy, which compensates the loss attributable to holdersprofit margin of Ordinary Sharesthat inventory. The amount of $3,774, which represents the net excess of the Company byreceivables from the weighted average number of Ordinary Shares outstanding duringgovernment authorities over the year, adjusted for treasury shares. Diluted loss per share is determined by adjusting the loss attributable to holders of Ordinary Sharescost of the Company and the weighted average number of Ordinary Shares outstanding, after adjustment for treasury shares, for the effects of all dilutive potential Ordinary Shares. inventory damaged, was recognized in other income.


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

F-21

Note 3.ACash

  December 31, 
  2019  2020 
  Thousands
USD
  Thousands
USD
 
Bank accounts- dominated in NIS 348  1,057 
Bank accounts- dominated in USD  3,536   584,205 
Bank accounts- other  10   76 
   3,894   585,338 

Note 3.BRestricted deposits

The Group has a restricted depositNano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in the amount of $468 thousand for the lease of its officesthousands (except share and labs and for credit cards. The deposit is not linked and bears an annual interest rate of 0.01%. The Group expects to lease its offices and labs for a period of more than a year, thus the restricted deposit was classified as a non-current asset.per share data)

Note 4.ATrade receivables

  December 31, 
  2019  2020 
  Thousands
USD
  Thousands
USD
 
Open balances 1,816  713 

Note 4.BOther receivables

  December 31, 
  2019  2020 
  Thousands
USD
  Thousands
USD
 
Government authorities  332   400 
Prepaid expenses  221   696 
Others  17   30 
   570   1,126 

Note 5Inventory

  December 31, 
  2019  2020 
  Thousands
USD
  Thousands
USD
 
Raw materials and work in progress (*)  2,636   2,692 
Finished goods  907   622 
   3,543   3,314 

(*)A part of the raw materials and work in progress are expected to be sold in a period longer than the operating cycle of the Company.

Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 67Property plant and equipment, net

 

  Machinery, equipment and vehicles  Computers  Office furniture and equipment  Leasehold improvements  Raw materials for property  Buildings  Total 
Cost                     
As of January 1, 2022  8,490   1,870   795   2,579   439   6,064   20,237 
Acquisitions through business combinations  391   65   120   43         619 
Additions  3,125   2,075   677   3,543      20   9,440 
Disposals  (464)  (23)        (439)     (926)
Effect of changes in exchange rates  267   (42)  (1)  (35)     (24)  165 
As of December 31, 2022  11,809   3,945   1,591   6,130      6,060   29,535 
Additions  7,179   984   241   3,509      110   12,023 
Disposals  (393)  (13)  (23)  (204)        (633)
Effect of changes in exchange rates  454   111   44   16      611   1,236 
As of December 31, 2023  19,049   5,027   1,853   9,451      6,781   42,161 
                             
Depreciation accrued                            
As of January 1, 2022  8,490   1,870   795   935   439   18   12,547 
Additions  99   496   74   838      205   1,712 
Impairment loss  3,343   1,552   696   4,326   (439)     9,478 
Effect of changes in exchange rates  (123)  27   26   31      (6)  (45)
As of December 31, 2022  11,809   3,945   1,591   6,130      217   23,692 
Additions  921   169   70   581      231   1,972 
Disposals  (253)  (8)  (7)  (111)        (379)
Effect of changes in exchange rates  (14)  81   43   11      39   160 
As of December 31, 2023  12,463   4,187   1,697   6,611      487   25,445 
                             
Carrying amount                            
As of December 31, 2022                 5,843   5,843 
As of December 31, 2023  6,586   840   156   2,840      6,294   16,716 

  Machinery and equipment  Computers  Office furniture and equipment  Leasehold improvements  Printers leased to clients  Total 
  Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
Cost                  
As of January 1, 2019  4,132   471   158   1,719   199   6,679 
Additions  770   5   32   26   -   833 
Disposals  (306)  -   (3)  -   (87)  (396)
Designation change  112   -   -   -   (112)  - 
As of December 31, 2019  4,708   476   187   1,745   -   7,116 
                         
Additions  1,163   124   85   12   -   1,384 
Disposals  -   (8)  (22)  -   -   (30)
As of December 31, 2020  5,871   592   250   1,757   -   8,470 
                         
Depreciation accrued                        
As of January 1, 2019  792   365   37   238   47   1,479 
Disposals  799   65   17   166   13   1,060 
Designation change  (133)  -   (1)  -   (32)  (166)
Disposals  28   -   -   -   (28)  - 
As of December 31, 2019  1,486   430   53   404   -   2,373 
                         
Additions  787   47   30   167   -   1,031 
Disposals  -   (8)  (18)  -   -   (26)
As of December 31, 2020  2,273   469   65   571   -   3,378 
                         
Carrying amount                        
As of December 31, 2020  3,598   123   185   1,186   -   5,092 
As of December 31, 2019  3,222   46   134   1,341   -   4,743 

During the year ended December 31, 2020,2023, the Group acquired $25,000$726 (2022: $512) of property and equipment on credit.

A. Impairment loss

As part of the impairment testing of cash generating units, impairment losses of property, plant and equipment on credit.were recognized in 2022 and 2021 in the amount of approximately $9,478 and $8,031. For further information regarding the impairment test, see Note 8.D.

F-22

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Note 78Intangible assets

A.Movement in carrying amount

  Goodwill  Technology  Development Costs  Other
intangible assets
  Total 
Cost               
As of January 1, 2022  89,244   39,987   7,672   2,853   139,756 
Acquisitions through business combinations  22,050   8,902      2,497   33,449 
Effect of changes in exchange rates     (453)     48   (405)
As of December 31, 2022  111,294   48,436   7,672   5,398   172,800 
Acquisitions of intangible     2,235         2,235 
As of December 31, 2023  111,294   50,671   7,672   5,398   175,035 
                     
Amortization and impairment losses                    
As of January 1, 2022  (89,244)  (39,987)  (7,672)  (2,853)  (139,756)
Amortization for the year     (1,654)     (348)  (2,002)
Effect of changes in exchange rates     13      (10)  3 
Impairment loss  (22,050)  (39,987)     (2,187)  (31,045)
As of December 31, 2022  (111,294)  (48,436)  (7,672)  (5,398)  (172,800)
As of December 31, 2023  (111,294)  (48,436)  (7,672)  (5,398)  (172,800)
Carrying amount                    
As of December 31, 2022               
As of December 31, 2023     2,235         2,235 

B.Acquisitions

Intangible assets includeIn August 2023, the Group acquired the technology and intellectual property of the U.K.-based company Additive Flow, which supplies solutions for 3D design simulation and optimization, for 1,760 thousand GBP ($2,235). An amount of 1,200 thousand GBP ($1,524) was paid immediately, and the rest of the consideration was transferred to the seller in February 2024. The Group intends to integrate Additive Flow’s technology as part of its research and development. Therefore, the acquired intangible asset has not yet begun to be amortized.

C.Amortization

No amortization was recognized in 2023. In 2022, the current amortization of technology and of development costs that were capitalized. The expenditure capitalizedand backlogs (included in respect of development activities includes“other intangibles assets”) was allocated to the cost of materials, direct laborrevenues. The current amortization of trademarks (included in “other intangibles assets”) was recognized in selling and overhead costsdistribution expenses. Amortization is recognized on a straight-line basis, except for backlogs which were amortized when inventory was sold.

D.Impairment testing for cash-generating units containing goodwill

In 2022 and 2021, for the purposes of goodwill impairment testing, goodwill acquired in a business combination is allocated to a group of cash-generating units, including those existing in the Group before the business combination, that are directly attributableexpected to preparingbenefit from the asset for its intended use. See also Note 2.M.synergies of the combination. Therefore, the Group tested the goodwill acquired from the acquisition of GIS and Formatec Holding (2021: the goodwill acquired from the acquisition of DeepCube, NanoFabrica and Essemtec), at the Group’s level, since the goodwill cannot be allocated to individual cash-generating units. Moreover, the Group recognized technology assets that were acquired in business combinations, as corporate assets that do not generate separate cash inflows and are utilized by more than one cash-generating unit. Those technology assets could not be allocated reasonably and consistently to cash-generating units and therefore were allocated to the Group level.

  2019  2020 
  Thousands
USD
  Thousands
USD
 
Balance as of January 1  5,983   5,211 
Amortization  (772)  (771)
Balance as of December 31  5,211   4,440 

F-23

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

 


Nano Dimension Ltd.The estimated recoverable amount of the cash generating units was based on the higher between the fair value less costs of disposal and the value-in-use of the Group. The value-in-use was determined by discounting the future cash flows to be generated from the continuing use of the Group, with the assistance of independent valuers. The carrying amount of the cash-generating units was determined to be higher than its recoverable amount and impairment losses of $40,523 and $140,290 were recognized in 2022 and 2021, respectively. The impairment losses were allocated to goodwill, intangible assets and property plant and equipment.

Notes

The estimated fair value less cost of sale of some property, plant and equipment assets and right of use assets was higher than its carrying amount, and therefore the impairment loss was not allocated to those assets.

Key assumptions used in calculation of recoverable amount

Key assumptions used in the Consolidated Financial Statementscalculation of recoverable amounts are discount rates, revenues terminal value growth rates and EBITDA (earnings before interest, tax, depreciation and amortization) margins. These assumptions are as follows:

(1) Discount rate

In 2022, the discount rate was estimated based on an industry average weighted average cost of capital, without debt leveraging, and was estimated to 21% (2021: 20%). The discount rate was based on the risk-free rate for 20-year debentures issued by the government in the relevant market and adjusted for a risk premium to reflect the increased risk of investing in equities, a small stock premium and a company specific risk premium.

(2) Revenues and revenues terminal growth rate

The Company’s estimated revenues were based on the Company’s budget, growth plans and available market information. Assumptions:

2022 2021
Revenues annual growth rate is expected to gradually decrease from 35.8% in 2023 to 21.5% in 2027. Revenues annual growth rate is expected to gradually decrease from 33.33% in 2026 to 5% in 2029. From 2030 onward, revenues are expected to increase at an annual rate of 3%, which reflects the long-term growth rate assumed.

(3) EBITDA margin

2022 2021
EBITDA margin is expected to gradually increase from negative 153.8% in 2023, to negative 47.6% in 2027. EBITDA margin is expected to gradually increase from negative 280.7% in 2022 to 17.1% in 2030 onward, which represents the EBITDA margin assumed for the long-term. This estimation is supported by a sample of projected EBITDA margin of comparable companies, according to analyst reports.

(4) Tax expense

In 2022, due to significant operating losses throughout the projection period, no tax expenses were recognized. In 2021, the effective tax rate during the projection period was 16%.

F-24

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Note 89Subsidiaries

A.Details in respect of subsidiaries

Presented hereunder is a list of the main Group’s subsidiaries:

 Principal location of the 2022  2023 
Name of company company’s activity  %   % 
Nano Dimension Technologies Ltd. Israel  100%  100%
Nano Dimension USA Inc. USA  100%  100%
Nano Dimension (HK) Limited Asia-Pacific  100%  100%
Nano Dimension Australia Pty Ltd. (1) Australia  %  100%
Nano Dimension GmbH Germany  100%  100%
J.A.M.E.S GmbH Germany  50%  50%
Essemtec AG Switzerland  100%  100%
Nano Dimension Swiss GmbH Switzerland  100%  100%
Global Inkjet Systems Ltd. (2) UK  100%  100%
Formatec Holding B.V. (2) Netherlands  100%  100%

  Principal location
of the company’s
activity
 The Group’s ownership interest in the subsidiary for the year ended December 31 
   2019  2020 
Name of company  %  % 
Nano Dimension Technologies Ltd. Israel  100%  100%
Nano Dimension IP Ltd. (*) Israel  100%  100%
Nano Dimension USA Inc. USA  100%  100%
Nano Dimension (HK) Limited (*) Asia-Pacific  100%  100%

(*)(1)In January 2023, the Company established an Australian-based subsidiary, Nano Australia. Nano Australia will perform sales and marketing activity and engage in possible collaboration agreements.
(2)See note 9B.

B.Acquisition of subsidiaries

Business combinations during 2022

(1) Acquisition of GIS

On January 4, 2022, the Company acquired 100% of the shares and voting interests in GIS, a company incorporated under the laws of England & Wales. GIS is a developer and supplier of high-performance control electronics, software, and ink delivery systems. Taking control of GIS will enable the Group access to GIS’s technology and software, and will enable faster product development.

Consideration transferred

The following table summarizes the acquisition date fair value of each major class of consideration:

Cash23,568
Deferred consideration772
Earn-out cash consideration – Contingent consideration5,196
Total consideration transferred29,536

F-25

Nano Dimension IP Ltd.Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and Nano Dimension (HK) Limited were incorporated by the Company in 2018. Nano Dimension IP Ltd. had no material activity until and during 2020.per share data)

a)Deferred consideration

 

The Company will pay GIS’s selling shareholders the amount of GBP 1,000 thousand (as of January 4, 2022, approximately $1,349) on April 1, 2024. The deferred consideration for shareholders who represent approximately 39% of the selling shareholders is contingent on their continued employment. Therefore, this amount is not part of the business combination, but of the employee benefits as described in note 18. Regarding the amendment of the share purchase agreement in respect of deferred consideration, see below.

b)Earn-out cash consideration – Contingent Consideration

The Company will pay GIS’s selling shareholders earn-out payments, depending on certain targets, in an aggregate amount of up to GBP 7,000 thousand (“GIS earn-out consideration”) as follows:

(i)

EBITDA based earn-out (maximum of up to GBP 1,000 thousand of the GIS earn-out consideration) – In the event that GIS generates, during the fiscal year ending on March 31, 2022, EBITDA of at least GBP 396 thousand (as of January 4, 2022, approximately $535) (“GIS EBITDA target”).

If the actual amount of EBITDA that was achieved by GIS during this period is equal to or lower than 50% of the GIS EBITDA target, then GIS’s selling shareholders shall not be entitled to receive any portion of the EBITDA based earn-out consideration.

If the actual amount of EBITDA that was achieved by GIS during this period is lower than the GIS EBITDA target but higher than 50% of the GIS EBITDA target, then GIS’s selling shareholders shall be entitled to a portion of the EBITDA-based earn-out consideration based according to this formula:

EBITDA consideration * (1 – (GIS EBITDA target - Actual EBITDA)*2/GIS EBITDA target).

(ii)

Gross profit based earn-out (maximum of up to GPB 3,000 thousand of the GIS earn-out consideration) – In the event that GIS generates, during the fiscal year ending on March 31, 2023, gross profit of at least GBP 6,962 thousand (as of January 4, 2022, approximately $9,364) (“GIS gross profit target”).

If the actual gross profit that was achieved by GIS during this period is equal to or lower than GBP 5,570 thousand (“GIS gross profit threshold”), then GIS’s selling shareholders shall not be entitled to receive any portion of the gross profit-based earn-out consideration.

If the actual gross profit that was achieved by GIS during this period is lower than GIS gross profit target but higher than the GIS gross profit threshold, then GIS’s selling shareholders shall be entitled to a portion of the GIS gross profit based earn-out consideration according to this formula:

Profit consideration * (1 - (GIS gross profit target – actual gross profit)*5/GIS gross profit target).

(iii)

Revenues based earn-out (maximum of up to GPB 3,000 thousand of the GIS earn-out consideration) – In the event that GIS generates, during the fiscal year ending on March 31, 2023, revenues of at least GBP 9,537 thousand (as of January 4, 2022, approximately $12,869) (“GIS revenues target”).

If the actual revenues that was achieved by GIS during this period is equal to or lower than GBP 8,584 thousand (“GIS revenues threshold”), then GIS’s selling shareholders shall not be entitled to receive any portion of the revenues based earn-out consideration.

If the actual revenues that was achieved by GIS during this period is lower than GIS revenues target but higher than the GIS revenues threshold, then GIS’s selling shareholders shall be entitled to a portion of the revenues-based earn-out consideration according to this formula:

GIS revenues consideration * (1 - (GIS revenues target – actual revenues)*10/GIS revenues target).

The earn-out consideration for shareholders who represent approximately 39% of the selling shareholders, is contingent on their continued employment. Therefore, this amount is not part of the business combination, but of the employee benefits as described in note 18.

In August 2022, the Company paid GBP 1,000 thousand ($1,163), after GIS surpassed the GIS EBITDA target.

Regarding the amendment of the GIS share purchase agreement in respect of contingent consideration, see below.

F-26

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Amendment to the deferred and Contingent Consideration

In July 2022, an amendment to the GIS share purchase agreement was signed, in which the terms of the deferred and contingent consideration were updated, as follows:

1)The deferred consideration will amount to GBP 750 thousand and will be paid on March 31, 2023 (except for one selling shareholder, as detailed below). There is no change in the condition that 39% of the selling shareholders are required to continued employment in order to be entitled to this consideration.

2)The remaining contingent consideration that has not yet been paid in the amount of up to GBP 6,000 thousand, will be reduced to amount of GBP 4,500 thousand and will be paid unconditionally on March 31, 2023 (except for one selling shareholder, as detailed below). There is no change in the condition that 39% of the selling shareholders are required to continue employment in order to be entitled to this consideration.

3)One selling shareholder (among the shareholders that are required to the continued employment) will receive his share of the updated deferred consideration on the following dates on the condition he remains employed: approximately GBP 522 thousand on June 30, 2023; approximately GBP 348 thousand on June 30, 2024; approximately GBP 435 thousand on June 30, 2025.

According to the amendment, the Company paid during 2023 an amount of $5,544 in order to settle the liabilities mentioned above.

c)Acquisition-related costs

The Group incurred acquisition-related costs of $1,094 of legal fees and due diligence costs. These costs have been included in general and administrative expenses.

Identifiable assets acquired and liabilities assumed

The following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition.

Cash and cash equivalents5,409
Inventories3,396
Other current assets1,199
Property and equipment, net139
Technology5,924
Customer relationships548
Goodwill14,580
Trade accounts payable(12)
Other accounts payable and accrued expenses(1,064)
Deferred tax(583)
Total identifiable net assets acquired29,536

F-27

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Measurement of fair value

Below is information regarding the way the Group determined the fair value of assets and liabilities recognized as part of the business combination:

a)Intangible assets

The fair value of the technology asset is determined using the multi-period excess earnings method, whereby the subject asset is valued by the discounted net cash flows expected to be generated by the technology, after deducting a fair return on all other assets that are part of creating the related cash flows. The fair value of customer relationship asset is based on the cost saving method, whereby the subject asset is valued by the discounted estimated payments that are expected to be avoided as a result of the customer relationship being owned.

b)Inventories

The fair value of inventories is determined based on estimated selling price in the ordinary course of business less estimated costs of completion and sale, and a reasonable profit margin based on the effort required to complete and sell the inventories.

c)Deferred revenues

The fair value of deferred revenues is determined based on estimated costs to be incurred in order to fulfill the performance obligation that exists.

The aggregate cash flows derived for the Group as a result of the acquisition:

Cash and cash equivalents paid(23,568)
Cash and cash equivalents of GIS5,409
(18,159)

Goodwill

The goodwill is attributable mainly to the skills and technical talent of GIS’s work force, its technology and the synergies expected to be achieved from integrating GIS into the Group’s existing 3D Technologies and business. None of the goodwill recognized is expected to be deductible for tax purposes.

(2)Acquisition of Formatec Holding

On July 7, 2022, the Group acquired 100% of the shares and voting interests in Formatec Holding. Formatec Holding is the owner of two Dutch companies: Admatec and Formatec. Admatec and Formatec operate in the field of 3D printing of non-electronic components from ceramic and metallic materials. Admatec is a manufacturer and marketer of these types of 3D printers and provides various services in this field of printing. Formatec develops and sells printers and materials and provides printing services to customers, both of models and of final products (which may also be produced using traditional systems, and not necessarily using 3D printing). Taking control of Formatec Holding will provide the Group access to Admatec’s and Formatec’s technology and customers, and benefit from its experienced scientists and engineers.

Consideration transferred

The total consideration for the purchased Formatec Holding shares was paid in cash in the amount of approximately $13,611.

The Group incurred acquisition-related costs of $888 of legal fees and due diligence costs. These costs have been included in general and administrative expenses.

F-28

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Identifiable assets acquired and liabilities assumed

The following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition.

Cash and cash equivalents712
Trade and other receivables691
Inventory827
Property and equipment, net480
Right-of-use assets627
Deferred tax asset857
Customer relationships1,690
Intangible assets3,237
Goodwill7,470
Trade and other payables(1,275)
Lease liability(434)
Deferred tax liabilities(1,271)
Total identifiable net assets acquired13,611

Measurement of fair value

The fair value of the intangible assets (Customer relationships, Technology and Backlog) is determined using the multi-period excess earnings method, whereby the subject asset is valued by the discounted net cash flows expected to be generated by the intangible asset, after deducting a fair return on all other assets that are part of creating the related cash flows.

The aggregate cash flows derived for the Group as a result of the acquisition:

Cash and cash equivalents paid(13,611)
Cash and cash equivalents of Formatec Holding712
(12,899)

Goodwill

The goodwill is attributable mainly to the skills and technical talent of Admatec’s and Formatec’s work force, their technology and the synergies expected to be achieved from integrating Admatec and Formatec into the Group’s existing business. Admatec and Formatec fit the Group’s target markets, and the combined offering will increase the number of applications that can be relevant for mass manufacturing. None of the goodwill recognized is expected to be deductible for tax purposes.

F-29

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Note 910Other payables

  December 31, 
  2022  2023 
Accrued expenses and other  4,899   7,208 
Contract liabilities  3,330   3,857 
Lease liability  4,846   4,473 
Employees and related liabilities  8,917   11,252 
Government authorities  1,664   2,686 
Current maturities in respect of government grants  494   262 
   24,150   29,738 

  December 31, 
  2019  2020 
  Thousands
USD
  Thousands
USD
 
Accrued expenses  406   1,635 
Contract liabilities  991   968 
Lease liability  1,055   1,148 
Employees and related liabilities  616   1,230 
Government authorities  249   659 
Current maturities in respect of government grants  231   226 
Others  27   44 
   3,575   5,910 

Note 1011Liability in respect of government grants

 2019 2020 
 Thousands
USD
 Thousands
USD
  2022  2023 
Balance as of January 1 1,445 1,275   1,988   1,986 
Amounts received during the year 121 55 
Payment of royalties (185) (158)  (219)  (298)
Amounts recognized as an offset from research and development expenses (49) (23)
Revaluation of the liability  (57)  (73)  217   469 
Balance as of December 31 1,275 1,076   1,986   2,157 
             
Current maturities in respect of government grants  231  226   494   262 
Long term liability in respect of government grants  1,044  850 
Non-current liability in respect of government grants  1,492   1,895 

DuringBetween the years 2014 to 2020, Nano-Technologies2023, Nano Tech received several approvalsgrants from the Israeli Innovation Authority (“IIA”), to finance development projects in an aggregate amount of up to $4,505,000,$8,745, while the Innovation AuthorityIIA share of financing the aforesaid amount was in a range of 30% to 50%85% of expenditures. As of December 31, 2020, the Company2023, Nano Tech received grants in the aggregate amount of $1,865,000.$3,843. In consideration, Nano-TechnologiesNano Tech undertook to pay the Innovation AuthorityIIA royalties inat the rate of 3%-3.5% of the future sales up to the amount of the grants received. On the date on which the grants were received, theThe Group recognized a liability using a discount rate ranging betweenof 19% to 30%.


Nano Dimension Ltd.Note 12 – Equity

Notes to the Consolidated Financial Statements

Note 11Equity

A.The Company’s share capital (in thousands of Ordinary Shares)ordinary shares)

 

 Ordinary Shares  Ordinary shares 
 2019(*) 2020  2022  2023 
Issued and paid-up share capital as at December 31  4,179   172,052 
Issued and paid-up share capital as of December 31  258,564   235,597 
Authorized share capital  10,000   250,000   500,000   500,000 

F-30

Nano Dimension Ltd
(*)Notes to Consolidated Financial Statements
Following the approval of its shareholders on April 16, 2020, the board of directors of the Company approved a 1-for-50 reverse split of the Company’sU.S. dollars in thousands (except share capital. The implementation of the reverse split resulted in a reduction in the issued and outstanding Ordinary Shares, and the increase of the par value per Ordinary Share from NIS 0.10 to NIS 5.00 per Ordinary Share. Concurrently with the reverse split, the Company effected a corresponding change in the ratio of ordinary shares to each of the Company’s ADSs, such that its ratio of ADSs to Ordinary Shares has changed from one (1) ADS representing fifty (50) Ordinary Shares to a new ratio of one (1) ADS representing one (1) Ordinary Share. The effective date of this reverse split was June 29, 2020. All options and warrants of the Company outstanding immediately prior to the reverse split were appropriately adjusted by dividing the number of Ordinary Shares into which the options and warrants are exercisable by 50 and multiplying the exercise price thereof by 50, as a result of the reverse split. All the figures in these financial statements relating to share capital were appropriately adjusted to reflect the above-mentioned reverse split.data)

Share capital (in thousands of shares of NIS 5 par value)value per share)

  Ordinary shares 
  2022  2023 
Issued as of January 1  257,376   258,564 
Repurchase of treasury shares     (32,016)
Exercise of warrants during the period (*)     3,559 
Exercise of share options and RSUs during the period  1,188   5,490 
Issued and paid-in share capital as of December 31  258,564   235,597 

(*)See note 23(L).

B.Financing transactions

  Ordinary Shares 
  2019  2020 
Issued as at January 1  1,931   4,179 
Issued for cash during the period  1,600   163,542 
Conversion into shares of convertible notes during the period  610   1,395 
Exercise of warrants during the period  38   2,918 
Exercise of share options during the period  -   18 
Issued and paid-in share capital as at December 31  4,179   172,052 

In April 2020, following approval of the general meeting of the Company’s shareholders,During 2021, the Company increased its authorized share capital by NIS 100,000,000, such thatissued, pursuant to two public offerings in the authorized share capitalUnited States, an aggregate of 74,100,000 ADSs. The total gross proceeds from the offerings were approximately $832,980, before deducting underwriting discounts and commissions and other offering-related expenses. The total net proceeds from the offerings, after deducting issuance expenses, were approximately $796,346. As a part of one of these offerings, the Company was NIS 150,000,000.

In May 2020, following approval of the general meeting of the Company’s shareholders, the Company increased its authorized share capital by NIS 100,000,000, such that the authorized share capital of the Company was NIS 250,000,000.

In June 2020, following approval of the general meeting of the Company’s shareholders, the Company increased its authorized share capital by NIS 1,000,000,000, such that the authorized share capital of the Company was NIS 1,250,000,000 divided into 250,000,000 Ordinary Shares, par value NIS 5.00 each.

After the reporting date, on February 2021, following approval of the general meeting of the Company’s shareholders, the Company increased its authorized share capital by NIS 1,250,000,000, such that the authorized share capital of the Company was NIS 2,500,000,000 divided into 500,000,000 Ordinary Shares, par value NIS 5.00 each.

B.Financing transactions

1.In February 2019, the Company issued, pursuant to a public offering in the United States, an aggregate of 1,600,000 ADSs, 1,600,000issued 1,137,500 non-tradable warrants with an exercise price of $8.625 per ADS and term of 5 years and 1,200,000 non-tradable rights to purchase shares with an exercise price of $7.50 per ADS and term of 6 months. In certain cases, the rights to purchase and the warrants may be exercised on a cashless basis. Therefore, the rights to purchase and the warrants are accounted for as derivative instruments which are classified as a liability and measured at fair value through profit or loss. The total gross consideration was $12,000,000 and was initially attributed to the financial liability for the rights to purchase and warrants based on their fair value in the amount of $10,201,000 and the remaining amount was attributed to the ADSs issued and recognized as an equity component in the amount of $1,799,000. Applicable issuance costs, amounting to $1,440,000, have been allocated in the same proportion as the allocation of the gross proceeds. An amount of $1,224,000 was considered as issuance costs allocated to the rights to purchase and the warrants and has been recorded in profit or loss as finance expense, while costs allocated as issuance costs of ADSs in the amount of $216,000 have been recorded in equity as a reduction of the share premium. The total net proceeds from the offering were approximately $10,560,000.

During the first quarter of 2019, investors exercised 37,620 of the rights to purchase 37,620 Ordinary Shares for a total consideration of $282,000.

The value of the financial liability in respect to the warrants was measured as of December 31, 2020, at an amount of approximately $10,892,000.


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 11Equity (Continued)

B.Financing transactions (Continued)

2.In August 2019, the Company issued, pursuant to a securities purchase agreement, convertible promissory notes, in an aggregate principal amount of $4,276,000 and an additional approximately $2,700,000 to be received in two subsequent closings, bringing the expected total gross proceeds from this funding to approximately $7,000,000. The notes were convertible into the Company’s ADSs. As a part of this transaction, the Company issued non-tradable warrants to purchase 62,668,850 ADSs. The warrants have an exercise price equal to 125% of the conversion price of the convertible promissory notes, will be exercisable upon the six-month anniversary of issuance and will expire five years from the date of issuance. The total gross proceeds from the first closing were $4,276,000.

The first tranche of the convertible promissory notes was unsecured, had a maturity date of March 4, 2021, bore no interest except in an event of default and could be converted, at the election of the holder, into ADSs at an initial per share conversion price of $2.90, subject to adjustments, including among others, revenue targets and the conversion prices of the subsequent tranches. The convertible notes have been designated as a financial liability measured at fair value through profit and loss since they were combined instruments including embedded derivatives.underwriters. The warrants are also classified as a financial liability that is measured at fair value through profit and loss as neither the exercise price nor the number of shares to be issued is fixed. The rights for the future issuance of the convertible notes and the warrants of the second and third tranches have been accounted for as derivatives.

The initial fair value of the financial liabilities issued in the transaction at their issuance date has been evaluated in the amount of $11,609,000, while the consideration received from this transaction was $4,276,000. The difference, in the amount of $7,333,000, has been allocated to the convertible notes, warrants and rights to purchase recognized with respect to this transaction.

The allocation was based on the proportion of the fair value of each instrument. The loss that has not been recognized for each instrument is amortized on a straight line basis over the term of each instrument.

Accordingly, from the consideration received, approximately $1,569,000 was attributed to the convertible notes of the first tranche, $1,902,000 was attributed to the warrants of the first tranche, and a total of approximately $805,000 was attributed to the rights with respect to the second and third tranches.

During 2019 and until December 31, 2019, $1,767,400 of the principal amount of the convertible notes was converted into 609,448 ADSs. As a result of the conversion, $2,003,000 of the loss that had not been initially recorded has been recognized as finance expenses in the year ended December 31, 2019.

Prior to February 4, 2020, an additional of approximately $204,000 of the principal amount of the convertible notes was converted.

On February 4, 2020, the Company and the holders of a significant portion of the remaining financial instruments agreed to amend the terms of this transaction such that the conversion price of the convertible notes decreased to $1.74 per ADS, and the holders of such notes agreed to convert such notes into ADSs. As a result, an aggregate of approximately $2,305,000 of the principal amount of the convertible notes was converted. Additionally, the Company agreed to amend the exercise price of the warrants of the first tranche to $1.914 per ADS, and the Company and the investors agreed to terminate substantially all remaining obligations in this transaction, including the instruments to be issued under the second and third tranche.

During the first quarter of 2020, all the outstanding balance of the convertible notes was converted.

The fair value of the remaining financial liabilities relating to the warrants issued in this transaction was measured as of December 31, 2020, at an amount of approximately $745,000.share-based payment expenses. See also Note 18.D - Financial Liabilities.19.

C.3.During 2020, the Company issued, pursuant to several public offerings in the United States, an aggregate of 163,542,447 ADSs and 430,000 pre-funded warrants (that were converted to ADSs during 2020). The total gross proceeds from the offerings were approximately $710,013,000, before deducting underwriting discounts and commissions and other offering-related expenses. The total net proceeds from the offerings, after deducting issuance expenses, were approximately $650,115,000. As a part of those offerings, the Company issued a total of 7,365,289 non-tradable warrants to the underwriters. The warrants are accounted for as share-based payment expenses, see also note 17.Treasury shares

4.See also Note 21.A regarding public offerings after the reporting date.

C.Treasury shares

As of December 31, 2020,2023, the Company held 10,540 Ordinary Shares,32,026,894 ordinary shares, constituting approximately 0.006%12% of its issued and paid uppaid-in share capital.


Nano Dimension Ltd.

Notes The rights attached to the Consolidated Financial StatementsCompany’s own shares that were acquired are suspended until their re-issuance.

 

NoteIn February 2023, the Company announced that it would put into action its previously authorized share repurchase plan allowing us to invest up to $100,000 to repurchase the Company’s ADSs from time to time in open market transactions, and/or in privately negotiated transactions or in any other legally permissible ways, depending on market conditions, share price, trading volume and other factors. The repurchase plan was approved by the Israeli court in in August 2022 for a period of up to 12Revenues months and later extended for an additional two months. The repurchase plan expired on October 12, 2023, with $4,160,138 remaining, and thereafter no longer eligible for repurchases under such plan.

 

  For the year ended
December 31
 
  2018  2019  2020 
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
Consumables  190   650   554 
Support services  400   598   654 
Sales of printers  4,320   5,770   2,191 
Total  4,910   7,018   3,399 
Printers rental  190   52   - 
Total revenue  5,100   7,070   3,399 

In August 2023, our board of directors authorized an additional 200 million repurchase plan (the “$200,000 Repurchase Plan”), allowing us to invest up to $200,000 to repurchase ADSs from time to time, in open market transactions, and/or in privately negotiated transactions or in any other legally permissible ways, depending on market conditions, share price, trading volume and other factors. The Israeli court approved the 200 million Repurchase Plan in October 2023 and extended for a twelve-month period. The $200,000 Repurchase Plan went into effect on October 17, 2023. Such repurchases will be made in accordance with applicable U.S. securities laws and regulations, under the Exchange Act, and other applicable law, and are subject to the approval of the Israeli court, which was granted in October 2023. Under the $200,000 Repurchase Plan, we may repurchase all or a portion of the authorized repurchase amount. The $200,000 Repurchase Plan does not obligate us to repurchase any specific number of the ordinary shares and may be suspended or terminated at any time at management’s discretion.

D.Translation reserve from foreign operations

The movement in the foreign currency translation reserve is as follows:

    For the year ended December 31, 
    2022  2023 
  Currency Thousand USD 
Net change in foreign currency translation reserve for:        
GIS GBP  (1,221)  205 
Admatec-Formatec EURO  302   85 
Essemtec and Nano Swiss CHF  114   1,910 
Other    (19)  146 
     (824)  2,346 

 

F-31

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

E.Rights Plan

In January 2024, the Company entered into a rights agreement, or the Rights Plan, with the intention to protect the long-term interests of the Company’s ADS holders and enable them to realize the full potential value of their investment in the Company. The Rights Plan is designed to reduce the likelihood that any entity, person or group would gain control of, or significant influence over our Company. Further to those goals, the rights under the Rights Plan may cause substantial dilution to a person or group that acquires beneficial ownership of 10% or more of the Company’s ordinary shares then outstanding or any existing holder of 10% or more of the beneficial ownership of the Company’s ordinary shares who shall acquire any additional ordinary shares.

Note 13 – Revenues

  For the year ended December 31 
  2021  2022  2023 
Consumables  1,631   5,487   7,795 
Support services  1,117   3,217   4,590 
Sales of systems  7,250   34,929   43,929 
Research and development services  495       
Total revenue  10,493   43,633   56,314 

Revenues per geographical locations:

  For the year ended
December 31,
 
  2018  2019  2020 
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
U.S.  2,727   3,367   1,263 
Asia Pacific  1,239   1,591   1,362 
Europe and Israel(*)  1,134   2,112   774 
Total revenue  5,100   7,070   3,399 
  For the year ended December 31 
  2021  2022  2023 
Americas  2,513   14,309   22,340 
APAC  743   4,361   2,947 
EMEA  7,237   24,963   31,027 
Total revenue  10,493   43,633   56,314 

(*)The Company combined all revenues into the Europe and Israel geography, due to immateriality of the amounts.

Timing of revenue recognition:

 For the year ended
December 31,
  For the year ended December 31 
 2018 2019  2020  2021  2022  2023 
 Thousands
USD
 Thousands
USD
  Thousands
USD
 
Goods and services transferred over time  590   650   654 
Services transferred over time  1,074   3,217   4,590 
Goods transferred at a point in time  4,510   6,420   2,745   9,419   40,416   51,724 
Total revenue  5,100   7,070   3,399   10,493   43,633   56,314 

Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 12Revenues (Continued)

The table below provides information regarding receivables contract assets and contract liabilities deriving from contracts with customers.

 December 31,  For the year ended
December 31
 
 2019  2020  2022  2023 
 Thousands
USD
  Thousands
USD
 
Open balances  1,816   713 
Trade receivables  6,342   12,710 
Contract liabilities  991   968   3,330   3,857 

 

The contract liabilities primarily relate to the advance consideration received from customers for contracts giving yearly maintenance for the printer. The revenue is recognized in a straight line basis over the contracts’ period.

Contract costs

Management expects that commissions paid to agents for obtaining contracts are recoverable. The Group applies the expedient included in IFRS 15.94 and recognizes incremental costs for obtaining the contract as an expense as incurred, where the amortization period of the asset it would have otherwise recognized is one year or less.

 

During 2020, the Company witnessed a significant decrease in its revenues due to the effects of the COVID-19 pandemic. See also note 1.D.

Note 1314Cost of revenues

  For the year ended
December 31
 
  2018  2019  2020 
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
According to sources of revenue -         
Consumables  195   240   169 
Support services  403   855   629 
Sales of printers  2,938   3,192   765 
Printers rental  58   25   - 
Total  3,594   4,312   1,563 
  For the year ended December 31 
  2021  2022  2023 
Raw materials, materials and consumables  3,585   15,915   18,696 
Payroll and related expenses  1,412   7,180   9,586 
Other  733   1,848   2,477 
Total  5,730   24,943   30,759 

Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

F-32

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Note 1415Further detail of profit or loss

 For the year ended
December 31
 
 2018 2019  2020  For the year ended December 31 
 Thousands
USD
 Thousands
USD
  Thousands
USD
 2021  2022  2023 
A. Research and development expenses, net              
Payroll  4,890   4,834   6,531   14,604   35,638   33,462 
Share-based payment expenses  14,238   17,424   7,722 
Materials  1,065   1,001   940   2,764   6,881   6,584 
Subcontractors  70   82   258   2,864   10,344   6,717 
Patent registration  70   144   160   441   506   689 
Depreciation  880   1,534   1,588   5,697   3,038   3,859 
Rental fees and maintenance  908   197   173   559   642   1,081 
Other  782   339   249   637   1,290   1,890 
  8,665   8,131   9,899   41,804   75,763   62,004 
Less – government grants  (42)  (49)  (21)  (118)      
  8,623   8,082   9,878   41,686   75,763   62,004 
B. Sales and marketing expenses                        
Payroll  2,226   2,873   5,326   8,283   20,057   19,075 
Marketing, advertising and commissions  1,381   1,808   577 
Share-based payment expenses  8,569   8,616   2,490 
Marketing and advertising  4,053   5,057   4,685 
Rental fees and maintenance  64   114   201   365   392   319 
Travel abroad  201   317   235   749   2,567   2,555 
Depreciation  186   212   223   318   1,502   1,369 
Other  201   145   35   376   642   1,214 
  4,259   5,469   6,597   22,713   38,833   31,707 
                        
C. General and administrative expenses                        
Payroll  819(*)  872(*)  1,377   2,880   9,321   14,032 
Share based payment expenses  206(*)  155(*)  16,837 
Fees  32   22   22 
Share-based payment expenses  6,974   4,940   8,448 
Professional services  1,114   1,358   1,064   6,993   9,701   29,122 
Directors pay  209(*)  187(*)  - 
Office expenses  311   359   386   1,065   2,704   1,613 
Travel abroad  45   37   44   461   743   674 
Depreciation  -   78   76   210   563   926 
Rental fees and maintenance  91   43   46   97   286   515 
Other  107   159   435   964   2,199   2,924 
  3,002   3,270   20,287   19,644   30,457   58,254 
D. Finance income            
D. Other income, net            
Other income (*)        3,774 
Other expenses (**)        (2,147)
        1,627 
            
E. Finance income            
Revaluation of liability in respect of government grants  -   58   75   25       
Exchange rate differences  -   -   123   3,444      1,568 
Revaluation of financial liabilities at fair value through profit or loss (**)  -   8,707   - 
Bank interest and fees  54   -   248 
Revaluation of liabilities (***)  10,608   4,516    
Revaluation of financial assets at fair value through profit and loss (****)        23,462 
Bank interest  3,832   18,449   45,904 
  54   8,765   446   17,909   22,965   70,934 
Finance expense            
Finance expenses            
Exchange rate differences  127   151   -      16,135    
Bank fees  -   14   28 
Bank and other fees  70   148   245 
Finance expense in respect of lease liability  -   425   390   237   180   477 
Revaluation of financial liabilities at fair value through profit or loss (**)  -   -   12,825 
Fundraising expenses  -   1,693   - 
Revaluation of financial assets at fair value through profit and loss (****)     62,791    
Revaluation of financial liabilities (***)        461 
Revaluation of liability in respect of government grants  265   -   -   121   217   469 
  392   2,283   13,243   428   79,471   1,652 

(*)(*)Reclassified.See note 6.

(**)See Note 11.Bnote 18(C) regarding termination liability due to reorganization.
(***) See note 20 regarding financing transactions that included issuance of financial instruments accounted at fair value through profit and loss.
(****)See note 20(C) regarding investment in securities measured at fair value through profit and loss.

F-33

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 1516Income Tax

A.Corporate tax rate

Presented hereunder are theThe tax ratesrate relevant to the Company in the years 20182021 to 2020:2023: 23%

2018 – 23%

2019 – 23%

2020 – 23%

On December 22, 2016, the Knesset plenum passed the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in the Years 2017 and 2018) – 2016, by which, inter alia, the corporate tax rate would be reduced from 25% to 23% in two steps. The first step will bewas to a rate of 24% as from January 2017 and the second step will bewas to a rate of 23% as from January 2018.

As a result of the reduction in the tax rate, the deferred tax balances as at December 31, 2019 and 2020 were calculated according to the new tax rates specified in the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in the Years 2017 and 2018), at the tax rate expected to apply on the date of reversal.

B.Benefits under the Law for the Encouragement of Industry (Taxes)

a.(a)The Company and some of its subsidiaries qualify as “Industrial Companies” as defined in the Law for the Encouragement of Industry (Taxes) – 1969, and accordingly they are entitled to benefits, of which the most significant are, under limited conditions, the possibility of submitting consolidated tax returns with related Israeli companies and amortization in three equal annual portions of issuance expenses when registering shares for trading as from the date the shares of the company were registered.

b.
(b)The Company and certain subsidiaries are submitting a consolidated tax return to the tax authorities in accordance with the Law for the Encouragement of Industry (Taxes) – 1969. As a result, the companies are, inter alia, entitled to offset their losses from the taxable income of other companies, subject to compliance with certain conditions.

C.TheoreticalDescription of the implications of the tax laws applicable to affiliated companies incorporated outside of Israel

The Group companies operating outside of Israel are subject to the tax laws applicable in the countries of residence and the activity of those companies. The tax rate applicable to material companies outside of Israel are:

Companies incorporated in Switzerland (varies from canton to canton) - tax rate of 12.44% (the relevant canton).

Company incorporated in UK - tax rate of 19% until March 31, 2023 and 25% from April 1, 2023, onward.

Companies incorporated in Netherlands - tax rate of 25.8% for taxable income above Euro 200 thousand and tax rate of 19% for taxable income up to Euro 200 thousand.

Company incorporated in U.S. - tax rate of 21%.

Companies incorporated in Germany - tax rate of 15.8%.

D.Composition of income tax expense (income)
  Year ended December 31 
  2021  2022  2023 
Current tax expense  107   845   73 
Deferred tax expenses (income)  (5,013)  (581)  (11)
Income tax expense (income)  (4,906)  264   62 

E.Deferred tax assets and liabilities

Deferred taxes are calculated according to the tax rate anticipated to be in effect on the date of reversal as stated above.

The movement in deferred tax assets and liabilities is attributable to the following items:

  Intangible
assets and
inventories
  Employee benefits  Carryforward
tax losses
  Total 
Balance of deferred tax asset (liability) as of January 1, 2022  (236)  516   491   771 
Deferred tax asset (liability) acquired in business combinations  (2,966)     1,968   (998)
Changes recognized in profit or loss  3,073   5   (2,497)  581 
Changes recognized in other comprehensive income  96   (373)  38   (239)
Balance of deferred tax asset (liability) as of December 31, 2022  (33)  148      115 
                 
   Intangible
assets and
inventories
   Employee benefits   Other   Total deferred tax asset (liability) 
Balance of deferred tax asset (liability) as of January 1, 2023  (33)  148      115 
Changes recognized in profit or loss  33   (22)     11 
Changes recognized in other comprehensive income     (126)  (75)  (201)
Balance of net deferred tax asset (liability) as of December 31, 2023        (75)  (75)

F-34

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

F.Theoretical tax

The following presents the adjustmentmain reconciliation between the theoretical tax amounton the pre-tax profit and the tax amount included in the financial statements:expense derives from temporary differences and tax losses for which deferred taxes are not created.

  For the year ended
December 31,
 
  2018  2019  2020 
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
Total comprehensive loss  (15,488)  (8,353)  (48,494)
Statutory tax rate  23%  23%  23%
Theoretical tax benefit  (3,562)  (1,921)  (11,154)
Increase in tax liability due to:            
Non-deductible expenses  280   75   4,299 
Losses and benefits for tax purposes for which no deferred taxes were recorded  3,282   1,846   6,855 
Taxes on income  -   -   - 


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 15Taxes on income (Continued)

D.G.Tax assessments

The Company has final tax assessments until and including the 2017 tax year.

 

Nano Dimension Technologies Ltd.Tech has final tax assessments until and including the 20152017 tax year.

E.H.Accumulated losses for tax purposes and other deductible temporary differences

As of the reporting date,December 31, 2023, the Group has a net operating loss for tax purposes of approximately $291,945, most of which originated in the amount of approximately $79,688,000 andCompany. The Group also has capital loss for tax purpose in the amountpurposes of approximately $840,000.$681.

As of December 31, 2020,2023, the Group has deductible temporary differences in the amount of approximately $31,634,000,$5,170, mainly relating to share-based payment expenses, revaluation of financial assets and liabilities, funding expenses and research and development expenses which are deductible over a period of three years for tax purposes.

The Group has not recognized a tax asset for the aforesaid losses and deductible temporary differences, due to the uncertainty regarding the ability to utilize those losses and deductible of temporary differences in the future.

E.I.Income Tax Regulations (Rules on Bookkeeping by Foreign Invested Companies and Certain Partnerships and Determination of their Taxable Income), 19861986.

As a “Controller Foreign Cooperation”“Foreign investment company” (as defined in the Israeli Law for the Encouragement of Capital Investments-1959), the Company'sCompany’s management has elected to apply Income Tax Regulations (Rules for Maintaining Accounting Records of Foreign Invested Companies and Certain Partnerships and Determining Their Taxable Income) – 1986, from January 2018. Accordingly, its taxable income or loss is calculated in US Dollars.USD.

J.During 2022, the Company completed a merger of two of its subsidiaries, that are located in Israel. NanoFabrica and DeepCube were merged into Nano Tech. The merger was approved by the Israeli tax authorities.

Note 1617Loss per share

A.Basic loss per share

The calculation of basic loss per share as of December 31, 2023 was based on the loss attributable to the owners of the company divided by a weighted average number of ordinary shares outstanding, calculated as follows:

  For the year ended December 31 
  2021  2022  2023 
Weighted average number of ordinary shares (thousands of shares)  247,335   257,794   248,019 
Loss attributable to the owners of the Company (thousands USD)  200,777   227,423   54,550 

F-35

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Weighted average number of ordinary shares:

 

  For the year ended
December 31
 
  2018(*)  2019(*)  2020 
Weighted average of number of Ordinary Shares used in the calculation of basic and diluted loss per share (in thousands)(*)  1,836   3,513   42,947 
Net loss used in calculation (thousands USD)  15,488   8,353   48,494 
  Year ended December 31 
  2021  2022  2023 
  Thousands of shares of NIS 5.0 par value  

Thousands of shares of NIS 5.0 par value

  Thousands of shares of NIS 5.0 par value 
Balance as of January 1  172,052   257,376   258,564 
Effect of share options exercised  2,558   418   687 
Effect of warrants exercised  575      2,307 
Effect of shares issued during the year  72,150      1,893 
Repurchase of treasury shares        (15,432)
Weighted average number of ordinary shares used to calculate basic loss per share as of December 31  247,335   257,794   248,019 

B.Diluted loss per share

The calculation of diluted loss per share as of December 31, 2023 was based on loss attributable to the owners of the company divided by a weighted average number of ordinary shares outstanding after adjustment for the effects of all dilutive potential ordinary shares, calculated as follows:

Loss attributable to owners of the company (diluted)

 

  Year ended December 31 
  2021  2022  2023 
Loss used to calculate basic loss per share  200,777   227,423   54,550 
Changes in fair value of share price protection liability  3,783       
Changes in fair value of warrants classified as liabilities  456   227   7 
Loss attributable to ordinary shareholders  205,016   227,650   54,557 

In 2020, 22,810,291

Weighted average number of ordinary shares (diluted)

  Year ended December 31 
  2021  2022  2023 
  Thousands of shares of NIS 5.0 par value  Thousands of shares of NIS 5.0 par value  Thousands of shares of NIS 5.0 par value 
Weighted average number of ordinary shares used to calculate loss per share  247,335   257,794   248,019 
Effect of share price protection on issue  702       
Effect of warrants issued  95   96   96 
Weighted average number of ordinary shares used to calculate diluted loss per share as of December 31  248,132   257,890   248,115 

As of December 31, 2023, 53,651,683 options and warrants (in 2019: 3,468,9482022: 63,478,648 and 2018: 170,341)2021: 55,817,296) were excluded from the diluted weighted average number of Ordinary Sharesordinary shares calculation as their effect would have been anti-dilutive.

F-36

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Note 18 – Employee Benefits

Employee benefits include post-employment benefits, short-term benefits, termination benefits, and share-based payments.

With regards to share-based payments, see Note 19 on share-based payments.

With regards to benefits to key management employees, see Note 23 on related and interested parties.

A.Composition of employee benefits:

  December 31,  December 31, 
  2022  2023 
Presented under current liabilities – other payables:      
Short-term employee benefits  8,917   11,252 
Total  8,917   11,252 
         
Presented under non-current liabilities – employee benefits:        
Long-term employee benefits  274   289 
Recognized liability for defined benefit plan, net  1,188   2,484 
Total  1,462   2,773 

Following note 9(B)(1), the amounts detailed above include 39% of the deferred and contingent consideration arises from acquisition of GIS, for selling shareholders that require continued employment in order to be entitled to this consideration, in the amount of $344 (2022 - $1,120) and $289 (2022 - $274) in short-term and in long-term, respectively.

B.Post-employment benefit plans – defined benefit plan

Essemtec, a subsidiary of the Company, located in Switzerland, participates in a defined benefit plan. Employees in Switzerland are insured against the risks of old age, death and disability. Essemtec is affiliated to the collective foundation Bâloise Collective BVG foundation. The supreme governing body of the pension fund is the Foundation Council, which is made up of an equal number of representatives from the employees and the employer. The pension fund rules, together with the legal provisions concerning occupational pension plans, constitute the formal regulatory framework of the pension plan. Individual retirement savings accounts are maintained for each beneficiary, which savings contributions varying with age are credited to as well as any interest which accrues. The rate of interest to be applied to the retirement savings accounts is set each year by the Foundation Council, having regard to the financial situation of the pension fund. The amounts credited to the individual savings accounts are funded by savings contributions from both the employer and employees. In addition, the employer pays risk contributions to fund death and disability benefits.

The standard retirement age is 64 for women and 65 for men. Employees are entitled to early retirement with a reduced old-age pension. The amount of the old-age pension is the result of multiplying the individual retirement savings account at the time of retirement by a conversion rate set out in the pension-fund rules. The retirement benefits can also be paid out in the form of a capital payment either in full or in part. The amount of disability pensions is determined as a percentage of the insured salary and is independent of the number of years of service.

The Group’s defined benefit obligations and the related defined benefit costs are determined at each balance sheet date by a qualified actuary using the Projected Unit Credit Method. The amount recognized in the consolidated balance sheet represents the present value of the defined benefit obligations reduced by the fair value of plan assets. Any surplus resulting from this calculation is limited to the present value of any economic benefits available in the form of refunds from the plans or reductions in future contributions to the plans.

F-37

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

1.Plan assets

As of December 31, 2023, plan assets were comprised of qualifying insurance policies of $17,109 (December 31, 2022: $12,913).

 

2.(*Movement in net defined benefit liabilities (assets) and in their components

  Defined benefit obligation  Fair value of plan assets  Net defined benefit
liability (asset)
 
  2022  2023  2022  2023  2022  2023 
Balance as of January 1  15,816   14,101   (11,671)  (12,913)  4,145   1,188 
Included in profit or loss                        
Current service cost  487   459         487   459 
Past service cost     (385)           (385)
Interest cost (income)  61   341   (45)  (312)  16   29 
Administrative cost  21   24         21   24 
Effect of movements in exchange rates     1,404      (1,286)     118 
Included in other comprehensive income                        
Actuarial loss (gain) arising from financial assumptions  (3,529)  1,284         (3,529)  1,284 
Actuarial loss arising from other assumptions  721            721    
Return on plan assets excluding interest income        (51)  361   (51)  361 
Effect of movements in exchange rates  (112)  260   14   (185)  (98)  75 
Other movements                        
Contributions paid by the employer        (524)  (669)  (524)  (669)
Contributions paid by the employees and plan participants  1,950   3,207   (1,950)  (3,207)      
Benefits paid  (1,314)  (1,102)  1,314   1,102       
Changes from business combinations and loss of control                  
Balance as of December 31  14,101   19,593   (12,913)  (17,109)  1,188   2,484 

3.The defined benefit liability is attributed to the plans’ participants as follows:

-Active members: 95% (2022: 95%)

All the figures-Pensioners: 5% (2022: 5%)

F-38

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in this note were adjusted to reflect the 1:50 reverse split effective June 29, 2020, see note 11.A.thousands (except share and per share data)

4.Actuarial assumptions and sensitivity analysis

 

Weighted average number of Ordinary Shares:Principal actuarial assumptions at the reporting date (expressed as weighted averages):

 

  Year ended
December 31
 
  2018(*)  2019(*)  2020 
  Thousands
of
  Thousands
of
  Thousands
of
 
  shares of
NIS 5.0
  shares of
NIS 5.0
  shares of
NIS 5.0
 
  par value  par value  par value 
Balance as at January 1  1,240   1,932   4,179 
Effect of share options exercised  1   135   9 
Effect of warrants exercised  -   -   1,184 
Effect of conversion of notes  -   -   1,236 
Effect of shares issued during the year  595   1,446   36,339 
Weighted average number of Ordinary Shares used to calculate basic and diluted earnings (loss) per share as at December 31  1,836   3,513   42,947 

4. Actuarial assumptions and sensitivity analysis

 2022  2023 
  %  % 
Discount rate as of December 31  2.35   1.9 
Future salary growth  1.25   1.9 
Interest rate on the savings account  1.75   1.9 
Price inflation  1.25   1.9 
Social security increase  1.25   1.9 
Future pension growth  0   0 

Assumptions regarding future mortality are based on published statistics and mortality tables (BVG 2020 generational).

The calculation of the defined benefit obligation is sensitive to the mortality assumptions in accepted mortality tables. As a result, an increase of one year in average life would cause an increase in the defined benefit obligation of $235 as of December 31, 2023.

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below:

  December 31, 
  0.5 percentage
point increase
  0.5 percentage
point decrease
 
  2022  2023  2022  2023 
Future salary growth  50   79   (49)  (78)
Discount rate  (884)  (1,273)  1,001   1,431 

 

(*)5.AllEffect of the figures in this note were adjusted to reflectplan on the 1:50 reverse split effective June 29, 2020, see note 11.A.Group’s future cash flows

 


Nano Dimension Ltd.

NotesThe Group expects $715 in contributions to be paid to the Consolidated Financial Statementsfunded defined benefit plan in 2024.

On December 31, 2023, the weighted-average duration of the defined benefit obligation was 13.9 years (2022: 13.6 years).

C.Termination liability

In October 2023 the Company’s board of directors approved, as part of a reorganization plan in several departments of the Company, an employment termination of Company employees worldwide, with preferable terms.

In the reporting period, an expense related to payroll compensation due to this plan, in the amount of $2,147, was recognized in other expenses. The remaining termination liability in the amount of $1,488 is presented under other payables.

F-39

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Note 1719Share-based payment

 

A.During 2018,2021, the Company granted to employees, a consultantofficers and officers 2,652,500consultants 10,967,162 non-tradable share options and RSUs, which are exercisable into 2,652,500 Ordinary Shares.10,967,162 ordinary shares. The share options vest over a period of one to three years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date, in consideration for an exercise price ranging between $0.28$0 to $1.59$7.50 for each share option. Some of the share options include a cashless exercise mechanism.

During 2021, the Company granted to underwriters in public offerings in the U.S. an aggregate of 1,137,500 warrants, which are exercisable into 1,137,500 ordinary shares. The exercise price is $11.875 for each warrant. The warrants are exercisable 6 months from the issuance date and expire 4 years after the issuance date.

 

During 2019,2022, the Company granted to employees, officers and consultants 6,029,00013,555,000 non-tradable share options and RSUs, which are exercisable into 6,029,000 Ordinary Shares.13,555,000 ordinary shares. The share options and the RSUs vest over a period of three to four years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date in consideration for an exercise price ranging between $0.14$2.52 to $0.17$ 3.79 for each share option. Some of the share options include a cashless exercise mechanism.

 

During 2019, the Company granted to employees 2,723,500 restricted shares units (“RSUs”). The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period of three years.

During 2020,2023, the Company granted to employees, officers and consultants 5,400,0005,838,000 non-tradable share options and RSUs, which are exercisable into 5,400,000 Ordinary Shares.5,838,000 ordinary shares. The share options and the RSUs vest over a period of threetwo to four years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date in consideration for an exercise price ranging between $0.70 to $4.12of $3.05 for each share option. Some of theThe share options include a cashless exercise mechanism.

During 2020, In addition, the Company changed the vesting terms of options to purchase 1,000,000 ADSs granted to employees 1,530,000 RSUs. The RSUs representsan officer of the right to receive Ordinary Shares at a future time and vest over a period of three years.

During 2020, the Company granted to underwriters in public offerings in the U.S. an aggregate of 7,365,289 warrants, which are exercisable into 7,365,289 Ordinary Shares. The exercise prices range between $0.875 to $9.375 for each warrant. The warrants are exercisable 6 months from the issuance date, and expire 5 years after the issuance date.Company.

 

B.In January 2018,May 2021, the Company issued non-tradable share options to purchase 300,000 Ordinary Shares131,000 ordinary shares to directors of the Company at an exercise price of $1.59ranging from $7.69 to $9.33 per share. The share options will vest in 12 equal quarterly batchesare vested over a period of three years.3 years from the grant date. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date. 275,000 of the share options include a cashless exercise mechanism.

 

In July 2019,June 2022, the Company issued non-tradable share options to purchase 2,545,000 Ordinary Shares210,000 RSUs to directors of the Company at an exercise price of $0.15 per share. One third of the share options will vest after one year from the grant date, and the remaining will vest in eight equal quarterly batches over a period of two years. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date.

In July 2020, the Company issued non-tradable share options to purchase 440,000 Ordinary Shares to directors of the Company at an exercise price of $0.70 per share. The share options are vested over a period of no more than 3 years from the grant date. The share options will be exercisable during the earlier of a period of four years from the vesting date, or 90 days from the end of employment date.

In December 2019, the Company signed an agreement for options grants in January 2, 2020 to purchase 286,172 ADSs with Yoav Stern, the Company’s Chief Executive Officer (“CEO”) and President, with an exercise price of $2.86 per ADS. The vesting start date of the share options is January 2, 2020.

In March 2020, the Company issued options to purchase 294,828 ADSs to Yoav Stern, the Company’s CEO and President, with an exercise price of $1.09 per ADS. 99.9% of the options vest at the grant date, and the remaining options will vest 3 years after the grant date.

In August 2020, following the approval of our shareholders, in consideration for his services as the Company’s President and CEO, and as appropriate incentive, the Company entered into a private placement of warrants (the “Stern Transaction”) with its CEO and President, Mr. Yoav Stern. In consideration of $150,000, the Company issued to Mr. Stern warrants to purchase 6,880,402 ADSs of the Company. The warrants have an exercise price of $0.75 per ADS, will vest over a period of two and a half years and will expire after 7 years. Simultaneously with the issuance of the warrants, Mr. Stern forfeited options to purchase 581,000 ADSs, previously granted to him, as described above. In addition, as long as Mr. Stern is employed by the Company or is a member of the Company’s board of directors, Mr. Stern may invest an additional amount up to $50,000 to buy Series B Warrants, in an amount equal to 10% of the Company’s fully diluted capital. The exercise price per ADS under the Series B Warrants will be the average of the daily volume weighted average price of the ADSs for the 10 consecutive trading days ending on the trading day that is immediately prior to the date of the applicable notice to purchase the Series B Warrants. The grant of the warrants was treated as a modification of the terms of equity-classified share based payment under IFRS 2. The fair value of the grant was measured at the grant date in an amount of approximately $18.7 million, and is recorded as share-based compensation expenses through the vesting period. In the same general meeting that approved the Stern Transaction, the Company’s shareholders approved the amended terms of compensation of the Company’s CEO and President. After the reporting date, in January 2021, Mr. Stern exercised 30% of the series A warrants.

In September 2020, the Company issued 1,500,000 warrants to purchase 1,500,000 ADSs to the Company’s director, Mr. Yaron Eitan, in consideration of $150,000. The warrants have an exercise price of $2.25 per ADS, willRSUs vest over a period of three years and will expire after 7 years.


Nano Dimension Ltd.

Notes tofrom the Consolidated Financial Statementsgrant date.

 

Note 17Share-basedIn November 2022, the Company issued 75,000 RSUs to directors of the Company. The RSUs vest over a period of three years from the grant date.

In September 2022, the Company re-priced the share options granted to a small group of certain employees, directors and senior management, after receiving approval to do so from the Israeli tax authorities. In accordance with the repricing, every two old share options were converted into one RSU, without an exercise price. The vesting period of the new RSUs will be 4 years. As a result of this modification, there was an increase in the fair value of the equity instruments granted, measured immediately before and after the modification. Hence, the Company measured the incremental fair value granted, and recognized it over the period from the modification date until the date when the modified equity instruments vest.

In June 2023, the Company issued 200,000 RSUs to directors of the Company. The RSUs vest over a period of three years from the grant date.

In October 2023, the Company issued 70,000 RSUs to directors of the Company. The RSUs vest over a period of three years from the grant date.

F-40

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

C.On April 22, 2021, the Group acquired 100% of the shares and voting interests in DeepCube. After the acquisition, one of DeepCube’s founders continued to work at DeepCube, in the role of Chief Technology Officer. In accordance with the terms of the acquisition agreement, 892,465 ordinary shares of the Company will be issued to this founder, with a share price protection mechanism. The granting of these shares is subject to conditions related to the continued employment of the founder. Hence these shares were not taken into account as part of the consideration for the business combination. The fair value of those shares, with the share price protection mechanism, was estimated at $7,756, and were recognized as post-acquisition compensation cost.

During 2022 and 2023, the Company chose to settle the share price protection mechanism in cash, and therefore the cash paid in the amount of 2023: $522 (2022: $489) was treated as repurchase of equity awards that was reduced from equity.

In addition, as part of the acquisition agreement, the Group exchanged equity-settled share-based payment (Continued) awards held by employees of DeepCube (the acquiree’s awards) for 299,455 RSUs of the Company (the replacement awards). The acquiree’s awards were granted during the years 2018 to 2021 and were generally subject to a 4-year vesting schedule. The replacement awards were granted on the acquisition date and are subject to a 3-year vesting schedule.

 

C.D.On April 26, 2021, the Group acquired 100% of the shares and voting interests in NanoFabrica. In accordance with the terms of the acquisition agreement, 1,178,008 ordinary shares of the Company will be issued to NanoFabrica’s founders, with a share price protection mechanism. The granting of these shares is subject to conditions related to the continued employment of the founders. Hence these shares were not taken into account as part of the consideration for the business combination. The fair value of those shares, with the share price protection mechanism, was estimated at $10,941, and were recognized as post-acquisition compensation cost.

During 2022 and 2023, the Company chose to settle the share price protection mechanism in cash, and therefore the cash paid in the amount of 2023: $3,937 (2022: $516) was treated as repurchase of equity awards that was reduced from equity.

In addition, as part of the acquisition agreement, the Group exchanged equity-settled share-based payment awards held by employees of NanoFabrica (the acquiree’s awards) for 76,928 RSUs of the Company (the replacement awards). The acquiree’s awards were granted during the years 2017 to 2020 and were generally subject to a 4-year vesting schedule. The replacement awards were granted on the acquisition date and are subject to a 3-year vesting schedule.

E.The fair value of share options is measured using the Black-ScholesBlack-Scholes-Merton formula, or the Binomial pricing model.model or Monte Carlo simulations. Measurement inputs include the share price on the measurement date, the exercise price of the instrument, expected volatility (based on the weighted average volatility of the Company’s shares, over the expected term of the options), expected term of the options (based on general option holder behavior and expected share price), expected dividends, and the risk-free interest rate (based on government debentures).

The following is the data used in determining the fair value of the share options granted:

 

  17.A-
Consultants and Employees
  17.B-
Directors and CEO (*)
 
Number of share options granted  14,638,264    8,942,202(*)
Fair value in the grant date (thousands USD)  43,979   23,434 
Range of share price (USD)  0.74-89.83   1.38-94.64 
Range of exercise price (USD)  0-114.77   0.7-92.04 
Range of expected share price volatility  40.3%-104.96%  53.75-104.96%
Range of estimated life (years)  4-9   4-7 
Range of weighted average of risk-free interest rate  0.36-1.98%  0.88%-1.32%
Expected dividend yield  -   - 
Outstanding as of December 31, 2020  12,603,828   8,839,482 
Exercisable as of December 31, 2020  880,734   8,679,113 

F-41

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

The following is the data used in determining the fair value of the options granted in 2022-2023:

 

(*)The options granted to directors 19.A - Consultants
and Employees
Fair value in the CEO do not include the series B warrants which the CEO is entitled to purchase, since the numbergrant date (thousands USD)2,049
Range of those warrants is not yet determined.share price (USD)2.46-2.86
Range of exercise price (USD)1.00-3.05
Range of expected share price volatility103.20%-121.85%
Range of estimated life (years)4.5-8
Range of weighted average of risk-free interest rate4.33%-4.50%
Expected dividend yield

 

  19.B - Directors
and CEO
 
  2022  2023 
Fair value in the grant date (thousands USD)  21,708    
Range of share price (USD)  1.38-6.52    
Range of exercise price (USD)  0-9.33    
Range of expected share price volatility  93.62%-125.9%  
Range of estimated life (years)  4-7.07         — 
Range of weighted average of risk-free interest rate  0.29%-1.33%  
Expected dividend yield      

The following is the range of fair value of the RSUs granted during the years 2021-2023:

(in U.S dollars)  2021   2022   2023 
Range of fair value of the RSUs granted during the year  4.62-10.94   2.47-3.82   2.39-2.86 

F-42

D.Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

F.The number of share options and RSUs granted to employees and consultants, and included in Note 17.A19.A are as follows:

 

 2019(*) 2020  2022  2023 
Outstanding at January 1 112,944 521,138 
 Share options
and RSU’s
  Replacement
awards
  Share options
and RSU’s
 
Outstanding of January 1  20,768,200   254,409   27,630,207 
Granted during the year 461,223 14,295,289   13,555,000      5,838,000 
Exercised during the year (24) (1,703,902)  (1,084,331)  (116,362)  (6,922,002)
Forfeited or expired during the year  (53,005)  (508,697)  (3,204,932)  (40,907)  (3,983,731)
Outstanding at December 31  521,138  12,603,828 
Share options exchange  (2,500,870)      
Outstanding of December 31  27,533,067   97,140   22,562,474 
Exercisable as of December 31  53,831  880,734   2,398,972      2,323,530 

 

The number of shareRSUs, options and warrants granted to directors and the CEO included in Note 17.B19.B are as follows:

 

 2019 2020  2022  2023 
Outstanding at January 1 41,400 78,435 
Outstanding of January 1  34,410,284   34,532,431 
Granted during the year 50,900 8,820,402   285,000   270,000 
Exercised during the year - -   (20,418)  (4,895,805)
Forfeited or expired during the year  (13,865)  (59,355)  (142,435)  (133,427)
Outstanding at December 31  78,435  8,839,482 
Outstanding of December 31  34,532,431   29,773,199 
Exercisable as of December 31  40,275  8,679,113   33,120,886   28,327,309 

 

E.G.The share-based payments expenses in 20202023 were $20,502,000$20,101 (in 2019: $445,000). In addition, the fair value of the warrants granted to underwriters2022: $32,563, in 2020 were $25,718,000 and has been recorded as a deduction of share premium.2021: $29,782).

Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 1820Financial instruments

 

A.Risk management policy

 

The actions of the Group expose it to various financial risks, such as a credit risk, market risk (including a foreign currency risk fair value risk regarding interest rate and share price risk), credit risk, liquidity risk and cash flow risk for the interest rate. The comprehensive risk-management policy of the Group focuses on actions to limit the potential negative impacts on financial performance of the Group to a minimum. The Group does not typically use derivative financial instruments in order to hedge exposures. Risk management is performed by the Group’s CEOChief Executive Officer in accordance with the policy approved by the board of directors.

 

The Group Audit Committee oversees how management monitors compliance with the Group’s risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The Group Audit Committee is assisted in its oversight role by Internal Audit. Internal Audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the Audit Committee.

B.Credit risk

 

The Group does not have a significant concentration of credit risks.

 

The cash of the Group is deposited in Israeli, European and U.S. banking corporations. In the estimation of the Group’s management, the credit risk for these financial instruments is low. The Company had bank accounts and deposits with Silicon Valley Bank, most of which were drawn and transferred to other banks in March 2023. As of the reporting date, the remaining cash and deposits balance in Silicon Valley Bank is immaterial.

 

In the estimation of the Group’s management, it does not have any material expected credit losses.

 

F-43

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

C.CurrencyMarket risk

(1)Foreign currency risk

 

A currency risk is the risk of fluctuations in a financial instrument as a result of changes in the exchange rate of the foreign currency.

 

The following is the classification and linkage terms of the financial instruments of the Group (in thousands USD):Group:

 

  NIS  Linked to the U.S. dollar  Linked to the Euro and other  Total
December 31, 2020            
Cash  1,057   584,205   76   585,338 
Bank deposits  -   85,596   -   85,596 
Restricted deposits  406   62   -   468 
Trade receivables  17   534   162   713 
Other receivables  410   19   -   429 
   1,890   670,416   238   672,544 
Financial liabilities at amortized cost  4,366   16,134   45   20,545 
Total net financial assets (liabilities)  (2,476)  654,282   193   651,999 
                 
December 31, 2019                
Cash  348   3,536   10   3,894 
Restricted deposits  377   31   -   408 
Trade receivables  -   1,586   230   1,816 
Other receivables  342   -   -   342 
   1,067   5,153   240   6,460 
Financial liabilities at amortized cost  4,503   6,740   13   11,256 
Total net financial assets (liabilities)  (3,436)  (1,587)  227   (4,796)

  NIS  USD  Other  Total 
December 31, 2023            
Cash  24,537   278,993   6,041   309,571 
Bank deposits  110,881   431,086      541,967 
Restricted deposits  555   386      941 
Trade receivables (net)  67   8,193   4,450   12,710 
Other receivables  5,126   2,935   1,452   9,513 
Investment in securities     138,446      138,446 
   141,166   860,039   11,943   1,013,148 
Financial liabilities at amortized cost  (9,415)  (10,019)  (11,161)  (30,595)
Total net financial assets  131,751   850,020   782   982,553 
                 
December 31, 2022                
Cash  37,812   639,318   8,232   685,362 
Bank deposits  100,289   246,374      346,663 
Restricted deposits  524   386      910 
Trade receivables (net)  46   1,867   4,429   6,342 
Other receivables  1,817   3,150   2,333   7,300 
Investment in securities     114,984      114,984 
   140,488   1,006,079   14,994   1,161,561 
Financial liabilities at amortized cost  (11,545)  (9,851)  (16,340)  (37,736)

 

F-44

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

The following is a sensitivity analysis of changes to profit (loss) and equity in the exchange rate of the NIS as of December 31:

  2022  2023 
Increase at a rate of 5%  6,447   6,588 
Increase at a rate of 10%  12,894   13,175 
Decrease at a rate of 5%  (6,447)  (6,588)
Decrease at a rate of 10%  (12,894)  (13,175)

(2)Share price risk

During 2022, the reporting date:Group acquired shares of Stratasys Ltd. (“Stratasys”), a technology company traded on the Nasdaq Stock Exchange and engaged in the 3D printing solutions area, for an amount of $177,775. As of December 31, 2023, the Company owns 9,695,115 of Stratasys’ ordinary shares, with a value of approximately $138,446 (2022: $114,984) which constitute, as of December 31, 2023, approximately 14.02% (2022: 14.5%) of Stratasys’ ordinary shares. Therefore. a revaluation profit was recorded in amount of $23,462 (2022: loss of $62,791). A change of 1% in Stratasys’ share price would have increased (decrease) profit or loss by the amount of $1,384 (2022: $1,150).

On July 24, 2022, Stratasys’ board of directors approved a poison pill mechanism, which will block the possibility of controlling or having a significant influence on Stratasys without the approval of Stratasys’ board of directors. In accordance with the approved poison pill, when there will be a shareholder who owns 15% of Stratasys, every other shareholder will be entitled to purchase a new share issued to such shareholder by Stratasys at a price of $0.01 per share, and in this way will be able to dilute the shareholder who owns 15%, which is not entitled to this right, unless the purchase of the shares that reached the 15% threshold was approved by the Stratasys’ board of directors. The poison pill was valid for one year, until July 24, 2023.

On December 21, 2023, Stratasys’ board of directors approved a new poison pill mechanism, which is substantially a duplication of the previous poison pill, with some minor changes (the “Revised Poison Pill”). The Revised Poison Pill is valid for one year, until December 2024.

 

Profit (loss)
from the change
Thousands
USD
Increase at a rate of 5%(124)
Increase at a rate of 10%(248)
Decrease at a rate of 5%124
Decrease at a rate of 10%248


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 18Financial instruments (Continued)

D.Fair value of financial instruments

 

  December 31, 2020 
  Level 1  Level 2  Level 3  Total 
  Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
Financial liabilities:            
Warrants           -   11,636       -   11,636 
Financial derivatives  -   350   -   350 
Total  -   11,986   -   11,986 

The carrying amounts of certain financial assets and liabilities, including cash and cash equivalents, trade receivables, other receivables, trade payables and other payables are the same or proximate to their fair value.

 

  December 31, 2019 
  Level 1  Level 2  Level 3  Total 
  Thousands
USD
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
Financial liabilities:            
Warrants         -   793   1,364   2,157 
Convertible notes  -   -   1,223   1,223 
Financial derivatives  -   -   318   318 
Total  -   793   2,905   3,698 

F-45

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

The table below presents an analysis of financial instruments measured at fair value through profit or loss using a valuation methodology in accordance with the fair value hierarchy levels (for a definition of the various hierarchy levels, see Note 2.E regarding the basis of preparation of the financial statements).

December 31, 2023         
  Level 1  Level 2  Total 
Financial assets:         
Traded shares  138,446      138,446 
Total assets:  138,446      138,446 
Financial liabilities:            
Liability in respect of warrants     56   56 
Total liabilities     56   56 
Presented under current liabilities     56   56 

December 31, 2022         
  Level 1  Level 2  Total 
Financial assets:         
Traded shares  114,984      114,984 
Total assets:  114,984      114,984 
Financial liabilities:            
Liability in respect of warrants     69   69 
Contingent consideration in business combination     4,982   4,982 
Total liabilities     5,051   5,051 
Presented under current liabilities     4,982   4,982 
Presented under non-current liabilities     69   69 

(1)Details regarding fair value measurement at Level 2

(a)Warrants Issued in February 2019

 

Details regardingIn February 2019, the Company issued, as part of a public offering in the United States, 1,600,000 non-tradable warrants with an exercise price of $8.625 per ADS and term of 5 years. In certain cases, the warrants may be exercised on a cashless basis. Therefore, the warrants are accounted for as derivative instruments which are classified as a liability and measured at fair value measurementthrough profit or loss.

Since the offering certain warrants were exercised. As of December 31, 2023, 1,316,010 warrants remained outstanding.

The fair value of the warrants was measured as of December 31, 2023 and December 31, 2022, at Level 2an amount of approximately $0 and $6, respectively.

 

The fair value of the warrants was measured using the Black-Scholes model. The following inputs were used to determine the fair value:

 

Expected term of warrant (1)(a)3.1-3.68 years.0.1 years (2022: 1.1 years).

Expected volatility (2)(b)118.77%-128.1%51.2% (2022: 48.5%).

Risk-free rate (3)(c)0.17%.-0.24%5.3% (2022: 4.7%).

Expected dividend yield – 0%.

 

(1)(a)Based on contractual terms.

(2)(b)Based on the historical volatility of the Company’s Ordinary Sharesordinary shares and ADSs.
(c)Based on traded zero-coupon U.S. treasury bonds with maturity equal to expected terms.

F-46

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

(b)(3)Warrants Issued in September 2019

In August 2019, the Company issued, as part of a securities purchase agreement of convertible promissory notes, non-tradable warrants to purchase 62,668,850 ADSs. The warrants have a variable exercise price, equal to 125% of the conversion price of the convertible promissory notes, and are exercisable upon the six-month anniversary of issuance and will expire five years from the date of issuance.

The warrants have been classified as financial liability that are measured at fair value through profit and loss as neither the exercise price nor the number of shares to be issued is fixed.

On February 4, 2020, the Company agreed to amend the exercise price of the warrants to $1.914 per ADS, and the Company and the investors agreed to terminate substantially all remaining warrants, besides warrants to purchase 95,620 ADSs.

The fair value of the warrants was measured as of December 31, 2023 and December 31, 2022, at an amount of approximately $56 and $63, respectively.

The fair value of the warrants was measured using the Black-Scholes model. The following inputs were used to determine the fair value:

Expected term of warrant (a) – 0.68 years (2022: 1.68 years).

Expected volatility (b) – 47.57% (2022: 48.15%).

Risk-free rate (c) – 4.84% (2022: 4.48%).

Expected dividend yield –0%.

(a)Based on contractual terms.
(b)Based on the historical volatility of the Company’s ordinary shares and ADSs.
(c)Based on traded zero-coupon U.S. treasury bonds with maturity equal to expected terms.

 

(C)Contingent consideration in business combination

On November 2, 2021, the Group acquired 100% of the shares and voting interests in Essemtec. The consideration transferred included earn-out cash consideration payments.

As of December 31, 2022, the fair value of the contingent consideration was determined by an external valuer. The fair value of the earn-out cash payment, in the amount of $4,982 was measured by discounting the expected earn-out payment based on the actual gross profit results recorded by Essemtec in the fiscal year ended December 31, 2022. Therefore, the measurement of the liability was based on level 2 data. The following inputs were used to determine the fair value:

Essemtec’s underlying gross profit – approximately CHF 13,850.

Risk free rate – 0.96%.

During 2023, the Company paid an amount of $5,295 and settled this liability.

(2)Sensitivity analysis for share price

If the share price had increased or decreased by 10%, the fair value of the warrants issued in February 2019 would not have changed (remains 0).

F-47

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

E.Liquidity risk

 

The table below presents the repayment dates of the Group’s financial liabilities based on the contractual terms in undiscounted amounts:

 

 First year More than a year Total  First year  More than
a year
  Total 
 Thousands
USD
 Thousands
USD
 Thousands
USD
 
December 31, 2020       
December 31, 2023       
Trade payables 776 - 776   4,696      4,696 
Other payables 5,910 - 5,910   9,838      9,838 
Financial derivatives and deferred consideration  56      56 
Lease liabilities  -  2,618  2,618   4,473   8,742   13,215 
Other long-term liability  38   595   633 
Liability in respect of government grants  -  850  850   262   1,895   2,157 
  6,686  3,468  10,154   19,363   11,232   30,595 
December 31, 2019       
December 31, 2022            
Trade payables 850 - 850   3,722      3,722 
Other payables 3,547 28 3,575   18,810      18,810 
Financial derivatives  8,798   69   8,867 
Lease liabilities  -  2,089��  2,089   4,846   12,374   17,220 
Other long-term liability  363   1,011   1,374 
Liability in respect of government grants  -  1,044  1,044   494   1,492   1,986 
  4,397  3,161  7,558   37,033   14,946   51,979 

Nano Dimension Ltd.

Notes to the Consolidated Financial StatementsNote 21 – Leases

 

Note 19Leases

The Group applies IFRS 16 as from January 1, 2019. The Group has lease agreements with respect to the following items:

1.Offices, labs and manufacturing facilities

2.Vehicles

A. Information regarding material lease agreementsagreements

 

a.The Group leases vehicles for approximately three-year periods from several different leasing companies and from time to time changes the number of leased vehicles according to its current needs. The leased vehicles are identified by means of license numbers and the vehicle’s registration, with the leasing companies not being able to switch vehicles, other than in cases of deficiencies. The leased vehicles are used by the Group’s headquarterheadquarters staff, marketing and sales personssalespersons and other employees whose employment agreements include an obligation of the Group to put a vehicle at their disposal. The Group accounted for the arrangement between it and the leasing companies as a lease arrangement in the scope of IFRS 16, “Leases” and for the arrangement between it and its employees as an arrangement in the scope of IAS 19, Employee Benefits.“Employee Benefits”. The agreements with the leasing companies do not contain extension and/or termination options that the Group is reasonably certain to exercise.

 

A lease liability in the amount of $106,000 and right-of-use asset in the amount of $91,000$316 have been recognized in the statement of financial position as atof December 31, 20202023, in respect of leases of vehicles.

 

b.The Group leases offices in Ness- Ziona from Africa-IsraelNess-Ziona for a period of up to five years under a few different contracts for three different floors used for offices, labs and manufacturing facilities, atin the same building. The contractual periods of the aforesaid lease agreements end in August 2021, August 2024, November 2026 and December 2023. The Group has an option to extend two of the lease agreements for an additional five years for an additional monthly fee (10% increase). The Company expects to extend the lease agreement ended in August 2021 for an additional five years.July 2027. The Group also leases offices in Hong-Kong. The contractual period of the aforesaid lease agreement ended in February 2021. The Group also leases offices in theWaltham, Massachusetts, U.S., for a contractual period of threeseven years, which ends in August 2023. AFebruary 2029 and in Munich, Germany for a contractual period of five years, which ends in December 2027.

F-48

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

The lease payments in some of the Group’s leases in Israel and Germany are linked to the local consumer price indexes known on the lease’s date of inception. The revaluation of the lease payments was recognized as a right-of-use asset. The asset was adjusted by the amount of $243 in 2023.

The Group has the option to extend some of its lease agreements. In measuring the lease liability and the right-of-use asset, the Group did not take into account those options since under the current management those options are not reasonably certain to be exercised.

c.In 2022, a lease liability in the amount of $3,660,000 and right-of-use asset inof $627 were recognized as part of the amountbusiness combination of $3,078,000 have been recognized inFormatec Holding. For more information, see Note 9.B(2). In December 2023, the statement of financial position as at December 31, 2020 in respect of leases of offices.Group extended the aforesaid lease until March 2029, recognizing additional $613 right-of-use asset.

 

Right of useB. Right-of-use assets:

 

 Buildings Vehicles Total  Buildings Vehicles Total 
 Thousands
USD
 Thousands
USD
 Thousands
USD
 
Balance as at January 1, 2019  1,687   204   1,891 
Depreciation  706   136   842 
Additions  1,525   99   1,624 
Balance as at January 1, 2020  2,506   167   2,673 
            
Balance as at January 1, 2022  4,192   299   4,491 
Acquisition through business combinations  627      627 
Depreciation 740  116  856   3,349   221   3,570 
Disposals  -   69   69   95   58   153 
Additions  1,312   109   1,421   14,419   319   14,738 
Balance as at December 31, 2020  3,078   91   3,169 
Remeasurement  459      459 
Effect of changes in exchange rates  (52)  (1)  (53)
Balance as at December 31, 2022  16,201   338   16,539 
Depreciation  4,316   256   4,572 
Disposals  293   46   339 
Additions  613   316   929 
Remeasurement  (536)     (536)
Effect of changes in exchange rates  44   7   51 
Balance as at December 31, 2023  11,713   359   12,072 

 

During the year ended December 31, 2020 and 2019, the Company paid a total of $1,118 thousands and $1,095 thousands, respectively, for lease payments.

See also note 14 regarding finance expenses in respect of lease liability.


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 19Leases (Continued)C. Lease liabilities

 

Maturity analysis of the Group’s lease liabilities:

 

  December 31,  December 31, 
  2022  2023 
Maturity analysis of the Group’s lease liabilities:        
Less than one year  4,846   4,473 
One to five years  12,189   8,520 
Above 5 years  185   222 
Total  17,220   13,215 

F-49

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

D. Amounts recognized in profit or loss

  2021  2022  2023 
Interest expenses on lease liability  237   180   477 
Expenses relating to leases  1,592   3,723   4,911 
   1,829   3,903   5,388 

During the years ended December 31, 2023 and 2022, the Company paid a total of $4,823 and $4,151, respectively, for lease payments.

Note 22 - Contingent liabilities

On February 12, 2023, Murchinson Ltd., BPY Limited, Nomis Bay Ltd., Boothbay Absolute Return Strategies, LP. and Boothbay Diversified Alpha Master Fund, LP., (collectively “Murchinson” or “Murchinson and Affiliates”) submitted a statement of claim to the Lod District Court (Economic Department) (the “Court”), in which they asserted that Company’s shares registered under Form S-8, filed with the SEC on January 27, 2023, were allocated unlawfully and in bad faith, resulting in the deprivation of shareholders’ rights. Murchinson also requested that the Court cancel the registration of the newly registered shares on the Company’s Form S-8. Furthermore, Murchinson demanded that the Court order the Company to refrain from any allocation of shares from the newly registered shares, or, in the alternative, to make any allocation subject to shareholder meeting approval or condition any future allocations from the newly registered shares on specific criteria related to employee and official compensation. Pre-trial hearings were held on June 18, 2023, and on February 21, 2024.

Separately, on February 27, 2023, the Company filed a claim against Murchinson in the Court, challenging Murchinson’s right to convene a shareholders’ meeting, contending that they are not shareholders (but rather ADS holders). Following a hearing on June 18, 2023, the matter was stayed until a verdict is reached in the March 26, 2023 claim Murchinson and Affiliates filed with the Court, as described below.

On March 26, 2023, Murchinson filed for temporary relief in the Court, in which it claimed that it had the right to convene a special general meeting of shareholders on March 20, 2023, and that the decisions in that special general meeting would be valid and legally binding. Specifically, the meeting Murchinson wanted to convene would amend the article of association and appoint two directors (the “Alleged Directors”), and remove from office Yoav Stern, Oded Gera, Igal Rotem and Dr. Yoav Nissan-Cohen. Following a hearing and submission of motions, on April 16, 2023, the Court rejected Murchinson’s request for temporary relief and request that the Company to refrain from doing any business outside the ordinary course of business. The Court, however, granted the alternative relief of appointing the Alleged Directors as board observers. The Company filed, with the Supreme Court of Israel, a request for interlocutory appeal, but was denied. This claim is currently pending before the Court.

On August 31, 2023, Murchinson filed a complaint against the Company and Mr. Yoav Stern, arguing that the Company wrongfully counted proxy cards at its September 7, 2023, annual general meeting (the “AGM”), and that the required majority for the dismissal of directors at the AGM are a simple majority rather than a special majority of 70%. In connection with this complaint, Murchinson requested temporary relief requesting that the Court instructs the Company (1) to refrain from implementing the decisions reached at the AGM; or (2) to refrain from convening board of directors and committee meetings with members comprising Ms. Hanna Caspi, Mr. Oded Gera and Dr. Yoav Cohen-Nissan; or (3) to refrain from doing any business outside the ordinary course of business, including changes in Company’s capital. A hearing took place on September 5, 2023, during which the Court denied the request for temporary reliefs. The Company filed a counterstatement of claims to Murchinson’s complaint on January 18, 2024, and its statement of defense on January 21, 2024. A hearing was held on February 21, 2024, in which the Court scheduled further proceedings starting in September 2024.

On March 27, 2023, the Company filed a complaint, in the United States District Court for the Southern District of New York alleging claims against Murchinson and Affiliates as well as Anson Funds, or Anson. The complaint alleges that defendants improperly engaged in coordinated efforts to acquire a large stake in the Company and interfered with its business operations, in violation of U.S. securities laws, New York law, and pertinent contracts governing Company’s ADSs. The complaint also alleges that defendants’ conduct was in violation of Section 13(d) of the Exchange Act and constituted breach of contract, tortious interference with prospective business relationships, and unjust enrichment. After the Company filed the complaint, on May 2, 2023 and June 23, 2023, Murchinson and Anson filed amended disclosures with the SEC. On July 10, 2023, the United States District Court dismissed Company’s federal securities claims against Murchinson and Anson and declined to exercise supplemental jurisdiction concerning Company’s state law claims, dismissing them without prejudice. On August 9, 2023, the Company appealed the District Court’s decision dismissing Company’s claims arising under Section 13(d) of the Exchange. That appeal remains pending.

On July 14, 2023, the Company filed a complaint against Murchinson and Affiliates and Anson in the Supreme Court of the State of New York. The complaint in this action alleges that Murchinson and Affiliates breached multiple provisions of the contract that governs there holdings of our ADSs and were unjustly enriched through their improper trading of our ADSs. On August 3, 2023, the Supreme Court of the State of New York issued a decision temporarily staying the Company’s claims pending a post-trial ruling in the March 26, 2023 claim Murchinson and Affiliates filed with the Court. The Company does not anticipate that any further action will take place in this matter until the stay is lifted.

On May 1, 2023, Murchinson filed a complaint in the Southern District of New York alleging that the Company and its directors violated New York Civil Rights Law §§ 70-a and 76- a when they initiated the above-referenced litigation in the Southern District of New York. On August 9, 2023, The Company filed a motion to dismiss the complaint in its entirety, arguing, inter alia, that the Southern District of New York lacks jurisdiction to hear the claims and that Murchinson’s complaint fails on the merits. The Company’s motion to dismiss remains pending.

F-50

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

On April 25, 2023, the Company filed a motion for the issuance of temporary relief against Stratasys and its board of directors, requesting that the Tel Aviv District Court prevent Stratasys from sabotaging a special tender offer that the Company announced it intended to publish according to the mechanism prescribed in the Companies Law for implementing an unlawful “poison pill.” On May 7, 2023, the Company filed a statement of claim (the “Poison Pill Claim”), against Stratasys and its board of directors. Following a hearing held in connection with the Poison Pill Claim, on July 18, 2023, the Tel Aviv District Court suggested, without making a conclusive decision, that he believes that there is no per se prohibition against such a plan as long as it does not discriminate between shareholders. On August 8, 2023, the Tel Aviv District Court stayed the proceedings in the Poison Pill Claim. On November 16, 2023, the Company asked the Tel Aviv District Court to resume the proceedings and to set dates for final briefing. The matter is currently pending before the Tel Aviv District Court.

On December 7, 2022, the Company was served with a motion requesting the discovery of documents in the Tel Aviv District Court (Economic Department) by an ADS holder, Mr. Kfir Sapir asserting, among other things, that the purchase price in the Company’s acquisition of DeepCube did not accurately reflect the acquired company’s value, that there were flaws in the approval process for the acquisition during the meeting of the Company’s board of directors, which allegedly resulted in a breach of the directors’ fiduciary duties, and that the Company had undervalued DeepCube in its financial reports for 2021, suggesting that the acquired company had no worth. Following the Company’s response, on October 19, 2023, upon a request from the plaintiff, the court dismissed the matter without prejudice because the plaintiff intended to file a derivative action. On September 5, 2023, Mr. Sapir filed a motion to certify a derivative action according to section 198 to the Israeli Companies Law 5759-1999 against the Company and its directors with the Tel Aviv District Court, arguing the decision to acquire DeepCube for approximately $40,000 in cash and $30,000 worth of ADSs, was unreasonable, based on his notion that DeepCube is only a “startup company” with allegedly no revenues and no products. A court hearing is scheduled for July 3, 2024. 

On March 18, 2024, the Company filed a motion for temporary injunction in the Court against Murchinson, and Affiliates and Mr. Moshe Sarfati, a senior analyst at Murchinson (the “Respondents”), in which the Company claims that the Respondents had contacted officers at certain third-party companies with whom Company have had business discussions, and committed tortious interference. The Company asked the Court to issue an injunction against the Respondents:

I.To refrain from contacting third parties – including companies in the field of 3D printing and/or companies engaged in negotiations with the Company – regarding the Company’s affairs, and to present them with misleading presentations casting doubt over the legality of the current board of directors of the Company and implying that the current board of directors and management are not authorized to make decisions regarding the Company’s transactions, or to threaten them that Respondents will act to thwart any negotiation, collaboration, or transaction with the Company under the guidance of the Company’s current board of directors.

 II.December 31,
2020
Thousands
USD
Less than one year1,148
OneTo avoid interfering with or undermining the Company’s business activities, including any attempts to five years2,618
Total3,766
Current maturitiesthwart transactions advancing the Company’s interests with third parties, including merger, acquisition, or stock exchange transactions. The Company also asked the Court to order the Respondents to provide a written affidavit to be submitted by each of lease liability1,148
Long-term lease liability2,618the Respondents, detailing all communications made to third parties engaged in business relations with the Company, with the aim of interfering in the Company's business affairs.

On March 21, 2024, we filed a complaint with the Court requesting a declaration that Respondents had breached their duties and requesting the remedies specified above. A hearing is scheduled for March 26, 2024.

Note 2023Transactions and balances with related parties

 

A.Balances with related parties

A. Balances with related parties

 

  December 31, 
  2019  2020 
  Thousands
USD
  Thousands
USD
 
Other payables  130   207 
  December 31, 
  2022  2023 
Employee benefits liabilities  387   1,474 

 

B.Shareholders and other related parties benefits

 

  Year ended on December 31, 
  2018  2019  2020 
  Thousands
USD
  Thousands
USD
  Thousands
USD
 
Salaries and related expenses- related parties employed by the Group  829   1,047   18,252(*)
Number of related parties  4   4   5 
Compensation for directors not employed by the Group  311   218   2,204 
Number of directors  7   6   6 

B. Shareholders and other related parties’ benefits

  Year ended on December 31, 
  2021  2022  2023 
Salaries and related expenses- related parties employed by the Group (*)  13,629   10,185   11,818 
Number of related parties  7   8   8 
Compensation for directors not employed by the Group  3,951   374   408 
Number of directors  8   7   8 

 

(*)IncludesThe figures include share-based payment expenses of $16,666,000, see note 17.B regarding warrants issued$6,692 (2022: $7,333, 2021: $10,925)

C. On April 22, 2021, the Company acquired 100% of the shares and voting interests in DeepCube. The founders of DeepCube are Mr. Eli David and Mr. Yaron Eitan (through his holding in Anaknu LLC (“Anaknu”), of which he is one of the shareholders). Mr. Eli David and Mr. Yaron Eitan were directors of DeepCube. Mr. Eli David also continued to work at DeepCube after the acquisition, in the role of Chief Technology Officer.

F-51

Nano Dimension Ltd
Notes to the CEO.Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

For the sale of their holdings in the company, the founders received the following consideration (Mr. Eli David and Anaknu in aggregate):

1.Cash payments - $19,420.

 

C.2.

On November 20, 2017, the boardPayment in equity instruments to Anaknu 1,339 thousand ordinary shares with a fair value of directors$11,682. Those shares were entitled to a share price protection mechanism for a period of the Company approved a non-exceptional transaction in which Mr. Avi Reichental, a then director12 months. In April 2022 an amount of the Company, has a personal interest, for open innovation and show room agreements between Nano Dimension USA Inc. and XponentialWorks Inc. and Techniplas, LLC, whereby the Company will lease space and use sales and marketing services in favor of the customer experience center in Ventura, CA, as well as establish cooperation in the field of car electronics starting on December 1, 2017. In March 2019, the Company ceased the obligations$3,661 was paid with XponentialWorks Inc. and Techniplas. LLC.

D.On November 12, 2019, the board of directors of the Company approved an arms-length transaction in which Mr. Ofir Baharav, the former chairman of the board of directors of the Company, has a personal interest, for an administrative services agreement between Nano Dimension USA Inc. and Breezer Holdings LLC, whereby the Company will lease space and will use logistics services for the Company’s office in Boca Raton, Florida, starting on February 1, 2020. In September 2020, the Company ceasedregards to this transaction.


Nano Dimension Ltd.

Notes to the Consolidated Financial Statements

Note 20Transactions and balances with related parties (Continued)

E.On December 5, 2019, the Company announced the appointment of Yoav Stern as CEO and President, effective January 2, 2020. See note 17.B regarding options granted to the CEO.price protection mechanism.

 

F.3.Post-acquisition compensation cost 892 thousand ordinary shares, with a share price protection mechanism for a period of 12 to 36 months, subject to conditions related to the continued employment of Mr. Eli David. These shares were not taken into account as part of the consideration for the business combination. The fair value of those shares, with the share price protection mechanism, was estimated at the transaction date at $7,756.

For the year ended December 31, 2023, $1,190 (2022: $3,286) of the share-based compensation was recognized as share-based payment expenses.

D.On July 7, 2020,May 25, 2021, following approval of the general meeting of the Company’s shareholders, the Company granted options to purchase 1,000,000131,000 ADSs to officer and additional 440,000directors of the Company with exercise prices ranging from $7.69 to $9.33 per ADS.

E.In May 2021, the Company granted options to purchase 3,000,000 ADSs and directorsto officers of the Company at an exercise price of $0.70$6.00 per ADS. In addition, the Company granted options to purchase 1,000,000 ADSs to an officer of the Company, subject to certain change-of-control events, which have not occurred during the reporting period.

F.In January 2022, the Company granted options to purchase 400,000 ADSs to an officer of the Company at an exercise price of $3.79 per ADS.

 

G.On July 7, 2020,In June 2022, the Company issued warrantsgranted 210,000 RSUs to directors of the Company’s President and CEO, Mr. Yoav Stern. See note 17.B.Company.

 

H.In August 2020,2022, the Company issuedgranted 1,270,000 RSUs to officers of the Company.

I.In September 2022, the Company replaced options to purchase 3,241,737 ADSs granted before to certain officers and directors of the Company with 1,620,869 RSUs.

J.In November 2022, the Company granted 75,000 RSUs to directors of the Company. In addition, the Company granted 500,000 RSUs to an officer of the Company.

K.In January 2023, the Company granted 350,000 RSUs to officers of the Company.

L.In April 2023, Mr. Yoav Stern exercised 4,816,282 warrants to the Company’s director, Mr. Yaron Eitan, see note 17.Binto 3,559,073 shares.

M.In June 2023, the Company granted 200,000 RSUs to directors of the Company. In addition, the Company granted 500,000 RSUs to an officer of the Company.

N.In October 2023 the Company granted 70,000 RSUs to directors of the Company and 850,000 RSUs to officers of the Company.

O.In November 2023, the Company changed the vesting terms of options to purchase 1,000,000 ADSs granted to an officer of the Company.

For additional information regarding share-based payments transactions with officers and directors see note 19.

F-52

Nano Dimension Ltd
Notes to Consolidated Financial Statements
U.S. dollars in thousands (except share and per share data)

Note 2124Events after the reporting date

 

A.After the reporting period, in January to March 15, 2024, the Company acquired 17,110,217 of the Company’s ADSs in a total amount of $46,150 and recorded an increase in the reserve for treasury shares accordingly.

B.In January 2024, the Company entered into the Rights Plan, with the intention to protect the long-term interests of the Company’s ADS holders and enable them to realize the full potential value of their investment in the Company. The Rights Plan is designed to reduce the likelihood that any entity, person or group would gain control of, or significant influence over the Company. Pursuant to the Rights Plan, the Company issued one special purchase right for every one ADS outstanding at the close of business on February 5, 2024. Each right allows its holder to purchase from the Company one-half (0.5) of one ADS, at a purchase price of $0.01 per ADS, once the rights become exercisable. The rights would become exercisable only if an entity, person or group acquires beneficial ownership of 10% or more of the Company’s outstanding ordinary shares in a transaction not approved by our board of directors. The rights will expire on January 25, 2025.

C.After the reporting period, in JanuaryFebruary and February 2021,March 2024, the Company issued, pursuantGroup granted 510,000 RSUs to two public offerings inemployees of the United States, an aggregateCompany. The RSUs represent the right to receive ordinary shares at a future time and vest over a period of 74,100,000 Ordinary Shares and 1,137,500 non-tradable warrantsthree to the underwriters. The total gross proceeds from the offerings were approximately $833,000,000, before deducting underwriting discounts and commissions and other offering-related expenses.four years.

 

F-53

F-36